



US009422293B2

(12) **United States Patent**
Allison et al.

(10) **Patent No.:** **US 9,422,293 B2**
(45) **Date of Patent:** ***Aug. 23, 2016**

- (54) **TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1**
- (71) Applicant: **Janssen Pharmaceutica NV**, Beerse (BE)
- (72) Inventors: **Brett D. Allison**, Del Mar, CA (US); **Bryan James Branstetter**, Carlsbad, CA (US); **J. Guy Breitenbucher**, Escondido, CA (US); **Michael D. Hack**, San Diego, CA (US); **Natalie A. Hawryluk**, San Diego, CA (US); **Alec D. Lebsack**, Ladera Ranch, CA (US); **Kelly J. McClure**, Ramona, CA (US); **Jeffrey E. Merit**, Stanford, CA (US)
- (73) Assignee: **Janssen Pharmaceutica NV**, Beerse (BE)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 40 days.
- This patent is subject to a terminal disclaimer.

2001/0041673	A1	11/2001	Fossa
2001/0041703	A1	11/2001	Carpino et al.
2002/0002137	A1	1/2002	Busch et al.
2002/0013320	A1	1/2002	Busch et al.
2002/0016320	A1	2/2002	Fang et al.
2002/0028838	A1	3/2002	MacLean et al.
2002/0042419	A1	4/2002	Hakkinen
2002/0045622	A1	4/2002	Carpino
2002/0045635	A1	4/2002	Bingeli et al.
2002/0072604	A1	6/2002	Carpino et al.
2002/0086865	A1	7/2002	Friedman et al.
2002/0094974	A1	7/2002	Castelhano et al.
2002/0103221	A1	8/2002	Petrie et al.
2002/0143177	A1	10/2002	Beck et al.
2002/0151551	A1	10/2002	Fryburg
2003/0055042	A1	3/2003	Masciadri et al.
2003/0104974	A1	6/2003	Pitts et al.
2003/0139427	A1	7/2003	Castelhano et al.
2003/0191086	A1	10/2003	Hanus et al.
2003/0191143	A1	10/2003	Pitts et al.
2003/0199514	A1	10/2003	Fryburg et al.
2003/0212059	A1	11/2003	Boyle et al.
2004/0034250	A1	2/2004	Hartig et al.
2004/0053908	A1	3/2004	Funahashi et al.
2004/0142945	A1	7/2004	Barbosa et al.
2004/0157845	A1	8/2004	Doherty et al.
2005/0009754	A1	1/2005	Pan et al.
2005/0020830	A1	1/2005	Allen et al.
2005/0049263	A1	3/2005	Kasibhatla et al.
2005/0165032	A1	7/2005	Norman et al.
2005/0182063	A1	8/2005	Yohannes

(Continued)

- (21) Appl. No.: **14/157,671**
- (22) Filed: **Jan. 17, 2014**

- (65) **Prior Publication Data**
US 2014/0135311 A1 May 15, 2014

FOREIGN PATENT DOCUMENTS

CA	2116068	A1	8/1994
CA	2128955	A1	1/1995

(Continued)

OTHER PUBLICATIONS

- Related U.S. Application Data**
- (63) Continuation of application No. 11/726,756, filed on Mar. 21, 2007, now Pat. No. 8,673,895.
- (60) Provisional application No. 60/785,415, filed on Mar. 21, 2006.
- (51) **Int. Cl.**
A61K 31/55 (2006.01)
C07D 487/04 (2006.01)
- (52) **U.S. Cl.**
CPC **C07D 487/04** (2013.01)
- (58) **Field of Classification Search**
CPC A61K 31/55; C07D 487/04
USPC 514/215; 540/578
See application file for complete search history.

Baxter et al "Hit to Lead Studies: The Discovery of Potent, Orally Bioavailable Thiazolopyrimidine CXCR2 Receptor Antagonists" Bioorg Med Chem Lett 2006 vol. 16 pp. 960-963.

Liu et al "Single Step Syntheses of 2-Amino-7-Chlorothiazolo[5,4-D]Pyrimidines: Intermediates for Bivalent Thiazolopyrimidines" J Org Chem 2005 vol. 70 pp. 10194-10197.

Makara et al "Synthesis of Bicyclic Pyrimidine Derivatives as ATP Analogues" J Org Chem 2001 vol. 66 pp. 5783-5789.

Xi et al "Synthesis and Evaluation of Thiazole Carboxamides as Vanilloid Receptor 1 (TRPV1) Antagonists" Bioorg Med Chem Lett 2005 vol. 15 pp. 5211-5217.

Banker et al Modern Pharmaceutics 3rd Ed 1996 pp. 415 and 596 Marcel Dekker New York.

Wolff et al Burger's Medicinal Chemistry 1995 5th Ed Part 1, pp. 975-977.

(Continued)

- (56) **References Cited**

U.S. PATENT DOCUMENTS

4,160,834	A	7/1979	Miesel
5,512,563	A	4/1996	Albright et al.
5,834,461	A	11/1998	Albright et al.
6,107,300	A	8/2000	Bakthavatchalam et al.
6,150,343	A	11/2000	Curran et al.
6,150,353	A	11/2000	Broekkamp et al.
6,232,320	B1	5/2001	Stewart et al.
6,369,222	B1	4/2002	Bingell et al.
6,686,352	B2	2/2004	Masciadri et al.
7,008,948	B2	3/2006	Bebbington et al.
7,087,603	B2	8/2006	Bebbington et al.

Primary Examiner — Brenda Coleman

- (57) **ABSTRACT**

Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.

10 Claims, No Drawings

(56)

References Cited

U.S. PATENT DOCUMENTS

2005/0187217 A1 8/2005 Wilson et al.
 2005/0277643 A1 12/2005 Kelly et al.
 2006/0010445 A1 1/2006 Peterson et al.
 2006/0100194 A1 5/2006 Blackburn et al.
 2006/0128710 A1 6/2006 Lee et al.
 2006/0223868 A1 10/2006 Besidski et al.
 2007/0032473 A1 2/2007 Gerlach et al.
 2007/0032481 A1 2/2007 Dvorak et al.
 2007/0037834 A1 2/2007 Arai et al.
 2007/0136603 A1 6/2007 Kucuekryan
 2007/0142386 A1 6/2007 Nordvall et al.
 2007/0149602 A1 6/2007 DuBois et al.
 2007/0232591 A1 10/2007 Gao et al.
 2008/0234252 A1 9/2008 Bryans et al.

FOREIGN PATENT DOCUMENTS

CL 2007 00720 3/2007
 DE 10200005 62987 A1 7/2007
 EP 612741 A1 2/1994
 EP 640592 A1 7/1994
 EP 1 731 523 A1 12/2006
 EP 1818330 A1 8/2007
 EP 2009003 A1 12/2008
 FR 2874015 A1 2/2006
 JP 3167178 A 7/1991
 JP 3255077 A 11/1991
 JP 6025243 A 2/1994
 JP 6172355 A 6/1994
 JP 11-513398 A 11/1999
 JP 2001 97979 4/2001
 JP 2001 294572 A 10/2001
 JP 2003 321472 A 11/2003
 JP 2004 509117 A 3/2004
 JP 2005 162673 A 6/2005
 JP 28006 083085 A 3/2006
 JP 2007168879 A1 1/2009
 WO WO 93 14080 A1 7/1993
 WO WO 95 06640 A1 3/1995
 WO WO 96 22282 A1 7/1996
 WO WO 97 13771 A1 4/1997
 WO WO 97 19087 A1 5/1997
 WO WO 97 47601 A1 12/1997
 WO WO 97 47624 A1 12/1997
 WO WO 97 48702 A1 12/1997
 WO WO 98 40385 A1 9/1998
 WO WO 98 58947 A1 12/1998
 WO WO 00 43394 A1 7/2000
 WO WO 02 06288 A1 1/2002
 WO WO 02 22602 A2 3/2002
 WO WO 02 32872 A1 4/2002
 WO WO 02 051813 A2 7/2002
 WO WO 02 094834 A1 11/2002
 WO WO 03 037860 A2 5/2003
 WO WO 03 062209 A2 7/2003
 WO WO 03 104230 A1 12/2003
 WO WO 2004 026880 A1 4/2004
 WO WO 2004 043367 A2 5/2004
 WO WO 2004 096784 A1 11/2004
 WO WO 2005 007655 A1 1/2005
 WO WO 2005 014548 A1 2/2005
 WO WO 2005 014558 A1 2/2005
 WO WO 2005 023807 A2 3/2005
 WO WO 2005 033105 A2 4/2005
 WO WO 2005 033115 A1 4/2005
 WO WO 2005 049613 A1 6/2005
 WO WO 2005 066171 A1 7/2005
 WO WO 2005 070929 A1 8/2005
 WO WO 2005 082865 A1 9/2005
 WO WO 2005 095419 A1 10/2005
 WO WO 2005 117890 A2 12/2005
 WO WO 2005 123666 A1 12/2005
 WO WO 2006 010445 A1 2/2006
 WO WO 2006 024776 A1 3/2006

WO WO 2006 030031 A1 3/2006
 WO WO 2006 041773 A1 4/2006
 WO WO 2006 044762 A2 4/2006
 WO WO 2006 062981 A2 6/2006
 WO WO 2006 065484 A2 6/2006
 WO WO 2006 081388 A2 8/2006
 WO WO 2006 123242 A1 11/2006
 WO WO 2007 003536 A1 1/2007
 WO WO 2007 009963 A1 1/2007
 WO WO 2007 019083 A1 2/2007
 WO WO 2007 062370 A2 5/2007
 WO WO 2007 079957 A1 7/2007
 WO WO 2007 093595 A1 8/2007
 WO WO 2007 098826 A2 9/2007
 WO WO 2007 109238 A1 9/2007
 WO WO 2007 136603 A2 11/2007
 WO WO 2007 146122 A2 12/2007
 ZA 9892368 A 9/1998

OTHER PUBLICATIONS

Freeman et al "Reaction of Aminopropanedinitrile 4-Methylbenzene Sulfonate (Aminomalononitrile P-Toluenesulfonate (Tosylate) with Isothiocyanates" J Org Chem 1991 vol. 56(15) pp. 4645-4648.
 Hicks et al "Potential Antiinflammatory Compounds 1. Antiinflammatory Phenylpiperidine Derivatives" J Med Chem 1979 vol. 22(12) pp. 1460-1464.
 Boechat et al "A Simple Reduction of Methyl Aromatic Esters to Alcohols Using Borohydride-Methanol System" Tetrahedron Lett 2004 vol. 45 pp. 6021-6022.
 Jassal et al "Sialylation of Human IgG-FC Carbohydrate by Transfected Rat A2,6-Sialyltransferase" Biochem Biophys Res Comm 2001 vol. 282(2) pp. 243-249.
 Enberg-Furmanov et al "Lyn is a Target Gene for Prostate Cancer Sequence Based Inhibition Induces Regression of Human Xenografts" Cancer Res 2004 vol. 64 pp. 1056-1064.
 Shah et al "Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor" Science 2004 vol. 305 pp. 399-401.
 Donato et al "BCR-ABL Independence and Lyn Kinase Overexpression in Chronic Myelogenous Leukemia Cells Selected from Resistance T ST1571" Blood 2003 vol. 10(12) pp. 690-698.
 Wobig et al "Darstellung Von Thiazolo[4,5,d]Pyrimidin-Derivativen" Liebigs Ann Chem 1989 pp. 409-412.
 McKee et al "P-Substituted Phenyl Isothiocyanates and Some Related Thioureas" J Am Chem Soc 1946 vol. 68 pp. 2506-2507.
 Paradisi et al "Stereoselective Synthesis of a-a-Diamino-Dicarboxylic Acids, Part 2" Tetrahedron Asymmetry 2000 vol. 11 pp. 4617-4622.
 CAS Printout pp. 1-9 Downloaded Apr. 24, 2008.
 Pyrimidinothiazole Search Results Apr. 7, 2000.
 Agopyan et al. "Vanilloid Receptor Activation by 2- and 10-Mm Particles Induces Responses Leading To Apoptosis in Human Airway Epithelial Cells" Toxicol Appl Pharmacol 2003 vol. 192 pp. 21-35.
 Agopyan et al. "Trpv1 Receptors Mediate Particulate Matter-Induced Apoptosis" Am J Physiol Lung Cell Mol Physiol 2004 vol. 286 pp. L563-572.
 Akiba et al. "Transient Receptor Potential Vanilloid Subfamily 1 Expressed in Pancreatic Islet B Cells Modulates Insulin Secretion in Rats" Biochem Biophys Res Commun 2004 vol. 321 pp. 219-225.
 Bagshawe et al. "Antibody-Directed Enzyme Prodrug Therapy: A Review" Drug Dev Res 1995 vol. 34 pp. 220-230.
 Berge et al. "Pharmaceutical Salts". J. Pharm Sci 1977 vol. 66 pp. 1-19.
 Bertolini et al. "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, A Potent Immunosuppressive Drug" J Med Chem 1997 vol. 40 pp. 2011-2016.
 Bodor et al. "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems" Adv Drug Res 1984 vol. 13 pp. 224-331.
 Boechat et al "A Simple Reduction of Methyl Aromatic Esters to Alcohols Using Sodium Borohydride-Methanol System" Tetrahedron Lett 2004 vol. 45 pp. 6021-6022.
 Bundgaard et al Design of Prodrugs H Bundgaard Ed. Elsevier 1985.
 Cordi et al "Novel Quinolinone-Phosphonic Acid Ampa Antagonists Devoid of Nephrotoxicity" II Farmaco 2002 vol. 57 Gps 787-802.

(56)

References Cited

OTHER PUBLICATIONS

- Fleisher et al "Improved Review Oral Drug Delivery: Solubility Limitations of Prodrugs Overcome by the Use" *Adv Drug Delivery Rev* 1996 vol. 19 pp. 115-130.
- Hamann et al "Synthesis and Biological Activity of a Novel Series of Nonsteroidal Peripherally Selective Androgen Receptor Antagonists Derived From 1,2-Dihydropyridono[5,6-*G*]Quinolines" *J Med Chem* 1998 vol. 41 (4) pp. 623-639.
- Higuchi et al "4-Alkyl-And 3,4-Dialkyl-1,2,3,4-Tetrahydro-8-Pyridono[5,6-*g*]Quinolines: Potent Nonsteroidal Androgen Receptor Agonists" *Bioorg Med Chem Lett* 1999 vol. 9 pp. 1335-1340.
- Horikawa et al "A Practical Preparation of Methyl 2-Methoxy-6-Methylaminopyridine-3-Carboxylate From 2,6-Dichloro-3-Trifluoromethylpyridine" *Chem Pharm Bull* 2001 vol. 49(12) pp. 1621-1627.
- Katritzky et al "Benzotriazole-Assisted Preparations of 2-(Substituted Amino)Pyridines and Pyrid-2-Ones" *J Org Chem* 1997 vol. 62(18) pp. 6210-6214.
- Larsen et al *Design and Application of Prodrugs Drug Design and Development Krogsgaard-Larsen et al Eds Harwood Academic Publishers* 1991.
- Marsais et al "Directed Lithiation of 4-Halopyridines: Chemoselectivity, Regioselectivity and Application to Synthesis" *J Heterocycl Chem* 1988 vol. 25(1) pp. 81-87.
- Ponticello et al "Synthesis of Novel 3-(Alkylthio)-2-Halopyridines and Related Derivatives" *J Org Chem* 1979 vol. 44(17) pp. 3080-3082.
- Richardson et al "Synthesis and Structure-Activity Relationship of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor" *J Med Chem* 2004 vol. 47(3) pp. 744-755.
- Robinson "Discovery of the Hemifumarate and (A-L-Alanyloxy)Methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic Oh Group" *J Med Chem* 1996 vol. 39 pp. 10-18.
- Shan et al "Prodrug Strategies Based on Intramolecular Cyclization Reactions" *J Pharm Sci* 1997 vol. 86(7) pp. 765-767.
- Stahl et al *Handbook of Pharmaceutical Salts Properties Selection and Use Stahl and Wermuth Eds Wiley-Vch and Vha Zurich* 2002.
- Chen et al "Synthesis of 7-Phenylpyrimido(5,4,-*D*[1]Benzazepin-2-Ones (1)" *Heterocyclic Chem* 1983 vol. 20(3) pp. 663-666.
- Eiden et al "Amino-Naphto-Und Amino-Benzazepino-Chinoline" *Archiv Der Pharmazie* 1979 vol. 312(9) pp. 708-714.
- Hirota et al "Polycyclic N-Hetero Compounds. Xx1. Synthesis of Novel Ring System, 4h-Imidazo[1,2':1,6]Pyrimido[4,5-*D*] [1] Benzazepine as B-Homo-6,11,13,15-Tetraasteroidal Analogue" *Heterocycles* 1986 vol. 21(1) pp. 143-154.
- Hirota et al "Polycyclic N-Hetero Compounds. Xxvi¹. Synthesis of 4-Substituted 6,7-Dihydro-5h-Pyrimido-[5,4-*D*] [1] Benzazepine" *Heterocycles* 1986 Volume 24(7) pp. 1997-2002.
- Hirota et al "Polycyclic N-Hetero Compounds. Xxviii. Synthesis and Antidepressive Evaluation of 4-Substituted 9-Chloro-6-7-Dihydro-5-H-Pyrimido [5,4,*D*] [1] Benzazepine" *Heterocycles* 1986 vol. 24(11) pp. 3223-3228.
- Nagamatsu et al "Polycyclic N-Heterocyclic Compounds. Xli. Synthesis of 4-Substituted 6,7-Dihydro-5h-Pyrimido[5,4,*D*][1] Benzazepines, 1,2,5,6-Tetrahydro-4-H-Imidazo[1',2'. 1,6']pyrimido[5,4,*D*][1]Benzazepines and Their Related Compounds as a Series of Potential Blood Platelet Aggregation Inhibitors" *J Heterocyclic Chem* 1993 vol. 30(1) pp. 193-202.
- Nagamatsu et al "Polycyclic N-Hetero Compounds. Xliii. Syntheses and Properties of 2-Substituted 1-Acetoxy-6-Acetyl-5,6-Dihydro-4-H-Imidazo[1',2'. 1,6']Pyrimido[5,4,*D*][1]Benzazepines Via N[6,7-Dihydro-5h-Pyrimido[5,4,*D*]-1] Benzazepin-4-Yl]Amino Acids and Their Analogous Mesoionic Compounds, and Their Related Compounds as a Series of Potential Blood Platelet Aggregation Inhibitors" *J Heterocyclic Chem* 1993 vol. 30(1) pp. 233-240.
- Nagamatsu et al "Polycyclic N-Hetero Compounds. Xlii. Convenient Syntheses of 6,7-Dihydro-5hpyrido[2,3-*B*]Pyrimido[4,5-*D*]Azepine as a Novel Polyheterocyclic Ring System and Its 4-Substituted Derivatives" *J Synthesis* 1991 vol. 11 pp. 942-946.
- Proctor et al "Azabenzocycloheptenones. Part 19.¹ Formation of Some Heterocyclic Annulated Compounds From 1,2,3,4-Tetrahydro-1-Benzazepine Derivatives" *J Chem Society* 1978 vol. 8 pp. 862-870.
- Yamamoto et al "Seven-Membered N-Heterocycles. Xv. ¹ Ethyl 2-Phenyl-7-Pyrimido[4,5-*D*]Azepine-7-Carboxylate" *Heterocycles* 1978 vol. 11 pp. 275-280.
- Yamamoto et al "Seven Membered N-Heterocycles. Xiii ¹³ Rearrangement of 7-Benzyl-4-Hydroxy-6,7,8,9-Tetrahydro-5-H-Pyrimido[4,5-*D*]Azepine to 7-Benzyl-4-Vinyl-6,7-Dihydro..5h-Pyrrolo[2,3-*D*]Pyrimidines" *Bulletin of the Chemical Society of Japan* 1977 vol. 50(2) pp. 453-458.
- Yamamoto et al "Studies of Seven-Membered Heterocyclic Compounds Containing Nitrogen. X. Syntheses of 5,6,8,9-Tetrahydro-7-H-Pyrimido[4,5-*D*]Azepine" *Bulletin of the Chemical Society of Japan* 1971 vol. 44(1) pp. 153-158.
- Barton et al. "Attenuation of Experimental Arthritis in Trpv1r Knock-out Mice" *Exp Mol Pathol* 2006 vol. 81 pp. 166-170.
- Menendez et al "Analgesic Effects of Capsazepine and Resiniferatoxin on Bone Cancer Pain in Mice" *Neurosci Lett* 2006 vol. 393 pp. 70-73.
- Moore et al "Tnbs Ileitis Evokes Hyperexcitability and Changes in Ionic Membrane Properties of Nociceptive Drg Neurons" *Am J Physiol Gastrointest Liver Physiol* 2002 vol. 282 pp. G1045-G1051.
- Morris et al "Characterisation of Capsaicin-Induced Mechanical Hyperalgesia as a Marker for Altered Nociceptive Processing in Patients With Rheumatoid Arthritis" *Pain* 1997 vol. 71 pp. 179-186.
- Pomonis et al "N-(4-Tertiarybutylphenyl)-4-(3-Chlorophyridin-2-Yl)Tetrahydropyrazine-1(2*h*)-Carbox-Amide (Bctc), A Novel, Orally Effective Vanilloid Receptor 1 Antagonist With Analgesic Properties: Ii. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain" *J Pharmacol Exp Ther* 2003 vol. 306(1) pp. 387-393.
- Razavi et al "TRPV1+ Sensory Neurons Control β Cell Stress and Islet Inflammation in Autoimmune Diabetes" *Cell* 2006 vol. 127 pp. 1123-1135.
- Sanchez et al "Expression of the Transient Receptor Potential Vanilloid 1 (Trpv1) in Lncap and Pc-3 Prostate Cancer Cells and in Human Prostate Tissue" *Eur J Pharmacol* 2005 vol. 515 pp. 20-27.
- Sculptoreanu et al "Protein Kinase C Contributes to Abnormal Capsaicin Responses in Drg Neurons From Cats With Feline Interstitial Cystitis" *Neurosci Lett* 2005 vol. 381 pp. 42-46.
- Stucky et al "Bradykinin Increases the Proportion of Neonatal Rat Dorsal Root Ganglion Neurons That Respond to Capsaicin and Protons" *Neuroscience* 1998 vol. 84(4) pp. 1257-1265.
- Swanson et al "Identification and Biological Evaluation of 4-(3-Trifluoromethylpyridin-2-Yl)Piperazine-1-Carboxylic Acid (5-Trifluoromethylpyridin-2-Yl)Amide, A High Affinity Trpv1 (Vr1) Vanilloid Receptor Antagonist" *J Med Chem* 2005 vol. 48 pp. 1857-1872.
- Szabo et al "Role of Transient Receptor Potential Vanilloid 1 Receptors in Adjuvant-Induced Chronic Arthritis: In Vivo Study Using Gene-Deficient Mice" *J Pharmacol Exp Ther* 2005 vol. 314 pp. 111-119.
- Tominaga et al "Thermosensation and Pain" *J Neurobiol* 2004 vol. 61 pp. 3-12.
- Voets et al "The Principle of Temperature-Dependent Gating in Cold- and Heat-Sensitive Trp Channels" *Nature* 2004 vol. 430 pp. 748-754.
- Walker et al "The Vr1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain" *J Pharmacol Exp Ther* 2003 vol. 304 pp. 56-62.
- Yiangou et al "Vanilloid Receptor 1 Immunoreactivity in Inflamed Human Bowel" *Lancet et al* 2001 vol. 357 pp. 1338-1339.
- Zheng et al "Vanilloid Receptors in Hearing: Altered Cochlear Sensitivity by Vanilloids and Expression of Trpv1 in the Organ of Corti" *J Neurophys* 2003 vol. 90 pp. 444-455.
- Apostolidis et al. "Capsaicin Receptor Trpv1 in Urothelium of Neurogenic Human Bladders and Effect of Intravesical Resiniferatoxin" *Urology* 2005 vol. 65 pp. 400-405.
- Asai et al. "Heat and Mechanical Hyperalgesia in Mice Model of Cancer Pain" *Pain* 2005 vol. 117 pp. 19-29.

(56)

References Cited**OTHER PUBLICATIONS**

Balaban et al. "Type 1 Vanilloid Receptor Expression by Mammalian Inner Ear Ganglion Cells" *Hear Res* 2003 vol. 175 pp. 165-170.

Bodo et al. "A Hot New Twist to Hair Biology Involvement of Vanilloid Receptor-1 (Vr1/Trpv1) Signaling in Human Hair Growth Control" *Am J Pathol* 2005 vol. 166(4) pp. 985-998.

Bolcskei et al. "Investigation of the Role of Trpv1 Receptors in Acute and Chronic Nociceptive Processes Using Gene-Deficient Mice" *Pain* 2005 vol. 117 pp. 368-376.

Calkins et al Abstract "Trpv1 Channels Modulate Pressure-Induced Death of Retinal Ganglion Cells" From Arvo 2006 Annual Meeting Program #1557 Poster #B93.

Caterina et al "Vanilloid Receptors Take a Trp Beyond the Sensory Afferent" *Pain* 2003 vol. 105 pp. 5-9.

Caterina et al "The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway" *Annu Rev Neurosci* 2001 vol. 24 pp. 487-517.

Chan et al "Sensory Fibres Expressing Capsaicin Receptor Trpv1 in Patients With Rectal Hypersensitivity and Faecal Urgency" *Lancet* 2003 vol. 361 pp. 385-391.

Dinis et al "An Andamide-Evoked Activation of Vanilloid Receptor 1 Contributes to the Development of Bladder Hyperreflexia and Nociceptive Transmission to Spinal Dorsal Horn Neurons in Cystitis" *J Neurosci* 2004 vol. 24 pp. 11253-11253.

Geppetti et al "Activation and Sensitisation of the Vanilloid Receptor: Role in Gastrointestinal Inflammation and Function" *Br J Pharmacol* 2004 vol. 141 pp. 1313-1320.

Ghilardi et al "Selective Blockade of the Capsaicin Receptor Trpv1 Attenuates Bone Cancer Pain" *J Neurosci* 2005 vol. 25(12) pp. 3126-3131.

Goadsby Peter J. "Post-Triptan Era for The treatment of Acute Migraine" *Curr Pain Headache Reports* 2004 vol. 8 pp. 393-398.

Greiff et al "Effects of Topical Capsaicin in Seasonal Allergic Rhinitis" *Thorax* 1995 vol. 50 pp. 225-229.

Honore et al "A-425619 [1-Isoquinolin-5-Yl-3-(4-Trifluoromethyl-Benzyl)-Urea], A Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated With Inflammation and Tissue Injury in Rats" *J Pharmacol Exp Ther* 2005 vol. 314 pp. 410-421.

Iida et al "Attenuated Fever Response in Mice Lacking Trpv1" *Neurosci Lett* 2005 vol. 378 pp. 28-33.

Jancso-Gabor et al "Irreversible Impairment of Thermoregulation Induced by Capsaicin and Similar Pungent Substances in Rats and Guinea-Pigs" *J Physiol* 1970 vol. 206 pp. 495-507.

Kim et al "Histamine-Induced Ca²⁺ Influx Via the Pla₂/Lipoxygenase/Trpv1 Pathway in Rat Sensory Neurons" *Neurosci Lett* 2004 vol. 361 pp. 159-162.

Kimball et al "Vanilloid Receptor 1 Antagonists Attenuate Disease Severity in Dextran Sulphate Sodium-Induced Colitis in Mice" *Neurogastroenterol Motil* 2004 vol. 16 pp. 811-818.

Kwak et al "A Capsaicin-Receptor Antagonist, Capsazepine Reduces Inflammation-Induced Hyperalgesic Responses in the Rat: Evidence for an Endogenous Capsaicin-Like Substance" *Neuroscience* 1998 vol. 86(2) pp. 619-626.

Laloo et al "Capsazepine Inhibits Cough Induced by Capsaicin and Citric Acid But Not by Hypertonic Saline in Guinea Pigs" *J Appl Physiol* 1995 vol. 79(4) Gps 1082-1087.

Lazzeri et al "Immunohistochemical Evidence Of vanilloid Receptor 1 in Normal Human Urinary Bladder" *Eur Urology* 2004 vol. 46 pp. 792-798.

Marsch et al "Reduced Anxiety, Conditioned Fear, and Hippocampal Long-Term Potentiation in Transient Receptor Potential vanilloid Type 1 Receptor-Deficient Mice" *J Neurosci* 2007 vol. 27(4) pp. 832-839.

U.S. Appl. No. 60/705,719, filed Aug. 4, 2005, Dvorak et al.

1

TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. Ser. No. 11/726,756, filed on Mar. 21, 2007, and claims priority the benefit of United States Provisional Application No. 60/785,415, filed on Mar. 21, 2006. The complete disclosures of the aforementioned related U.S. patent applications are hereby incorporated herein by reference for all purposes.

FIELD OF THE INVENTION

The present invention relates to certain tetrahydro-pyrimidoazepine compounds, pharmaceutical compositions containing them, and methods of using them for the treatment of disease states, disorders, and conditions mediated by TRPV1 activity.

BACKGROUND OF THE INVENTION

Transient receptor potential (TRP) channel proteins constitute a large and diverse family of proteins that are expressed in many tissues and cell types. One TRP channel protein of particular interest is the vanilloid receptor 1 (TRPV1 or VR1), a non-selective Ca^{+2} channel that is the molecular target of vanilloid compounds (e.g., capsaicin and resiniferatoxin). Such vanilloid compounds are known to selectively depolarize nociceptors, specialized primary afferent neurons involved in the signaling pathway that leads to the sensation of pain. TRPV1 is activated by a diverse range of stimuli, including vanilloids, membrane depolarization, heat, stretch, low pH, inflammatory mediators (e.g., lipoxygenase metabolites), and endocannabinoid compounds. Because heightened activity of nociceptors contributes to unwanted pain, inflammatory conditions, thermoregulation, and control of smooth muscle tone and reflexes in mammals, modulation of signaling in this pathway is important in treatment and prophylaxis of various clinical syndromes (Caterina, M. J., *Pain* 2003, 105(1-2), 5-9; Caterina, M. J. et al., *Annu. Rev. Neurosci.* 2001, 24, 487-517; Tominaga, M. et al., *J. Neurobiol.* 2004, 61, 3-12; Voets, T. et al., *Nature* 2004, 430, 748-754).

Because of TRPV1's connection with the sensory nervous system, TRPV1 agonists and antagonists may be therapeutically useful in the treatment or prophylaxis of disease states, disorders, and conditions mediated by TRPV1 activity, such as: i) pain (e.g., acute, chronic, inflammatory, or neuropathic pain); ii) itch (Kim et al., *Neurosci. Lett.* 2004, 361, 159) and various inflammatory disorders (Stucky, C. L. et al., *Neuroscience* 1998, 84, 1257; Moore, B. A. et al., *Am. J. Physiol. Gastrointest. Liver Physiol.* 2002, 282, G1045; Kwak, J. Y. et al., *Neuroscience* 1998, 86, 619; Morris, V. H. et al., *Pain* 1997, 71, 179; Greiff, L. et al., *Thorax* 1995, 50, 225); iii) inner ear disorders (Balaban, C. D. et al., *Hear. Res.* 2003, 175, 165-70; Zheng, J. et al., *J. Neurophys.* 2003, 90, 444-55); iv) fever and other disorders or symptoms affected by thermoregulation (Jancso-Gabor et al., *J. Physiol.* 1970, 206, 495; Swanson et al., *J. Med. Chem.* 48, 1857; Iida et al., *Neurosci. Lett.* 2005, 378, 28); v) tracheobronchial and diaphragmatic dysfunction; and vi) gastrointestinal and urinary tract disorders (Lazzeri, M. et al., *Eur. Urology* 200, 792-798; Apostolidis, A. et al., *Urology* 2005, 65, 400-405). Additionally, TRPV1 modulators may be therapeutically useful in the treatment or prophylaxis of anxiety (Marsch, R. et al., *J. Neurosci.* 2007, 27(4), 832-839); eye-related disorders (such as glau-

2

coma, vision loss, and increased intraocular pressure) (Calkins, D. J. et al., *Abstract from ARVO 2006 Annual Meeting*, Program #1557, Poster #B93); baldness (e.g., by stimulating hair growth) (Bodo, E. et al., *Am. J. Pathol.* 2005, 166(4), 985-998); diabetes (including insulin-resistant diabetes or diabetic conditions mediated by insulin sensitivity or secretion) (Razavi, R. et al., *Cell* 2006, 127(6), 1097-1099; Akiba, Y. et al., *Biochem. Biophys. Res. Commun.* 2004, 321(1), 219-225).


Acidosis is a well-established feature of cerebral ischaemia. Tissue pH may fall to 6 or lower, sufficient to activate TRPV1 channels expressed in the CNS. TRPV1 antagonists therefore may be useful in the treatment of disorders associated with reduced blood flow to the CNS or CNS hypoxia, such as head trauma, spinal injury, thromboembolic or hemorrhagic stroke, transient ischaemic attacks, cerebral vasospasm, hypoglycaemia, cardiac arrest, status epilepticus, perinatal asphyxia, Alzheimer's disease, and Huntington's Disease.

International Publication No. WO05/014558 (Feb. 17, 2005) describes certain aminopyrimidine inhibitors of voltage-gated sodium and potassium channel. Various bicyclic pyrimidines are disclosed as serotonin receptor modulators in U.S. patent application Ser. No. 11/460,294, filed Jul. 27, 2006. Condensed pyrimidine compounds are disclosed as inhibitors of voltage-gated ion channels in Intl. Publication No. WO 05/014558. Various bicyclic pyrimidines are also disclosed in Intl. Publication No. WO 05/066171 and U.S. Patent Appl. Publ. 2005/0165032 as inhibitors of the TRPV1 channel. However, there remains a need for potent TRPV1 modulators with desirable pharmaceutical properties.

SUMMARY OF THE INVENTION

Certain tetrahydro-pyrimidoazepine derivatives have now been found to have TRPV1-modulating activity. Thus, the invention is directed to the general and preferred embodiments defined, respectively, by the independent and dependent claims appended hereto, which are incorporated by reference herein.

Thus, in one general aspect the invention relates to compounds of the following Formula (I):



(I)

wherein:

R^1 is —H; — NR^aR^b ; —OH; a — C_{1-6} alkyl, — OC_{1-6} alkyl, —O-(saturated monocyclic cycloalkyl), — OC_{1-6} alkyl-(saturated monocyclic cycloalkyl), —O-(saturated monocyclic heterocycloalkyl), —O-phenyl, —O-benzyl, —S— C_{1-6} alkyl, —S-(saturated monocyclic cycloalkyl), — SC_{1-6} alkyl-(saturated monocyclic cycloalkyl), —S-(saturated monocyclic heterocycloalkyl), —S-phenyl, —S-benzyl, or — SO_2 — C_{1-6} alkyl group unsubstituted or substituted with one or two moieties independently selected from the group consisting of — C_{1-6} alkyl, —OH, — OC_{1-6} alkyl,

3

—NR^eR^f, and halo substituents; or a phenyl, monocyclic cycloalkyl, or monocyclic heteroaryl group unsubstituted or substituted with a —C₁₋₆alkyl, —OH, —OC₁₋₄alkyl, —NR^eR^f, or halo substituent;

where R^a and R^b are each independently —H; —C₁₋₆alkyl; a —C₂₋₃alkyl group substituted with a —OH, —OC₁₋₄alkyl, —NR^cR^d, or halo substituent; or a saturated monocyclic cycloalkyl, —C₁alkyl-(saturated monocyclic cycloalkyl), saturated monocyclic heterocycloalkyl, —C₁alkyl-(saturated monocyclic heterocycloalkyl), phenyl, benzyl, or —C₁alkyl-(monocyclic heteroaryl) group unsubstituted or substituted with one, two, or three moieties independently selected from the group consisting of —C₁₋₆alkyl, —OH, —OC₁₋₄alkyl, —NR^pR^q, and halo substituents; or

R^a and R^b taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl or bridged bicyclic heterocycloalkyl group unsubstituted or substituted with one, two, or three moieties independently selected from the group consisting of —C₁₋₆alkyl, —C₁₋₄alkyl-OH, —C₁₋₂alkyl-OC₁₋₂alkyl, —OH, —OC₁₋₄alkyl, —NR^pR^q, halo, —CO₂H, and benzyl substituents;

where R^c and R^d are each independently —H or —C₁₋₆alkyl; or R^c and R^d taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl;

where R^p and R^q are each independently —H or —C₁₋₆alkyl; or R^p and R^q taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl;

where R^e and R^f are each independently —H or —C₁₋₆alkyl; or R^e and R^f taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl;

R² is —H or —C₁₋₆alkyl;

R³ is a monocyclic cycloalkyl, phenyl, benzyl, phenethyl, indanyl, thiazolyl, thiophenyl, pyridyl, pyridylmethyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, or tetrahydroisoquinolinyl group unsubstituted or substituted with one, two, or three R^g substituents;

where each R^g substituent is —C₁₋₆alkyl; —C₁₋₄alkyl-OH unsubstituted or substituted with —CF₃; saturated monocyclic cycloalkyl; —OH; —OC₁₋₆alkyl; phenoxy; —CN; —NO₂; —N(R^h)Rⁱ; —C₁₋₄alkyl-N(R^h)Rⁱ; —C(O)N(R^h)Rⁱ; —N(R^h)C(O)Rⁱ; —N(R^h)SO₂C₁₋₆alkyl; —C(O)C₁₋₆alkyl; —S(O)₀₋₂—C₁₋₆alkyl; —SO₂CF₃; —SO₂N(R^h)Rⁱ; —SCF₃; halo; —CF₃; —OCF₃; —CO₂H; —CO₂C₁₋₆alkyl; —C(R^j)(R^k)—CN; —C(R^j)(R^k)—OH; —C(R^j)(R^k)—CO₂C₁₋₆alkyl; —C(R^j)(R^k)—CO₂H; —C(R^j)(R^k)—C(O)N(R^h)Rⁱ; phenyl; or monocyclic heteroaryl; or two adjacent R^g substituents taken together form —OC₁₋₂alkylO—;

where R^h and Rⁱ are each independently —H or —C₁₋₆alkyl; or R^h and Rⁱ (when both are present) taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl group;

R^j is independently —H, —C₁₋₆alkyl, or —CF₃;

R^k is —H or —C₁₋₆alkyl; or R^j and R^k taken together with the carbon to which they are attached form a monocyclic cycloalkyl ring;

and

Ar is a phenyl, pyridyl, imidazolyl, pyrimidinyl, pyridazinyl, or fused-bicyclic heteroaryl group unsubstituted or substituted with one, two, or three R^k substituents;

4

where each R^k substituent is independently —C₁₋₆alkyl, —C₁₋₂alkyl-OH, —OH, —OC₁₋₆alkyl, phenoxy, —CN, —NO₂, —N(R^l)R^m, —C(O)N(R^l)R^m, —N(R^l)C(O)R^m, —N(R^l)SO₂C₁₋₆alkyl, —N(R^l)SO₂CF₃, —C(O)C₁₋₆alkyl, —S(O)₀₋₂—C₁₋₆alkyl, —SO₂CF₃, —SO₂N(R^l)R^m, —SCF₃, halo, —CF₃, —OCF₃, —CO₂H, or —CO₂C₁₋₆alkyl; or two adjacent R^k substituents taken together form —OC₁₋₂alkylO—;

where R^l and R^m are each independently —H, —C₁₋₆alkyl, saturated monocyclic cycloalkyl, or —CF₃.

The invention also relates to pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of compounds of Formula (I). In certain preferred embodiments, the compound of Formula (I) is a compound selected from those species described or exemplified in the detailed description below.

In a further general aspect, the invention relates to pharmaceutical compositions each comprising: (a) an effective amount of an agent selected from compounds of Formula (I) and pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites thereof; and (b) a pharmaceutically acceptable excipient.

In another general aspect, the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by TRPV1 activity, comprising administering to the subject in need of such treatment an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of such compound. In certain preferred embodiments of the inventive method, the disease, disorder, or medical condition is selected from: pain (acute, chronic, inflammatory, or neuropathic pain); itch or various inflammatory disorders; inner ear disorders; fever and other conditions or disorders of thermoregulation; tracheobronchial and diaphragmatic dysfunction; gastrointestinal and urinary tract disorders; and disorders associated with reduced blood flow to the CNS or CNS hypoxia.

Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.

DETAILED DESCRIPTION OF INVENTION AND ITS PREFERRED EMBODIMENTS

The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples. For the sake of brevity, the disclosures of the publications, including patents, cited in this specification are herein incorporated by reference.

As used herein, the terms “including”, “containing” and “comprising” are used herein in their open, non-limiting sense.


The term “alkyl” refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. Exemplary alkyl groups include methyl (Me, which also may be structurally depicted by a / symbol), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like.

The term “alkenyl” refers to a straight- or branched-chain alkenyl group having from 2 to 12 carbon atoms in the chain. (The double bond of the alkenyl group is formed by two sp² hybridized carbon atoms.) Illustrative alkenyl groups include prop-2-enyl, but-2-enyl, but-3-enyl, 2-methylprop-2-enyl, hex-2-enyl, and the like.

The term “cycloalkyl” refers to a saturated or partially saturated, monocyclic, fused polycyclic, or bridged polycy-


5

clic carbocycle having from 3 to 12 ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following moieties:




and the like.

A "heterocycloalkyl" refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated or partially saturated and has from 3 to 12 ring atoms per ring structure selected from carbon atoms and up to three heteroatoms selected from nitrogen, oxygen, and sulfur. The ring structure may optionally contain up to two oxo groups on carbon or sulfur ring members. Illustrative examples of heterocycloalkyl groups include:




6

-continued



and the like.

The term "heteroaryl" refers to a monocyclic, fused bicyclic, or fused polycyclic aromatic heterocycle (ring structure having ring atoms selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen, and sulfur) having from 3 to 12 ring atoms per heterocycle. Illustrative examples of heteroaryl groups include the following moieties:



and the like.

Those skilled in the art will recognize that the species of cycloalkyl, heterocycloalkyl, and heteroaryl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.

The term "halogen" represents chlorine, fluorine, bromine or iodine. The term "halo" represents chloro, fluoro, bromo or iodo.

The term "substituted" means that the specified group or moiety bears one or more substituents. The term "unsubsti-

tuted" means that the specified group bears no substituents. The term "optionally substituted" means that the specified group is unsubstituted or substituted by one or more substituents. Where the term "substituted" is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. In cases where a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted.

Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula. Thus, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof.

Furthermore, certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers. Additionally, any formula given herein is intended to embrace hydrates, solvates, and polymorphs of such compounds, and mixtures thereof.

Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , ^{36}Cl , ^{125}I , respectively. Such isotopically labeled compounds are useful in metabolic studies (preferably with ^{14}C), reaction kinetic studies (with, for example ^2H or ^3H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an ^{18}F or ^{11}C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., ^2H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the moiety for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula.

In preferred embodiments of agents of Formula (I), R^1 is $-\text{H}$ or $-\text{OH}$. In further preferred embodiments, R^1 is isopropyl or cyclopropyl. In further preferred embodiments, R^1 is a $-\text{O}-(\text{saturated monocyclic cycloalkyl})$, $-\text{OC}_1\text{alkyl}-(\text{saturated monocyclic cycloalkyl})$, $-\text{O}-(\text{saturated monocyclic heterocycloalkyl})$, $-\text{O-phenyl}$, or $-\text{O-benzyl}$ group unsubstituted or substituted with one or two moieties inde-

pendently selected from the group consisting of methyl, ethyl, and isopropyl substituents. In further preferred embodiments, R^1 is a $-\text{S}-\text{C}_{1-6}\text{alkyl}$, $-\text{S}-(\text{saturated monocyclic cycloalkyl})$, $-\text{SC}_1\text{alkyl}-(\text{saturated monocyclic cycloalkyl})$, $-\text{S}-(\text{saturated monocyclic heterocycloalkyl})$, $-\text{S-phenyl}$, or $-\text{S-benzyl}$ group unsubstituted or substituted with a methyl, ethyl, or isopropyl substituent. In further preferred embodiments, R^1 is methylsulfanyl or methylsulfonyl. In further preferred embodiments, R^1 is a monocyclic heteroaryl group unsubstituted or substituted with a methyl substituent. In further preferred embodiments, R^1 is a furanyl, thiophenyl, thiazolyl, or pyridyl group unsubstituted or substituted with a methyl substituent.

In preferred embodiments, R^a and R^b are each independently $-\text{H}$; methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl; an ethyl or propyl group substituted with an $-\text{OC}_{1-4}\text{alkyl}$ or $-\text{NR}^c\text{R}^d$ substituent; or a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, aziridinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-1 λ^6 -thiomorpholin-4-yl, phenyl, or furanylmethyl group unsubstituted or substituted with a methyl or methoxy substituent. In further preferred embodiments, R^a and R^b are each independently $-\text{H}$, methyl, isopropyl, methoxyethyl, cyclopropyl, cyclohexyl, cyclopropylmethyl, 2-piperidin-1-yl-ethyl, or 2-dimethylamino-ethyl. In further preferred embodiments, R^a and R^b taken together with their nitrogen of attachment form an aziridinyl, pyrrolidinyl, piperidinyl, 2-oxo-piperidin-1-yl, piperazinyl, oxo-piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-1 λ^6 -thiomorpholin-4-yl, 1,1-dioxo-1 λ^6 -[1,2]thiazinan-2-yl, azepanyl, 1,4-oxazepanyl, or 7-azabicyclo[2.2.1]hept-7-yl group unsubstituted or substituted with a $-\text{C}_{1-6}\text{alkyl}$, hydroxymethyl, hydroxyethyl, methoxymethyl, methoxyethyl, fluoro, $-\text{OH}$, or $-\text{CO}_2\text{H}$ substituent.

In preferred embodiments, R^c and R^d taken together with their nitrogen of attachment form piperidinyl, morpholinyl, or pyrrolidinyl.

In preferred embodiments, R^3 is a monocyclic cycloalkyl, pyridylmethyl, benzothiadiazolyl, tetrahydroquinolinyl, or tetrahydroisoquinolinyl group unsubstituted or substituted with one, two, or three R^8 substituents. In further preferred embodiments, R^3 is a 2-pyridyl group unsubstituted or substituted with one or two R^8 substituents. In further preferred embodiments, R^3 is a 2-pyridyl group unsubstituted or substituted with one or two R^8 substituents. In further preferred embodiments, R^3 is a 3-pyridyl group unsubstituted or substituted with one R^8 substituent.

In preferred embodiments, each R^8 substituent is independently methyl, isopropyl, tert-butyl, $-\text{CF}_3$, fluoro, chloro, bromo, $-\text{OCF}_3$, $-\text{SO}_2\text{NH}_2$, $-\text{OCH}_3$, phenoxy, $-\text{C}(\text{CH}_3)_2-\text{CN}$, $-\text{C}(\text{CH}_3)_2-\text{OH}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{NH}_2$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{SO}_2\text{CF}_3$, $-\text{SCF}_3$, $-\text{CON}(\text{CH}_3)_2$, $-\text{CO}_2\text{H}$, phenyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, $-\text{SCH}_3$, oxazolyl, $-\text{SO}_2-(\text{pyrrolidinyl})$, $-\text{SO}_2\text{N}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-\text{CO}_2\text{CH}_3$, $-\text{C}(\text{CH}_3)_2-\text{CO}_2\text{H}$, 1-hydroxyethyl, 2-hydroxy-1,1-dimethyl-ethyl, 3,3,3-trifluoro-1-hydroxy-propyl, 3,3,3-trifluoro-1-hydroxy-1-methyl-propyl, or $-\text{SO}_2\text{CH}_3$; or two adjacent R^8 substituents taken together form $-\text{OC}_{1-2}\text{alkylO}-$. In further preferred embodiments, each R^8 substituent is independently methyl, isopropyl, tert-butyl, fluoro, $-\text{CF}_3$, chloro, $-\text{C}(\text{CH}_3)_2-\text{CN}$, $-\text{C}(\text{CH}_3)_2-\text{OH}$, $-\text{C}(\text{CH}_3)_2-\text{CH}_2\text{OH}$, $-\text{C}(\text{CH}_3)_2-\text{CO}_2\text{H}$, acetyl, $-\text{SO}_2\text{CH}_3$, or $-\text{SO}_2\text{CF}_3$.

In preferred embodiments, R^h and R^i taken together with their nitrogen of attachment form pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl.

In preferred embodiments, R^j is —H, methyl, or —CF₃. In preferred embodiments, R^k is —H or methyl. In further preferred embodiments, R^j and R^k taken together with the carbon to which they are attached form a cyclopropyl ring.

In preferred embodiments, Ar is 2-pyridyl substituted with —CF₃. In further preferred embodiments, Ar is 2-pyridyl substituted with —Cl, —Br, —F, methyl, —SO₂CH₃, or —SO₂CH₂CH₃. In further preferred embodiments, Ar is 2-pyridyl, substituted with one or two R^k substituents independently selected from the group consisting of: —CF₃, fluoro, chloro, bromo, —SO₂CH₃, —NH₂, —NO₂, —CO₂CH₃, —NHSO₂CH₃, —CN, —CONH₂, —SO₂CH₂CH₃, —SO₂NH₂, —SO₂NH-cyclopropyl, —SO₂NH-isopropyl, —CO₂H, —CH₂OH, and methyl.

In preferred embodiments, R^l and R^m are each independently —H, methyl, ethyl, isopropyl, —CF₃, or cyclopropyl.

In preferred embodiments, R^1 is —H. In other preferred embodiments, R^1 is —NR^aR^b, and R^a and R^b are as previously defined. In further preferred embodiments, R^1 is a —C₁₋₆alkyl group unsubstituted or substituted with a —OH, —OC₁₋₄alkyl, —NR^eR^f, or halo substituent, and R^e and R^f are as previously defined. In further preferred embodiments, R^1 is methyl or isopropyl. In still further preferred embodiments, R^1 is a methyl group substituted with a —OC₁₋₄alkyl or —NR^eR^f substituent, and R^e and R^f are as previously defined. In further preferred embodiments, R^1 is methoxymethyl or piperidinylmethyl. In other preferred embodiments, R^1 is methoxy, methylsulfanyl, or methylsulfonyl. In additional preferred embodiments, R^1 is cyclopropyl.

In preferred embodiments, R^a and R^b are each independently —H; methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl; an ethyl or propyl group substituted with an —OC₁₋₄alkyl or —NR^eR^f substituent; or a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropylmethyl, cyclopentylmethyl, aziridinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranal, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-1λ⁶-thiomorpholin-4-yl, or phenyl group unsubstituted or substituted with a —C₁₋₆alkyl, —OC₁₋₄alkyl, or halo substituent; and R^c and R^d are as previously defined. In other preferred embodiments, R^a and R^b are each independently —H, methyl, methoxyethyl, cyclopropyl, cyclopropylmethyl, 2-piperidin-1-yl-ethyl, or 2-dimethylamino-ethyl. Alternatively, R^a and R^b taken together with their nitrogen of attachment form an aziridinyl, pyrrolidinyl, piperidinyl, 2-oxo-piperidin-1-yl, piperazinyl, oxo-piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-1λ⁶-thiomorpholin-4-yl, 1,1-dioxo-1λ⁶-[1,2]thiazinan-2-yl, or azepanyl group unsubstituted or substituted with a —C₁₋₆alkyl, —OH, or —CO₂H substituent.

In preferred embodiments, R^c and R^d are each independently —H, methyl, or ethyl. Alternatively, R^c and R^d taken together with their nitrogen of attachment form piperidinyl.

In preferred embodiments, R^p and R^q are each independently —H, methyl, or ethyl.

In preferred embodiments, R^e and R^f are each independently —H, methyl, or ethyl.

Preferably, R^2 is —H or methyl; more preferably, R^2 is —H.

Preferably, R^3 is a phenyl, pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, or isoquinolinyl group unsubstituted or substituted with one or two R^g substituents, and each R^g substituent is as previously defined. In further preferred embodiments, R^3 is a pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, or isoquino-

linyl group unsubstituted or substituted with one or two R^g substituents, and each R^g substituent is as previously defined. In additional preferred embodiments, R^3 is a pyridyl, thiazolyl, or pyridazinyl group unsubstituted or substituted with one or two R^g substituents, and each R^g substituent is as previously defined. In still further preferred embodiments, R^3 is a phenyl group substituted with one or two R^g substituents, and each R^g substituent is as previously defined. In still further preferred embodiments, R^3 is a benzyl or phenethyl group unsubstituted or substituted with one or two R^g substituents, and each R^g substituent is as previously defined. In still further preferred embodiments, R^3 is a 2-pyridyl group unsubstituted or substituted with one R^g substituent, and R^g substituent is as previously defined.

Preferably, each R^g substituent is —C₁₋₆alkyl, —OH, —OC₁₋₆alkyl, phenoxy, —CN, —NO₂, —N(R^h)Rⁱ, —C(O)N(R^h)Rⁱ, —N(R^h)C(O)Rⁱ, —N(R^h)SO₂C₁₋₆alkyl, —C(O)C₁₋₆alkyl, —S(O)₀₋₂C₁₋₆alkyl, —SO₂CF₃, —SO₂N(R^h)Rⁱ, —SCF₃, halo, —CO₂H, —CO₂C₁₋₆alkyl, —C(R^j)₂—CN, or —C(R^j)₂—OH, and R^h , R^i , and R^j are as previously defined. Alternatively, two adjacent R^g moieties taken together form —OC₁₋₂alkylO—. In further preferred embodiments, each R^g substituent is isopropyl, tert-butyl, —CF₃, chloro, —OCF₃, —SO₂NH₂, —OCH₃, phenoxy, bromo, —C(CH₃)₂—CN, —C(CH₃)₂—OH, —NO₂, —CN, —NH₂, —C(O)CH₃, —SO₂CF₃, or —SCF₃; or two adjacent R^g substituents taken together form —OC₁₋₂alkylO—. In still further preferred embodiments, each R^g substituent is isopropyl, tert-butyl, —CF₃, chloro, —C(CH₃)₂—CN, —C(CH₃)₂—OH, or —SO₂CF₃.

In preferred embodiments, R^h and R^i are each independently —H, methyl, or ethyl.

In preferred embodiments, R^j is —H, methyl, or ethyl.

In preferred embodiments, Ar is a phenyl group unsubstituted or substituted with one or two R^k substituents, and each R^k substituent is as previously defined. In further preferred embodiments, Ar is a phenyl group substituted with a —NO₂, —N(R^j)R^m, —C(O)N(R^j)R^m, —N(R^j)C(O)R^m, —N(R^j)SO₂C₁₋₆alkyl, —N(R^j)SO₂CF₃, —SO₂CH₃, or —SO₂CF₃ substituent, and R^j and R^m are as previously defined. In still further preferred embodiments, Ar is a fused-bicyclic heteroaryl group unsubstituted or substituted with one or two R^k substituents, and each R^k substituent is as previously defined. In still further preferred embodiments, Ar is 2-pyridyl substituted with —CF₃, —NO₂, or —N(R^j)R^m, and R^j and R^m are as previously defined. In still further preferred embodiments, Ar is 2-pyridyl substituted with —Cl, —Br, methyl, or —SO₂CH₃. In still further preferred embodiments, Ar is quinolinyl or phthalizinyl. In still further preferred embodiments, Ar is a phenyl, pyridyl, pyrimidinyl, or fused-bicyclic heteroaryl group substituted on a carbon ring atom at a position ortho to the point of attachment with an R^k substituent, and the R^k substituent is as previously defined.

In preferred embodiments, each R^k substituent is —C₂₋₆alkyl, —OH, phenoxy, —CN, —NO₂, —N(R^j)R^m, —C(O)N(R^j)R^m, —N(R^j)C(O)R^m, —N(R^j)SO₂C₁₋₆alkyl, —N(R^j)SO₂CF₃, —C(O)C₁₋₆alkyl, —S(O)₀₋₂C₁₋₆alkyl, —SO₂CF₃, —SO₂N(R^j)R^m, —SCF₃, —OCF₃, —CO₂H, or —CO₂C₁₋₆alkyl; or two adjacent R^k substituents taken together form —OC₁₋₂alkylO—; and R^j and R^m are as previously defined. In still further preferred embodiments, each R^k substituent is —N(R^j)R^m, —NO₂, —N(R^j)SO₂CF₃, or —N(R^j)SO₂CH₃, and R^j and R^m are as previously defined.

In preferred embodiments, R^l and R^m are each independently —H, methyl, ethyl, or —CF₃.

Further preferred embodiments of the present invention include compounds of Formula (I) wherein:

a) R^1 is $-H$, $-NR^aR^b$, $-C_{1-6}alkyl$, $-O-C_{1-6}alkyl$, $-S-C_{1-6}alkyl$, $-SO_2-C_{1-6}alkyl$, $-CH_2-O-C_{1-4}alkyl$, or $-CH_2-NR^eR^f$; R^2 is $-H$; R^3 is a pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, or isoquinolinyl group unsubstituted or substituted with one or two R^g substituents; and Ar is a phenyl group substituted with one or two R^k substituents; and R^a , R^b , R^e , R^f , R^g , and R^k are as previously defined; or

b) R^1 is $-H$, $-NR^aR^b$, $-C_{1-6}alkyl$, $-O-C_{1-6}alkyl$, $-S-C_{1-6}alkyl$, $-SO_2-C_{1-6}alkyl$, $-CH_2-O-C_{1-4}alkyl$, or $-CH_2-NR^eR^f$; R^2 is $-H$; R^3 is a benzyl, phenethyl, indanyl, pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, or isoquinolinyl group unsubstituted or substituted with one or two R^g substituents; and Ar is a phenyl group substituted with one or two R^k substituents, where each R^k substituent is $-C_{2-6}alkyl$, $-OH$, phenoxy, $-CN$, $-NO_2$, $-N(R^i)R^m$, $-C(O)N(R^i)R^m$, $-N(R^i)C(O)R^m$, $-N(R^i)SO_2C_{1-6}alkyl$, $-N(R^i)SO_2CF_3$, $-C(O)C_{1-6}alkyl$, $-S(O)_{0-2}C_{1-6}alkyl$, $-SO_2CF_3$, $-SO_2N(R^i)R^m$, $-SCF_3$, $-OCF_3$, $-CO_2H$, or $-CO_2C_{1-6}alkyl$; or two adjacent R^k substituents taken together form $-OC_{1-2}alkylO-$; and R^a , R^b , R^e , R^f , R^g , R^i , and R^m are as previously defined; or

c) R^1 is $-H$, $-NR^aR^b$, $-C_{1-6}alkyl$, $-O-C_{1-6}alkyl$, $-S-C_{1-6}alkyl$, $-SO_2-C_{1-6}alkyl$, $-CH_2-O-C_{1-4}alkyl$, or $-CH_2-NR^eR^f$; R^2 is $-H$; R^3 is a benzyl or phenethyl group unsubstituted or substituted with one or two R^g substituents; and Ar is 2-pyridyl substituted with $-CF_3$, $-NO_2$, or $-N(R^i)R^m$; and R^a , R^b , R^e , R^f , R^g , R^i , and R^m are as previously defined; or

d) R^1 is $-C_{1-6}alkyl$; R^2 is $-H$; R^3 is a phenyl, pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, or isoquinolinyl group unsubstituted or substituted with one or two R^g substituents; and Ar is a phenyl, pyridyl, pyrimidinyl, or fused-bicyclic heteroaryl group unsubstituted or substituted with one or two R^k substituents; and R^g and R^k are as previously defined; or

e) R^1 is $-H$, $-NR^aR^b$, $-C_{1-6}alkyl$, $-O-C_{1-6}alkyl$, $-S-C_{1-6}alkyl$, $-SO_2-C_{1-6}alkyl$, $-CH_2-O-C_{1-4}alkyl$, or $-CH_2-NR^eR^f$; R^2 is $-H$; R^3 is a phenyl, benzyl, phenethyl, indanyl, pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, or isoquinolinyl group unsubstituted or substituted with one or two R^g substituents; and Ar is a fused-bicyclic heteroaryl group unsubstituted or substituted with one or two R^k substituents; and R^a , R^b , R^e , R^f , R^g , and R^k are as previously defined; or

f) R^1 is $-NR^aR^b$; R^2 is $-H$; R^3 is a phenyl group substituted with one or two R^g substituents, where each R^g substituent is $-C_{1-6}alkyl$, $-OH$, $-OC_{1-6}alkyl$, phenoxy, $-CN$, $-NO_2$, $-N(R^h)R^i$, $-C(O)N(R^h)R^i$, $-N(R^h)C(O)R^i$, $-N(R^h)SO_2C_{1-6}alkyl$, $-C(O)C_{1-6}alkyl$, $-S(O)_{0-2}C_{1-6}alkyl$, $-SO_2CF_3$, $-SO_2N(R^h)R^i$, $-SCF_3$, halo, $-CO_2H$, $-CO_2C_{1-6}alkyl$, $-C(R^j)_2-CN$, or $-C(R^j)_2-OH$; or two adjacent R^g substituents taken together form $-OC_{1-2}alkylO-$; and Ar is a phenyl, pyridyl, pyrimidinyl, or fused-bicyclic heteroaryl group unsubstituted or substituted with one or two R^k substituents; and R^a , R^b , R^h , R^i , R^j , and R^k are as previously defined; or

g) R^1 is $-NR^aR^b$; R^2 is $-H$; R^3 is a phenyl, benzyl, phenethyl, indanyl, pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, or isoquinolinyl group unsubstituted or substituted with one or two R^g substituents; and Ar is a phenyl group unsubstituted or substituted with one or two R^k substituents; and R^a , R^b , R^g , and R^k are as previously defined.

The invention includes also pharmaceutically acceptable salts of the compounds represented by Formula (I), preferably

of those described above. Pharmaceutically acceptable salts of the specific compounds exemplified herein are especially preferred.

A "pharmaceutically acceptable salt" is intended to mean a salt of a free acid or base of a compound represented by Formula (I) that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, S. M. Berge et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66:1-19, and *Handbook of Pharmaceutical Salts, Properties, Selection, and Use*, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. A compound of Formula (I) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. Exemplary pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrate, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrate, citrates, lactates, γ -hydroxybutyrate, glycolates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

If the compound of Formula (I) contains a basic nitrogen, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an α -hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a sulfonic acid, such as laurylsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, or ethanesulfonic acid, or the like.

If the compound of Formula (I) is an acid, such as a carboxylic acid or sulfonic acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, or alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

In preferred embodiments, the present invention relates to compounds of Formula (I) and to sulfate, hydrochloride, fumarate, tartrate, phosphate, methanesulfonic acid (mesylate), benzenesulfonic acid (besylate), and p-toluenesulfonic acid (tosylate) salts thereof.

The invention also relates to treatment methods employing pharmaceutically acceptable prodrugs of the compounds of Formula (I). The term "prodrug" means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (I)). A "pharmaceutically acceptable prodrug" is a prodrug that is not toxic, biologically intolerable, or otherwise biologically unsuitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of a compound of Formula (I). Examples of amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.

Additional types of prodrugs may be produced, for instance, by derivatizing free carboxyl groups of structures of Formula (I) as amides or alkyl esters. Exemplary amides include those derived from ammonia, primary C_{1-6} alkyl amines and secondary di(C_{1-6} alkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyl or heteroaryl ring moieties. Preferred amides are derived from ammonia, C_{1-3} alkyl primary amines, and di(C_{1-2} alkyl) amines. Exemplary esters of the invention include C_{1-7} alkyl, C_{5-7} cycloalkyl, phenyl, and phenyl(C_{1-6} alkyl) esters. Preferred esters include methyl esters. Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in *Adv. Drug Delivery Rev.* 1996, 19, 115. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs. Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs. Prodrugs of this type may be prepared as described in *J. Med. Chem.* 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphoramides. All of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.

Pharmaceutically active metabolites may also be used in the methods of the invention. A "pharmaceutically active metabolite" means a pharmacologically active product of metabolism in the body of a compound of Formula (I) or salt thereof. Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini et al., *J. Med. Chem.* 1997, 40, 2011-2016; Shan et al., *J. Pharm. Sci.* 1997, 86 (7), 765-767;

Bagshawe, *Drug Dev. Res.* 1995, 34, 220-230; Bodor, *Adv. Drug Res.* 1984, 13, 224-331; Bundgaard, *Design of Prodrugs* (Elsevier Press, 1985); and Larsen, *Design and Application of Prodrugs, Drug Design and Development* (Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, 1991).

The compounds of Formula (I) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites (collectively, "agents") of the present invention are useful as TRPV1 modulators in the methods of the invention. The agents may be used in the inventive methods for the treatment or prevention of medical conditions, diseases, or disorders mediated through modulation of TRPV1, such as those described herein. Symptoms or disease states are intended to be included within the scope of "medical conditions, disorders, or diseases."

Accordingly, the invention relates to methods of using the pharmaceutical agents described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated through TRPV1 activity, such as: i) pain (acute, chronic, inflammatory, or neuropathic pain); ii) itch or various inflammatory disorders; iii) inner ear disorders; iv) fever and other disorders of thermoregulation; v) tracheobronchial and diaphragmatic dysfunction; vi) gastrointestinal and urinary tract disorders; and vii) disorders associated with reduced blood flow to the CNS or CNS hypoxia.

In a preferred embodiment, an agent of the present invention is administered to treat pain. Pain may be associated with various diseases, disorders, or conditions, and may include various etiologies. Exemplary types of pain treatable with a TRPV1-modulating agent according to the invention include pain arising from or caused by: osteoarthritis, rotator cuff disorders, arthritis (e.g., rheumatoid arthritis or inflammatory arthritis), fibromyalgia, migraine and headache (e.g. cluster headache, sinus headache, or tension headache; see, Goadsby *Curr. Pain Headache Reports* 2004, 8, 393), sinusitis, oral mucositis, toothache, dental trauma, dental extractions, dental infections, burn, sunburn, dermatitis, psoriasis, eczema, insect sting or bite, burn pain (Bolkskei et al., *Pain* 2005, in press), musculoskeletal disorders, bony fractures, ligamentous sprains, plantar fasciitis, costochondritis, tendonitis, bursitis, tennis elbow, pitcher's elbow, patellar tendonitis, repetitive strain injury, myofascial syndrome, muscle strain, myositis, temporomandibular joint disorder, amputation, low back pain, spinal cord injury, neck pain, whiplash, bladder spasms, GI tract disorders, interstitial cystitis, urinary tract infection, urethral colic, renal colic, pharyngitis, cold sores, stomatitis, external otitis, otitis media (Chan et al., *Lancet* 2003, 361, 385), burning mouth syndrome, mucositis, esophageal pain, esophageal spasms, abdominal disorders, gastroesophageal reflux disease, pancreatitis, enteritis, irritable bowel disorder, inflammatory bowel disease, Crohn's disease, ulcerative colitis, colon distension, abdominal constriction, diverticulosis, diverticulitis, intestinal gas, hemorrhoids, anal fissures, anorectal disorders, prostatitis, epididymitis, testicular pain, proctitis, rectal pain, cholecystitis, labor, childbirth, endometriosis, menstrual cramps, pelvic pain, vulvodynia, vaginitis, orolabial and genital infections (e.g. herpes simplex), pleurisy, pericarditis, non-cardiac chest pain, contusions, abrasions, skin incision (Honore, P. et al., *J. Pharmacol. Exp. Ther.* 2005, 314, 410-21), postoperative pain, peripheral neuropathy, central neuropathy, diabetic neuropathy, acute herpetic neuralgia, post-herpetic neuralgia, trigeminal neuralgia, glossopharyngeal neuralgia, atypical facial pain, radiculopathy, HIV associated neuropathy, physical nerve damage, causalgia, reflex sympathetic dystrophy, sciatica, cervical, thoracic or lumbar radiculopathy, bra-

chial plexopathy, lumbar plexopathy, neurodegenerative disorders, occipital neuralgia, intercostal neuralgia, supraorbital neuralgia, inguinal neuralgia, meralgia paresthetica, genitofemoral neuralgia, carpal tunnel syndrome, Morton's neuroma, post-mastectomy syndrome, post-thoracotomy syndrome, post-polio syndrome, Guillain-Barré syndrome, Raynaud's syndrome, coronary artery spasm (Prinzmetal's or variant angina), visceral hyperalgesia (Pomonić, J. D. et al. *J. Pharmacol. Exp. Ther.* 2003, 306, 387; Walker, K. M. et al., *J. Pharmacol. Exp. Ther.* 2003, 304(1), 56-62), thalamic pain, cancer (e.g. pain caused by cancer, by treatment of cancer by radiation or chemotherapy, or by nerve or bone lesions associated with cancer (see, Menendez, L. et al., *Neurosci. Lett.* 2005, 393 (1), 70-73; Asai, H. et al., *Pain* 2005, 117, 19-29), or bone destruction pain (see, Ghilardi, J. R. et al., *J. Neurosci.* 2005, 25, 3126-31)), infection, or metabolic disease. Additionally, the compounds may be used to treat pain indications such as visceral pain, ocular pain, thermal pain, dental pain, capsaicin-induced pain (as well as other symptoms induced by capsaicin such as cough, lachrymation, and bronchospasm).

In another preferred embodiment, agents are administered to treat: itch, which may arise from various sources, such as dermatological or inflammatory disorders; or inflammatory disorders selected from the group consisting of: renal or hepatobiliary disorders, immunological disorders, medication reactions and unknown/idiopathic conditions. Inflammatory disorders treatable with an inventive agent include, for example, inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis (Geppetti, P. et al., *Br. J. Pharmacol.* 2004, 141, 1313-20; Yiangou, Y. et al., *Lancet* 2001, 357, 1338-39; Kimball, E. S. et al., *Neurogastroenterol. Motil.* 2004, 16, 811), osteoarthritis (Szabo, A. et al., *J. Pharmacol. Exp. Ther.* 2005, 314, 111-119), psoriasis, psoriatic arthritis, rheumatoid arthritis, myasthenia gravis, multiple sclerosis, scleroderma, glomerulonephritis, pancreatitis, inflammatory hepatitis, asthma, chronic obstructive pulmonary disease, allergic rhinitis, uveitis, and cardiovascular manifestations of inflammation including atherosclerosis, myocarditis, pericarditis, and vasculitis.

In another preferred embodiment, inner ear disorders are treated with an inventive agent. Such disorders include, for example, hyperacusis, tinnitus, vestibular hypersensitivity, and episodic vertigo.

In another preferred embodiment, tracheobronchial and diaphragmatic dysfunctions are treated with an inventive agent, including, for example, asthma and allergy-related immune responses (Agopyan, N. et al., *Am. J. Physiol. Lung Cell Mol. Physiol.* 2004, 286, L563-72; Agopyan, N. et al., *Toxicol. Appl. Pharmacol.* 2003, 192, 21-35), cough (e.g., acute or chronic cough, or cough caused by irritation from gastroesophageal reflux disease; see, Laloo, U. G. et al., *J. Appl. Physiol.* 1995, 79(4), 1082-7), bronchospasm, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, and hiccups (hiccupping, singultus).

In yet another preferred embodiment, gastrointestinal and urinary tract disorders are treated with an inventive agent, such as, bladder overactivity, inflammatory hyperalgesia, visceral hyperreflexia of the urinary bladder, hemorrhagic cystitis (Dinis, P. et al., *J. Neurosci.* 2004, 24, 11253-11263), interstitial cystitis (Sculptoreanu, A. et al., *Neurosci. Lett.* 2005, 381, 42-46), inflammatory prostate disease, prostatitis (Sanchez, M. et al., *Eur. J. Pharmacol.* 2005, 515, 20-27), nausea, vomiting, intestinal cramping, intestinal bloating, bladder spasms, urinary urgency, defecation urgency and urge incontinence.

In another preferred embodiment, disorders associated with reduced blood flow to the CNS or CNS hypoxia are treated with an inventive agent. Such disorders include, for example, head trauma, spinal injury, thromboembolic or hemorrhagic stroke, transient ischaemic attacks, cerebral vasospasm, hypoglycaemia, cardiac arrest, status epilepticus, perinatal asphyxia, Alzheimer's disease, and Huntington's Disease.

In other embodiments, agents are administered to treat other diseases, disorders, or conditions mediated through TRPV1 activity, such as: anxiety; learning or memory disorders; eye-related disorders (such as glaucoma, vision loss, increased intraocular pressure, and conjunctivitis); baldness (e.g., by stimulating hair growth); diabetes (including insulin-resistant diabetes or diabetic conditions mediated by insulin sensitivity or secretion); obesity (e.g., through appetite suppression); dyspepsia; biliary colic; renal colic; painful bladder syndrome; inflamed esophagus; upper airway disease; urinary incontinence; acute cystitis; and envenomations (such as marine, snake, or insect stings or bites, including jellyfish, spider, or stingray envenomations).

In especially preferred embodiments of the therapeutic methods of the invention, effective amounts of the TRPV1 modulators of the present invention are administered to treat pain, itch, cough, asthma, or inflammatory bowel disease.

The term "treat" or "treating" as used herein is intended to refer to administration of an agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of TRPV1 activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of TRPV1 activity. The term "subject" refers to a mammalian patient in need of such treatment, such as a human. "Modulators" include both inhibitors and activators, where "inhibitors" refer to compounds that decrease, prevent, inactivate, desensitize or down-regulate TRPV1 expression or activity, and "activators" are compounds that increase, activate, facilitate, sensitize, or up-regulate TRPV1 expression or activity.

In treatment methods according to the invention, an effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition. An "effective amount" means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the agents of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An exemplary dose is in the range of from about 0.001 to about 200 mg of agent per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, or about 0.1 to 10 mg/kg daily in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day. Once improvement of the patient's disease, disorder, or condition has occurred, the dose may be adjusted for preventative or maintenance treatment. For example, the dosage or the frequency of adminis-

tration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.

In addition, the agents of the invention may be used in combination with additional active compounds in the treatment of the above conditions. The additional compounds may be coadministered separately with an agent of Formula (I) or included with such an agent as an additional active ingredient in a pharmaceutical composition according to the invention. In an exemplary embodiment, additional active compounds are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by TRPV1 activity, such as another TRPV1 modulator or a compound active against another target associated with the particular condition, disorder, or disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an agent according to the invention), decrease one or more side effects, or decrease the required dose of the agent according to the invention. In one illustrative embodiment, a composition according to the invention may contain one or more additional active ingredients selected from opioids, NSAIDs (e.g., ibuprofen, cyclooxygenase-2 (COX-2) inhibitors, and naproxen), gabapentin, pregabalin, tramadol, acetaminophen, and aspirin.

The agents of the invention are used, alone or in combination with one or more other active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises: (a) an effective amount of a pharmaceutical agent in accordance with the invention; and (b) a pharmaceutically acceptable excipient.

A "pharmaceutically acceptable excipient" refers to a substance that is not toxic, biologically intolerable, or otherwise biologically unsuitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of a pharmaceutical agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

Delivery forms of the pharmaceutical compositions containing one or more dosage units of the pharmaceutical agents may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art. The compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.

The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories. Preferably, the compositions are formulated for intravenous infusion, topical administration, or oral administration.

For oral administration, the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the agents may be formulated to yield a dosage of, e.g., from about 0.05 to about 50 mg/kg daily, or from about 0.05 to about 20 mg/kg daily, or from about 0.1 to about 10 mg/kg daily.

Oral tablets may include the agent and any other active ingredients mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, bind-

ing agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginate are exemplary disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.

Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, active ingredient may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil such as peanut oil, sesame oil, or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.

Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.

The active agents of this invention may also be administered by non-oral routes. For example, the compositions may be formulated for rectal administration as a suppository. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringier's solution and isotonic sodium chloride. Such forms may be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses range from about 1 to 1000 µg/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.

For topical administration, the agents may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle. Another mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.


Agents may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.

Preferred agents useful in methods of the invention will now be described by reference to illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suit-

19

ably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Unless otherwise specified, the variables are as defined above in reference to Formula (I).

SCHEME A



Referring to general Scheme A, compounds of Formula (I) may be prepared from β -ketoesters (VI), where X^1 is a suitable amino protecting group, such as a benzyl or carbamate group. Protected piperidones (V) are commercially available or may be prepared according to known methods. Preferred protecting groups for amines include tert-butyl carbamate (Boc) or benzyl groups. β -Ketoesters (VI) may be prepared according to general techniques known in the art. For example, β -ketoesters (VI) may be accessed from piperidones (V) by ring expansion of piperidones (V) with ethyl


20

diazoacetate in the presence of a Lewis acid, such as $\text{BF}_3 \cdot \text{OEt}$, in a suitable solvent, such as Et_2O or CH_2Cl_2 or a mixture thereof, at temperatures ranging from about 0°C . to about room temperature (rt). β -Ketoesters (VI) may be reacted with amidines or carboximidamides (VII), or with ureas or thioureas (VIII), for example, in the presence of NaOEt or KOTBu , in a solvent such as EtOH or tBuOH or a mixture thereof, at temperatures between rt and the reflux temperature of the solvent, to form hydroxy pyrimidines (IX). Where the condensation is done with a urea or thiourea, in situ alkylation with an alkyl chloride or bromide provides pyrimidines (IX) where R^1 is $-\text{S}-\text{C}_{1-6}\text{alkyl}$ or $-\text{O}-\text{C}_{1-6}\text{alkyl}$. The X^1 protecting group may be removed using known methods. For example, a Boc group may be removed with an acid such as TFA or HCl, in a solvent such as Et_2O , dioxane, EtOH , or MeOH or a mixture thereof, to form amines (IX) where $X^1 = \text{H}$. Where an acid salt is obtained, the corresponding free base may be obtained by suitable general methods known in the art. Preferably, the free base is obtained by filtration of the salt through resin-bound carbonate using an alcoholic solvent, preferably MeOH. Where X^1 is a benzyl group, the group may be removed according to standard methods, such as hydrogenation in the presence of a palladium catalyst such as Pd/C or $\text{Pd(OH)}_2/\text{C}$, in a solvent such as EtOH . Hydroxy pyrimidines (IX) where X^1 is $-\text{H}$ may then be converted to amines (X) using known methods such as S_N -aryl substitution, or palladium-mediated cross-couplings. S_N -Aryl substitution may be accomplished by treatment of hydroxy pyrimidines (XI), where X^1 is $-\text{H}$, with Ar-HAL (where HAL is halo), such as 2-chloro-3-trifluoromethyl-pyridine, in the presence of a base such as K_2CO_3 , in a polar solvent such as DMSO, at temperatures between about rt and the reflux temperature of the solvent. Palladium-mediated cross-couplings are done by reacting Ar-HAL in the presence of a palladium catalyst. Preferably, hydroxy pyrimidines (IX), where X^1 is $-\text{H}$, are treated with Et_3N or $(i\text{Pr})_2\text{NEt}$, in suitable solvents, such as $n\text{-BuOH}$, tBuOH , $t\text{-amyl alcohol}$, DMF, DMSO, DME, or NMP, or a mixture thereof, at temperatures from about 100 to about 200°C . Pyrimidines (X) can then be activated for use in palladium-mediated cross-coupling reactions or S_N2 reactions by general procedures known in the art. For example, treatment with POCl_3 , PCl_3 , PBr_3 , or POBr_3 affords the corresponding halopyrimidines (XI) where Z is chloride or bromide. Treatment of pyrimidines (X) with trifluoromethane-sulfonic anhydride or N-phenyl-bis(trifluoromethanesulfonimide) in DCE, CH_2Cl_2 , or THF, or a mixture thereof, in the presence of a base such as pyridine, Et_3N , $(i\text{Pr})_2\text{NEt}$, or KOTBu , provides triflates (XI) where Z is $-\text{OSO}_2\text{CF}_3$. In a preferred embodiment, pyrimidines (X) are treated with POCl_3 in CH_3CN at temperatures from about 80 to about 100°C .


Substitution of pyrimidines (XI) with amines $\text{HN(R}^2\text{)R}^3$ to produce compounds of Formula (I) may be accomplished by various suitable methods within the routine purview of artisans. Where Z is Cl, substitution may involve heating chloropyrimidines (XI) with suitable amines (XII) in alcoholic solvents such as MeOH, EtOH , tBuOH , $n\text{-BuOH}$, or $t\text{-amyl-OH}$, or a mixture thereof, at temperatures from about rt to about the reflux temperature of the solvent. Preferably, the solvent is $n\text{-BuOH}$ and the temperature is about 130°C . Alternatively, chloropyrimidines (XI) may be reacted with amines (XII) in the presence of an acid catalyst, preferably p-toluenesulfonic acid or TFA, in toluene or dioxane, at temperatures from about 100 to about 150°C ., to provide compounds of Formula (I). Coupling of halides or triflates (XI) with amines (XII), in the presence of a catalyst such as Pd(OAc)_2 , $\text{Pd(PPh}_3)_4$, $\text{PdCl}_2(\text{PPh}_3)_2$, or $\text{PdCl}_2(\text{Po-tol}_3)_2$, in a solvent such as THF, 1,4-dioxane, DMA, DMF, DME, or toluene, or mixtures thereof, in the presence of a base such as NaOtBu , Na_2CO_3 , K_2CO_3 , Cs_2CO_3 , or K_3PO_4 , with or without an additive such

21


as 2-(dicyclohexylphosphanyl)biphenyl (DCPB), also affords pyrimidines (I). In a preferred embodiment, coupling is accomplished in the presence of $\text{Pd}(\text{OAc})_2$ catalyst, DCPB, and NaOtBu in toluene at temperatures from about 100 to about 200° C. in a microwave reactor.



Referring to Scheme B, compounds of Formula (I) may be prepared by an alternate general route. Protected piperidones (XV), such as 1,4-dioxo-8-aza-spiro[4.5]decane (where PG is $-\text{O}-(\text{CH}_2)_2-\text{O}-$), may be converted to aryl amines (XIV) by $\text{S}_{\text{N}}^{\text{Ar}}$ -aryl substitution or palladium-mediated cross-couplings as described in Scheme A. Deprotection of the protecting group using known general procedures, such as concentrated HCl, provides ketones (XV). Ketones (XV) may be processed into compounds of Formula (I) generally according to the ring expansion, condensation, activation, and displacements described in Scheme A.



22



Referring to Scheme C, thioethers (XVI), obtained as described in Scheme A, may be oxidized using generally known methods to provide sulfones (XVII). Displacement of the sulfone substituent is attained by reaction with alcohols $\text{HO}-\text{C}_{1-6}\text{alkyl}$ or amines $\text{HN}(\text{R}^a)\text{R}^b$ in solvents such as MeOH, EtOH, n-BuOH, THF, DMF, DMSO, or toluene, or a mixture thereof, with or without the presence of a suitable base such as NaOMe, NaOEt, KOtBu, NaH, Et_3N , $(\text{iPr})_2\text{EtN}$, or pyridine, at temperatures between rt and the reflux temperature of the solvent. Preferably, displacement with amines $\text{HN}(\text{R}^a)\text{R}^b$ is performed by heating with sulfones (XVII) in toluene in a sealed tube at 110° C.

Compounds of Formula (I) may be converted to their corresponding salts using methods known to those skilled in the art. For example, amines of Formula (I) may be treated with trifluoroacetic acid, HCl, citric acid, H_2SO_4 , methanesulfonic acid (MsOH), benzenesulfonic acid, or p-toluenesulfonic acid (TsOH) in a solvent such as Et_2O , EtOAc, CH_2Cl_2 , THF, or MeOH, or a mixture thereof, to provide the corresponding salt forms.

Compounds prepared according to the schemes described above may be obtained as single enantiomers, diastereomers, or regioisomers, or as racemic mixtures or mixtures of enantiomers, diastereomers, or regioisomers. Where regioisomeric or diastereomeric mixtures are obtained, isomers may be separated using conventional methods such as chromatography or crystallization. Where racemic (1:1) and non-racemic (not 1:1) mixtures of enantiomers are obtained, single enantiomers may be isolated using conventional separation methods known to one skilled in the art. Particularly useful separation methods may include chiral chromatography, recrystallization, diastereomeric salt formation, or derivatization into diastereomeric adducts followed by separation.

The following examples are provided to further illustrate aspects of the invention and various preferred embodiments.

EXAMPLES

Chemistry:

In obtaining the characterization data described in the examples below, the following analytical protocols were followed unless otherwise indicated.

23

NMR spectra were obtained on Bruker model DRX spectrometers. The format of ^1H NMR data below is: chemical shift in ppm downfield of the tetramethylsilane reference (multiplicity, coupling constant J in Hz, integration).

Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in either positive or negative modes as indicated. Calculated mass corresponds to the exact mass.

Thin-layer chromatography was performed using Merck silica gel 60 F₂₅₄ 2.5 cm×7.5 cm 250 μm or 5.0 cm×10.0 cm 250 μm pre-coated silica gel plates. Preparative thin-layer chromatography was performed using EM Science silica gel 60 F₂₅₄ 20 cm×20 cm 0.5 mm pre-coated plates with a 20 cm×4 cm concentrating zone.

Normal phase purification was typically done by normal phase flash column chromatography (FCC) with RediSep® silica gel columns using EtOAc/hexanes as eluent unless otherwise specified.

Reverse phase high performance liquid chromatography (HPLC) was performed under the following conditions: Instrument, Shimadzu; Column, Phenomenex Gemini column 5 μm C18 (150×21.2 mm) or Waters Xterra RP18 OBD 5 μm (100×30 mm); Gradient, 95:5 to 0:100 water (0.05% TFA)/CH₃CN (0.05% TFA); Flow rate, 30 mL/min; Detection, UV at λ =254 nm.


Microwave reactions were carried out in either a CEM Discover® or a Biotage Initiator™ Microwave at specified temperatures.

Where solutions were "concentrated", they were concentrated using a rotary evaporator under reduced pressure. Unless otherwise specified, reaction solutions were stirred at room temperature (rt) under a N_{2(g)} atmosphere.

Hydrochloride salts were obtained by treating the corresponding free bases with HCl (4 N in dioxane) at rt. The mixtures were either concentrated to obtain the HCl salt, or the resulting solid was isolated by filtration.

Trifluoroacetic acid salts were obtained by purification of the crude reaction product by preparative reverse phase HPLC.

Intermediate A: 5-Oxo-azepane-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester




To a 0° C. solution of 1-BOC-4-piperidone (20 g, 0.10 mol) in Et₂O (200 mL) was added BF₃·Et₂O (14 mL, 0.11 mol) followed by drop-wise addition of ethyl diazoacetate (13.7 mL, 0.11 mol) over 1 h. After addition was complete, the mixture was stirred at 0° C. for 1 h. The mixture was diluted with 30% aq. Na₂CO₃ and water at 0° C. and extracted with EtOAc. The combined organic layers were dried (Na₂SO₄) and concentrated. Purification of the residue (FCC) afforded

24

the title compound (25.6 g, 98%). ^1H NMR (CDCl₃): 4.25-2.03 (m, 11H), 1.47-1.45 (d, J=7.8 Hz, 9H), 1.31-1.24 (m, 3H).


Intermediate B: 5-Oxo-1-(3-trifluoromethyl-pyridin-2-yl)-azepane-4-carboxylic acid ethyl ester




The title compound was prepared analogously to Intermediate A from 3'-trifluoromethyl-2,3,5,6-tetrahydro-[1,2']bi-pyridinyl-4-one (see U.S. Pat. Appl. Publ. US 2005/080095), using CH₂Cl₂ instead of Et₂O, and with a reaction time of 12 h at rt. MS (ESI): mass calcd. for C₁₅H₁₇F₃N₂O₃, 330.12; m/z found, 331.1 [M+H]⁺. ^1H NMR (mixture of enol and keto forms; CDCl₃): 12.75 (s, 1.4H), 8.44-8.41 (m, 1.0H), 8.40-8.38 (m, 1.4H), 7.90-7.83 (m, 2.5H), 7.04-6.99 (m, 1.0H), 6.97-6.92 (m, 1.5H), 4.26-4.19 (m, 5.6H), 3.77-3.65 (m, 3.1H), 3.51-3.45 (m, 4.4H), 3.39-3.33 (m, 4.2H), 3.02-2.94 (m, 1.0H), 2.83-2.75 (m, 4.1H), 2.70-2.66 (m, 3.1H), 2.34-2.15 (m, 2.0H), 1.36-1.23 (m, 8.9H).

Example 1

(4-tert-Butyl-phenyl)-[7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




Step A. 4-Hydroxy-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepine-7-carboxylic acid tert-butyl ester.



25


To solution of 5-oxo-azepane-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (8.8 g, 30.8 mmol) in EtOH (308 mL) was added NaOEt (21% in EtOH; 38 mL) followed by formamidine acetate (4.8 g, 45.9 mmol). The mixture was heated at reflux for 2 h, then was concentrated, azeotrope with toluene. The residue was dissolved in water and made basic via addition of 50% aq. NaOH. The aqueous layer was extracted with toluene and then acidified to pH=7 with HOAc (precipitate formed). The mixture was heated at 100° C. for 1 h, cooled to 0° C., and filtered to give the title compound (2.5 g, 31%), which was used without further purification.

Step B. 6,7,8,9-Tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol.



To a solution of 4-hydroxy-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepine-7-carboxylic acid tert-butyl ester (1.0 g, 3.77 mmol) in CH₂Cl₂ (14 mL) was added 4 M HCl in dioxane (4 mL, 15 mmol). After 24 h, the mixture was concentrated to afford the HCl salt (923 mg). The salt (200 mg, 1.0 mmol) was dissolved in MeOH (10 mL) and filtered through quaternary amine resin, carbonate form (1.0 g) and concentrated to provide the title compound (159 mg, 97%).


Step C. 7-(3-Trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol.



A solution of 6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol (353 mg, 1.76 mmol), 2-fluoro-3-trifluoromethyl-pyridine (582 mg, 3.53 mmol), iPr₂NEt (0.9 mL, 5.28 mmol), and t-amyl alcohol (5 mL) was heated in a microwave at 180° C. for 5 h. The mixture was concentrated, diluted with water, and extracted with EtOAc. The combined organic layers were dried (Na₂SO₄) and concentrated to give the title compound (185 mg, 34%), which was used in the next step without further purification.

26

Step D. 4-Chloro-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine.



To a solution of 7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol (185 mg, 0.60 mmol) in CH₃CN (2 mL) was added POCl₃ (0.11 mL, 1.19 mmol). The reaction mixture was heated at 90° C. for 2 h. The mixture was cooled to rt, diluted with EtOAc, and quenched slowly with saturated (satd.) aq. NaHCO₃. The combined organic layers were dried (Na₂SO₄) and concentrated. The crude residue was purified (FCC) to give the title compound (65 mg, 33%).

Step E. To a solution of 4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine (27 mg, 0.085 mmol) in n-BuOH (1 mL) was added 4-tert-butylaniline (27 μL, 0.17 mmol). After 2 h at 135° C., the mixture was cooled to rt, quenched with saturated aqueous (satd. aq.) NaHCO₃, and extracted with EtOAc. The combined organic layers were dried (Na₂SO₄) and concentrated. The residue was purified (FCC) to give the title compound (33 mg, 89%). MS (ESI): mass calcd. for C₂₄H₂₆F₃N₅, 441.21; m/z found, 442.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.50 (s, 1H), 8.40-8.37 (m, 1H), 7.90-7.85 (m, 1H), 7.46-7.36 (m, 4H), 6.98-6.93 (m, 1H), 6.45 (s, 1H), 3.70-3.65 (m, 2H), 3.64-3.60 (m, 2H), 3.26-3.20 (m, 2H), 3.02-2.95 (m, 2H), 1.32 (s, 9H). Alternatively, the reaction of this step may be performed in the microwave at 180° C. for 30 min.


Example 1A

(4-tert-Butyl-phenyl)-[7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine hydrochloride salt

The following Examples 2-16 were prepared using methods analogous to those described in Example 1, substituting the appropriate amidines in Step A and amines in Step E.

Example 2

(4-Trifluoromethyl-phenyl)-[7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



27


MS (ESI): mass calcd. for $C_{21}H_{17}F_6N_5$, 453.14; m/z found, 454.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.56 (s, 1H), 8.39-8.36 (m, 1H), 7.89-7.86 (m, 1H), 7.68 (d, $J=8.8$ Hz, 2H), 7.59 (d, $J=8.8$ Hz, 2H), 6.98-6.94 (m, 1H), 6.65 (s, 1H), 3.68-3.64 (m, 2H), 3.63-3.59 (m, 2H), 3.27-3.22 (m, 2H), 3.04-3.00 (m, 2H).

Example 2A

(4-Trifluoromethyl-phenyl)-[7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetra-hydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine hydrochloride salt

Example 3


(4-tert-Butyl-phenyl)-[2-cyclopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for $C_{27}H_{30}F_3N_5$, 481.25; m/z found, 482.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38-8.35 (m, 1H), 7.87-7.83 (m, 1H), 7.50-7.45 (m, 2H), 7.36-7.31 (m, 2H), 6.94-6.91 (m, 1H), 6.40 (s, 1H), 3.66-3.53 (m, 4H), 3.21-3.12 (m, 2H), 2.94-2.86 (m, 2H), 2.09-2.02 (m, 1H), 1.32 (s, 9H), 1.11-1.06 (m, 2H), 0.97-0.92 (m, 2H).

Example 4

(4-Chloro-phenyl)-[2-cyclopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for $C_{23}H_{21}ClF_3N_5$, 459.14; m/z found, 460.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.35 (m, 1H),

28

7.88-7.83 (m, 1H), 7.50-7.45 (m, 2H), 7.30-7.26 (m, 2H), 6.97-6.91 (m, 1H), 6.41 (s, 1H), 3.65-3.55 (m, 4H), 3.20-3.15 (m, 2H), 2.94-2.89 (m, 2H), 2.08-2.01 (m, 1H), 1.05-1.01 (m, 2H), 0.97-0.92 (m, 2H).

Example 5

[2-Cyclopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine

10


15

20

25

30

35



MS (ESI): mass calcd. for $C_{24}H_{21}F_6N_5$, 493.17; m/z found, 494.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.35 (m, 1H), 7.88-7.85 (m, 1H), 7.73-7.65 (m, 2H), 7.60-7.51 (m, 2H), 6.97-6.92 (m, 1H), 6.59 (s, 1H), 3.66-3.55 (m, 4H), 3.23-3.15 (m, 2H), 2.99-2.90 (m, 2H), 2.12-2.05 (m, 1H), 1.09-0.95 (m, 4H).

Example 5A

[2-Cyclopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine hydrochloride salt

Example 6

(4-tert-Butyl-phenyl)-[2-phenyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine


45

50

55

60

65




MS (ESI): mass calcd. for $C_{30}H_{30}F_3N_5$, 517.25; m/z found, 518.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.37 (m, 3H), 7.89-

29

7.86 (m, 1H), 7.65-7.59 (m, 2H), 7.49-7.39 (m, 5H), 6.97-6.91 (m, 1H), 6.54 (s, 1H), 3.73-3.69 (m, 2H), 3.68-3.64 (m, 2H), 3.35-3.29 (m, 2H), 3.06-3.00 (m, 2H), 1.35 (s, 3H).

Example 7


[2-Phenyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for $C_{27}H_{21}F_6N_5$, 529.17; m/z found, 530.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.33 (m, 3H), 7.89-7.85 (m, 1H), 7.81 (d, $J=8.5$ Hz, 2H), 7.65-7.63 (d, $J=8.5$ Hz, 2H), 7.49-7.43 (m, 3H), 6.98-6.93 (m, 1H), 6.72 (s, 1H), 3.72-3.67 (m, 2H), 3.66-3.62 (m, 2H), 3.36-3.32 (m, 2H), 3.11-3.02 (m, 2H).

Example 8

(4-tert-Butyl-phenyl)-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




MS (ESI): mass calcd. for $C_{27}H_{32}F_3N_5$, 483.26; m/z found, 484.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38-8.35 (m, 1H), 7.87-7.83 (m, 1H), 7.50-7.45 (m, 2H), 7.62-7.57 (m, 2H), 6.94-6.91 (m, 1H), 6.45 (s, 1H), 3.67-3.63 (m, 2H), 3.62-3.58 (m,

30

2H), 3.21-3.17 (m, 2H), 3.05-2.97 (m, 1H), 2.95-2.90 (m, 2H), 1.34-1.31 (m, 12H), 1.30 (s, 3H).

Example 9

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for $C_{24}H_{23}F_6N_5$, 495.19; m/z found, 496.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.36 (m, 1H), 7.88-7.84 (m, 1H), 7.79 (d, $J=9.1$ Hz, 2H), 7.58 (d, $J=8.8$ Hz, 2H), 6.97-6.93 (m, 1H), 6.64 (s, 1H), 3.67-3.63 (m, 2H), 3.61-3.57 (m, 2H), 3.24-3.20 (m, 2H), 3.09-3.00 (m, 1H), 3.00-2.95 (m, 2H), 1.31 (d, $J=6.86$ Hz, 6H).


Example 9A

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine hydrochloride salt

1H NMR (CD_3OD): 8.47-8.45 (m, 1H), 8.04 (dd, $J=1.7, 7.8$ Hz, 1H), 7.82 (d, $J=8.6$ Hz, 2H), 7.75 (d, $J=8.6$ Hz, 2H), 7.18-7.14 (m, 1H), 3.71-3.67 (m, 2H), 3.65-3.62 (m, 2H), 3.40-3.35 (m, 2H), 3.27-3.23 (m, 2H), 3.12 (td, $J=6.8, 13.6$ Hz, 1H), 1.32 (d, $J=6.8$ Hz, 6H).

Example 10

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(3-trifluoromethyl-phenyl)-amine




31

MS (ESI): mass calcd. for $C_{24}H_{23}F_6N_5$, 495.19; m/z found, 496.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 8.30 (s, 1H), 7.91-7.88 (m, 1H), 7.69-7.66 (m, 1H), 7.47-7.43 (m, 1H), 7.32-7.31 (m, 1H), 6.99-6.95 (m, 1H), 6.63 (s, 1H), 3.70-3.66 (m, 2H), 3.64-3.61 (m, 2H), 3.26-3.22 (m, 2H), 3.10-3.02 (m, 1H), 3.01-2.97 (m, 2H), 1.33 (d, $J=6.9$ Hz, 6H).

Example 11


[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethoxy-phenyl)-amine



MS (ESI): mass calcd. for $C_{24}H_{23}F_6N_5O$, 511.18; m/z found, 512.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.37 (m, 1H), 7.89-7.86 (m, 1H), 7.73-7.67 (m, 2H), 7.20 (d, $J=8.3$ Hz, 2H), 6.97-6.93 (m, 1H), 6.53 (s, 1H), 3.67-3.64 (m, 2H), 3.63-3.58 (m, 2H), 3.25-3.19 (m, 2H), 3.09-2.93 (m, 3H), 1.31 (d, $J=6.8$ Hz, 6H).

Example 12

[2-(4-Fluoro-phenyl)-ethyl]-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




MS (ESI): mass calcd. for $C_{25}H_{27}F_4N_5$, 473.22; m/z found, 474.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38-8.35 (m, 1H), 7.87-7.84 (m, 1H), 7.19-7.14 (m, 2H), 7.03-6.96 (m, 2H), 6.95-6.90 (m, 1H), 4.65-4.59 (m, 1H), 3.77-3.70 (m, 2H), 3.60-

32

3.54 (m, 4H), 3.16-3.11 (m, 2H), 3.02-2.88 (m, 3H), 2.69-2.64 (m, 2H), 1.30 (d, $J=7.1$ Hz, 6H).

Example 13


[2-(2-Chloro-phenyl)-ethyl]-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for $C_{25}H_{27}ClF_3N_5$, 489.19; m/z found, 490.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.37 (m, 1H), 7.89-7.86 (m, 1H), 7.40-7.37 (m, 1H), 7.25-7.16 (m, 3H), 6.96-6.92 (m, 1H), 4.73-4.67 (m, 1H), 3.84-3.78 (m, 2H), 3.61-3.56 (m, 4H), 3.17-3.07 (m, 4H), 3.02-2.93 (m, 1H), 2.72-2.67 (m, 2H), 1.31 (d, $J=6.9$ Hz, 6H).

Example 14

(3,4-Dichloro-benzyl)-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




MS (ESI): mass calcd. for $C_{24}H_{24}Cl_2F_3N_5$, 509.14; m/z found, 510.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.36 (m, 1H), 7.89-7.86 (m, 1H), 7.50 (d, $J=2.2$ Hz, 1H), 7.40 (d, $J=8.2$ Hz, 1H), 7.22-7.19 (m, 1H), 6.96-6.93 (m, 1H), 4.99-4.94 (m,

33

1H), 4.68 (d, J=6.0 Hz, 2H), 3.64-3.57 (m, 4H), 3.18-3.14 (m, 2H), 2.99-2.91 (m, 1H), 2.82-2.79 (m, 2H), 1.26 (d, J=6.9 Hz, 6H).

Example 15


(4-tert-Butyl-phenyl)-[2-methyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for $C_{25}H_{28}F_3N_5$, 455.23; m/z found, 456.9 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.38 (m, 1H), 7.89-7.86 (m, 1H), 7.53-7.50 (m, 2H), 7.39-7.35 (m, 2H), 6.97-6.93 (m, 1H), 6.50 (s, 1H), 3.66-3.59 (m, 4H), 3.22-3.18 (m, 2H), 2.96-2.93 (m, 2H), 2.55 (s, 3H), 1.34 (s, 9H).

Example 16

[2-Methyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine




MS (ESI): mass calcd. for $C_{22}H_{19}F_6N_5$, 467.15; m/z found, 468.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.41-8.39 (m, 1H), 7.90-7.87 (m, 1H), 7.74 (d, J=8.5 Hz, 2H), 7.60 (d, J=8.8 Hz, 2H),

34

7.00-6.95 (m, 1H), 6.66 (s, 1H), 3.67-3.64 (m, 2H), 3.63-3.59 (m, 2H), 3.25-3.20 (m, 2H), 3.02-2.98 (m, 2H), 2.59 (s, 3H).

Example 17

(5-Trifluoromethyl-pyridin-2-yl)-[7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




The title compound was synthesized in a manner similar to Example 1 with modifications to Step E as follows:

Step E. To a solution of 4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine (38 mg, 0.12 mmol), 4-trifluoromethyl-amino-pyridine (28 mg, 0.17 mmol), and NaOtBu (16 mg, 0.16 mmol) in toluene (1.2 mL) in a microwave vial was added a solution of Pd(OAc)₂ (0.4 mg, 0.002 mmol) and 2-(dicyclohexylphosphino)biphenyl (DCPB) (1.2 mg, 0.004 mmol) in toluene (1 mL). The mixture was flushed with N_{2(g)} and heated in a microwave at 200° C. for 30 min. The mixture was cooled, filtered through a plug of diatomaceous earth, and concentrated. The residue was purified (FCC) to afford the title compound (35 mg, 66%). MS (ESI): mass calcd. for $C_{20}H_{16}F_6N_6$, 454.13; m/z found, 453.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.65 (s, 1H), 8.61 (d, J=8.8 Hz, 1H), 8.54-8.51 (m, 1H), 8.41-8.38 (m, 1H), 7.95-7.85 (m, 2H), 7.64 (s, 1H), 7.01-6.95 (m, 1H), 3.67-3.57 (m, 4H), 3.31-3.25 (m, 2H), 3.14-3.07 (m, 2H).

The following Examples 18-25 below were prepared using methods analogous to those described in Example 17, substituting the appropriate amidines in Step A and amines in Step E.

Example 18

Isoquinolin-1-yl-[7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




35

MS (ESI): mass calcd. for $C_{23}H_{19}F_3N_6$, 436.16; m/z found, 437.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.83 (d, J=8.0 Hz, 1H), 8.65 (s, 1H), 8.42-8.39 (m, 1H), 7.90-7.86 (m, 1H), 7.69-7.64 (m, 1H), 7.60-7.53 (m, 2H), 7.32-7.29 (m, 1H), 6.97-6.93 (m, 1H), 6.71 (d, J=6.9 Hz, 1H), 3.64-3.54 (m, 6H), 3.30-3.24 (m, 2H).

Example 19


[2-Cyclopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine



MS (ESI): mass calcd. for $C_{23}H_{20}F_6N_6$, 494.17; m/z found, 495.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.54-8.47 (m, 2H), 8.40-8.37 (m, 1H), 7.93-7.84 (m, 2H), 7.54 (s, 1H), 7.00-6.89 (m, 1H), 3.62-3.54 (m, 4H), 3.24-3.19 (m, 2H), 3.04-2.99 (m, 2H), 2.19-2.08 (m, 1H), 1.13-1.08 (m, 2H), 1.05-1.00 (m, 2H).

Example 20

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine



MS (ESI): mass calcd. for $C_{23}H_{22}F_6N_6$, 496.18; m/z found, 497.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.73 (d, J=9.1 Hz, 1H), 8.50 (s, 1H), 8.40-8.37 (m, 1H), 7.94-7.90 (m, 1H), 7.88-7.85

36


(m, 1H), 7.60 (s, 1H), 6.98-6.93 (m, 1H), 3.65-3.54 (m, 4H), 3.28-3.20 (m, 2H), 3.14-3.01 (m, 3H), 1.34 (d, J=6.9 Hz, 6H).

Example 20A

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine hydrochloride salt

Example 21


[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-quinolin-3-yl-amine



MS (ESI): mass calcd. for $C_{26}H_{25}F_3N_6$, 478.21; m/z found, 479.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.99 (d, J=2.2 Hz, 1H), 8.86 (d, J=2.5 Hz, 1H), 8.43-8.40 (m, 1H), 8.07 (d, J=8.2 Hz, 1H), 7.92-7.88 (m, 1H), 7.83-7.80 (m, 1H), 7.65-7.61 (m, 1H), 7.58-7.54 (m, 1H), 7.00-6.95 (m, 1H), 6.75 (s, 1H), 3.74-3.70 (m, 2H), 3.67-3.63 (m, 2H), 3.29-3.25 (m, 2H), 3.14-3.05 (m, 3H), 1.38 (d, J=6.9 Hz, 6H).

Example 22

[2-Phenyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine




MS (ESI): mass calcd. for $C_{26}H_{20}F_6N_6$, 530.17; m/z found, 531.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.76 (d, J=8.8 Hz, 1H),

37

8.57 (s, 1H), 8.44-8.39 (m, 3H), 8.04-8.00 (m, 1H), 7.91-7.88 (m, 1H), 7.67 (s, 1H), 7.55-7.48 (m, 3H), 7.00-6.96 (m, 1H), 3.72-3.62 (m, 4H), 3.41-3.36 (m, 2H), 3.18-3.11 (m, 2H).

Example 23


[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine



MS (ESI): mass calcd. for $C_{23}H_{22}F_6N_6$, 496.18; m/z found, 497.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.86 (d, $J=2.5$ Hz, 1H), 8.54-8.51 (m, 1H), 8.42-8.39 (m, 1H), 7.91-7.90 (m, 1H), 7.69 (d, $J=8.5$ Hz, 1H), 7.01-6.96 (m, 1H), 6.71 (s, 1H), 3.70-3.67 (m, 2H), 3.64-3.60 (m, 2H), 3.29-3.24 (m, 2H), 3.12-3.02 (m, 3H), 1.33 (d, $J=6.6$ Hz, 6H).

Example 24

[2-Methyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine




MS (ESI): mass calcd. for $C_{21}H_{18}F_6N_6$, 468.15; m/z found, 469.8 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.84 (d, $J=2.5$ Hz, 1H), 8.47-8.43 (m, 1H), 8.40-8.38 (m, 1H), 7.90-7.87 (m, 1H), 7.68 (d, $J=8.8$ Hz, 1H), 7.00-6.96 (m, 1H), 6.81 (s, 1H),

38

3.67-3.63 (m, 2H), 3.62-3.59 (m, 2H), 3.25-3.22 (m, 2H), 3.06-3.03 (m, 2H), 2.58 (s, 3H).

Example 25


[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-phenoxy-phenyl)-amine



MS (ESI): mass calcd. for $C_{29}H_{28}F_3N_5O$, 519.22; m/z found, 520.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.42-8.39 (m, 1H), 7.90-7.87 (m, 1H), 7.67-7.62 (m, 2H), 7.37-7.32 (m, 2H), 7.12-7.08 (m, 1H), 7.05-7.01 (m, 4H), 6.98-6.94 (m, 1H), 6.48 (s, 1H), 3.70-3.66 (m, 2H), 3.65-3.61 (m, 2H), 3.24-3.21 (m, 2H), 3.07-2.94 (m, 3H), 1.32 (d, $J=6.9$ Hz, 6H).

Example 26

(4-Trifluoromethyl-phenyl)-[7-(4-trifluoromethyl-pyrimidin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



The title compound was synthesized a manner similar to Example 1 with modifications to Step C as follows and using 4-trifluoromethylaniline in Step E:

Step C. 7-(4-Trifluoromethyl-pyrimidin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol


A solution of 6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol (60 mg, 0.30 mmol), 2-chloro-4-trifluoropyrimidine (36 μ L, 0.30 mmol), and Et_3N (0.11 mL, 0.81 mmol) in DMF (1.2 mL) was heated at $120^\circ C$. for 2 h. The mixture was cooled to rt, diluted with water, and extracted with EtOAc. The combined organic layers were dried (Na_2SO_4) and concentrated to give the title compound (69 mg, 68%), which was used without further purification.

39

Step E. MS (ESI): mass calcd. for $C_{20}H_{16}F_6N_6$, 454.13; m/z found, 455.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.56 (s, 1H), 8.53 (d, J=5.2 Hz, 1H), 7.67 (d, J=8.2 Hz, 2H), 7.59 (d, J=8.5 Hz, 2H), 6.80 (d, J=5.2 Hz, 1H), 6.60 (s, 1H), 4.30-4.26 (m, 2H), 4.13-4.09 (m, 2H), 3.31-3.26 (m, 2H), 2.96-2.90 (m, 2H).

Example 27


(7-Pyrimidin-2-yl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)-(4-trifluoromethyl-phenyl)-amine



The title compound was prepared analogously to the methodology described in Example 26, substituting 2-chloropyrimidine in Step C. MS (ESI): mass calcd. for $C_{19}H_{17}F_3N_6$, 386.15; m/z found, 387.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.57 (s, 1H), 8.35 (d, J=4.8 Hz, 2H), 7.68 (d, J=8.8 Hz, 2H), 7.59 (d, J=8.8 Hz, 2H), 6.61 (s, 1H), 6.55-6.52 (m, 1H), 4.28-4.23 (m, 2H), 4.11-4.06 (m, 2H), 3.32-3.25 (m, 2H), 2.95-2.90 (m, 2H).

Example 28

(7-Pyrazin-2-yl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)-(4-trifluoromethyl-phenyl)-amine




The title compound was prepared analogously to Example 26, substituting 2-chloropyrazine in Step C. MS (ESI): mass calcd. for $C_{19}H_{17}F_3N_6$, 386.15; m/z found, 387.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.56 (s, 1H), 8.12-8.10 (m, 1H), 8.08-8.06 (m, 1H), 7.86 (d, J=2.7 Hz, 1H), 7.67 (d, J=8.8 Hz, 2H), 7.59

40

(d, J=8.8 Hz, 2H), 6.57 (s, 1H), 4.25-4.20 (m, 2H), 3.92-3.88 (m, 2H), 3.38-3.34 (m, 2H), 2.96-2.91 (m, 2H).

Example 29


(7-Quinoxalin-2-yl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)-(4-trifluoromethyl-phenyl)-amine



The title compound was prepared analogously to Example 26, substituting 2-chloroquinoxaline in Step C. MS (ESI): mass calcd. for $C_{23}H_{19}F_3N_6$, 436.16; m/z found, 437.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.58 (d, J=11.2 Hz, 2H), 7.92-7.89 (m, 1H), 7.73-7.66 (m, 3H), 7.63-7.58 (m, 3H), 7.44-7.39 (m, 1H), 6.61 (s, 1H), 4.42-4.35 (m, 2H), 4.16-4.07 (m, 2H), 3.46-3.38 (m, 2H), 3.09-3.02 (m, 2H).

Example 30

[7-(3-Chloro-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine




The title compound was prepared analogously to Example 26, substituting 2,3-dichloropyridine in Step C. MS (ESI): mass calcd. for $C_{20}H_{17}ClF_3N_5$, 419.11; m/z found, 420.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.57 (s, 1H), 8.15-8.13 (m, 1H),

41

7.68 (d, J=9.3 Hz, 2H), 7.63-7.58 (m, 3H), 6.84-6.79 (m, 1H), 6.65 (s, 1H), 3.77-3.67 (m, 4H), 3.31-3.24 (m, 2H), 3.08-3.01 (m, 2H).

Example 31


(4-tert-Butyl-phenyl)-[7-(6-chloro-5-methyl-pyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



The title compound was prepared analogously to Example 26, substituting 4,6-dichloro-5-methylpyrimidine in Step C and 4-tert-butyl-aniline in Step E. MS (ESI⁻): mass calcd. for C₂₃H₂₇ClN₆, 422.20; m/z found, 421.2 [M-H]⁻. ¹H NMR (CDCl₃): 8.50 (s, 1H), 8.33 (s, 1H), 7.44-7.36 (m, 4H), 6.43 (s, 1H), 3.91-3.84 (m, 2H), 3.81-3.75 (m, 2H), 3.26-3.19 (m, 2H), 3.04-2.98 (m, 2H), 2.31 (s, 3H), 1.32 (s, 9H).

Example 32

(4-tert-Butyl-phenyl)-[7-(3-methyl-quinoxalin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




The title compound was prepared analogously to Example 26, substituting 2-chloro-3-methylquinoline in Step C and 4-tert-butyl-aniline in Step E. MS (ESI⁻): mass calcd. for C₂₇H₃₀N₆, 438.25; m/z found, 437.2 [M-H]⁻. ¹H NMR (CDCl₃): 8.51 (s, 1H), 7.90-7.87 (m, 1H), 7.79-7.76 (m, 1H), 7.60-7.55 (m, 1H), 7.53-7.48 (m, 1H), 7.43-7.36 (m, 4H),

42

6.47 (s, 1H), 3.80-3.76 (m, 2H), 3.74-3.70 (m, 2H), 3.31-3.26 (m, 2H), 3.07-3.02 (m, 2H), 2.75 (s, 3H), 1.32 (s, 9H).

Example 33


(4-tert-Butyl-phenyl)-[2-isopropyl-7-(3-methyl-quinoxalin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



The title compound was prepared analogously to Example 26, substituting 2-chloro-3-methylquinoline in Step C and 4-tert-butyl-aniline in Step E. MS (ESI⁻): mass calcd. for C₃₀H₃₆N₆, 480.3; m/z found, 479.3 [M-H]⁻. ¹H NMR (CDCl₃): 7.89-7.86 (m, 1H), 7.78-7.76 (m, 1H), 7.62-7.54 (m, 3H), 7.51-7.47 (m, 1H), 7.37-7.34 (m, 2H), 6.48 (s, 1H), 3.77-3.73 (m, 2H), 3.71-3.67 (m, 2H), 3.29-3.23 (m, 2H), 3.02-2.97 (m, 3H), 2.74 (s, 3H), 1.33-1.32 (m, 12H), 1.31 (s, 3H).

Example 34

[2-Isopropyl-7-(3-methyl-quinoxalin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine




The title compound was prepared analogously to Example 26, substituting 2-chloro-3-methylquinoline in Step C. MS (ESI⁺): mass calcd. for C₂₇H₂₇F₃N₆, 492.22; m/z found, 493.2 [M+H]⁺. ¹H NMR (CDCl₃): 7.89-7.86 (m, 1H), 7.81-7.75 (m, 3H), 7.61-7.55 (m, 3H), 7.53-7.48 (m, 1H), 6.67 (s, 1H),

43

3.78-3.75 (m, 2H), 3.72-3.68 (m, 2H), 3.32-3.27 (m, 2H),
3.09-3.02 (m, 3H), 2.75 (s, 3H), 1.32 (d, J=7.1 Hz, 6H).

Example 35


[2-Isopropyl-7-(3-trifluoromethyl-quinoxalin-2-yl)-
6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-
(4-trifluoromethyl-phenyl)-amine



The title compound was prepared analogously to Example 26, substituting 2-chloro-3-trifluoromethylquinoline in Step C. MS (ESI): mass calcd. for $C_{27}H_{24}F_6N_6$, 546.2; m/z found, 547.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.06-8.03 (m, 1H), 7.88-7.71 (m, 4H), 7.65-7.57 (m, 3H), 6.66 (s, 1H), 3.87-3.77 (m, 4H), 3.33-3.27 (m, 2H), 3.10-3.00 (m, 3H), 1.32 (d, J=6.8 Hz, 6H).

Example 36

[2-Isopropyl-7-(3-methanesulfonyl-pyridin-2-yl)-6,7,
8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-
trifluoromethyl-phenyl)-amine



The title compound was prepared analogously to Example 26, substituting 2-chloro-3-(methylsulfonyl)pyridine (see, Ponticello, G. S. et al., *J. Org. Chem.* 1979, 44(17), 3080-3082) in Step C. MS (ESI): mass calcd. for $C_{24}H_{26}F_3N_5O_2S$, 505.18; m/z found, 506.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.54-8.51 (m, 1H), 8.38-8.34 (m, 1H), 7.80 (d, J=8.3 Hz, 2H), 7.60 (d, J=8.6 Hz, 2H), 7.25-7.21 (m, 1H), 6.89 (s, 1H), 3.60-3.55 (m, 2H), 3.54-3.50 (m, 2H), 3.24-3.20 (m, 2H), 3.11-2.99 (m, 6H), 1.32 (d, J=6.8 Hz, 6H).

44

Example 37


(4-tert-Butyl-phenyl)-(7-phthalazin-1-yl-6,7,8,9-
tetrahydro-5H-pyrimido-[4,5-d]azepin-4-yl)-amine

5

10

15

20



The title compound was synthesized in a manner similar to Example 1 with modifications to Step C as follows and using 4-tert-butyl-aniline in Step E:

Step C. 7-Phthalazin-1-yl-6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepin-4-ol. A solution of 6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol (50 mg, 0.33 mmol), 1,4-dichlorophthalazine (55 mg, 0.28 mmol), and Et_3N (0.11 mL, 0.81 mmol) in DMF (5 mL) was heated at 120° C. for 2 h. The mixture was cooled to rt, diluted with water, and extracted with EtOAc. The combined organic layers were dried (Na_2SO_4) and concentrated to give 7-(4-chloro-phthalazin-1-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol (50 mg, 55%), of which 23 mg (0.14 mmol) was treated with ammonium formate (116 mg, 1.85 mmol) and $Pd(OH)_2/C$ (14 mg, 0.08 mmol) in MeOH/dioxane (1:1; 4 mL). After 1 h at 100° C., the mixture was cooled to rt, filtered through diatomaceous earth, and concentrated to give the title compound, which was carried on to Step D as in Example 1. MS (ESI-): mass calcd. for $C_{26}H_{28}N_6$, 424.24; m/z found, 423.2 $[M-H]^-$. 1H NMR ($CDCl_3$): 9.13 (s, 1H), 8.51 (s, 1H), 8.08-8.04 (m, 1H), 7.91-7.80 (m, 3H), 7.48-7.36 (m, 4H), 6.56 (s, 1H), 4.04-3.97 (m, 2H), 3.96-3.89 (m, 2H), 3.37-3.30 (m, 2H), 3.20-3.08 (m, 2H), 1.32 (s, 9H).


45

Example 38

(4-tert-Butyl-phenyl)-[7-(5-methyl-pyrimidin-4-yl)-
6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-
amine

50

55




65

45

The title compound was prepared analogously to Example 37 using 4,6-dichloro-5-methyl pyrimidine in Step C. MS (ESI): mass calcd. for $C_{23}H_{28}N_6$, 388.24; m/z found, 389.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.53 (s, 1H), 8.49 (s, 1H), 8.09 (s, 1H), 7.43-7.35 (m, 4H), 6.43 (s, 1H), 3.97-3.94 (m, 2H), 3.88-3.84 (m, 2H), 3.25-3.21 (m, 2H), 3.03-2.97 (m, 2H), 2.28 (s, 3H), 1.31 (s, 9H).

Example 39

[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



Step A. 2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol. To solution of KOtBu (1.3 g, 5.77 mmol) in tBuOH (32 mL) was added 5-oxo-1-(3-trifluoromethyl-pyridin-2-yl)-azepane-4-carboxylic acid ethyl ester (Intermediate B; 1.27 g, 3.85 mmol), followed by piperidine-1-carboximidamide hydrobromide (1.2 g, 5.77 mmol). After heating at reflux for 24 h, the mixture was cooled and concentrated. The residue was dissolved in water and CH_2Cl_2 . The aqueous layer was acidified to pH=7 with HOAc. The layers were separated and the aqueous layer was extracted with CH_2Cl_2 . The combined organic layers were dried (Na_2SO_4) and concentrated. The residue was triturated with Et_2O and filtered. The filtrate was concentrated and the residue was purified (FCC) to give the title compound (776.4 g, 51%—combined filtered and chromatographed).

Step B. 4-Chloro-2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine. To a solution of 2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol (435 mg, 1.11 mmol) in CH_3CN (9 mL) was added $POCl_3$ (0.41 mL, 4.43 mmol). After 1.5 h at 80° C., the mixture was cooled to rt, diluted with EtOAc, and quenched slowly with satd. aq. $NaHCO_3$. The organic layers were combined, dried (Na_2SO_4), and concentrated. The crude residue was purified (FCC) to give the title compound (160 mg, 35%).

Step C. [2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine. To a solution of 4-chloro-2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine (50 mg, 0.12 mmol), 4-trifluoromethyl aniline (0.02 mL, 0.18 mmol), and NaOtBu (16 mg, 0.17 mmol) in toluene (1.5 mL) in a microwave vial was added a solution of $Pd(OAc)_2$ (0.4 mg, 0.002 mmol) and

46

DCPB (1.3 mg, 0.004 mmol) in toluene (1 mL). The mixture was flushed with $N_2(g)$ and heated in a microwave at 200° C. for 50 min. The mixture was cooled and filtered through a plug of diatomaceous earth. The filtrate was concentrated and the residue was purified (FCC) to afford the title compound (48 mg, 89%). MS (ESI): mass calcd. for $C_{26}H_{26}F_6N_6$, 536.21; m/z found, 537.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.37 (m, 1H), 7.87 (d, J=1.8 Hz, 1H), 7.65 (d, J=8.6 Hz, 2H), 7.55 (d, J=8.8 Hz, 2H), 6.97-6.91 (m, 1H), 6.49 (s, 1H), 3.77-3.71 (m, 4H), 3.62-3.54 (m, 4H), 3.10-3.06 (m, 2H), 2.89-2.84 (m, 2H), 1.70-1.56 (m, 6H).

Example 39A

[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine hydrochloride salt

1H NMR (CD_3OD): 8.47-8.45 (m, 1H), 8.05 (dd, J=7.8, 1.8 Hz, 1H), 7.74 (q, J=8.8 Hz, 4H), 7.16 (dd, J=7.8, 4.8 Hz, 1H), 3.74-3.69 (m, 4H), 3.64-3.59 (m, 2H), 3.57-3.54 (m, 2H), 3.31-3.27 (m, 2H), 3.13-3.02 (m, 2H), 1.80-1.72 (m, 2H), 1.72-1.65 (m, 4H).

Example 39B


[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine sulfate salt

1H NMR (CD_3OD): 8.48-8.45 (m, 1H), 8.05 (dd, J=7.8, 1.6 Hz, 1H), 7.78-7.68 (m, 4H), 7.19-7.13 (m, 1H), 3.75-3.69 (m, 4H), 3.65-3.59 (m, 2H), 3.58-3.53 (m, 2H), 3.33-3.28 (m, 2H), 3.13-3.09 (m, 2H), 1.79-1.62 (m, 6H).

The following Examples 40-45 were prepared using methodology similar to that described in Example 39, substituting the appropriate carboximidamides in Step A.

Example 40

[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for $C_{25}H_{24}F_6N_6O$, 538.19; m/z found, 539.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.37 (m, 1H), 7.89-7.85 (m, 1H), 7.63 (d, J=9.1 Hz, 2H), 7.57 (d, J=9.1 Hz, 2H), 6.98-6.92 (m, 1H), 6.53 (s, 1H), 3.80-3.71 (m, 8H), 3.63-3.54 (m, 4H), 3.13-3.06 (m, 2H), 2.92-2.86 (m, 2H).

47


Example 40A

[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine hydrochloride salt

¹H NMR (CD₃OD): 8.49-8.46 (m, 1H), 8.05 (dd, J=1.7, 7.4 Hz, 1H), 7.75 (s, 4H), 7.17 (dd, J=4.9, 7.4 Hz, 1H), 3.79-3.75 (m, 4H), 3.73-3.71 (m, 4H), 3.65-3.62 (m, 2H), 3.59-3.55 (m, 2H), 3.31-3.29 (m, 2H), 3.15-3.11 (m, 2H).

Example 41


[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine



MS (ESI): mass calcd. for C₂₄H₂₃F₆N₇O, 539.19; m/z found, 540.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.52-8.51 (m, 1H), 8.42-8.40 (m, 1H), 8.38 (d, J=8.8 Hz, 1H), 7.92-7.87 (m, 2H), 7.49-7.46 (m, 1H), 6.99-6.95 (m, 1H), 3.84-3.77 (m, 8H), 3.60-3.54 (m, 4H), 3.15-3.10 (m, 2H), 2.97-2.94 (m, 2H).

Example 42

(4-tert-Butyl-phenyl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




MS (ESI): mass calcd. for C₂₉H₃₅F₃N₆, 524.29; m/z found, 525.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.36 (m, 1H), 7.87-7.84 (m, 1H), 7.50-7.46 (m, 2H), 7.35-7.31 (m, 2H), 6.94-

48

6.89 (m, 1H), 6.31 (s, 1H), 3.76-3.71 (m, 4H), 3.63-3.55 (m, 4H), 3.09-3.03 (m, 2H), 2.86-2.81 (m, 2H), 1.67-1.57 (m, 6H), 1.32 (s, 9H).

Example 43

N²,N²-Dimethyl-N⁴-(6-trifluoromethyl-pyridin-3-yl)-7-(3-trifluoro-methyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




Example 43B

N²,N²-Dimethyl-N⁴-(6-trifluoromethyl-pyridin-3-yl)-7-(3-trifluoro-methyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

MS (ESI): mass calcd. for C₂₂H₂₁F₆N₇, 497.18; m/z found, 498.8 [M+H]⁺. ¹H NMR (CDCl₃): 9.04 (d, J=1.9 Hz, 1H), 8.76 (s, 1H), 8.39 (d, J=4.4 Hz, 1H), 8.16-8.13 (m, 1H), 8.03-8.00 (m, 1H), 7.74 (d, J=8.2 Hz, 1H), 7.12-7.08 (m, 1H), 3.67-3.62 (m, 4H), 3.38-3.33 (m, 2H), 3.22 (s, 6H), 3.12-3.08 (m, 2H).

Example 44

N²,N²-Dimethyl-N⁴-(5-trifluoromethyl-pyridin-2-yl)-7-(3-trifluoro-methyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




MS (ESI): mass calcd. for C₂₂H₂₁F₆N₇, 497.18; m/z found, 498.8 [M+H]⁺. ¹H NMR (CDCl₃): 8.58 (d, J=9.1 Hz, 1H), 8.51-8.49 (m, 1H), 8.42-8.40 (m, 1H), 7.90-7.86 (m, 2H),

49

7.48 (s, 1H), 6.98-6.94 (m, 1H), 3.59-3.54 (m, 4H), 3.21 (s, 6H), 3.14-3.10 (m, 2H), 2.95-2.92 (m, 2H).

Example 45

N⁴-(3-Chloro-4-trifluoromethyl-phenyl)-N²,N²-dimethyl-7-(3-trifluoro-methyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




The title compound was synthesized like Example 39 with modifications to Step C as follows:

Step C. A mixture of [4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepin-2-yl]-dimethyl-amine (50 mg, 0.14 mmol), 3-chloro-4-trifluoro-methylaniline (40 mg, 0.20 mmol), and p-toluenesulfonic acid (51 mg, 0.27 mmol) in toluene (2 mL) was heated in a sealed tube at 120° C. for 18 h. The mixture was cooled, diluted with satd. aq. NaHCO₃, and extracted with CH₂Cl₂. The organic layer was dried (MgSO₄) and concentrated. The residue was purified (FCC) to give the title compound (55 mg, 78%). MS (ESI): mass calcd. for C₂₃H₂₁ClF₆N₆, 530.14; m/z found, 531.8 [M+H]⁺. ¹H NMR (CD₃OD): 8.43-8.40 (m, 1H), 8.25 (d, J=1.9 Hz, 1H), 8.08-7.98 (m, 1H), 7.66-7.62 (m, 1H), 7.57 (d, J=8.8 Hz, 1H), 7.11-7.08 (m, 1H), 3.45-3.39 (m, 4H), 3.33-3.31 (m, 1H), 3.13 (s, 6H), 3.06-3.03 (m, 2H), 2.97-2.93 (m, 2H).

Example 46

(4-Bromo-phenyl)-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido [4,5-d]azepin-4-yl]-amine




50

The title compound was prepared using methods similar to those in Example 1 with modifications to Step E as follows:

Step E A mixture of 4-chloro-2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine (50 mg, 0.14 mmol), 4-bromoaniline (35 mg, 0.36 mmol), and p-toluenesulfonic acid (51 mg, 0.27 mmol) in toluene (2 mL) was heated in a sealed tube at 130° C. for 18 h. The mixture was cooled, diluted with satd. aq. NaHCO₃, and extracted with EtOAc. The organic layer was dried (Na₂SO₄) and concentrated. The residue was purified (FCC) to give the title compound (57 mg, 77%). MS (ESI): mass calcd. for C₂₃H₂₃BrF₃N₅, 505.11; m/z found, 506.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.41-8.39 (m, 1H), 7.90-7.87 (m, 1H), 7.61-7.56 (m, 2H), 7.48-7.43 (m, 2H), 6.99-6.95 (m, 1H), 6.49 (s, 1H), 3.68-3.65 (m, 2H), 3.63-3.60 (m, 2H), 3.25-3.21 (m, 2H), 3.08-2.99 (m, 1H), 2.98-2.94 (m, 2H), 1.32 (d, J=6.9 Hz, 6H).

Example 47

(4-tert-Butyl-phenyl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



The title compound was synthesized in accordance with Example 39 with modifications to Step C as follows:


Step C. To a solution of 4-chloro-2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine (30 mg, 0.08 mmol) in n-BuOH (2 mL) was added 4-tert-butylaniline (23 μL, 0.15 mmol). The mixture was heated in the microwave at 180° C. for 90 min, then was cooled to rt, diluted with MeOH, and filtered through quaternary amine resin, carbonate form (500 mg). The filtrate was concentrated and the residue was purified (FCC) to give the title compound (39 mg, 99%). MS (ESI): mass calcd. for C₂₈H₃₃F₃N₆O, 526.27; m/z found, 527.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.37 (m, 1H), 7.87 (d, J=1.8 Hz, 1H), 7.48-7.43 (m, 2H), 7.37-7.31 (m, 2H), 6.96-6.89 (m, 1H), 6.35 (s, 1H), 3.80-3.70 (m, 8H), 3.64-3.54 (m, 4H), 3.11-3.04 (m, 2H), 2.88-2.82 (m, 2H), 1.33 (s, 9H).

51

The following Examples 48-51 were prepared analogously to the methods used in Example 47, substituting the appropriate carboximidamides in Step A and amines in Step C.

Example 48

N⁴-(4-tert-Butyl-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₆H₃₁F₃N₆, 484.26; m/z found, 485.9 [M+H]⁺.


Example 48

N⁴-(4-tert-Butyl-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.47-8.45 (m, 1H), 8.05-8.02 (m, 1H), 7.51-7.47 (m, 2H), 7.46-7.42 (m, 2H), 7.17-7.13 (m, 1H), 3.64-3.60 (m, 2H), 3.57-3.53 (m, 2H), 3.30-3.27 (m, 2H), 3.18 (s, 6H), 3.11-3.06 (m, 2H), 1.35 (s, 9H).

Example 49

N²,N²-Dimethyl-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




MS (ESI): mass calcd. for C₂₃H₂₂F₆N₆, 496.18; m/z found, 497.8 [M+H]⁺. ¹H NMR (CDCl₃): 8.41-8.39 (m, 1H), 7.89-7.86 (m, 1H), 7.73 (d, J=8.8 Hz, 2H), 7.57 (d, J=8.8 Hz, 2H),

52

6.97-6.93 (m, 1H), 6.55 (s, 1H), 3.62-3.56 (m, 4H), 3.18 (s, 6H), 3.13-3.09 (m, 2H), 2.90-2.87 (m, 2H).

Example 50

N⁴-(4-Chloro-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




Example 50B

N⁴-(4-Chloro-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

MS (ESI): mass calcd. for C₂₂H₂₂ClF₃N₆, 462.15; m/z found, 463.8 [M+H]⁺. ¹H NMR (CD₃OD): 8.47-8.45 (m, 1H), 8.05-8.02 (m, 1H), 7.57-7.53 (m, 2H), 7.42-7.38 (m, 2H), 7.17-7.13 (m, 1H), 3.63-3.59 (m, 2H), 3.57-3.53 (m, 2H), 3.31-3.27 (m, 2H), 3.18 (s, 6H), 3.10-3.06 (m, 2H).

Example 51

N⁴-(4-Trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




MS (ESI): mass calcd. for C₂₁H₁₈F₆N₆, 468.15; m/z found, 469.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.41-8.39 (m, 1H), 7.90-7.87 (m, 1H), 7.67 (d, J=8.2 Hz, 2H), 7.58 (d, J=8.5 Hz, 2H),

53

6.99-6.95 (m, 1H), 6.55 (s, 1H), 4.73 (s, 2H), 3.63-3.57 (m, 4H), 3.11-3.07 (m, 2H), 2.93-2.89 (m, 2H).

Example 52

[2-Methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



Step A. 2-Methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol. To solution of 5-oxo-1-(3-trifluoromethyl-pyridin-2-yl)-azepane-4-carboxylic acid ethyl ester (3.0 g, 9.09 mmol) in EtOH (40 mL) was added NaOEt (1.97 g, 29.1 mmol) and thiourea (1.1 g, 13.6 mmol). The mixture was heated at reflux for 12 h. The mixture was cooled, treated with MeI (0.74 mL, 11.8 mmol) drop-wise, and stirred at rt for 1 h. The mixture was concentrated and the residue was dissolved in water and acidified to pH=7 with HOAc (a precipitate formed). The solid was filtered to give the title compound (3.3 g, >99%), which was used in the next step without further purification.

Step B. 4-Chloro-2-methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine. To a solution of 2-methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol (1.8 g, 4.92 mmol) in CH₃CN (40 mL) was added POCl₃ (1.4 mL, 14.8 mmol). After 15 min at 80° C., the mixture was cooled to rt, diluted with EtOAc, and quenched slowly with satd. aq. NaHCO₃. The organic layer was separated, dried (MgSO₄), and concentrated. The crude residue was purified (FCC) to give the title compound (1.6 g, 89%).


Step C. To a solution of 4-chloro-2-methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine (830 mg, 2.22 mmol) in n-BuOH (5 mL) was added 4-trifluoromethylaniline (0.4 mL, 3.30 mmol). The mixture was heated in the microwave at 160° C. for 30 min, then was cooled to rt, quenched with satd. aq. NaHCO₃, and extracted with EtOAc. The combined organic layers were dried (MgSO₄) and concentrated. The residue was purified (FCC) to give the title compound (950 mg, 86%). MS (ESI): mass calcd. for C₂₂H₁₉F₆N₅S, 499.13; m/z found, 500.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.37 (m, 1H), 7.89-7.86 (m, 1H), 7.69 (d, J=8.6 Hz, 2H), 7.58 (d, J=9.1 Hz, 2H),

54

6.99-6.94 (m, 1H), 6.65 (s, 1H), 3.66-3.62 (m, 2H), 3.60-3.56 (m, 2H), 3.21-3.16 (m, 2H), 2.99-2.94 (m, 2H), 2.53 (s, 3H).


Example 53

[2-Methanesulfonyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



To a solution of [2-methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine (Example 52; 513 mg, 1.02 mmol) in CH₂Cl₂ (10 mL) was added m-CPBA (77%; 480 mg, 2.22 mmol). After 2 h, the mixture was diluted with satd. aq. NaHCO₃ and extracted with CH₂Cl₂. The combined organic layers were dried (MgSO₄) and concentrated. The residue was purified (FCC; MeOH/CH₂Cl₂) to afford the title compound (500 mg, 92%). MS (ESI): mass calcd. for C₂₂H₁₉F₆N₅O₂S, 531.12; m/z found, 532.8 [M+H]⁺. ¹H NMR (CD₃OD): 8.46-8.44 (m, 1H), 8.04-8.01 (m, 1H), 7.88 (d, J=8.8 Hz, 2H), 7.66 (d, J=8.5 Hz, 2H), 7.15-7.11 (m, 1H), 3.60-3.54 (m, 4H), 3.37-3.31 (m, 2H), 3.28-3.23 (m, 5H).

Example 54


N²-Phenyl-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine

55

A solution of [2-methanesulfonyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine (Example 53; 30 mg, 0.06 mmol), aniline (8 mg, 0.09 mmol), and p-toluenesulfonic acid (21.3 mg, 0.11 mmol) in toluene (2 mL) was heated at 125° C. for 12 h. The mixture was cooled and directly purified using Preparative HPLC to give the title compound (20 mg, 67%). MS (ESI): mass calcd. for C₂₇H₂₂F₆N₆, 544.18; m/z found, 545.9 [M+H]⁺. ¹H NMR (CD₃OD): 8.46-8.44 (m, 1H), 8.00-7.97 (m, 1H), 7.66-7.58 (m, 4H), 7.48 (s, 1H), 7.45-7.42 (m, 2H), 7.24-7.19 (m, 2H), 7.16-7.11 (m, 2H), 3.63-3.59 (m, 2H), 3.57-3.53 (m, 2H), 3.29-3.25 (m, 2H), 3.11-3.07 (m, 2H).

Example 55

N²-Cyclopropyl-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



The title compound was prepared using methods analogous to those described in Example 54, with n-butanol or t-amyl alcohol as the solvent, in a sealed tube at 130° C., and without the addition of p-toluenesulfonic acid.

Example 55B

N²-Cyclopropyl-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt


MS (ESI): mass calcd. for C₂₄H₂₂F₆N₆, 508.18; m/z found, 509.8 [M+H]⁺. ¹H NMR (CD₃OD): 8.49-8.44 (m, 1H), 8.04 (d, J=7.7 Hz, 1H), 7.92 (s, 2H), 7.69 (d, J=8.8 Hz, 2H), 7.18-7.13 (m, 1H), 3.66-3.61 (m, 2H), 3.59-3.54 (m, 2H), 3.31-3.24 (m, 2H), 3.15-3.11 (m, 2H), 2.76-2.66 (m, 1H), 0.94-0.86 (m, 2H), 0.69-0.64 (m, 2H).

56

The compounds in Examples 56-61 were prepared using methods analogous to those described in Example 55.

Example 56

[2-Azetidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine




Example 56B

[2-Azetidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine trifluoroacetic acid salt

MS (ESI): mass calcd. for C₂₄H₂₂F₆N₆, 508.18; m/z found, 509.8 [M+H]⁺. ¹H NMR (CD₃OD): 8.47-8.45 (m, 1H), 8.05-8.02 (m, 1H), 7.85 (d, J=8.5 Hz, 2H), 7.69 (d, J=8.8 Hz, 2H), 7.17-7.13 (m, 1H), 4.32-4.22 (m, 4H), 3.64-3.60 (m, 2H), 3.57-3.53 (m, 2H), 3.26-3.22 (m, 2H), 3.13-3.09 (m, 2H), 2.53-2.45 (m, 2H).

Example 57

1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidine-4-carboxylic acid



57


Example 57B

1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidine-4-carboxylic acid trifluoroacetic acid salt

MS (ESI): mass calcd. for $C_{27}H_{26}F_6N_6O_2$, 580.2; m/z found, 581.9 $[M+H]^+$. 1H NMR (CD_3OD): 8.49-8.44 (m, 1H), 8.07-8.02 (m, 1H), 7.74-7.72 (m, 4H), 7.18-7.13 (m, 1H), 4.30-4.22 (m, 2H), 3.65-3.61 (m, 2H), 3.58-3.54 (m, 2H), 3.34-3.25 (m, 4H), 3.14-3.09 (m, 2H), 2.74-2.66 (m, 1H), 2.08-2.01 (m, 2H), 1.80-1.68 (m, 2H).

Example 58

N^2 -(2-Piperidin-1-yl-ethyl)- N^4 -(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



Example 58B


N^2 -(2-Piperidin-1-yl-ethyl)- N^4 -(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

MS (ESI): mass calcd. for $C_{28}H_{31}F_6N_7$, 579.25; m/z found, 581.0 $[M+H]^+$. 1H NMR (CD_3OD): 8.47-8.44 (m, 1H), 8.05-8.01 (m, 1H), 7.79-7.70 (m, 4H), 7.18-7.12 (m, 1H), 3.76-3.71 (m, 2H), 3.64-3.59 (m, 2H), 3.57-3.52 (m, 2H), 3.44-3.36 (m, 2H), 3.24-3.17 (m, 4H), 3.13-3.07 (m, 2H), 2.81-2.70 (m, 2H), 1.82-1.32 (m, 6H).

58

Example 59

1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidin-4-ol




Example 59B

1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidin-4-ol trifluoroacetic acid salt

MS (ESI): mass calcd. for $C_{26}H_{26}F_6N_6O$, 552.21; m/z found, 553.9 $[M+H]^+$. 1H NMR (CD_3OD): 8.47-8.43 (m, 1H), 8.05-8.00 (m, 1H), 7.75-7.68 (m, 4H), 7.17-7.11 (m, 1H), 4.07-3.98 (m, 2H), 3.97-3.88 (m, 1H), 3.64-3.57 (m, 2H), 3.56-3.42 (m, 4H), 3.32-3.25 (m, 2H), 3.13-3.06 (m, 2H), 1.98-1.87 (m, 2H), 1.64-1.49 (m, 2H).

Example 60

[2-(4-Isopropyl-piperazin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



59


Example 60B

[2-(4-Isopropyl-piperazin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine trifluoroacetic acid salt

MS (ESI): mass calcd. for $C_{28}H_{31}F_6N_7$, 579.25; m/z found, 581.0 $[M+H]^+$. 1H NMR (CD_3OD): 8.47-8.44 (m, 1H), 8.05-8.01 (m, 1H), 7.73-7.71 (m, 4H), 7.18-7.12 (m, 1H), 3.66-3.24 (m, 15H), 3.18-3.07 (m, 2H), 1.38 (d, $J=6.3$ Hz, 6H).

Example 61

N^2 -(Tetrahydro-pyran-4-yl)- N^4 -(4-trifluoromethyl-phenyl)-7-(3-trifluoro-methyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




Example 61B

N^2 -(Tetrahydro-pyran-4-yl)- N^4 -(4-trifluoromethyl-phenyl)-7-(3-trifluoro-methyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

MS (ESI): mass calcd. for $C_{26}H_{26}F_6N_6O$, 552.21; m/z found, 553.9 $[M+H]^+$. 1H NMR (CD_3OD): 8.48-8.45 (m, 1H), 8.06-8.03 (m, 1H), 7.77 (d, $J=8.5$ Hz, 2H), 7.72 (d, $J=8.8$ Hz, 2H), 7.18-7.14 (m, 1H), 3.98-3.84 (m, 3H), 3.64-3.60 (m, 2H), 3.58-3.54 (m, 2H), 3.43-3.35 (m, 2H), 3.21-3.17 (m, 2H), 3.12-3.09 (m, 2H), 1.92-1.84 (m, 2H), 1.65-1.54 (m, 2H).

Example 62

[2-Methoxy-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine




60

A solution of [2-methanesulfonyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine (Example 53; 44 mg, 0.08 mmol) and NaOMe (100 mg, 0.25 mmol) in MeOH (1.5 mL) was heated at 60° C. for 1 h. The mixture was cooled, acidified with HOAc (3 drops), and directly purified using Preparative HPLC (conditions as in Example 54) to give the title compound (35 mg, 89%). MS (ESI): mass calcd. for $C_{22}H_{19}F_6N_5O$, 483.15; m/z found, 484.8 $[M+H]^+$. 1H NMR ($CDCl_3$): 9.63 (s, 1H), 8.39 (d, $J=3.3$ Hz, 1H), 7.89 (d, $J=7.7$ Hz, 1H), 7.73 (d, $J=8.5$ Hz, 2H), 7.63 (d, $J=8.5$ Hz, 2H), 7.06-7.02 (m, 1H), 3.88 (s, 3H), 3.50-3.44 (m, 4H), 3.26-3.22 (m, 2H), 3.11-3.07 (m, 2H).

The following Examples 63-109 were prepared using methods analogous to those described in the preceding examples.

Example 63

N^4 -(3,4-Dichloro-phenyl)- N^2,N^2 -dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for $C_{22}H_{21}Cl_2F_3N_6$, 496.12; m/z found, 497.8 $[M+H]^+$.


Example 63B

N^4 -(3,4-Dichloro-phenyl)- N^2,N^2 -dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

1H NMR (CD_3OD): 8.46 (dd, $J=4.7, 1.4$ Hz, 1H), 8.03 (dd, $J=7.8, 1.8$ Hz, 1H), 7.93-7.92 (m, 1H), 7.53-7.52 (m, 2H), 7.17-7.12 (m, 1H), 3.64-3.58 (m, 2H), 3.56-3.52 (m, 2H), 3.32-3.29 (m, 2H), 3.22 (s, 6H), 3.11-3.06 (m, 2H).

Example 64

N^4 -(4-Methoxy-3-trifluoromethyl-phenyl)- N^2,N^2 -dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




61

MS (ESI): mass calcd. for $C_{24}H_{24}F_6N_6O$, 526.19; m/z found, 527.9 $[M+H]^+$. 1H NMR (CD_3OD): 8.42 (dd, $J=4.7$, 1.6 Hz, 1H), 8.13 (d, $J=2.7$ Hz, 1H), 7.90 (dd, $J=7.8$, 1.8 Hz, 1H), 7.56 (dd, $J=8.9$, 2.7 Hz, 1H), 7.04-6.93 (m, 2H), 6.35 (s, 1H), 3.94 (s, 3H), 3.66-3.57 (m, 4H), 3.16 (s, 6H), 3.14-3.09 (m, 2H), 2.90-2.85 (m, 2H).

Example 65

2-{4-[2-Dimethylamino-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-2-methyl-propionitrile



MS (ESI): mass calcd. for $C_{26}H_{28}F_3N_7$, 495.24; m/z found, 496.9 $[M+H]^+$.


Example 65B

2-{4-[2-Dimethylamino-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-2-methyl-propionitrile trifluoroacetic acid salt

1H NMR (CD_3OD): 8.45 (dd, $J=4.7$, 1.4 Hz, 1H), 8.02 (dd, $J=7.8$, 1.8 Hz, 1H), 7.66-7.60 (m, 2H), 7.58-7.53 (m, 2H), 7.17-7.11 (m, 1H), 3.64-3.58 (m, 2H), 3.56-3.51 (m, 2H), 3.30-3.25 (m, 2H), 3.18 (s, 3H), 3.11-3.06 (m, 2H), 1.73 (s, 6H).

Example 66

(4-tert-Butyl-phenyl)-[2-piperidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for $C_{30}H_{37}F_3N_6$, 538.30; m/z found, 540.0 $[M+H]^+$.

62


Example 66B

(4-tert-Butyl-phenyl)-[2-piperidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine trifluoroacetic acid salt

1H NMR (CD_3OD): 8.46 (dd, $J=4.7$, 1.4 Hz, 1H), 8.04 (dd, $J=7.8$, 1.7 Hz, 1H), 7.53-7.49 (m, 2H), 7.39-7.35 (m, 2H), 7.17-7.13 (m, 1H), 4.41 (s, 2H), 3.65-3.60 (m, 4H), 3.33-3.31 (m, 2H), 3.23-3.18 (m, 2H), 1.80-1.69 (m, 4H), 1.68-1.58 (m, 2H), 1.36 (s, 9H), 1.29-1.21 (m, 2H).

Example 67

(4-tert-Butyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for $C_{26}H_{30}F_3N_5O$, 485.24; m/z found, 468.9 $[M+H]^+$.


Example 67B

(4-tert-Butyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine trifluoroacetic acid salt

1H NMR (CD_3OD): 8.66 (d, $J=8.9$ Hz, 1H), 8.52 (s, 1H), 8.40 (dd, $J=4.7$, 1.5 Hz, 1H), 7.93 (dd, $J=8.9$, 2.3 Hz, 1H), 7.88 (dd, $J=7.8$, 1.8 Hz, 1H), 7.63 (s, 1H), 7.00-6.95 (m, 1H), 3.65-3.56 (m, 4H), 3.28-3.21 (m, 2H), 3.09-3.03 (m, 2H), 2.63 (s, 3H).

Example 68

N^4 -(2,3-Dihydro-benzo[1,4]dioxin-6-yl)- N^2,N^2 -dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for $C_{24}H_{25}F_3N_6O_2$, 486.20; m/z found, 487.8 $[M+H]^+$.

63


Example 68B

N⁴-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.46-8.44 (m, 1H), 8.03 (dd, J=7.8, 1.7 Hz, 1H), 7.16-7.12 (m, 1H), 7.11 (d, J=2.4 Hz, 1H), 6.98 (dd, J=8.7, 2.5 Hz, 1H), 6.84 (d, J=8.7 Hz, 1H), 4.25 (s, 4H), 3.62-3.58 (m, 2H), 3.55-3.51 (m, 2H), 3.29-3.24 (m, 2H), 3.17 (s, 6H), 3.07-3.02 (m, 2H).

Example 69


[2-Methyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine



MS (ESI): mass calcd. for C₂₁H₁₈F₆N₆, 468.15; m/z found, 469.8 [M+H]⁺. ¹H NMR (CDCl₃): 8.66 (d, J=8.9 Hz, 1H), 8.52 (s, 1H), 8.40 (dd, J=4.7, 1.5 Hz, 1H), 7.93 (dd, J=8.9, 2.3 Hz, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.63 (s, 1H), 7.00-6.95 (m, 1H), 3.65-3.56 (m, 4H), 3.28-3.21 (m, 2H), 3.09-3.03 (m, 2H), 2.63 (s, 3H).

Example 70

N⁴-Benzyl-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₃H₂₅F₃N₆, 442.21; m/z found, 443.8 [M+H]⁺.

64


Example 70B

N⁴-Benzyl-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.40-8.38 (m, 1H), 8.00-7.97 (m, 1H), 7.34-7.26 (m, 4H), 7.25-7.20 (m, 1H), 7.10-7.06 (m, 1H), 4.70 (s, 2H), 3.60-3.56 (m, 2H), 3.54-3.50 (m, 2H), 3.26-3.20 (m, 2H), 3.15 (s, 6H), 2.97-2.93 (m, 2H).

Example 71

4-[2-Dimethylamino-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzenesulfonamide



MS (ESI): mass calcd. for C₂₂H₂₄F₃N₇O₂S, 507.17; m/z found, 508.8 [M+H]⁺.


Example 71B

4-[2-Dimethylamino-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzenesulfonamide trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.47-8.45 (m, 1H), 8.04 (dd, J=7.8, 1.7 Hz, 1H), 7.94-7.91 (m, 2H), 7.81-7.77 (m, 2H), 7.19-7.11 (m, 1H), 3.66-3.58 (m, 2H), 3.58-3.52 (m, 1H), 3.34-3.29 (m, 2H), 3.21 (s, 6H), 3.13-3.10 (m, 2H).

Example 72

N²,N²-Dimethyl-N⁴-(4-nitro-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₂H₂₂F₃N₇O₂, 473.18; m/z found, 474.8 [M+H]⁺.

65


Example 72B

N²,N²-Dimethyl-N⁴-(4-nitro-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.48-8.45 (m, 1H), 8.31-8.26 (m, 2H), 8.04 (dd, J=7.8, 1.8 Hz, 1H), 7.92-7.87 (m, 2H), 7.19-7.12 (m, 1H), 3.66-3.59 (m, 2H), 3.58-3.54 (m, 2H), 3.37-3.33 (m, 2H), 3.24 (s, 3H), 3.16-3.12 (m, 2H).

Example 73

N⁴-(3,4-Dichloro-benzyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₃H₂₃Cl₂F₃N₆, 510.13; m/z found, 511.1 [M+H]⁺.


Example 73B

N⁴-(3,4-Dichloro-benzyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.40 (dd, J=4.7, 1.3 Hz, 1H), 7.99 (dd, J=7.8, 1.8 Hz, 1H), 7.48-7.46 (m, 1H), 7.44 (s, 1H), 7.24 (dd, J=8.3, 2.0 Hz, 1H), 7.12-7.06 (m, 1H), 4.65 (s, 2H), 3.61-3.55 (m, 2H), 3.54-3.49 (m, 2H), 3.25-3.18 (m, 2H), 3.14 (s, 6H), 2.97-2.91 (m, 2H).

Example 74

[2-Methyl sulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine



MS (ESI): mass calcd. for C₂₁H₁₈F₆N₆S, 500.12; m/z found, 501.8 [M+H]⁺.

66


Example 74B

[2-Methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.84-8.81 (m, 1H), 8.35 (dd, J=8.0, 1.5 Hz, 1H), 8.19 (s, 1H), 7.75-7.65 (m, 2H), 6.71 (d, J=9.0 Hz, 1H), 4.32-4.24 (m, 2H), 3.90-3.84 (m, 2H), 3.30-3.23 (m, 2H), 2.98 (t, J=6.3 Hz, 2H), 2.32 (s, 3H).

Example 75

[2-Methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine



MS (ESI): mass calcd. for C₂₁H₁₈F₆N₆S, 500.12; m/z found, 501.8 [M+H]⁺.


Example 75B

[2-Methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine trifluoroacetic acid salt

¹H NMR (CD₃OD): 9.00 (d, J=2.4 Hz, 1H), 8.46-8.43 (m, 1H), 8.36 (dd, J=8.6, 2.4 Hz, 1H), 8.02 (dd, J=7.8, 1.8 Hz, 1H), 7.78 (d, J=8.6 Hz, 1H), 7.16-7.10 (m, 1H), 3.56-3.48 (m, 4H), 3.20-3.10 (m, 4H), 2.50 (s, 3H).

Example 76

[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for C₂₃H₂₁F₆N₅O, 497.17; m/z found, 489.3 [M+H]⁺.

67


Example 76B

[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.46-8.44 (m, 1H), 8.03 (dd, J=7.9, 1.7 Hz, 1H), 7.79-7.68 (m, 4H), 7.18-7.11 (m, 1H), 4.57 (s, 2H), 3.68-3.59 (m, 4H), 3.52 (s, 3H), 3.46-3.42 (m, 2H), 3.28-3.23 (m, 2H).

Example 77

4-[2-Dimethylamino-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester



MS (ESI): mass calcd. for C₂₄H₂₅F₃N₆O₂, 486.20; m/z found, 487.8 [M+H]⁺.


Example 77B

4-[2-Dimethylamino-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.47 (dd, J=4.7, 1.5 Hz, 1H), 8.08-8.04 (m, 2H), 8.04 (d, J=1.8 Hz, 1H), 7.75-7.72 (m, 2H), 7.18-7.13 (m, 1H), 3.92 (s, 3H), 3.64-3.60 (m, 2H), 3.58-3.53 (m, 2H), 3.32-3.29 (m, 2H), 3.22 (s, 6H), 3.15-3.09 (m, 2H).

Example 78

4-[2-Dimethylamino-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzonitrile



MS (ESI): mass calcd. for C₂₃H₂₂F₃N₇, 453.19; m/z found, 454.8 [M+H]⁺.

68


Example 78B

4-[2-Dimethylamino-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzonitrile trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.46 (dd, J=4.7, 1.4 Hz, 1H), 8.04 (dd, J=7.8, 1.8 Hz, 1H), 7.85-7.81 (m, 2H), 7.79-7.76 (m, 2H), 7.18-7.13 (m, 1H), 3.65-3.59 (m, 2H), 3.57-3.52 (m, 2H), 3.34-3.32 (m, 2H), 3.23 (s, 6H), 3.15-3.09 (m, 2H).

Example 79

N⁴-(4-Dimethylamino-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₄H₂₈F₃N₇, 471.24; m/z found, 472.2 [M+H]⁺.


Example 79B

N⁴-(4-Dimethylamino-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.46-8.43 (m, 1H), 8.02 (dd, J=7.8, 1.7 Hz, 1H), 7.82-7.76 (m, 2H), 7.62-7.58 (m, 2H), 7.17-7.10 (m, 1H), 3.64-3.57 (m, 2H), 3.56-3.51 (m, 2H), 3.31-3.28 (m, 2H), 3.27 (s, 6H), 3.19 (s, 6H), 3.12-3.06 (m, 2H).

Example 80

(3-Chloro-4-trifluoromethyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for C₂₃H₂₀ClF₆N₅O, 531.13; m/z found, 532.3 [M+H]⁺.

69


Example 80B

(3-Chloro-4-trifluoromethyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.44 (dd, J=4.8, 1.4 Hz, 1H), 8.02 (dd, J=7.8, 1.8 Hz, 1H), 7.44-7.38 (m, 2H), 7.16-7.10 (m, 1H), 6.96-6.91 (m, 2H), 3.80 (s, 3H), 3.62-3.57 (m, 2H), 3.56-3.50 (m, 2H), 3.29-3.23 (m, 2H), 3.14 (s, 3H), 3.08-3.02 (m, 2H).

Example 81

N⁴-(4-Methoxy-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₃H₂₅F₃N₆O, 458.20; m/z found, 459.8 [M+H]⁺.


Example 81B

N⁴-(4-Methoxy-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.44 (dd, J=4.8, 1.4 Hz, 1H), 8.02 (dd, J=7.8, 1.8 Hz, 1H), 7.44-7.38 (m, 2H), 7.16-7.10 (m, 1H), 6.96-6.91 (m, 2H), 3.80 (s, 3H), 3.62-3.57 (m, 2H), 3.56-3.50 (m, 2H), 3.29-3.23 (m, 2H), 3.14 (s, 3H), 3.08-3.02 (m, 2H).

Example 82

N⁴-Indan-2-yl-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₅H₂₇F₃N₆, 468.22; m/z found, 469.9 [M+H]⁺.

70


Example 82B

N⁴-Indan-2-yl-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.44-8.41 (m, 1H), 8.02 (dd, J=7.8, 1.7 Hz, 1H), 7.25-7.20 (m, 2H), 7.18-7.15 (m, 2H), 7.15-7.11 (m, 1H), 5.04-4.95 (m, 1H), 3.60-3.54 (m, 2H), 3.47-3.43 (m, 2H), 3.42-3.35 (m, 2H), 3.24 (s, 6H), 3.23-3.20 (m, 2H), 3.10-3.02 (m, 2H), 2.95-2.90 (m, 2H).

Example 83


[7-(5-Amino-3-methyl-pyridin-2-yl)-2-isopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for C₂₄H₂₇F₃N₆, 456.22; m/z found, 455.2 [M-H]⁻. ¹H NMR (CDCl₃): 7.79 (d, J=8.6 Hz, 2H), 7.67 (d, J=2.9 Hz, 1H), 7.58 (d, J=8.7 Hz, 2H), 6.90-6.85 (m, 1H), 6.69-6.65 (m, 1H), 3.46-3.37 (m, 2H), 3.34-3.29 (m, 2H), 3.26-3.22 (m, 2H), 3.21-3.17 (m, 2H), 3.10-3.03 (m, 1H), 2.96-2.90 (m, 2H), 2.27 (s, 3H), 1.34 (d, J=6.9 Hz, 6H).

Example 84

[7-(2-Amino-phenyl)-2-isopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine




MS (ESI): mass calcd. for C₂₄H₂₆F₃N₅, 441.21; m/z found, 442.2 [M+H]⁺. ¹H NMR (CDCl₃): 7.44-7.33 (m, 2H), 7.17-

71

7.09 (m, 2H), 6.89-6.81 (m, 2H), 6.67-6.59 (m, 2H), 4.10-3.97 (m, 2H), 3.60-3.47 (m, 2H), 3.13-3.03 (m, 2H), 3.02-2.92 (m, 1H), 2.90-2.85 (m, 2H), 1.28-1.26 (m, 6H).

Example 85


[2-Isopropyl-7-(2-nitro-phenyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for $C_{24}H_{24}F_3N_5O_2$, 471.19; m/z found, 472.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 7.99 (dd, $J=8.2, 1.5$ Hz, 1H), 7.66-7.56 (m, 1H), 7.42-7.35 (m, 2H), 7.34-7.28 (m, 2H), 6.67-6.51 (m, 2H), 4.22-4.02 (m, 2H), 3.62-3.47 (m, 2H), 3.15-3.04 (m, 2H), 2.96-2.83 (m, 3H), 1.21 (d, $J=6.9$ Hz, 6H).

Example 86

[7-(3-Amino-pyridin-2-yl)-2-isopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine




MS (ESI): mass calcd. for $C_{23}H_{25}F_3N_6$, 442.21; m/z found, 443.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 7.86-7.72 (m, 3H), 7.64-7.57 (m, 2H), 7.04-6.95 (m, 1H), 6.90-6.85 (m, 1H), 6.71-6.67 (m, 1H), 3.89-3.77 (m, 2H), 3.47-3.40 (m, 2H), 3.39-

72

3.35 (m, 2H), 3.26-3.21 (m, 2H), 3.13-3.04 (m, 1H), 3.01-2.94 (m, 2H), 1.36 (d, $J=6.9$ Hz, 6H).

Example 87


[2-Isopropyl-7-(3-methyl-5-nitro-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for $C_{24}H_{25}F_3N_6O_2$, 486.20; m/z found, 487.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.93 (d, $J=2.6$ Hz, 1H), 8.16-8.05 (m, 1H), 7.81 (d, $J=8.5$ Hz, 2H), 7.62 (d, $J=8.4$ Hz, 2H), 7.35-7.28 (m, 1H), 6.76-6.60 (m, 1H), 4.04-3.90 (m, 2H), 3.89-3.82 (m, 2H), 3.35-3.22 (m, 2H), 3.12-3.02 (m, 3H), 2.41 (s, 3H), 1.33 (d, $J=6.9$ Hz, 6H).

Example 88

[2-Isopropyl-7-(3-nitro-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine




MS (ESI): mass calcd. for $C_{23}H_{23}F_3N_6O_2$, 472.18; m/z found, 473.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.28 (m, 1H), 8.15-8.12 (m, 1H), 7.36-7.21 (m, 4H), 6.84-6.69 (m, 1H), 3.81-3.67 (m, 4H), 3.47-3.37 (m, 2H), 3.36-3.30 (m, 2H), 3.22-3.07 (m, 1H), 1.32 (d, $J=6.9$ Hz, 6H).

73

Example 89


N-{2-[2-Isopropyl-4-(4-trifluoromethyl-phenylamino)-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl]-phenyl}-methanesulfonamide



MS (ESI): mass calcd. for $C_{25}H_{28}F_3N_5O_2S$, 519.19; m/z found, 520.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 9.03-8.84 (m, 1H), 7.63-7.54 (m, 1H), 7.43-7.37 (m, 2H), 7.32-7.28 (m, 2H), 6.69-6.57 (m, 2H), 4.18-4.01 (m, 2H), 3.65-3.52 (m, 2H), 3.13-2.97 (m, 3H), 2.93-2.84 (m, 4H), 1.31 (d, $J=6.9$ Hz, 6H).

Example 90

4-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperazin-2-one



MS (ESI): mass calcd. for $C_{25}H_{23}F_6N_7O$, 551.19; m/z found, 552.9 $[M+H]^+$.

Example 90B

4-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperazin-2-one trifluoroacetic acid salt

1H NMR ($CDCl_3$): 8.41 (dd, $J=4.8, 1.4$ Hz, 1H), 7.91 (dd, $J=7.8, 1.8$ Hz, 1H), 7.70 (d, $J=8.7$ Hz, 2H), 7.61 (d, $J=8.6$ Hz, 2H), 7.34-7.31 (m, 1H), 7.05-7.01 (m, 1H), 6.53-6.45 (m, 1H), 4.39-4.31 (m, 2H), 4.14-4.09 (m, 2H), 3.65-3.57 (m, 4H), 3.57-3.52 (m, 2H), 3.40-3.31 (m, 2H), 3.02-2.90 (m, 2H).

74

Example 91

(R)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidin-3-ol


5

10

15

20

25



MS (ESI): mass calcd. for $C_{26}H_{26}F_6N_6O$, 552.21; m/z found, 553.9 $[M+H]^+$.

Example 91B

(R)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidin-3-ol trifluoroacetic acid salt

30

35

40

1H NMR ($CDCl_3$): 8.42-8.38 (m, 1H), 7.89 (dd, $J=7.8, 1.6$ Hz, 1H), 7.67-7.59 (m, 5H), 7.02 (dd, $J=7.7, 4.8$ Hz, 1H), 4.33-4.23 (m, 1H), 4.20-4.11 (m, 1H), 4.08-4.00 (m, 1H), 3.63-3.49 (m, 5H), 3.39-3.33 (m, 2H), 3.31-3.22 (m, 1H), 2.99-2.90 (m, 2H), 2.03-1.90 (m, 1H), 1.89-1.73 (m, 2H), 1.58-1.49 (m, 1H).

Example 92


[2-(4-Methyl-piperazin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine

45

50

55

60



MS (ESI): mass calcd. for $C_{26}H_{27}F_6N_7$, 551.22; m/z found, 552.9 $[M+H]^+$.

65

75


Example 92B

[2-(4-Methyl-piperazin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine trifluoroacetic acid salt

¹H NMR (CDCl₃): 8.38 (dd, J=4.6, 1.4 Hz, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.64 (d, J=8.6 Hz, 2H), 7.56 (d, J=8.7 Hz, 2H), 6.97-6.91 (m, 1H), 6.52 (s, 1H), 3.83-3.75 (m, 4H), 3.62-3.53 (m, 4H), 3.13-3.04 (m, 2H), 2.90-2.84 (m, 2H), 2.52-2.42 (m, 4H), 2.34 (s, 3H).

Example 93

N²-(2-Methoxy-ethyl)-N²-methyl-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₅H₂₆F₆N₆O, 540.21; m/z found, 541.3 [M+H]⁺.

Example 93B


N²-(2-Methoxy-ethyl)-N²-methyl-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.45 (dd, J=4.8, 1.3 Hz, 1H), 8.03 (dd, J=7.8, 1.8 Hz, 1H), 7.76 (d, J=8.6 Hz, 2H), 7.70 (d, J=8.7 Hz, 2H), 7.17-7.11 (m, 1H), 3.78-3.76 (m, 2H), 3.64-3.59 (m, 2H), 3.59-3.52 (m, 4H), 3.21 (s, 3H), 3.13-3.08 (m, 2H).

76

Example 94

(S)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidin-3-ol



MS (ESI): mass calcd. for C₂₆H₂₆F₆N₆O, 552.21; m/z found, 553.3 [M+H]⁺.


Example 94B

(S)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidin-3-ol trifluoroacetic acid salt

¹H NMR (CD₃OD): 8.45 (dd, J=4.7, 1.4 Hz, 1H), 8.03 (dd, J=7.8, 1.8 Hz, 1H), 7.77-7.68 (m, 4H), 7.14 (dd, J=7.6, 4.8 Hz, 1H), 3.88-3.76 (m, 2H), 3.70-3.51 (m, 7H), 3.30-3.25 (m, 2H), 3.13-3.07 (m, 2H), 2.00-1.86 (m, 2H), 1.74-1.50 (m, 2H), 1.36-1.24 (m, 1H).

Example 95

N²-Cyclopropylmethyl-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



77

MS (ESI): mass calcd. for $C_{25}H_{24}F_6N_6$, 522.20; m/z found, 523.3 $[M+H]^+$.


Example 95B

N^2 -Cyclopropylmethyl- N^4 -(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt

1H NMR (CD_3OD): 8.45 (dd, $J=4.7, 1.4$ Hz, 1H), 8.04-8.01 (m, 1H), 7.81-7.67 (m, 4H), 7.16-7.11 (m, 1H), 3.65-3.51 (m, 4H), 3.26-3.13 (m, 4H), 3.11-3.06 (m, 2H), 1.10-1.00 (m, 1H), 0.52-0.45 (m, 2H), 0.22-0.15 (m, 2H).

Example 96


1-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-ethanone



MS (ESI): mass calcd. for $C_{25}H_{26}F_3N_5O$, 469.21; m/z found, 470.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.37 (m, 1H), 8.00-7.95 (m, 2H), 7.87 (dd, $J=7.8, 1.8$ Hz, 1H), 7.81-7.77 (m, 2H), 6.98-6.94 (m, 1H), 6.73 (s, 1H), 3.68-3.57 (m, 4H), 3.25-3.21 (m, 2H), 3.10-3.03 (m, 1H), 3.02-2.96 (m, 2H), 2.59 (s, 3H), 1.34 (d, $J=6.9$ Hz, 6H).

Example 97

4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzonitrile




78

MS (ESI): mass calcd. for $C_{24}H_{23}F_3N_6$, 452.19; m/z found, 453.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.38 (m, 1H), 7.89 (dd, $J=7.8, 1.8$ Hz, 1H), 7.85-7.81 (m, 2H), 7.66-7.61 (m, 2H), 7.00-6.95 (m, 1H), 6.72 (s, 1H), 3.69-3.57 (m, 4H), 3.28-3.23 (m, 2H), 3.13-3.04 (m, 1H), 3.03-2.98 (m, 2H), 1.34 (d, $J=6.9$ Hz, 6H).

Example 98


(3,4-Dichloro-benzyl)-[2-methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for $C_{22}H_{20}Cl_2F_3N_5S$, 513.08; m/z found, 514.0 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38-8.34 (m, 1H), 7.88-7.84 (m, 1H), 7.43-7.38 (m, 2H), 7.18-7.14 (m, 1H), 6.96-6.91 (m, 1H), 5.05-4.97 (m, 1H), 4.66 (d, $J=5.7$ Hz, 2H), 3.63-3.50 (m, 4H), 3.14-3.08 (m, 2H), 2.80-2.76 (m, 2H), 2.44 (s, 3H).

Example 99

[2-Piperazin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for $C_{25}H_{25}F_6N_7$, 537.21; m/z found, 538.2 $[M+H]^+$.

79


Example 99B

[2-Piperazin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-
6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-
(4-trifluoromethyl-phenyl)-amine trifluoroacetic
salt

¹H NMR (CD₃OD): 8.47-8.44 (m, 1H), 8.03 (dd, J=7.8, 1.8
Hz, 1H), 7.74-7.67 (m, 4H), 7.17-7.13 (m, 1H), 4.02-3.93 (m,
4H), 3.59-3.50 (m, 4H), 3.35-3.21 (m, 6H), 3.13-3.07 (m,
2H).

Example 100


[2-Thiomorpholin-4-yl-7-(3-trifluoromethyl-pyridin-
2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-
4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for C₂₅H₂₄F₆N₆S, 554.17; m/z
found, 555.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.44-8.41 (m, 1H),
7.91 (dd, J=7.8, 1.8 Hz, 1H), 7.67-7.57 (m, 4H), 7.02-6.96 (m,
1H), 6.56 (s, 1H), 4.20-4.08 (m, 4H), 3.68-3.57 (m, 4H),
3.16-3.08 (m, 2H), 2.95-2.89 (m, 2H), 2.71-2.66 (m, 4H).

Example 101

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,
8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-
trifluoromethanesulfonyl-phenyl)-amine



MS (ESI): mass calcd. for C₂₄H₂₃F₆N₅O₂S, 559.15; m/z
found, 560.1 [M+H]⁺.

80


Example 101B

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,
8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-
trifluoromethanesulfonyl-phenyl)-amine trifluoroacetic
acid salt

¹H NMR (CD₃OD): 8.44-8.42 (m, 1H), 8.02-7.94 (m, 3H),
7.88-7.84 (m, 2H), 7.14-7.09 (m, 1H), 3.83-3.76 (m, 1H),
3.69-3.60 (m, 6H), 3.29-3.22 (m, 2H), 1.32-1.27 (m, 6H).

Example 102


[2-(4-Benzyl-piperazin-1-yl)-7-(3-trifluoromethyl-
pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]
azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for C₃₂H₃₁F₆N₇, 627.25; m/z found,
628.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.41-8.38 (m, 1H), 7.88
(dd, J=7.8, 1.9 Hz, 1H), 7.66-7.61 (m, 2H), 7.57-7.53 (m,
2H), 7.39-7.28 (m, 5H), 6.98-6.93 (m, 1H), 6.51 (s, 1H),
3.82-3.76 (m, 4H), 3.63-3.55 (m, 6H), 3.12-3.07 (m, 2H),
2.91-2.86 (m, 2H), 2.54-2.49 (m, 4H).

Example 103

4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,
7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-
ylamino]-benzoic acid methyl ester




81

MS (ESI): mass calcd. for $C_{25}H_{26}F_3N_5O_2$, 485.20; m/z found, 486.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 8.07-8.02 (m, 2H), 7.89 (dd, $J=7.8, 1.8$ Hz, 1H), 7.80-7.75 (m, 2H), 6.99-6.95 (m, 1H), 6.71 (s, 1H), 3.92 (s, 3H), 3.68-3.59 (m, 4H), 3.27-3.22 (m, 2H), 3.11-3.03 (m, 1H), 3.02-2.98 (m, 2H), 1.35 (d, $J=6.9$ Hz, 6H).

Example 104


[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethylsulfanyl-phenyl)-amine



MS (ESI): mass calcd. for $C_{24}H_{23}F_6N_5S$, 527.16; m/z found, 528.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.89 (dd, $J=7.8, 1.8$ Hz, 1H), 7.81-7.77 (m, 2H), 7.65-7.61 (m, 2H), 6.99-6.95 (m, 1H), 6.65 (s, 1H), 3.70-3.58 (m, 4H), 3.27-3.22 (m, 2H), 3.12-3.03 (m, 1H), 3.02-2.97 (m, 2H), 1.34 (d, $J=6.9$ Hz, 6H).

Example 105

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-pyrimidin-4-yl-amine




MS (ESI): mass calcd. for $C_{21}H_{22}F_3N_7$, 429.19; m/z found, 430.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.83-8.81 (m, 1H), 8.60 (d, $J=5.9$ Hz, 1H), 8.58-8.55 (m, 1H), 8.42-8.40 (m, 1H), 7.89 (dd, $J=7.8, 1.8$ Hz, 1H), 7.51 (s, 1H), 7.01-6.97 (m, 1H),

82

3.65-3.56 (m, 4H), 3.29-3.25 (m, 2H), 3.17-3.10 (m, 1H), 3.08-3.04 (m, 2H), 1.38 (d, $J=6.9$ Hz, 6H).

Example 106


[2-Pyrrolidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for $C_{25}H_{24}F_6N_6$, 522.20; m/z found, 523.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.38 (m, 1H), 7.88 (dd, $J=7.8, 1.8$ Hz, 1H), 7.82-7.77 (m, 2H), 7.59-7.54 (m, 2H), 6.97-6.92 (m, 1H), 6.55 (s, 1H), 3.64-3.53 (m, 8H), 3.13-3.08 (m, 2H), 2.91-2.87 (m, 2H), 2.02-1.94 (m, 4H).

Example 107

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-pyrimidin-2-yl-amine




MS (ESI): mass calcd. for $C_{21}H_{22}F_3N_7$, 429.19; m/z found, 430.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.45 (d, $J=4.8$ Hz, 2H), 8.43-8.41 (m, 1H), 7.88 (dd, $J=7.8, 1.8$ Hz, 1H), 7.36 (s, 1H), 7.00-6.95 (m, 1H), 6.85-6.83 (m, 1H), 3.65-3.58 (m, 2H),

83

3.55-3.50 (m, 2H), 3.35-3.30 (m, 2H), 3.14-3.06 (m, 1H),
2.93-2.88 (m, 2H), 1.33 (d, J=6.9 Hz, 6H).

Example 108


[2-(3,4-Dichloro-phenyl)-ethyl]-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for $C_{25}H_{26}Cl_2F_3N_5$, 523.15; m/z found, 524.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.37 (m, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.38 (d, J=8.2 Hz, 1H), 7.32 (d, J=2.0 Hz, 1H), 7.06 (dd, J=8.1, 2.0 Hz, 1H), 6.96-6.92 (m, 1H), 4.68-4.63 (m, 1H), 3.80-3.70 (m, 2H), 3.61-3.57 (m, 4H), 3.18-3.13 (m, 2H), 3.03-2.95 (m, 1H), 2.95-2.89 (m, 2H), 2.72-2.68 (m, 2H), 1.32 (d, J=6.8 Hz, 6H).


Example 109

(3,4-Dichloro-phenyl)-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




MS (ESI): mass calcd. for $C_{23}H_{22}Cl_2F_3N_5$, 495.12; m/z found, 496.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.41-8.38 (m, 1H), 8.10 (d, J=2.4 Hz, 1H), 7.89 (dd, J=7.8, 1.8 Hz, 1H), 7.43-7.37 (m, 2H), 6.99-6.95 (m, 1H), 6.50 (s, 1H), 3.69-3.57 (m, 4H), 3.26-3.21 (m, 2H), 3.10-3.01 (m, 1H), 2.98-2.94 (m, 2H), 1.34 (d, J=6.9 Hz, 6H).


The following compounds in Examples 110-114 are prepared according to the procedures described above.

84**Example 110**

N-{2-[2-Isopropyl-4-(4-trifluoromethyl-phenyl-amino)-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl]-pyridin-3-yl}-methanesulfonamide

**Example 111**


N-{2-[2-Isopropyl-4-(4-trifluoromethyl-phenyl-lamino)-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl]-phenyl}-methanesulfonamide



85


Example 112

2-{4-[2-Azetidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol



Example 113


2-{4-[2-Azepan-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol



Example 114

N²-(2-Dimethylamino-ethyl)-N²-methyl-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine


Intermediate C: 5-Trifluoromethyl-pyrazin-2-ylamine



86


The title compound was prepared using known procedures (See: U.S. Pat. No. 4,160,834).

Intermediate D: 6-Chloro-5-trifluoromethyl-pyridin-2-ylamine




The title compound was prepared from 2,6-dichloro-3-trifluoromethyl-pyridine using methods analogous to Intermediate C (See: Hirokawa et al. *Chem. Pharm. Bull.* 2001, 49(12), 1621; Katritzky, A. R. et al. *J. Org. Chem.* 1997, 62, 6412).

Intermediate E: 6-Methoxy-5-trifluoromethyl-pyridin-2-ylamine




The title compound was prepared as described by Hirokawa et al. *Chem. Pharm. Bull.* 2001, 49(12), 1621 and WO 2006/081388.

Intermediate F: 1-Methyl-1,2,3,4-tetrahydro-quinolin-7-ylamine



The title compound was prepared using methods analogous to those described by Hamann, L. G. et al. *J. Med. Chem.* 1998, 41, 623 and Higuchi, R. I. et al. *Bioorg. Med. Chem. Lett.* 1999, 9, 1335.


Intermediate G: 1,4,4-Trimethyl-1,2,3,4-tetrahydro-quinolin-7-ylamine



The title compound was prepared using methods analogous to Intermediate F.

Intermediate H:

2-(4-Amino-phenyl)-2-methyl-propionic acid methyl ester



87


Step A: 2-Methyl-2-(4-nitrophenyl)-propionic acid methyl ester. To a solution of 2-methyl-2-(4-nitrophenyl)-propionic acid (1.0014 g, 4.76 mmol) in 10% MeOH/benzene (20 mL) was added dropwise (trimethylsilyl)-diazomethane (2.0 M in hexanes, 3.5 mL, 7.0 mmol). The reaction mixture was stirred at rt until evolution of N₂ ceased (<5 min) and then concentrated. The crude residue was purified (FCC) to give the title compound (937.6 mg, 88%).

Step B. To a solution of 2-methyl-2-(4-nitrophenyl)-propionic acid methyl ester (932.2 mg, 4.16 mmol) and ammonium formate (1.58 g, 25.1 mmol) in MeOH was added Pd/C (10%, 441.2 mg, 0.414 mmol). The reaction mixture was stirred at rt until gas evolution ceased, then filtered through a plug of diatomaceous earth and concentrated. The residue was redissolved in H₂O and extracted with EtOAc. The organic layers were combined, dried, and concentrated to provide the title compound which was used without further purification.

The following Examples 115-126 were prepared using methods analogous to those described in Example 1, substituting the appropriate amidines in Step A and amines in Step E.

Example 115

N-[[4-Chloro-3-(trifluoromethyl)phenyl]methyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for C₂₅H₂₄ClF₆N₅, 543.16; m/z found, 544.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.37-8.35 (m, 1H), 7.87-7.84 (m, 1H), 7.73-7.71 (m, 1H), 7.49-7.43 (m, 2H), 6.95-6.91 (m, 1H), 5.05-4.99 (m, 1H), 4.72 (d, J=5.8 Hz, 2H), 3.63-3.55 (m, 4H), 3.18-3.12 (m, 2H), 2.98-2.89 (m, 1H), 2.82-2.77 (m, 2H), 1.22 (d, J=6.9 Hz, 6H).

88

Example 116


2-(1-Methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for C₂₄H₂₄F₆N₆, 510.20; m/z found, 511.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.75-8.73 (m, 1H), 8.38-8.35 (m, 1H), 7.89-7.84 (m, 2H), 7.62 (d, J=8.1 Hz, 1H), 6.95-6.92 (m, 1H), 5.11-5.07 (m, 1H), 4.81 (d, J=5.8 Hz, 2H), 3.62-3.55 (m, 4H), 3.18-3.13 (m, 2H), 2.97-2.87 (m, 1H), 2.84-2.79 (m, 2H), 1.20 (d, J=6.9 Hz, 6H).

Example 117

2-(1-Methylethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for C₂₅H₂₅F₆N₅, 509.20; m/z found, 510.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.37-8.35 (m, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.58 (d, J=8.1 Hz, 2H), 7.47 (d, J=8.1 Hz, 2H), 6.95-6.91 (m, 1H), 5.00-4.95 (m, 1H), 4.79 (d, J=5.7

89

Hz, 2H), 3.63-3.56 (m, 4H), 3.17-3.13 (m, 2H), 2.98-2.88 (m, 1H), 2.82-2.77 (m, 2H), 1.23 (d, J=6.9 Hz, 6H).

Example 118


N-[2-(2-Fluorophenyl)ethyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{25}H_{27}F_4N_5$, 473.22; m/z found, 474.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.38-8.36 (m, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.24-7.17 (m, 2H), 7.10-7.02 (m, 2H), 6.95-6.91 (m, 1H), 4.73-4.69 (m, 1H), 3.78-3.74 (m, 2H), 3.59-3.56 (m, 4H), 3.14-3.12 (m, 2H), 3.01-2.93 (m, 3H), 2.69-2.67 (m, 2H), 1.30 (d, J=6.9 Hz, 6H).

Example 119

N-[2-(2-Bromophenyl)ethyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{25}H_{27}BrF_3N_5$, 534.14; m/z found, 536.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.38-8.36 (m, 1H), 7.85 (dd, J=7.8, 1.8 Hz, 1H), 7.57-7.54 (m, 1H), 7.25-7.20 (m, 2H), 7.11-7.07 (m, 1H), 6.94-6.90 (m, 1H), 4.70-4.67 (m,

90

1H), 3.82-3.77 (m, 2H), 3.60-3.54 (m, 4H), 3.16-3.08 (m, 4H), 3.02-2.93 (m, 1H), 2.71-2.68 (m, 2H), 1.31 (d, J=6.9 Hz, 6H).

Example 120


N-[(2,6-Dichlorophenyl)methyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{24}H_{24}Cl_2F_3N_5$, 509.14; m/z found, 510.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.36-8.34 (m, 1H), 7.84 (dd, J=7.8, 1.8 Hz, 1H), 7.33 (d, J=8.0 Hz, 2H), 7.20-7.16 (m, 1H), 6.93-6.90 (m, 1H), 5.05 (d, J=5.5 Hz, 2H), 4.95-4.92 (m, 1H), 3.61-3.54 (m, 4H), 3.16-3.10 (m, 2H), 3.01-2.94 (m, 1H), 2.75-2.72 (m, 2H), 1.31 (d, J=6.9 Hz, 6H).

Example 121

N-[(2-Chlorophenyl)methyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{24}H_{25}ClF_3N_5$, 475.18; m/z found, 477.1 [M+H]⁺. ¹H NMR (CD₃OD): 8.40-8.38 (m, 1H), 8.02-7.98 (m, 1H), 7.42-7.39 (m, 1H), 7.29-7.20 (m,

91

3H), 7.10-7.06 (m, 1H), 3.67-3.64 (m, 2H), 3.61-3.57 (m, 2H), 3.31-3.26 (m, 4H), 3.09-3.06 (m, 2H), 3.01-2.92 (m, 1H), 1.20 (d, J=6.8 Hz, 6H).

Example 122


N-[4-(1,1-Dimethylethyl)cyclohexyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{38}F_3N_5$, 489.31; m/z found, 490.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.38-8.36 (m, 1H), 7.85 (dd, J=7.8, 1.8 Hz, 1H), 6.94-6.90 (m, 1H), 4.34-4.31 (m, 1H), 3.96-3.86 (m, 1H), 3.64-3.54 (m, 4H), 3.14-3.09 (m, 2H), 2.96-2.89 (m, 1H), 2.74-2.69 (m, 2H), 2.25-2.18 (m, 2H), 1.88-1.80 (m, 2H), 1.27 (d, J=6.9 Hz, 6H), 1.25-0.95 (m, 5H), 0.89 (s, 9H).

Example 123

N-[2-(3-Chlorophenyl)ethyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{25}H_{27}ClF_3N_5$, 489.19; m/z found, 490.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.36 (m, 1H), 7.85 (dd, J=7.8, 1.8 Hz, 1H), 7.25-7.20 (m, 3H), 7.11-7.08 (m, 1H), 6.95-6.90 (m, 1H), 4.68-4.60 (m, 1H), 3.77-3.73 (m,

92

2H), 3.61-3.55 (m, 4H), 3.18-3.11 (m, 2H), 3.02-2.88 (m, 3H), 2.69-2.64 (m, 2H), 1.31 (d, J=6.9 Hz, 6H).

Example 124


N-[2-(4-Chlorophenyl)ethyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{25}H_{27}ClF_3N_5$, 489.19; m/z found, 490.4 [M+H]⁺. ¹H NMR (CDCl₃): 8.38-8.36 (m, 1H), 7.86-7.85 (m, 1H), 7.29-7.26 (m, 2H), 7.15-7.13 (m, 2H), 6.95-6.92 (m, 1H), 4.64-4.61 (m, 1H), 3.73 (dd, J=13.2, 6.7 Hz, 2H), 3.61-3.54 (m, 4H), 3.16-3.11 (m, 2H), 3.00-2.93 (m, 1H), 2.91 (t, J=7.1 Hz, 2H), 2.68-2.65 (m, 2H), 1.31 (d, J=6.9 Hz, 6H).

Example 125

N-[2-(2,6-Dichlorophenyl)ethyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{25}H_{26}Cl_2F_3N_5$, 523.15; m/z found, 524.4 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.37 (m, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.29 (d, J=8.0 Hz, 2H), 7.11-7.07 (m, 1H), 6.95-6.91 (m, 1H), 4.79-4.75 (m, 1H), 3.85 (dd,

93

J=6.8, 12.8 Hz, 2H), 3.62-3.54 (m, 4H), 3.30 (t, J=13.8, 6.9 Hz, 2H), 3.14-3.10 (m, 2H), 2.96-2.90 (m, 1H), 2.74-2.70 (m, 2H), 1.28 (d, J=6.9 Hz, 6H).

Example 126


2-(1-Methylethyl)-N-{2-[2-(methyloxy)phenyl]ethyl}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{26}H_{30}F_3N_5O$, 485.24; m/z found, 486.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.37-8.35 (m, 1H), 7.85 (dd, J=7.8, 1.7 Hz, 1H), 7.25-7.20 (m, 1H), 7.16-7.14 (m, 1H), 6.94-6.87 (m, 3H), 5.03-4.99 (m, 1H), 3.86 (s, 3H), 3.72-3.68 (m, 2H), 3.58-3.56 (m, 4H), 3.13-3.10 (m, 2H), 2.97-2.90 (m, 3H), 2.69-2.65 (m, 2H), 1.29 (d, J=6.9 Hz, 6H).

Example 127

N,N-Dimethyl-4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)benzamide




The title compound was prepared using methods analogous to those described in Example 1, using isobutyramidine in Step A, 4-amino-N,N-dimethyl-benzamide in Step E, and substituting t-amyl alcohol for n-butanol in Step E. MS (ESI): mass calcd. for $C_{26}H_{29}F_3N_6O$, 498.24; m/z found, 499.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.89 (dd, J=7.8, 1.8 Hz, 1H), 7.75-7.72 (m, 2H), 7.47-7.44 (m, 2H), 6.99-6.95 (m, 1H), 6.63 (s, 1H), 3.72-3.60 (m, 4H), 3.27-3.21 (m, 2H), 3.16-3.02 (m, 7H), 3.00-2.97 (m, 2H), 1.34 (d, 6.9 Hz, 6H).

94

The following Examples 128-175 were prepared using methods analogous to those described in Example 46, substituting the appropriate amidines in Step A and amines in Step E.

Example 128


N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{24}H_{22}ClF_6N_5$, 529.14; m/z found, 530.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.38 (m, 1H), 8.16 (d, J=2.0 Hz, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.62 (d, 8.7 Hz, 1H), 7.55-7.52 (m, 1H), 6.99-6.95 (m, 1H), 6.66 (s, 1H),

Example 129

2-Methyl-2-[4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanenitrile




MS (ESI): mass calcd. for $C_{27}H_{29}F_3N_6$, 494.24; m/z found, 495.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.38 (m, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.74-7.70 (m, 2H), 7.45-7.42 (m, 2H), 6.97-6.93 (m, 1H), 6.53 (s, 1H), 3.67-3.60 (m, 4H),

95

3.24-3.21 (m, 2H), 3.06-3.01 (m, 1H), 2.98-2.94 (m, 2H), 1.74 (s, 6H), 1.32 (d, J=6.9 Hz, 6H).

Example 130


4-({2-(1-Methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)benzoic acid



MS (ESI): mass calcd. for $C_{24}H_{24}F_3N_5O_2$, 471.19; m/z found, 472.1 $[M+H]^+$. 1H NMR (CD_3OD): 8.46-8.43 (m, 1H), 8.07-8.01 (m, 3H), 7.76-7.72 (m, 2H), 7.16-7.12 (m, 1H), 3.68-3.58 (m, 4H), 3.34-3.30 (m, 2H), 3.24-3.20 (m, 2H), 3.12-3.05 (m, 1H), 1.31 (d, J=6.8 Hz, 6H).

Example 131

N-Biphenyl-4-yl-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{29}H_{28}F_3N_5$, 503.23; m/z found, 504.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 7.89-7.86 (m, 1H), 7.77-7.74 (m, 2H), 7.64-7.58 (m, 4H), 7.46-7.42 (m, 2H), 7.35-7.30 (m, 1H), 6.97-6.93 (m, 1H), 6.57 (s,

96

1H), 3.70-3.65 (m, 2H), 3.64-3.60 (m, 2H), 3.24-3.20 (m, 2H), 3.08-3.01 (m, 1H), 2.99-2.96 (m, 2H), 1.34 (d, J=6.9 Hz, 6H).

Example 132


N-(4-Cyclohexylphenyl)-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{29}H_{34}F_3N_5$, 509.27; m/z found, 510.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.60-7.57 (m, 2H), 7.20-7.16 (m, 2H), 6.95-6.92 (m, 1H), 6.44 (s, 1H), 3.68-3.58 (m, 4H), 3.22-3.18 (m, 2H), 3.05-2.97 (m, 1H), 2.95-2.91 (m, 2H), 2.52-2.44 (m, 1H), 1.93-1.80 (m, 4H), 1.78-1.70 (m, 2H), 1.46-1.36 (m, 4H), 1.31 (d, J=6.9 Hz, 6H).

Example 133

2-(1-Methylethyl)-N-(4-piperidin-1-ylphenyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{28}H_{33}F_3N_6$, 510.27; m/z found, 511.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.37 (m, 1H), 7.88-7.85 (m, 1H), 7.53-7.49 (m, 2H), 6.97-6.91 (m, 3H), 6.35 (s, 1H), 3.68-3.57 (m, 4H), 3.22-3.17 (m, 2H), 3.15-3.09 (m,

97

4H), 3.03-2.95 (m, 1H), 2.93-2.88 (m, 2H), 1.76-1.71 (m, 4H), 1.60-1.54 (m, 2H), 1.29 (d, J=6.9 Hz, 6H).

Example 134


2-(1-Methylethyl)-N-(4-morpholin-4-ylphenyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{31}F_3N_6O$, 512.25; m/z found, 513.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.57-7.53 (m, 2H), 6.95-6.90 (m, 3H), 6.37 (s, 1H), 3.90-3.86 (m, 4H), 3.67-3.59 (m, 4H), 3.21-3.17 (m, 2H), 3.15-3.12 (m, 4H), 3.03-2.96 (m, 1H), 2.93-2.90 (m, 2H), 1.29 (d, J=6.9 Hz, 6H).

Example 135

2-(1-Methylethyl)-N-[4-(methylsulfanyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{24}H_{26}F_3N_5S$, 473.19; m/z found, 474.4 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.37 (m, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.63-7.60 (m, 2H), 7.30-7.26 (m, 2H), 6.97-6.92 (m, 1H), 6.46 (s, 1H), 3.69-3.57 (m, 4H),

98

3.24-3.18 (m, 2H), 3.06-2.97 (m, 1H), 2.95-2.92 (m, 2H), 2.49 (s, 3H), 1.31 (d, J=6.9 Hz, 6H).

Example 136


2-(1-Methylethyl)-N-(4-nitrophenyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{23}H_{23}F_3N_6O_2$, 472.18; m/z found, 473.4 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 8.26-8.23 (m, 2H), 7.89-7.84 (m, 3H), 6.98-6.95 (m, 1H), 6.85 (s, 1H), 3.66-3.63 (m, 2H), 3.61-3.59 (m, 2H), 3.27-3.23 (m, 2H), 3.13-3.05 (m, 1H), 3.04-2.99 (m, 2H), 1.34 (d, J=6.9 Hz, 6H).

Example 137

2-(1-Methylethyl)-N-[4-(1-methylethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{26}H_{30}F_3N_5$, 469.25; m/z found, 470.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.60-7.57 (m, 2H), 7.23-7.18 (m, 2H), 6.96-6.92 (m, 1H), 6.45 (s, 1H), 3.69-3.58 (m, 4H),

99

3.24-3.17 (m, 2H), 3.06-2.97 (m, 1H), 2.96-2.85 (m, 3H), 1.32 (d, J=6.9 Hz, 6H), 1.26 (d, J=6.8, 6H).

Example 138


2-(1,1-Dimethylethyl)-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{28}H_{34}F_3N_5$, 497.28; m/z found, 498.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.86 (d, J=7.8, 1.8 Hz, 1H), 7.64-7.60 (m, 2H), 7.39-7.33 (m, 2H), 6.96-6.91 (m, 1H), 6.43 (s, 1H), 3.71-3.58 (m, 4H), 3.24-3.18 (m, 2H), 2.96-2.92 (m, 2H), 1.38 (s, 9H), 1.33 (s, 9H).

Example 139

2-(1,1-Dimethylethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{25}H_{25}F_6N_5$, 509.20; m/z found, 510.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.90-7.86 (m, 1H), 7.80 (d, J=8.5 Hz, 2H), 7.59 (d, J=8.6 Hz, 2H),

100

6.98-6.93 (m, 1H), 6.62 (s, 1H), 3.69-3.64 (m, 2H), 3.63-3.58 (m, 2H), 3.27-3.21 (m, 2H), 3.02-2.95 (m, 2H), 1.38 (s, 9H).

Example 140


N-[3-Fluoro-4-(trifluoromethyl)phenyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{24}H_{22}F_7N_5$, 513.18; m/z found, 514.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.38 (m, 1H), 8.05-8.00 (m, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.54-7.49 (m, 1H), 7.27-7.25 (m, 1H), 6.99-6.94 (m, 1H), 6.71 (s, 1H), 3.69-3.57 (m, 4H), 3.27-3.21 (m, 2H), 3.12-3.03 (m, 1H), 3.01-2.95 (m, 2H), 1.34 (d, J=6.9 Hz, 6H).

Example 141

N-(2,3-Dihydro-1H-inden-5-yl)-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine hydrochloride salt




MS (ESI): mass calcd. for $C_{26}H_{28}F_3N_5$, 467.23; m/z found, 468.2 $[M+H]^+$. 1H NMR (CD_3OD): 8.46-8.43 (m, 1H), 8.02 (dd, J=7.8, 1.7 Hz, 1H), 7.40-7.38 (m, 1H), 7.26-7.21 (m, 2H), 7.14-7.11 (m, 1H), 3.66-3.63 (m, 2H), 3.61-3.57 (m,

101

2H), 3.19-3.14 (m, 2H), 3.06-2.97 (m, 1H), 2.96-2.90 (m, 6H), 2.15-2.08 (m, 2H), 1.26 (d, J=6.8 Hz, 6H).

Example 142


2-(1-Methylethyl)-N-[4-(1,3-oxazol-5-yl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{26}H_{25}F_3N_6O$, 494.20; m/z found, 495.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 7.90-7.86 (m, 2H), 7.78-7.75 (m, 2H), 7.66-7.62 (m, 2H), 7.30 (s, 1H), 6.98-6.93 (m, 1H), 6.61 (s, 1H), 3.70-3.58 (m, 4H), 3.26-3.19 (m, 2H), 3.10-2.94 (m, 3H), 1.33 (d, J=6.9 Hz, 6H).

Example 143

N-[4-(1,1-Dimethylethyl)-3-nitrophenyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{27}H_{31}F_3N_6O_2$, 528.24; m/z found, 529.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 8.10 (d, J=2.4 Hz, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.53 (dd, J=8.8, 2.4 Hz, 1H), 7.47 (d, J=8.8 Hz, 1H), 6.99-6.94 (m, 1H),

102

6.57 (s, 1H), 3.68-3.56 (m, 4H), 3.26-3.17 (m, 2H), 3.07-2.99 (m, 1H), 2.98-2.93 (m, 2H), 1.41 (s, 9H), 1.31 (d, J=6.9 Hz, 6H).

Example 144


2-Furan-2-yl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{25}H_{19}F_6N_5O$, 519.15; m/z found, 520.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.32-8.31 (m, 1H), 7.81 (dd, J=7.8, 1.8 Hz, 1H), 7.73 (d, J=8.6 Hz, 2H), 7.56 (d, J=8.6 Hz, 2H), 7.53-7.52 (m, 1H), 7.14-7.11 (m, 1H), 6.92-6.87 (m, 1H), 6.68 (s, 1H), 6.49-6.46 (m, 1H), 3.64-3.52 (m, 4H), 3.30-3.23 (m, 2H), 3.01-2.95 (m, 2H).

Example 145

N-[4-(1,1-Dimethylethyl)phenyl]-2-furan-2-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{28}H_{28}F_3N_5O$, 507.22; m/z found, 508.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.33-8.31 (m, 1H), 7.80 (dd, J=7.8, 1.9 Hz, 1H), 7.54-7.50 (m, 3H), 7.35-7.31 (m, 2H), 7.13-7.11 (m, 1H), 6.89-6.85 (m, 1H), 6.48 (s, 1H),

103

6.46-6.44 (m, 1H), 3.63-3.53 (m, 4H), 3.27-3.21 (m, 2H),
2.96-2.90 (m, 2H), 1.27 (s, 9H).

Example 146


2-Furan-3-yl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{25}H_{19}F_6N_5O$, 519.15; m/z found, 520.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.33-8.31 (m, 1H), 8.10-8.08 (m, 1H), 7.81 (dd, $J=7.8, 1.8$ Hz, 1H), 7.70 (d, $J=8.5$ Hz, 2H), 7.55 (d, $J=8.7$ Hz, 2H), 7.41-7.39 (m, 1H), 6.94-6.92 (m, 1H), 6.91-6.87 (m, 1H), 6.62 (s, 1H), 3.64-3.52 (m, 4H), 3.24-3.17 (m, 2H), 2.99-2.93 (m, 2H).

Example 147

N-[4-(1,1-Dimethylethyl)phenyl]-2-furan-3-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{28}H_{28}F_3N_5O$, 507.22; m/z found, 508.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.33-8.31 (m, 1H), 8.09-8.07 (m, 1H), 7.80 (dd, $J=7.8, 1.8$ Hz, 1H), 7.52-7.48 (m, 2H), 7.39-7.37 (m, 1H), 7.34-7.30 (m, 2H), 6.95-6.93 (m,

104

1H), 6.89-6.86 (m, 1H), 6.42 (s, 1H), 3.64-3.52 (m, 4H),
3.21-3.14 (m, 2H), 2.95-2.88 (m, 2H), 1.28 (s, 9H).

Example 148


Benzo[1,2,5]thiadiazol-5-yl-[2-isopropyl-7-(3-trifluoromethyl-pyridin-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for $C_{23}H_{22}F_3N_7S$, 485.16; m/z found, 486.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.56-8.53 (m, 1H), 8.34-8.31 (m, 1H), 7.85 (d, $J=9.4$ Hz, 1H), 7.81 (dd, $J=7.8, 1.8$ Hz, 1H), 7.59 (dd, $J=9.4, 2.2$ Hz, 1H), 6.91-6.87 (m, 1H), 6.68 (s, 1H), 3.63-3.59 (m, 2H), 3.57-3.54 (m, 2H), 3.21-3.16 (m, 2H), 3.07-2.99 (m, 1H), 2.98-2.95 (m, 2H), 1.30 (d, $J=6.9$ Hz, 6H).

Example 149

2-(2-Thienyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{25}H_{19}F_6N_5S$, 535.13; m/z found, 536.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.33-8.31 (m, 1H), 7.86-7.83 (m, 1H), 7.81 (dd, $J=7.8, 1.8$ Hz, 1H), 7.76 (d, $J=8.5$ Hz, 2H), 7.57 (d, $J=8.6$ Hz, 2H), 7.37-7.34 (m, 1H), 7.06-7.04

105

(m, 1H), 6.91-6.87 (m, 1H), 6.64 (s, 1H), 3.65-3.53 (m, 4H), 3.26-3.20 (m, 2H), 3.00-2.94 (m, 2H).

Example 150


2-(3-Thienyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{25}H_{19}F_6N_5S$, 535.13; m/z found, 536 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 8.20-8.18 (m, 1H), 7.90-7.86 (m, 1H), 7.84-7.78 (m, 3H), 7.65-7.63 (m, 2H), 7.36-7.34 (m, 1H), 6.99-6.94 (m, 1H), 6.69 (s, 1H), 3.72-3.60 (m, 4H), 3.35-3.26 (m, 2H), 3.08-3.02 (m, 2H).

Example 151

2-(1-Methylethyl)-N-(4-methylphenyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine hydrochloride salt




MS (ESI): mass calcd. for $C_{24}H_{26}F_3N_5$, 441.21; m/z found, 442.2 $[M+H]^+$. 1H NMR (CD_3OD): 8.46-8.44 (m, 1H), 8.03 (dd, $J=7.8, 1.7$ Hz, 1H), 7.42-7.39 (m, 2H), 7.24-7.22 (m,

106

2H), 7.17-7.13 (m, 1H), 3.68-3.58 (m, 4H), 3.35-3.30 (m, 2H), 3.21-3.15 (m, 2H), 3.10-3.00 (m, 1H), 2.37 (s, 3H), 1.26 (d, $J=6.8$ Hz, 6H).

Example 152


2-(1-Methylethyl)-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{31}F_3N_6O_2S$, 560.22; m/z found, 561.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 7.90-7.85 (m, 3H), 7.82-7.78 (m, 2H), 6.99-6.94 (m, 1H), 6.74 (s, 1H), 3.66-3.57 (m, 4H), 3.29-3.21 (m, 6H), 3.11-2.97 (m, 3H), 1.81-1.74 (m, 4H), 1.34 (d, $J=6.9$ Hz, 6H).

Example 153

2-(2-Methyl-1,3-thiazol-4-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{25}H_{20}F_6N_6S$, 550.14; m/z found, 551.2 $[M+H]^+$. 1H NMR (CD_3OD): 8.48-8.44 (m, 1H), 8.34 (s, 1H), 8.07-8.02 (m, 1H), 7.89-7.86 (m, 2H),

107

7.82-7.77 (m, 2H), 7.18-7.13 (m, 1H), 3.72-3.62 (m, 4H), 3.56-3.53 (m, 2H), 3.33-3.30 (m, 2H), 2.84 (s, 3H).

Example 154


N,N-Dimethyl-4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)benzenesulfonamide



MS (ESI): mass calcd. for $C_{25}H_{29}F_3N_6O_2S$, 534.20; m/z found, 535.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.42-8.40 (m, 1H), 7.92-7.89 (m, 3H), 7.78-7.75 (m, 2H), 7.01-6.96 (m, 1H), 6.77 (s, 1H), 3.69-3.60 (m, 4H), 3.29-3.24 (m, 2H), 3.14-3.06 (m, 1H), 3.04-3.00 (m, 2H), 2.74 (s, 6H), 1.36 (d, 6.9 Hz, 6H).

Example 155

N-[2-Fluoro-4-(trifluoromethyl)phenyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{24}H_{22}F_7N_5$, 513.18; m/z found, 514.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.93-8.88 (m, 1H), 8.42-8.40 (m, 1H), 7.89 (dd, $J=7.8, 1.8$ Hz, 1H), 7.49-7.46 (m, 1H), 7.41-7.38 (m, 1H), 7.00-6.97 (m, 2H), 3.70-3.67 (m, 2H),

108

3.63-3.60 (m, 2H), 3.28-3.25 (m, 2H), 3.13-3.06 (m, 1H), 3.04-3.01 (m, 2H), 1.36 (d, $J=6.9$ Hz, 6H).

Example 156


1-[4-({2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]ethanone



MS (ESI): mass calcd. for $C_{27}H_{29}F_3N_6O$, 510.24; m/z found, 511.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.98-7.95 (m, 2H), 7.88 (dd, $J=7.8, 1.8$ Hz, 1H), 7.66-7.64 (m, 2H), 6.98-6.94 (m, 1H), 6.60 (s, 1H), 3.81-3.74 (m, 4H), 3.64-3.55 (m, 4H), 3.14-3.08 (m, 2H), 2.92-2.86 (m, 2H), 2.60 (s, 3H), 1.71-1.60 (m, 6H).

Example 157

N-[3-Fluoro-4-(trifluoromethyl)phenyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{26}H_{25}F_7N_6$, 554.20; m/z found, 555.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.88 (dd, $J=7.8, 1.8$ Hz, 1H), 7.84-7.81 (m, 1H), 7.50 (t, $J=8.4$ Hz, 1H), 7.18-7.14 (m, 1H), 6.98-6.95 (m, 1H), 6.57 (s, 1H),

109

3.81-3.73 (m, 4H), 3.63-3.55 (m, 4H), 3.13-3.07 (m, 2H), 2.91-2.85 (m, 2H), 1.73-1.60 (m, 6H).

Example 158


N,N-Dimethyl-4-({2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)benzenesulfonamide



MS (ESI): mass calcd. for $C_{27}H_{32}F_3N_7O_2S$, 575.23; m/z found, 576.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.42-8.40 (m, 1H), 7.90-7.88 (m, 1H), 7.76-7.72 (m, 4H), 6.98-6.95 (m, 1H), 6.60 (s, 1H), 3.79-3.75 (m, 4H), 3.61-3.56 (m, 4H), 3.12-3.08 (m, 2H), 2.92-2.87 (m, 2H), 2.73 (s, 6H), 1.72-1.63 (m, 6H).

Example 159

N-[4-(1,1-Dimethylethyl)-3-nitrophenyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{29}H_{34}F_3N_7O_2$, 569.27; m/z found, 570.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.41-8.39 (m, 1H), 8.08 (d, J=2.5 Hz, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.45 (d, J=8.8 Hz, 1H), 7.31-7.28 (m, 1H), 6.97-6.93 (m, 1H), 6.42 (s,

110

1H), 3.77-3.71 (m, 4H), 3.64-3.55 (m, 4H), 3.11-3.06 (m, 2H), 2.88-2.83 (m, 2H), 1.71-1.59 (m, 6H), 1.41 (s, 9H).

Example 160


N-[4-(Methylsulfonyl)phenyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{26}H_{29}F_3N_6S$, 514.21; m/z found, 515.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.39 (m, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.52-7.47 (m, 2H), 7.30-7.26 (m, 2H), 6.97-6.92 (m, 1H), 6.32 (s, 1H), 3.77-3.70 (m, 4H), 3.65-3.56 (m, 4H), 3.11-3.06 (m, 2H), 2.87-2.84 (m, 2H), 2.50 (s, 3H), 1.69-1.57 (m, 6H).

Example 161

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(1-methyl-1,2,3,4-tetrahydro-quinolin-7-yl)-amine




MS (ESI): mass calcd. for $C_{27}H_{31}F_3N_6$, 496.26; m/z found, 497.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.36 (m, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.20 (d, J=2.0 Hz, 1H), 6.96-6.86 (m, 2H), 6.68 (dd, J=8.0, 2.1 Hz, 1H), 6.40 (s, 1H), 3.72-3.56 (m,

111

4H), 3.27-3.16 (m, 4H), 3.05-2.90 (m, 6H), 2.74 (t, J=6.4 Hz, 2H), 2.02-1.94 (m, 2H), 1.32 (d, J=6.9 Hz, 6H).

Example 162


[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(1,4,4-trimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-amine



MS (ESI): mass calcd. for $C_{29}H_{35}F_3N_6$, 524.29; m/z found, 525.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.23 (d, J=2.2 Hz, 1H), 7.14 (d, J=8.3 Hz, 1H), 6.97-6.92 (m, 1H), 6.78 (dd, J=8.2, 2.2 Hz, 1H), 6.43 (s, 1H), 3.70-3.60 (m, 4H), 3.29-3.25 (m, 2H), 3.23-3.20 (m, 2H), 3.06-3.00 (m, 1H), 2.98-2.93 (m, 5H), 1.80-1.77 (m, 2H), 1.35 (d, J=6.9 Hz, 6H), 1.30 (s, 6H).

Example 163

(1-Methyl-1,2,3,4-tetrahydro-quinolin-7-yl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine hydrochloride salt




MS (ESI): mass calcd. for $C_{29}H_{34}F_3N_7$, 537.28; m/z found, 538.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.89 (dd, J=7.8, 1.7 Hz, 1H), 7.02-6.98 (m, 1H), 6.97-6.94 (m, 2H), 6.75-6.72 (m, 1H), 6.66-6.62 (m, 1H), 4.09-3.78 (m,

112

6H), 3.69-3.61 (m, 4H), 3.31-3.25 (m, 2H), 2.92-2.87 (m, 5H), 2.80-2.75 (m, 2H), 2.04-1.97 (m, 2H), 1.74-1.66 (m, 6H).

Example 164


[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(1,4,4-trimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-amine hydrochloride salt



MS (ESI): mass calcd. for $C_{31}H_{38}F_3N_7$, 565.31; m/z found, 566.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.90-7.88 (m, 1H), 7.19 (d, J=8.2 Hz, 1H), 7.02-6.93 (m, 2H), 6.78-6.69 (m, 2H), 4.10-3.90 (m, 4H), 3.87-3.80 (m, 2H), 3.69-3.61 (m, 4H), 3.33-3.26 (m, 2H), 2.94-2.87 (m, 5H), 1.82-1.77 (m, 2H), 1.75-1.67 (m, 6H), 1.31 (s, 6H).

Example 165

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(6-pyrrolidin-1-yl-pyridin-3-yl)-amine




MS (ESI): mass calcd. for $C_{26}H_{30}F_3N_7$, 497.25; m/z found, 498.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 8.20 (d, J=2.6 Hz, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.85 (dd, J=9.0, 2.7 Hz, 1H), 6.98-6.94 (m, 1H), 6.41 (d, J=9.0 Hz, 1H), 6.21

113

(s, 1H), 3.70-3.66 (m, 2H), 3.64-3.62 (m, 2H), 3.50-3.48 (m, 4H), 3.23-3.18 (m, 2H), 2.99-2.92 (m, 3H), 2.07-2.01 (m, 4H), 1.27 (d, J=6.9 Hz, 6H).

Example 166


((2-Fluoro-4-(trifluoromethyl)phenyl)-[2-piperidin-1-yl-7-(3-trifluoromethylpyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS (ESI): mass calcd. for $C_{26}H_{25}F_7N_6$, 554.25; m/z found, 555.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.36 (m, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.84-7.78 (m, 1H), 7.48 (t, J=8.4 Hz, 1H), 7.16-7.11 (m, 1H), 6.97-6.91 (m, 1H), 6.55 (s, 1H), 3.78-3.70 (m, 4H), 3.61-3.52 (m, 4H), 3.11-3.05 (m, 2H), 2.88-2.83 (m, 2H), 1.72-1.56 (m, 6H).

Example 167

2-Pyridin-4-yl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{26}H_{20}F_6N_6$, 530.17; m/z found, 531.5 $[M+H]^+$. 1H NMR (MeOD): 8.90 (d, J=6.6 Hz, 2H), 8.81 (d, J=6.7 Hz, 1H), 8.45-8.42 (m, 1H), 8.02 (dd, J=7.8, 1.8

114

Hz, 1H), 7.87 (d, J=8.5 Hz, 2H), 7.69 (d, J=8.6 Hz, 2H), 7.12 (dd, J=7.7, 4.9 Hz, 1H), 3.62-3.56 (m, 4H), 3.42-3.37 (m, 2H), 3.29-3.25 (m, 2H).

Example 168


N-[4-(1,1-Dimethylethyl)phenyl]-2-pyridin-4-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{29}H_{29}F_3N_7$, 518.24; m/z found, 519.5 $[M+H]^+$. 1H NMR (MeOD): 8.89 (d, J=6.6 Hz, 2H), 8.72 (d, J=6.7 Hz, 2H), 8.44 (dd, J=4.7, 1.4 Hz, 1H), 8.02 (dd, J=7.8, 1.8 Hz, 1H), 7.58-7.54 (m, 2H), 7.47-7.44 (m, 2H), 7.12 (dd, J=7.8, 4.8 Hz, 1H), 3.63-3.57 (m, 4H), 3.40-3.35 (m, 2H), 3.26-3.21 (m, 2H), 1.36 (s, 9H).

Example 169

N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-pyridin-4-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{26}H_{19}ClF_6N_6$, 564.13; m/z found, 565.4 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.76 (d, J=5.1 Hz, 2H), 8.40 (d, J=3.7 Hz, 1H), 8.22 (d, J=5.3 Hz, 2H), 8.09 (s, 1H), 7.91-7.87 (m, 1H), 7.70 (d, J=8.8 Hz, 1H), 7.58 (d, J=9.0

115

Hz, 1H), 7.01-6.95 (m, 1H), 6.81 (s, 1H), 3.75-3.61 (m, 4H), 3.41-3.32 (m, 2H), 3.13-3.06 (m, 2H).

Example 170


2-Pyridin-4-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{25}H_{19}F_6N_7$, 531.16; m/z found, 532.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 9.04 (d, $J=2.3$ Hz, 1H), 8.90 (d, $J=6.4$ Hz, 2H), 8.73 (d, $J=6.4$ Hz, 2H), 8.43-8.41 (m, 1H), 8.21 (dd, $J=8.5$, 2.3 Hz, 1H), 7.94 (dd, $J=7.8$, 1.6 Hz, 1H), 7.79 (d, $J=8.6$ Hz, 1H), 7.33 (s, 1H), 7.06-7.02 (m, 1H), 3.77-3.72 (m, 2H), 3.71-3.65 (m, 2H), 3.43-3.38 (m, 2H), 3.25-3.19 (m, 2H).

Example 171

N-[4-(1,1-Dimethylethyl)phenyl]-2-pyridin-2-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{29}H_{29}F_3N_6$, 518.24; m/z found, 519.5 $[M+H]^+$. 1H NMR (MeOD): 8.84-8.82 (m, 1H), 8.45 (dd, $J=4.7$, 1.5 Hz, 1H), 8.27-8.23 (m, 1H), 8.09-8.00 (m,

116

2H), 7.72-7.65 (m, 1H), 7.54 (s, 4H), 7.16-7.12 (m, 1H), 3.72-3.63 (m, 4H), 3.57-3.52 (m, 2H), 3.30-3.26 (m, 2H), 1.39 (s, 9H).

Example 172


2-Pyridin-2-yl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine le 1 trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{26}H_{20}F_6N_6$, 530.17; m/z found, 531.5 $[M+H]^+$. 1H NMR (MeOD): 8.88-8.81 (m, 1H), 8.47-8.44 (m, 1H), 8.34-8.31 (m, 1H), 8.16 (dt, $J=7.8$, 1.6 Hz, 1H), 8.03 (dd, $J=7.8$, 1.7 Hz, 1H), 7.86 (d, $J=8.6$ Hz, 2H), 7.80 (d, $J=8.6$ Hz, 2H), 7.77-7.73 (m, 1H), 7.17-7.12 (m, 1H), 3.71-3.64 (m, 4H), 3.60-3.55 (m, 2H), 3.35-3.31 (m, 2H).

Example 173

N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-pyridin-2-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{26}H_{19}ClF_6N_6$, 564.13; m/z found, 565.1 $[M+H]^+$. 1H NMR (MeOD): 8.92-8.82 (m, 1H), 8.47-8.44 (m, 1H), 8.44-8.41 (m, 1H), 8.27 (dt, $J=7.8$, 1.6 Hz,

117

1H), 8.05-8.01 (m, 2H), 7.88 (d, J=8.7 Hz, 1H), 7.84-7.80 (m, 2H), 7.17-7.13 (m, 1H), 3.70-3.62 (m, 4H), 3.60-3.55 (m, 2H), 3.35-3.31 (m, 2H).

Example 174


Methyl 2-methyl-2-[4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanoate



MS (ESI): mass calcd. for $C_{28}H_{32}F_3N_5O_2$, 527.25; m/z found, 528.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.39 (m, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.69-7.65 (m, 2H), 7.35-7.31 (m, 2H), 6.98-6.94 (m, 1H), 6.51 (s, 1H), 3.70-3.60 (m, 7H), 3.25-3.20 (m, 2H), 3.08-3.00 (m, 1H), 2.98-2.95 (m, 2H), 1.61 (s, 6H), 1.34 (d, J=6.9 Hz, 6H).

Example 175

Methyl 2-methyl-2-[4-({2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanoate



MS (ESI): mass calcd. for $C_{30}H_{35}F_3N_6O_2$, 568.27; m/z found, 569.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.39 (m, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.56-7.52 (m, 2H), 7.32-7.28 (m, 2H), 6.97-6.92 (m, 1H), 6.36 (s, 1H), 3.78-3.72 (m, 4H), 3.67 (s, 3H), 3.64-3.56 (m, 4H), 3.11-3.05 (m, 2H), 2.88-2.83 (m, 2H), 1.70-1.58 (m, 12H).

118

Example 176

2-Pyridin-3-yl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt

5

10

15

20

25

30

35

40


45

50

55

60

65



A microwave vial containing [2-methylsulfanyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido [4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine (Example 53; 100 mg, 0.20 mmol), Pd₂(dba)₃ (7.3 mg, 0.008 mmol), tri-(2-furyl)phosphine (7.4 mg, 0.032 mmol), copper (I) thiophene-2-carboxylate (49 mg, 0.260 mmol), and 3-pyridyl boronic acid (27 mg, 0.22 mmol) was sealed and evacuated under N₂. Upon complete flushing with N₂, THF (3 mL) was added. The reaction mixture was stirred at 50° C. for 18 h. The reaction mixture was filtered through a plug of diatomaceous earth, concentrated, and purified directly using Preparative HPLC (conditions as in Example 54) to give the title compound (40 mg, 40%). MS (ESI): mass calcd. for $C_{26}H_{20}F_6N_6$, 530.17; m/z found, 531.2 [M+H]⁺. ¹H NMR (MeOD): 9.32-9.28 (m, 1H), 8.54-8.36 (m, 1H), 8.03 (dd, J=7.8, 1.6 Hz, 1H), 7.88 (d, J=8.0 Hz, 2H), 7.73-7.69 (m, 1H), 7.17-7.11 (m, 1H), 3.64-3.57 (m, 4H), 3.42-3.37 (m, 2H), 3.29-3.24 (m, 2H).

Example 177

2-[4-({2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propan-2-ol


45

50

55

60

65




119

To a solution of methylmagnesium bromide (170 mL of a 3.0 M solution in Et₂O, 0.51 mmol) in THF at 0° C. was added a solution of 1-[4-(2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]amino)phenyl]ethanone (Example 156; 59.8 mg, 0.117 mmol) in THF. The solution was allowed to warm to rt over 1 h, and stirred at rt for an additional 5 min. The reaction mixture was then quenched with satd. aq. NH₄Cl and extracted with EtOAc. The organic layers were combined, dried, and concentrated. The crude residue was purified (FCC) to give the title compound (51 mg, 83%). MS (ESI): mass calcd. for C₂₈H₃₃F₃N₆O, 526.27; m/z found, 527.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.37 (m, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.55-7.51 (m, 2H), 7.46-7.41 (m, 2H), 6.94-6.90 (m, 1H), 6.35 (s, 1H), 3.77-3.69 (m, 4H), 3.63-3.53 (m, 4H), 3.10-3.03 (m, 2H), 2.87-2.80 (m, 2H), 1.70 (s, 1H), 1.66-1.60 (m, 6H), 1.54 (s, 6H).

Example 178

2-[4-(2-(1-Methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]amino)phenyl]propan-2-ol




The title compound was prepared using methods analogous to those described in Example 167, starting with 1-[4-(2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]amino)phenyl]ethanone (Example 96). MS (ESI): mass calcd. for C₂₆H₃₀F₃N₅O, 485.24; m/z found, 486.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.37 (m, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.68-7.63 (m, 2H), 7.48-7.45 (m, 2H), 6.97-6.92 (m, 1H), 6.50 (s, 1H), 3.69-3.58 (m, 4H), 3.25-3.17 (m, 2H), 3.08-2.98 (m, 1H), 2.98-2.92 (m, 2H), 1.61 (s, 6H), 1.32 (d, J=6.9 Hz, 6H).

120

Example 179


1,1,1-Trifluoro-2-[4-(2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]amino)phenyl]propan-2-ol



The title compound was prepared using methods analogous to those described in Example 167, starting with 2,2,2-trifluoro-1-[4-[2-isopropyl-7-(3-trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl]-ethanone (prepared analogously to Example 1). MS (ESI): mass calcd. for C₂₆H₂₇F₆N₅O, 539.21; m/z found, 540.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.41-8.40 (m, 1H), 7.89 (dd, J=7.8, 1.8 Hz, 1H), 7.77-7.73 (m, 2H), 7.59-7.54 (m, 2H), 6.99-6.95 (m, 1H), 6.58 (s, 1H), 3.71-3.60 (m, 4H), 3.27-3.21 (m, 2H), 3.09-3.02 (m, 1H), 3.01-2.96 (m, 2H), 2.42 (s, 1H), 1.82 (s, 3H), 1.34 (d, J=6.9 Hz, 6H).

Example 180

1,1,1-Trifluoro-2-[4-(2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]amino)phenyl]propan-2-ol




The title compound was prepared using methods analogous to those described in Example 167, starting with 2,2,2-trifluoro-1-[4-[2-isopropyl-7-(3-trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl]-ethanone (prepared analogously to Example 1). MS (ESI): mass calcd. for C₂₈H₃₀F₆N₆O, 580.24; m/z found, 581.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.38 (m, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.63-7.60 (m, 2H), 7.54-7.51 (m, 2H), 6.97-6.92 (m, 1H), 6.42 (s, 1H), 3.80-3.71 (m, 4H), 3.66-3.56 (m, 4H), 3.12-3.06 (m, 2H), 2.90-2.84 (m, 2H), 2.37 (s, 1H), 1.81 (s, 3H), 1.70-1.59 (m, 6H).

121

Example 181


2-Methyl-2-[4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propan-1-ol



To a solution of methyl 2-methyl-2-[4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanoate (Example 174, 73 mg, 0.14 mmol) in THF was added LiAlH_4 (14.2 mg, 0.374 mmol). After stirring at rt for 4 h, the reaction mixture was quenched with satd. aq. Na_2SO_4 . The reaction mixture was then filtered through a plug of diatomaceous earth and concentrated. The crude residue was purified (FCC) to give the title compound (45.4 mg, 66%). MS (ESI): mass calcd. for $\text{C}_{27}\text{H}_{32}\text{F}_3\text{N}_5\text{O}$, 499.26; m/z found, 500.3 $[\text{M}+\text{H}]^+$. ^1H NMR (CDCl_3): 8.41-8.39 (m, 1H), 7.89 (dd, $J=7.8, 1.8$ Hz, 1H), 7.70-7.66 (m, 2H), 7.40-7.36 (m, 2H), 6.98-6.94 (m, 1H), 6.51 (s, 1H), 3.70-3.60 (m, 6H), 3.26-3.20 (m, 2H), 3.08-3.00 (m, 1H), 2.98-2.94 (m, 2H), 1.37 (s, 6H), 1.34 (d, 6.9 Hz, 6H).

Example 182

1-[4-({2-(1-Methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]ethanol




To a solution of 1-[4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]ethanone (Example 96; 37 mg, 0.079 mmol) in MeOH was added NaBH_4 (4.1 mg, 0.11 mmol). The mixture was stirred at rt for 4 h, then concentrated. The residue was redissolved in water and extracted

122

with EtOAc. The organic layers were combined, dried, and concentrated. The crude residue was purified (FCC) to give the title compound (32.1 mg, 86%). MS (ESI): mass calcd. for $\text{C}_{25}\text{H}_{28}\text{F}_3\text{N}_5\text{O}$, 471.22; m/z found, 472.2 $[\text{M}+\text{H}]^+$. ^1H NMR (CDCl_3): 8.40-8.38 (m, 1H), 7.87 (dd, $J=7.8, 1.8$ Hz, 1H), 7.67-7.64 (m, 2H), 7.38-7.34 (m, 2H), 6.97-6.92 (m, 1H), 6.51 (s, 1H), 4.93-4.88 (m, 1H), 3.69-3.60 (m, 4H), 3.24-3.18 (m, 2H), 3.06-2.98 (m, 1H), 2.98-2.94 (m, 2H), 1.76 (d, $J=3.6$ Hz, 1H), 1.52 (d, $J=6.4$ Hz, 3H), 1.31 (d, $J=6.9$ Hz, 6H).

Example 183


2,2,2-Trifluoro-1-[4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]ethanol



The title compound was prepared using methods analogous to those described in Example 172, starting with 2,2,2-trifluoro-1-[4-({2-isopropyl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino)phenyl]-ethanone (prepared analogously to Example 1). MS (ESI): mass calcd. for $\text{C}_{25}\text{H}_{25}\text{F}_6\text{N}_5\text{O}$, 525.20; m/z found, 526.1 $[\text{M}+\text{H}]^+$. ^1H NMR (CDCl_3): 8.32-8.30 (m, 1H), 7.80 (dd, $J=7.8, 1.8$ Hz, 1H), 7.69-7.65 (m, 2H), 7.40-7.36 (m, 2H), 6.90-6.86 (m, 1H), 6.51 (s, 1H), 4.97-4.91 (m, 1H), 3.59-3.56 (m, 2H), 3.54-3.51 (m, 2H), 3.17-3.12 (m, 2H), 3.00-2.92 (m, 1H), 2.90-2.87 (m, 2H), 2.66-2.60 (m, 1H), 1.26-1.23 (m, 6H).

Example 184

2-Methyl-2-[4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanoic acid




123

To a solution of methyl 2-methyl-2-[4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanoate (Example 174; 63 mg, 0.12 mmol) in 1:2 THF:H₂O (3 mL:6 mL) was added lithium hydroxide monohydrate (8.0 mg, 0.19 mmol). The mixture was heated at 60° C. for 5 h. The THF was removed under reduced pressure, and the resulting solution was acidified to neutral pH with 10% aq. HCl. The solution was then extracted with EtOAc. The organic layers were combined, dried, and concentrated. The crude residue was purified (FCC) to give the title compound (37 mg, 60%). MS (ESI): mass calcd. for C₂₇H₃₀F₃N₅O₂, 513.24; m/z found, 514.1 [M+H]⁺. ¹H NMR (CD₃OD): 8.45-8.42 (m, 1H), 8.01 (dd, J=7.9, 1.7 Hz, 1H), 7.69-7.63 (m, 2H), 7.38-7.33 (m, 2H), 7.13-7.09 (m, 1H), 3.57-3.50 (m, 4H), 3.21-3.16 (m, 2H), 3.13-3.08 (m, 2H), 3.01-2.93 (m, 1H), 1.57 (s, 6H), 1.28 (d, J=6.9 Hz, 6H).

Example 185

4-({2-(1-Methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)benzoic acid trifluoroacetic acid salt




The title compound was prepared using methods analogous to those described in Example 184, starting with methyl 4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)benzoate (Example 103) and purified using preparative HPLC. MS (ESI): mass calcd. for C₂₄H₂₄F₃N₅O₂, 471.19; m/z found, 472.1 [M+H]⁺. ¹H NMR (CD₃OD): 8.46-8.43 (m, 1H), 8.07-8.01 (m, 3H), 7.76-7.72 (m, 2H), 7.16-7.12 (m, 1H), 3.68-3.58 (m, 4H), 3.34-3.30 (m, 2H), 3.24-3.20 (m, 2H), 3.12-3.05 (m, 1H), 1.31 (d, J=6.8 Hz, 6H).

124

Example 186

2-Methyl-2-[4-({2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanoic acid




The title compound was prepared using methods analogous to those described in Example 184, starting with of methyl 2-methyl-2-[4-({2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanoate (Example 174). MS (ESI): mass calcd. for C₂₉H₃₃F₃N₆O₂, 554.26; m/z found, 555.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.37 (m, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.56-7.52 (m, 2H), 7.37-7.32 (m, 2H), 6.95-6.90 (m, 1H), 6.35 (s, 1H), 3.76-3.70 (m, 4H), 3.62-3.54 (m, 4H), 3.07-3.03 (m, 2H), 2.85-2.80 (m, 2H), 1.68-1.56 (m, 12H).

The following Examples 187-190 were prepared using methods analogous to those described in Example 17, substituting the appropriate amidines in Step A and amines in Step E.

Example 187

2-(1-Methylethyl)-N-(5-methylpyrazin-2-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine hydrochloride salt




125

MS (ESI): mass calcd. for $C_{22}H_{24}F_3N_7$, 443.20; m/z found, 444.1 $[M+H]^+$. 1H NMR (CD_3OD): 9.15-9.13 (m, 1H), 8.44-8.41 (m, 1H), 8.39-8.38 (m, 1H), 8.00 (dd, $J=7.8, 1.6$ Hz, 1H), 7.15-7.09 (m, 1H), 3.66-3.53 (m, 4H), 3.39-3.33 (m, 2H), 3.27-3.21 (m, 2H), 3.19-3.09 (m, 1H), 2.55 (s, 3H), 1.32 (d, $J=6.8$ Hz, 6H).

Example 188


N-[6-Chloro-5-(trifluoromethyl)pyridin-2-yl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine hydrochloride salt



MS (ESI): mass calcd. for $C_{23}H_{21}ClF_6N_6$, 530.14; m/z found, 531.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.57-8.52 (m, 1H), 8.47-8.44 (m, 1H), 8.18 (d, $J=8.6$ Hz, 1H), 8.12 (s, 1H), 7.95-7.91 (m, 1H), 7.02-7.07 (m, 1H), 4.09-3.99 (m, 1H), 3.93-3.84 (m, 2H), 3.71-3.64 (m, 4H), 3.21-3.13 (m, 2H), 1.48 (d, $J=6.7$ Hz, 6H).

Example 189

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(6-methoxy-5-trifluoromethyl-pyridin-2-yl)-amine hydrochloride salt



MS (ESI): mass calcd. for $C_{24}H_{24}F_6N_6O$, 526.19; m/z found, 527.2 $[M+H]^+$. 1H NMR (CD_3OD): 8.48-8.45 (m, 1H), 8.10-8.02 (m, 2H), 7.89-7.85 (m, 1H), 7.19-7.14 (m,

126

1H), 4.06 (s, 3H), 3.71-3.66 (m, 2H), 3.64-3.59 (m, 2H), 3.44-3.39 (m, 2H), 3.34-3.28 (m, 2H), 3.24-3.17 (m, 1H), 1.41-1.39 (m, 6H).

Example 190

2-Pyridin-4-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt


10

15

20

25

30



35

40

MS (ESI): mass calcd. for $C_{25}H_{19}F_6N_7$, 531.16; m/z found, 532.5 $[M+H]^+$. 1H NMR ($MeOD$): 8.96-8.92 (m, 2H), 8.92-8.89 (m, 2H), 8.66-8.63 (m, 1H), 8.44 (dd, $J=4.8, 1.4$ Hz, 1H), 8.30 (d, $J=8.8$ Hz, 1H), 8.12 (dd, $J=9.0, 2.3$ Hz, 1H), 8.02 (dd, $J=7.9, 1.8$ Hz, 1H), 7.15-7.10 (m, 1H), 3.64-3.55 (m, 4H), 3.48-3.40 (m, 2H), 3.30-3.27 (m, 2H).

Examples 191-192 were prepared using methods analogous to those described in Example 17, substituting the appropriate amidines in Step A, amines in Step E, and substituting $Pd_2(dba)_3$ (5 mol %) for $Pd(OAc)_2$ and 1,2,3,4,5-pentaphenyl-1'-(di-*t*-butylphosphino)ferrocene (Qphos, 10 mol %) for DCPB.

Example 191


45

[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyrazin-2-yl)-amine

50

55

60




MS (ESI): mass calcd. for $C_{22}H_{21}F_6N_7$, 497.18; m/z found, 498.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 10.02-10.01 (m, 1H),

127

8.56-8.55 (m, 1H), 8.40-8.38 (m, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.56 (s, 1H), 7.01-6.96 (m, 1H), 3.67-3.55 (m, 4H), 3.31-3.24 (m, 2H), 3.16-3.04 (m, 3H), 1.36 (d, J=6.9 Hz, 6H).

Example 192

[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyrazin-2-yl)-amine




MS (ESI): mass calcd. for $C_{24}H_{24}F_6N_8$, 538.20; m/z found, 539.2 [M+H]⁺. ¹H NMR (CDCl₃): 9.76-9.73 (m, 1H), 8.56-8.54 (m, 1H), 8.42-8.40 (m, 1H), 7.89 (dd, J=7.8, 1.8 Hz, 1H), 7.43 (s, 1H), 6.99-6.95 (m, 1H), 3.81-3.75 (m, 4H), 3.62-3.53 (m, 4H), 3.15-3.09 (m, 2H), 2.98-2.92 (m, 2H), 1.75-1.58 (m, 6H).

The following Examples 193-197 were prepared using methods analogous to those described in Example 39, substituting the appropriate carboximidamides in Step A and amines in Step C.

Example 193

2-(4-Methylpiperazin-1-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




128

MS (ESI): mass calcd. for $C_{25}H_{26}F_6N_8$, 552.22; m/z found, 553.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.50-8.48 (m, 1H), 8.41-8.38 (m, 2H), 7.90-7.86 (m, 2H), 7.44 (s, 1H), 6.97-6.94 (m, 1H), 3.86-3.79 (m, 4H), 3.58-3.52 (m, 4H), 3.13-3.08 (m, 2H), 2.95-2.91 (m, 2H), 2.51-2.47 (m, 4H), 2.35 (s, 3H).

Example 194


2-Azepan-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{26}H_{27}F_6N_7$, 551.22; m/z found, 552.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.80 (d, J=8.8 Hz, 1H), 8.49-8.48 (m, 1H), 8.40-8.38 (m, 1H), 7.88-7.84 (m, 2H), 7.44 (s, 1H), 6.96-6.92 (m, 1H), 3.81-3.72 (m, 4H), 3.59-3.52 (m, 4H), 3.12-3.08 (m, 2H), 2.94-2.90 (m, 2H), 1.84-1.78 (m, 4H), 1.59-1.55 (m, 4H).

Example 195

N²-[2-(Dimethylamino)ethyl]-N²-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]-N⁴-[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




MS (ESI): mass calcd. for $C_{25}H_{28}F_6N_8$, 554.23; m/z found, 555.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.56 (d, J=8.9 Hz, 1H),

129

8.49-8.48 (m, 1H), 8.40-8.38 (m, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.84-7.82 (m, 1H), 7.45 (s, 1H), 6.96-6.94 (m, 1H), 3.79-3.73 (m, 2H), 3.57-3.52 (m, 4H), 3.19 (s, 3H), 3.11-3.09 (m, 2H), 2.93-2.90 (m, 2H), 2.55-2.50 (m, 2H), 2.30 (s, 6H).

Example 196


N²-Methyl-N²-[2-(methoxy)ethyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-N⁴-[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₄H₂₅F₆N₇O, 541.20; m/z found, 542.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.55 (d, J=8.8 Hz, 1H), 8.49-8.48 (m, 1H), 8.40-8.39 (m, 1H), 7.88-7.84 (m, 2H), 7.46 (s, 1H), 6.97-6.94 (m, 1H), 3.84-3.80 (m, 2H), 3.64-3.61 (m, 2H), 3.56-3.53 (m, 4H), 3.38 (s, 3H), 3.23 (s, 3H), 3.11-3.09 (m, 2H), 2.93-2.91 (m, 2H).

Example 197

2-Azetidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for C₂₃H₂₁F₆N₇, 509.18; m/z found, 510.5 [M+H]⁺. ¹H NMR (MeOD): 8.69 (s, 1H), 8.47-8.42 (m, 1H), 8.41 (d, J=8.8 Hz, 1H), 8.14 (dd, J=8.9, 2.3 Hz, 1H), 8.02


130

(dd, J=7.8, 1.7 Hz, 1H), 7.16-7.11 (m, 1H), 4.37-4.32 (m, 4H), 3.63-3.58 (m, 2H), 3.55-3.51 (m, 2H), 3.29-3.24 (m, 2H), 3.15-3.10 (m, 2H), 2.57-2.48 (m, 2H).

The following Examples 198-201 were prepared using reduction methods analogous to those described in US Pat. Appl. Publ. 2000/006150343.

Example 198


N-[2-(1-Methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]benzene-1,4-diamine trifluoroacetic acid salt



The title compound was prepared from 2-(1-methylethyl)-N-(4-nitrophenyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine (Example 136). MS (ESI): mass calcd. for C₂₃H₂₅F₃N₆, 442.21; m/z found, 443.1 [M+H]⁺. ¹H NMR (CD₃OD): 8.38-8.36 (m, 1H), 7.97-7.94 (m, 1H), 7.59-7.53 (m, 2H), 7.27-7.19 (m, 2H), 7.10-7.06 (m, 1H), 3.60-3.51 (m, 4H), 3.27-3.24 (m, 2H), 3.14-3.11 (m, 2H), 3.03-2.96 (m, 1H), 1.20 (d, J=6.8 Hz, 6H).

Example 199

4-(1,1-Dimethylethyl)-N1-[2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]benzene-1,3-diamine




The title compound was prepared from N-[4-(1,1-dimethylethyl)-3-nitrophenyl]-2-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine (Example 143). MS (ESI): mass calcd. for C₂₇H₃₃F₃N₆, 498.27; m/z found, 499.2 [M+H]⁺. ¹H NMR

131

(CDCl₃): 8.31-8.29 (m, 1H), 7.80-7.78 (m, 1H), 7.21 (d, J=2.3 Hz, 1H), 7.10 (d, J=8.5 Hz, 1H), 6.87-6.84 (m, 1H), 6.82 (dd, J=8.5, 2.3 Hz, 1H), 6.31 (s, 1H), 3.82-3.70 (br s, 2H), 3.59-3.51 (m, 4H), 3.16-3.10 (m, 2H), 3.02-2.91 (m, 1H), 2.87-2.82 (m, 2H), 1.35 (s, 9H), 1.26 (d, J=6.9 Hz, 6H).

Example 200


4-(1,1-Dimethylethyl)-N1-{2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}benzene-1,3-diamine



The title compound was prepared from N-[4-(1,1-dimethylethyl)-3-nitrophenyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine (Example 159). MS (ESI): mass calcd. for C₂₉H₃₆F₃N₇, 539.30; m/z found, 540.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.38 (m, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.16 (d, J=8.5 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.95-6.91 (m, 1H), 6.85 (dd, J=2.3, 8.5 Hz, 1H), 6.24 (s, 1H), 3.83-3.74 (m, 6H), 3.63-3.56 (m, 4H), 3.10-3.05 (m, 2H), 2.85-2.80 (m, 2H), 1.70-1.59 (m, 6H), 1.43 (s, 9H).

Example 201

7-[5-Amino-3-(trifluoromethyl)pyridin-2-yl]-N-[4-(1,1-dimethylethyl)phenyl]-2-(1-methylethyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




132

The title compound was prepared from N-[4-(1,1-dimethylethyl)phenyl]-2-(1-methylethyl)-7-[5-nitro-3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine (Example 290). MS (ESI): mass calcd. for C₂₇H₃₃F₃N₆, 498.27; m/z found, 499.5 [M+H]⁺. ¹H NMR (CDCl₃): 7.99-7.95 (m, 1H), 7.63-7.56 (m, 2H), 7.38-7.32 (m, 2H), 7.26-7.24 (m, 1H), 6.48 (s, 1H), 3.75-3.68 (m, 2H), 3.25-3.18 (m, 4H), 3.19-3.12 (m, 2H), 3.08-2.97 (m, 1H), 2.91-2.84 (m, 2H), 1.61-1.48 (m, 9H), 1.35-1.30 (m, 6H).

The following Examples 202-206 were prepared using methods analogous to those described in Example 52, substituting the appropriate amidines in Step A and amines in Step C.

Example 202


N-[4-(1,1-Dimethylethyl)phenyl]-2-(methylsulfonyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for C₂₅H₂₈F₃N₅S, 487.20; m/z found, 488.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.37 (m, 1H), 7.88-7.86 (m, 1H), 7.51-7.47 (m, 2H), 7.36-7.34 (m, 2H), 6.97-6.93 (m, 1H), 6.48 (s, 1H), 3.65-3.62 (m, 2H), 3.60-3.57 (m, 2H), 3.18-3.14 (m, 2H), 2.94-2.90 (m, 2H), 2.52 (s, 3H), 1.33 (s, 9H).

Example 203

N-[2-Chloro-4-(trifluoromethyl)phenyl]-2-(methylsulfonyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for C₂₂H₁₈ClF₆N₅S, 533.09; m/z found, 534.1 [M+H]⁺. ¹H NMR (DMSO): 9.48 (s, 1H), 9.16-

133

9.14 (m, 1H), 8.74-8.71 (m, 1H), 8.60 (d, J=2.0 Hz, 1H), 8.48 (d, J=8.5 Hz, 1H), 8.41-8.39 (m, 1H), 7.81-7.78 (m, 1H), 4.20-4.17 (m, 4H), 3.78-3.72 (m, 4H), 2.91 (s, 3H).

Example 204


2-(Methylsulfonyl)-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{23}H_{21}F_6N_5S$, 513.14; m/z found, 514 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.7, 1.5 Hz, 1H), 8.08 (d, J=8.6 Hz, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.49-7.44 (m, 2H), 6.99-6.92 (m, 1H), 6.42 (bs, 1H), 3.68-3.62 (m, 2H), 3.62-3.54 (m, 2H), 3.21-3.15 (m, 2H), 2.98-2.92 (m, 2H), 2.45 (s, 3H), 2.36 (s, 3H).

Example 205

2-(Methylsulfonyl)-N-(1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{25}H_{27}F_3N_5S$, 500.20; m/z found, 501 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.7, 1.5 Hz, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 6.97-6.91 (m, 1H), 6.89 (d, J=7.9 Hz, 1H), 6.78 (d, J=2.0 Hz, 1H), 6.74 (dd, J=7.9, 2.1 Hz, 1H), 6.41 (bs, 1H), 3.66-3.61 (m, 2H), 3.61-3.55 (m, 2H),

134

3.23 (t, J=5.6 Hz, 2H), 3.19-3.11 (m, 2H), 2.93-2.83 (m, 2H), 2.89 (s, 3H), 2.73 (t, J=6.4 Hz, 2H), 2.52 (s, 3H), 2.03-1.93 (m, 2H).

Example 206

2-(Methylsulfonyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-(1,4,4-trimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{27}H_{31}F_3N_5S$, 528.23; m/z found, 529 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.7, 1.5 Hz, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.12 (d, J=8.2 Hz, 1H), 6.93 (dd, J=7.4, 4.7 Hz, 1H), 6.84-6.78 (m, 2H), 6.41 (bs, 1H), 3.66-3.61 (m, 2H), 3.61-3.55 (m, 2H), 3.27-3.21 (m, 2H), 3.17-3.11 (m, 2H), 2.93-2.86 (m, 2H), 2.91 (s, 3H), 2.53 (s, 3H), 1.78-1.72 (m, 2H), 1.28 (s, 6H).

Examples 207-211 synthesized in a manner similar to Example 53 substituting the appropriate amines in Step C of Example 52.

Example 207

N-[4-(1,1-Dimethylethyl)phenyl]-2-(methylsulfonyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




The title compound was prepared starting with N-[4-(1,1-dimethylethyl)phenyl]-2-(methylsulfonyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine (Example 202). MS (ESI): mass calcd. for $C_{25}H_{28}F_3N_5O_2S$, 519.19; m/z found, 520.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 7.88 (dd, J=7.8, 1.8 Hz,

135

1H), 7.49-7.45 (m, 2H), 7.41-7.38 (m, 2H), 7.00-6.96 (m, 1H), 6.77 (s, 1H), 3.72-3.67 (m, 2H), 3.64-3.59 (m, 2H), 3.36-3.31 (m, 2H), 3.25 (s, 3H), 3.07-3.02 (m, 2H), 1.33 (s, 9H).

Example 208


2-(Methylsulfonyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-(1,4,4-trimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



The title compound was prepared starting with 2-(methylsulfonyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-(1,4,4-trimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine (Example 206). MS (ESI): mass calcd. for $C_{27}H_{31}F_3N_6O_2S$, 560.22; m/z found, 561 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.57 (d, J=2.2 Hz, 0.6H), 8.51 (d, J=2.0 Hz, 0.4H), 8.43-8.37 (m, 1H), 8.07-7.94 (m, 1H), 7.91-7.85 (m, 1H), 7.30-7.20 (m, 1H), 7.02-6.95 (m, 1H), 5.75-5.40 (m, 1H), 3.93-3.78 (m, 2H), 3.68-3.47 (m, 7H), 3.44-3.21 (m, 4H), 2.90 (s, 1.5H), 2.87 (s, 1.5H), 2.05-1.90 (m, 2H), 1.39 (s, 3H), 1.37 (s, 1.5H), 1.35 (s, 1.5H).

Example 209

2-(Methylsulfonyl)-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




The title compound was prepared starting with 2-(methylsulfonyl)-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine (Example 204). MS (ESI): mass

136

calcd. for $C_{23}H_{21}F_6N_5O_2S$, 545.13; m/z found, 546 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.6, 1.4 Hz, 1H), 7.96 (d, J=8.2 Hz, 1H), 7.89 (dd, J=7.8, 1.8 Hz, 1H), 7.55-7.48 (m, 2H), 7.00 (dd, J=7.4, 4.7 Hz, 1H), 6.71 (bs, 1H), 3.74-3.67 (m, 2H), 3.66-3.59 (m, 2H), 3.38-3.32 (m, 2H), 3.20 (s, 3H), 3.11-3.05 (m, 2H), 2.37 (s, 3H).

Example 210


2-(1-Methylethyl)-N-[4-(methylsulfonyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



The title compound was prepared starting with 2-(1-methylethyl)-N-[4-(methylsulfonyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine (Example 135). MS (ESI): mass calcd. for $C_{24}H_{26}F_3N_5O_2S$, 505.18; m/z found, 506.4 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.37 (m, 1H), 7.92-7.86 (m, 5H), 6.99-6.94 (m, 1H), 6.77 (s, 1H), 3.69-3.57 (m, 4H), 3.28-3.21 (m, 2H), 3.11-3.04 (m, 4H), 3.02-2.99 (m, 2H), 1.33 (d, J=6.9 Hz, 6H).

Example 211

Methyl 5-chloro-6-[2-(methylsulfonyl)-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl]pyridine-3-carboxylate



The title compound was prepared starting from methyl 5-chloro-6-[2-(methylsulfonyl)-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl]pyridine-3-carboxylate (Example 303). MS (ESI): mass calcd. for $C_{23}H_{21}ClF_3N_5O_4S$, 555.10; m/z found, 556.1


137

[M+H]⁺. ¹H NMR (CD₃OD): 8.50 (d, J=2.00 Hz, 1H), 7.96 (d, J=2.00 Hz, 1H), 7.54 (d, J=8.55 Hz, 2H), 7.44 (d, J=8.64 Hz, 2H), 6.93 (s, 1H), 3.86-3.71 (m, 4H), 3.70 (s, 3H), 3.26-3.11 (m, 2H), 3.02-2.95 (m, 2H).

The following Examples 212-277 were prepared using methods analogous to those described in Example 55, substituting the appropriate amines.

Example 212


2-(1,1-Dioxido-1,2-thiazinan-2-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for C₂₅H₂₄F₆N₆O₂S, 586.16; m/z found, 587.5 [M+H]⁺. ¹H NMR (CDCl₃): 9.89-9.69 (m, 1H), 8.49-8.34 (m, 1H), 7.92 (d, J=7.0 Hz, 1H), 7.68-7.54 (m, 4H), 7.05 (dd, J=7.6, 4.7 Hz, 1H), 4.15-4.08 (m, 2H), 3.68-3.52 (m, 4H), 3.43-3.34 (m, 2H), 3.28-3.08 (m, 4H), 2.39-2.23 (m, 2H), 1.82-1.65 (m, 2H).

Example 213

N²-[2-(Methyloxy)ethyl]-N⁴-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt




138

MS (ESI): mass calcd. for C₂₄H₂₄F₆N₆O, 526.19; m/z found, 527.5 [M+H]⁺. ¹H NMR (CD₃OD): 8.45 (dd, J=4.7, 1.4 Hz, 1H), 8.02 (dd, J=7.8, 1.8 Hz, 1H), 7.79 (d, J=8.5 Hz, 2H), 7.69 (d, J=8.6 Hz, 2H), 7.14 (dd, J=7.7, 4.8 Hz, 1H), 3.65-3.59 (m, 2H), 3.58-3.47 (m, 6H), 3.33-3.31 (m, 3H), 3.20-3.15 (m, 2H), 3.11-3.07 (m, 2H).

Example 214


2-[3-(Methyloxy)piperidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for C₂₇H₂₈F₆N₆O, 566.22; m/z found, 567.6 [M+H]⁺. ¹H NMR (CD₃OD): 8.47-8.43 (m, 1H), 8.03 (dd, J=7.8, 1.7 Hz, 1H), 7.71 (s, 4H), 7.17-7.10 (m, 1H), 3.91-3.67 (m, 3H), 3.65-3.50 (m, 5H), 3.43-3.36 (m, 1H), 3.29-3.26 (m, 2H), 3.20 (s, 3H), 3.12-3.07 (m, 2H), 1.95-1.73 (m, 3H), 1.61-1.50 (m, 1H).

Example 215

2-{(2S)-2-[(Methyloxy)methyl]pyrrolidin-1-yl}-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for C₂₇H₂₈F₆N₆O, 566.22; m/z found, 567.6 [M+H]⁺. ¹H NMR (CD₃OD): 8.46-8.43 (m,

139

1H), 8.03 (dd, J=7.8, 1.7 Hz, 1H), 7.80 (d, J=8.5 Hz, 2H), 7.69 (d, J=8.6 Hz, 2H), 7.14 (dd, J=7.8, 4.8 Hz, 1H), 4.34-4.25 (m, 1H), 3.66-3.37 (m, 9H), 3.29-3.20 (m, 4H), 3.14-3.07 (m, 2H), 2.23-1.90 (m, 4H).

Example 216


N²-(Furan-2-ylmethyl)-N²-methyl-N⁴-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt



MS (ESI): mass calcd. for C₂₇H₂₄F₆N₆O, 562.19; m/z found, 563.5 [M+H]⁺. ¹H NMR (CD₃OD): 8.46-8.43 (m, 1H), 8.03 (dd, J=7.8, 1.7 Hz, 1H), 7.74 (d, J=8.6 Hz, 2H), 7.66 (d, J=8.7 Hz, 2H), 7.50-7.46 (m, 1H), 7.14 (dd, J=7.8, 4.8 Hz, 1H), 6.37 (dd, J=3.2, 1.9 Hz, 1H), 6.17 (d, J=2.5 Hz, 1H), 4.76 (s, 2H), 3.65-3.58 (m, 2H), 3.58-3.53 (m, 2H), 3.34-3.30 (m, 2H), 3.21 (s, 3H), 3.14-3.09 (m, 2H).

Example 217

2-Azetidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for C₂₃H₂₁F₆N₇, 509.18; m/z found, 510.1 [M+H]⁺. ¹H NMR (DMSO): 9.07 (d, J=2.4 Hz, 1H), 8.89 (s, 1H), 8.45 (dd, J=4.7, 1.5 Hz, 1H), 8.43 (dd, J=8.7, 2.4

140

Hz, 1H), 8.03 (dd, J=7.8, 1.8 Hz, 1H), 7.77 (d, J=8.7 Hz, 1H), 7.10 (dd, J=7.6, 4.7 Hz, 1H), 3.97 (t, J=7.4 Hz, 4H), 3.45-3.38 (m, 4H), 3.00-2.96 (m, 4H), 2.27-2.22 (m, 2H).

Example 218


N²,N²-Dimethyl-7-[3-(trifluoromethyl)pyridin-2-yl]-N⁴-{[6-(trifluoromethyl)pyridin-3-yl]methyl}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt



MS (ESI): mass calcd. for C₂₃H₂₃F₆N₇, 511.19; m/z found, 512.4 [M+H]⁺. ¹H NMR (MeOD): 8.69 (d, J=1.6 Hz, 1H), 8.40 (dd, J=4.8, 1.5 Hz, 1H), 8.02-7.96 (m, 2H), 7.77 (d, J=8.0 Hz, 1H), 7.10 (dd, J=7.5, 4.7 Hz, 1H), 4.80 (s, 2H), 3.60-3.55 (m, 2H), 3.54-3.49 (m, 2H), 3.24-3.20 (m, 2H), 3.13 (s, 6H), 2.96-2.93 (m, 2H).

Example 219

N²-[2-(Dimethylamino)ethyl]-N²-methyl-N⁴-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt




MS (ESI): mass calcd. for C₂₆H₂₉F₆N₇, 553.24; m/z found, 554.2 [M+H]⁺. ¹H NMR (MeOD): 8.48-8.45 (m, 1H), 8.04 (dd, J=7.9, 1.7 Hz, 1H), 7.78 (d, J=8.6 Hz, 2H), 7.67 (d, J=8.4 Hz, 2H), 7.19-7.12 (m, 1H), 3.93 (t, J=6.1 Hz, 2H), 3.63-3.59

141

(m, 2H), 3.58-3.53 (m, 2H), 3.36-3.31 (m, 2H), 3.29-3.24 (m, 2H), 3.23 (s, 3H), 3.12-3.08 (m, 2H), 2.57 (s, 6H).

Example 220


2-(4-Methylpiperazin-1-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{25}H_{26}F_6N_8$, 552.22; m/z found, 553.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.86 (d, $J=2.4$ Hz, 1H), 8.40-8.37 (m, 1H), 8.14 (dd, $J=8.4$, 2.3 Hz, 1H), 7.87 (dd, $J=7.8$, 1.8 Hz, 1H), 7.65 (d, $J=8.6$ Hz, 1H), 6.98-6.93 (m, 1H), 6.55 (s, 1H), 3.82-3.75 (m, 4H), 3.63-3.53 (m, 4H), 3.14-3.05 (m, 2H), 2.95-2.87 (m, 2H), 2.50-2.43 (m, 4H), 2.34 (s, 3H).

Example 221

N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-(4-methylpiperazin-1-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{26}H_{26}ClF_6N_7$, 585.18; m/z found, 586.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.6$, 1.5 Hz, 1H), 8.01 (d, $J=1.9$ Hz, 1H), 7.87 (dd, $J=7.8$, 1.8 Hz, 1H), 7.59 (d, $J=8.7$ Hz, 1H), 7.37-7.31 (m, 1H), 6.95 (dd, $J=7.5$, 4.9

142

Hz, 1H), 6.53 (s, 1H), 3.84-3.77 (m, 4H), 3.62-3.52 (m, 4H), 3.13-3.03 (m, 2H), 2.90-2.83 (m, 2H), 2.51-2.46 (m, 4H), 2.35 (s, 3H).

Example 222


2-Azepan-1-yl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6$, 550.23; m/z found, 551.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.36 (m, 1H), 7.86 (dd, $J=7.8$, 1.8 Hz, 1H), 7.72 (d, $J=8.5$ Hz, 2H), 7.54 (d, $J=8.6$ Hz, 2H), 6.93 (dd, $J=7.5$, 4.9 Hz, 1H), 6.50 (s, 1H), 3.78-3.67 (m, 4H), 3.63-3.53 (m, 4H), 3.12-3.01 (m, 2H), 2.89-2.83 (m, 2H), 1.83-1.74 (m, 4H), 1.65-1.47 (m, 4H).

Example 223

2-Azepan-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{26}H_{27}F_6N_7$, 551.22; m/z found, 552.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.78 (d, $J=2.5$ Hz, 1H), 8.40-8.34 (m, 2H), 7.87 (dd, $J=7.8$, 1.8 Hz, 1H), 7.62 (d, $J=8.7$ Hz, 1H), 6.97-6.91 (m, 1H), 6.54 (s, 1H), 3.76-3.68 (m, 4H),

143

3.63-3.52 (m, 4H), 3.13-3.05 (m, 2H), 2.93-2.87 (m, 1H), 1.83-1.72 (m, 4H), 1.60-1.49 [(m, 4H) coincidental with water peak].

Example 224


2-Azepan-1-yl-N-[3-chloro-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{27}ClF_6N_6$, 584.19; m/z found, 585.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.36 (m, 1H), 8.25 (d, $J=1.9$ Hz, 1H), 7.86 (dd, $J=7.8, 1.8$ Hz, 1H), 7.56 (d, $J=8.7$ Hz, 1H), 7.32-7.28 (m, 1H), 6.96-6.91 (m, 1H), 6.52 (s, 1H), 3.80-3.68 (m, 4H), 3.62-3.52 (m, 4H), 3.12-3.03 (m, 2H), 2.89-2.83 (m, 2H), 1.86-1.76 (m, 4H), 1.61-1.50 [(m, 4H) coincidental with water peak].

Example 225

N^2 -[2-(Dimethylamino)ethyl]- N^2 -methyl-7-[3-(trifluoromethyl)pyridin-2-yl]- N^4 -[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




MS (ESI): mass calcd. for $C_{25}H_{28}F_6N_8$, 554.23; m/z found, 555.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.77 (s, 1H), 8.40-8.37 (m, 1H), 8.36-8.32 (m, 1H), 7.87 (dd, $J=7.8, 1.8$ Hz, 1H), 7.61 (d,

144

$J=8.6$ Hz, 1H), 6.98-6.92 (m, 1H), 6.54 (s, 1H), 3.78-3.67 (m, 2H), 3.63-3.52 (m, 4H), 3.15 (s, 3H), 3.12-3.06 (m, 2H), 2.94-2.87 (m, 2H), 2.54-2.46 (m, 2H), 2.28 (s, 6H).

Example 226


N^4 -[3-Chloro-4-(trifluoromethyl)phenyl]- N^2 -[2-(dimethylamino)ethyl]- N^2 -methyl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for $C_{26}H_{28}ClF_6N_7$, 587.20; m/z found, 588.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.6, 1.4$ Hz, 1H), 8.02 (s, 1H), 7.87 (dd, $J=7.8, 1.8$ Hz, 1H), 7.57 (d, $J=8.7$ Hz, 1H), 7.43 (d, $J=8.6$ Hz, 1H), 6.94 (dd, $J=7.4, 4.9$ Hz, 1H), 6.53 (s, 1H), 3.78-3.69 (m, 2H), 3.61-3.49 (m, 4H), 3.17 (s, 3H), 3.11-3.05 (m, 2H), 2.89-2.82 (m, 2H), 2.54-2.48 (m, 2H), 2.28 (s, 6H).

Example 227

N^4 -[(3,4-Dichlorophenyl)methyl]- N^2 -[2-(dimethylamino)ethyl]- N^2 -methyl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt




145

MS (ESI): mass calcd. for $C_{26}H_{30}Cl_2F_3N_7$, 567.19; m/z found, 568.5 $[M+H]^+$. 1H NMR (MeOD): 8.42 (dd, $J=4.7, 1.4$ Hz, 1H), 8.01 (dd, $J=7.8, 1.8$ Hz, 1H), 7.51 (d, $J=8.3$ Hz, 1H), 7.47-7.44 (m, 1H), 7.22 (dd, $J=8.3, 2.1$ Hz, 1H), 7.14-7.08 (m, 1H), 4.73 (s, 2H), 4.00-3.93 (m, 2H), 3.62-3.58 (m, 2H), 3.57-3.52 (m, 2H), 3.29-3.22 (m, 2H), 3.21 (s, 3H), 3.01-2.96 (m, 2H), 2.78 (s, 6H).

Example 228


N^2 -Methyl- N^2 -[2-(methyloxy)ethyl]-7-[3-(trifluoromethyl)pyridin-2-yl]- N^4 -[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{24}H_{25}F_6N_7O$, 541.20; m/z found, 542.5 $[M+H]^+$. 1H NMR (MeOD): 8.47-8.44 (m, 1H), 8.26 (dd, $J=8.5, 2.2$ Hz, 1H), 8.03 (dd, $J=7.8, 1.7$ Hz, 1H), 7.86 (d, $J=8.6$ Hz, 1H), 7.18-7.12 (m, 1H), 3.79 (t, $J=5.1$ Hz, 2H), 3.65-3.53 (m, 6H), 3.32 (s, 3H), 3.32-3.29 (m, 2H), 3.23 (s, 3H), 3.15-3.11 (m, 2H).

Example 229

N^4 -[3-Chloro-4-(trifluoromethyl)phenyl]- N^2 -methyl- N^2 -[2-(methyloxy)ethyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt




146

MS (ESI): mass calcd. for $C_{25}H_{25}ClF_6N_6O$, 574.17; m/z found, 575.5 $[M+H]^+$. 1H NMR (MeOD): 8.45 (dd, $J=4.7, 1.3$ Hz, 1H), 8.05 (d, $J=1.8$ Hz, 1H), 8.03 (dd, $J=7.9, 1.7$ Hz, 1H), 7.80-7.76 (m, 1H), 7.64 (d, $J=8.7$ Hz, 1H), 7.18-7.11 (m, 1H), 3.86-3.79 (m, 2H), 3.65-3.58 (m, 4H), 3.56-3.51 (m, 2H), 3.34 (s, 3H), 3.33-3.30 (m, 2H), 3.25 (s, 3H), 3.12-3.07 (m, 2H).

Example 230


N^4 -[(3,4-Dichlorophenyl)methyl]- N^2 -methyl- N^2 -[2-(methyloxy)ethyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{25}H_{27}Cl_2F_3N_6O$, 554.16; m/z found, 554.2 $[M+H]^+$. 1H NMR (MeOD): 8.42-8.39 (m, 1H), 8.00 (dd, $J=7.8, 1.7$ Hz, 1H), 7.46 (d, $J=8.3$ Hz, 1H), 7.44-7.42 (m, 1H), 7.21 (dd, $J=8.3, 2.0$ Hz, 1H), 7.12-7.07 (m, 1H), 4.62 (s, 2H), 3.70 (t, $J=5.1$ Hz, 2H), 3.61-3.57 (m, 2H), 3.56-3.50 (m, 2H), 3.38-3.32 (m, 2H), 3.25 (s, 3H), 3.24-3.19 (m, 2H), 3.15 (s, 3H), 2.98-2.93 (m, 2H).

Example 231

2-Azetidin-1-yl-N-[3-chloro-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




147

MS (ESI): mass calcd. for $C_{24}H_{21}ClF_6N_6$, 542.14; m/z found, 543.5 $[M+H]^+$. 1H NMR (MeOD): 8.46-8.43 (m, 1H), 8.16-8.13 (m, 1H), 8.02 (dd, $J=7.8, 1.8$ Hz, 1H), 7.76-7.73 (m, 2H), 7.16-7.11 (m, 1H), 4.30 (t, $J=7.7$ Hz, 4H), 3.62-3.58 (m, 2H), 3.55-3.49 (m, 2H), 3.27-3.21 (m, 2H), 3.12-3.07 (m, 2H), 2.55-2.45 (m, 2H).

Example 232


2-Azetidin-1-yl-N-[(3,4-dichlorophenyl)methyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{24}H_{23}Cl_2F_3N_6$, 522.13; m/z found, 523.5 $[M+H]^+$. 1H NMR (MeOD): 8.43-8.35 (m, 1H), 7.98 (dd, $J=7.8, 1.7$ Hz, 1H), 7.50-7.42 (m, 2H), 7.27-7.20 (m, 1H), 7.11-7.05 (m, 1H), 4.62-4.55 (m, 2H), 4.23-4.13 (m, 4H), 3.61-3.53 (m, 2H), 3.51-3.46 (m, 2H), 3.16-3.09 (m, 2H), 2.94-2.86 (m, 2H), 2.49-2.37 (m, 2H).

Example 233

N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{26}H_{25}ClF_6N_6$, 570.17; m/z found, 571.5 $[M+H]^+$. 1H NMR (MeOD): 8.47-8.44 (m, 1H), 8.06-7.98 (m, 2H), 7.79 (d, $J=8.7$ Hz, 1H), 7.62 (dd, $J=8.6, 1.3$

148

Hz, 1H), 7.18-7.12 (m, 1H), 3.79-3.71 (m, 4H), 3.63-3.56 (m, 2H), 3.56-3.51 (m, 2H), 3.32-3.25 (m, 2H), 3.12-3.07 (m, 2H), 1.81-1.66 (m, 6H).

Example 234


2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{25}H_{25}F_6N_7$, 537.21; m/z found, 538.5 $[M+H]^+$. 1H NMR (MeOD): 8.94 (d, $J=2.4$ Hz, 1H), 8.46 (dd, $J=4.7, 1.3$ Hz, 1H), 8.20 (dd, $J=8.3, 2.2$ Hz, 1H), 8.04 (dd, $J=7.9, 1.7$ Hz, 1H), 7.87 (d, $J=8.6$ Hz, 1H), 7.18-7.13 (m, 1H), 3.74-3.68 (m, 4H), 3.64-3.58 (m, 2H), 3.58-3.52 (m, 2H), 3.32-3.27 (m, 2H), 3.14-3.09 (m, 2H), 1.78-1.62 (m, 6H).

Example 235

2-(2,6-Dimethylmorpholin-4-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6O$, 566.22; m/z found, 566.2 $[M+H]^+$. 1H NMR (MeOD): 8.45 (d, $J=4.7$ Hz, 1H), 8.03 (dd, $J=7.8, 1.6$ Hz, 1H), 7.74-7.67 (m, 4H), 7.18-7.12 (m, 1H), 4.19 (d, $J=13.1$ Hz, 2H), 3.69-3.58 (m, 4H),

149

3.58-3.52 (m, 2H), 3.30-3.25 (m, 2H), 3.14-3.08 (m, 2H), 2.80-2.69 (m, 2H), 1.19 (d, J=6.2 Hz, 6H).

Example 236


2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6O$, 566.22; m/z found, 567.5 $[M+H]^+$. 1H NMR (MeOD): 8.47-8.44 (m, 1H), 8.03 (dd, J=7.8, 1.7 Hz, 1H), 7.74-7.68 (m, 4H), 7.17-7.12 (m, 1H), 4.20 (d, J=13.0 Hz, 2H), 3.71-3.58 (m, 4H), 3.58-3.52 (m, 2H), 3.30-3.26 (m, 2H), 3.14-3.08 (m, 2H), 2.80-2.68 (m, 2H), 1.19 (d, J=6.2 Hz, 6H).

Example 237

2-(1,4-Oxazepan-4-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{26}H_{26}F_6N_6O$, 552.20; m/z found, 553.2 $[M+H]^+$. 1H NMR (CDCl₃): 8.40-8.37 (m, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.66 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.6 Hz, 1H), 6.97-6.89 (m, 1H), 6.52 (s, 1H), 3.94-3.85 (m,

150

4H), 3.84-3.78 (m, 2H), 3.74-3.70 (m, 2H), 3.63-3.54 (m, 4H), 3.11-3.04 (m, 2H), 2.91-2.85 (m, 2H), 2.04-1.95 (m, 2H).

Example 238


2-(3,3-Difluoropiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{26}H_{24}F_8N_6$, 572.19; m/z found, 573.1 $[M+H]^+$. 1H NMR (MeOD): 8.46-8.43 (m, 1H), 8.02 (dd, J=7.8, 1.7 Hz, 1H), 7.73-7.67 (m, 4H), 7.16-7.11 (m, 1H), 4.02 (t, J=11.4 Hz, 2H), 3.79-3.74 (m, 2H), 3.64-3.59 (m, 2H), 3.57-3.53 (m, 2H), 3.30-3.27 (m, 2H), 3.13-3.08 (m, 2H), 2.21-2.09 (m, 2H), 1.91-1.80 (m, 2H).

Example 239

2-(4-Methylpiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6$, 550.2; m/z found, 551.5 $[M+H]^+$. 1H NMR (MeOD): 8.47-8.43 (m, 1H), 8.03 (dd, J=7.8, 1.7 Hz, 1H), 7.75-7.67 (m, 4H), 7.18-7.10 (m,

151

1H), 4.34 (d, J=13.5 Hz, 2H), 3.66-3.57 (m, 2H), 3.57-3.51 (m, 2H), 3.30-3.24 (m, 2H), 3.15-3.02 (m, 4H), 1.85-1.67 (m, 3H), 1.29-1.09 (m, 2H), 0.99 (d, J=6.3 Hz, 3H).

Example 240


2-(3-Methylpiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6$, 550.2; m/z found, 551.6 $[M+H]^+$. 1H NMR (MeOD): 8.47-8.43 (m, 1H), 8.03 (dd, J=7.8, 1.7 Hz, 1H), 7.75-7.67 (m, 4H), 7.19-7.10 (m, 1H), 4.32-4.15 (m, 2H), 3.63-3.57 (m, 2H), 3.57-3.51 (m, 2H), 3.30-3.24 (m, 2H), 3.13-3.01 (m, 3H), 2.82-2.66 (m, 1H), 1.93-1.73 (m, 2H), 1.73-1.45 (m, 2H), 1.34-1.17 (m, 1H), 0.94 (d, J=6.6 Hz, 3H).

Example 241

2-(3,3-Difluoroazetidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{24}H_{20}F_8N_6$, 544.16; m/z found, 545.5 $[M+H]^+$. 1H NMR (MeOD): 8.45 (dd, J=4.8, 1.4 Hz, 1H), 8.03 (dd, J=7.8, 1.8 Hz, 1H), 7.80 (d, J=8.5 Hz, 2H), 7.71

152

(d, J=8.6 Hz, 2H), 7.18-7.11 (m, 1H), 4.64-4.59 (m, 4H), 3.65-3.59 (m, 2H), 3.58-3.53 (m, 2H), 3.29-3.23 (m, 2H), 3.16-3.10 (m, 2H).

Example 242


2-(4,4-Difluoropiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{26}H_{24}F_8N_6$, 572.19; m/z found, 573.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39 (dd, J=4.7, 1.6 Hz, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.63-7.55 (m, 4H), 6.98-6.91 (m, 1H), 6.53 (s, 1H), 3.95-3.88 (m, 4H), 3.62-3.58 (m, 2H), 3.58-3.54 (m, 2H), 3.11-3.06 (m, 2H), 2.91-2.86 (m, 2H), 2.04-1.93 (m, 4H).

Example 243

2-(3,3-Difluoropyrrolidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{25}H_{22}F_8N_6$, 558.18 m/z found, 559.5 $[M+H]^+$. 1H NMR (MeOD): 8.45 (dd, J=4.4, 1.4 Hz, 1H), 8.02 (dd, J=7.8, 1.8 Hz, 1H), 7.81 (d, J=8.6 Hz, 2H), 7.71

153

(d, J=8.661 Hz, 2H), 7.16-7.11 (m, 1H), 3.99-3.92 (m, 2H), 3.84 (t, J=7.4 Hz, 2H), 3.64-3.58 (m, 2H), 3.57-3.52 (m, 2H), 3.31-3.27 (m, 2H), 3.15-3.10 (m, 2H), 2.62-2.50 (m, 2H).

Example 244


2-(2-Methylpyrrolidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{26}H_{26}F_6N_6$, 536.21; m/z found, 537.6 [M+H]⁺. ¹H NMR (CDCl₃): 8.38 (dd, J=4.7, 1.6 Hz, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.77 (d, J=8.6 Hz, 2H), 7.55 (d, J=8.6 Hz, 2H), 6.95-6.91 (m, 1H), 6.52 (s, 1H), 4.33-4.24 (m, 1H), 3.68-3.49 (m, 6H), 3.13-3.05 (m, 2H), 2.90-2.85 (m, 2H), 2.13-2.00 (m, 2H), 1.97-1.88 (m, 1H), 1.74-1.65 (m, 1H), 1.26 (d, J=6.3 Hz, 3H).

Example 245

N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-(1,4-oxazepan-4-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{26}H_{25}ClF_6N_6O$, 586.17; m/z found, 587.5 [M+H]⁺. ¹H NMR (MeOD): 8.46-8.44 (m, 1H), 8.04-8.00 (m, 2H), 7.79 (d, J=8.7 Hz, 1H), 7.64-7.59 (m, 1H),

154

7.17-7.11 (m, 1H), 3.92-3.81 (m, 6H), 3.80-3.76 (m, 2H), 3.64-3.59 (m, 2H), 3.57-3.52 (m, 2H), 3.36-3.32 (m, 2H), 3.13-3.09 (m, 2H).

Example 246


2-(2-Methylpiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine hydrochloride salt



MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6$, 550.23; m/z found, 551.6 [M+H]⁺. ¹H NMR (MeOD): 8.45 (dd, J=4.7, 1.4 Hz, 1H), 8.03 (dd, J=7.8, 1.8 Hz, 1H), 7.74-7.68 (m, 4H), 7.17-7.11 (m, 1H), 4.70-4.63 (m, 1H), 4.19-4.11 (m, 1H), 3.64-3.58 (m, 2H), 3.56-3.52 (m, 2H), 3.30-3.26 (m, 2H), 3.24-3.15 (m, 1H), 3.12-3.07 (m, 2H), 1.85-1.62 (m, 5H), 1.58-1.46 (m, 1H), 1.27 (d, J=6.9 Hz, 3H).

Example 247

2-(1,1-Dioxidothiomorpholin-4-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{25}H_{24}F_6N_6O_2S$, 586.16; m/z found, 587.1 [M+H]⁺. ¹H NMR ((CD₃)₂CO): 8.46-8.44 (m,

155

1H), 8.02-8.00 (m, 1H), 7.88-7.84 (m, 2H), 7.64-7.62 (m, 2H), 7.13-7.08 (m, 1H), 4.31-4.25 (m, 4H), 3.56-3.48 (m, 4H), 3.14-3.04 (m, 6H), 2.07-2.04 (m, 2H).

Example 248


N-[4-(1,1-Dimethylethyl)phenyl]-2-pyrrolidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{28}H_{33}F_3N_6$, 510.27; m/z found, 511.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38-8.36 (m, 1H), 7.85 (dd, $J=7.8, 1.8$ Hz, 1H), 7.62-7.58 (m, 2H), 7.34-7.31 (m, 2H), 6.94-6.90 (m, 1H), 6.35 (s, 1H), 3.61-3.56 (m, 8H), 3.09-3.06 (m, 2H), 2.86-2.82 (m, 2H), 1.99-1.92 (m, 4H), 1.32 (s, 9H).

Example 249

2-Azetidin-1-yl-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{27}H_{31}F_3N_6$, 496.26; m/z found, 497.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38-8.37 (m, 1H), 7.85 (dd, $J=7.7, 1.9$ Hz, 1H), 7.58-7.54 (m, 2H), 7.33-7.30 (m, 2H), 6.94-6.90 (m, 1H), 6.37 (s, 1H), 4.15-4.10 (m, 4H),

156

3.62-3.54 (m, 4H), 3.10-3.05 (m, 2H), 2.86-2.81 (m, 2H), 2.35-2.28 (m, 2H), 1.31 (s, 9H).

Example 250


2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{25}H_{25}F_6N_7$, 537.21; m/z found, 538.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.49-8.47 (m, 1H), 8.43 (d, $J=8.9$ Hz, 1H), 8.40-8.39 (m, 1H), 7.89-7.85 (m, 2H), 7.42 (s, 1H), 6.97-6.92 (m, 1H), 3.79-3.74 (m, 4H), 3.58-3.52 (m, 4H), 3.12-3.06 (m, 2H), 2.95-2.88 (m, 2H), 1.73-1.59 (m, 6H).

Example 251

N-[(3,4-Dichlorophenyl)methyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{26}H_{27}Cl_2F_3N_6$, 551.16; m/z found, 551.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.36-8.35 (m, 1H), 7.84 (dd, $J=7.8, 1.8$ Hz, 1H), 7.44-7.43 (m, 1H), 7.37 (d, $J=8.2$ Hz, 1H), 7.18-7.16 (m, 1H), 6.92-6.89 (m, 1H), 4.82-4.79 (m,

157

1H), 4.59 (d, J=5.7 Hz, 2H), 3.69-3.65 (m, 4H), 3.57-3.52 (m, 4H), 3.03-2.99 (m, 2H), 2.72-2.69 (m, 2H), 1.64-1.59 (m, 2H), 1.56-1.50 (m, 4H).

Example 252


N-[4-(1,1-Dimethylethyl)phenyl]-2-(4-methylpiperazin-1-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{29}H_{36}F_3N_7$, 539.30; m/z found, 540.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.37 (m, 1H), 7.86 (dd, J=7.8, 1.7 Hz, 1H), 7.48-7.45 (m, 2H), 7.36-7.32 (m, 2H), 6.94-6.90 (m, 1H), 6.34 (s, 1H), 3.84-3.76 (m, 4H), 3.64-3.55 (m, 4H), 3.09-3.04 (m, 2H), 2.87-2.81 (m, 2H), 2.51-2.42 (m, 4H), 2.34 (s, 3H), 1.33 (s, 9H).

Example 253

2-Azepan-1-yl-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{30}H_{37}F_3N_6$, 538.30; m/z found, 539.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.37 (m, 1H), 7.85 (dd, J=7.8, 1.7 Hz, 1H), 7.56-7.53 (m, 2H), 7.33-7.30 (m, 2H), 6.93-6.90 (m, 1H), 6.31 (s, 1H), 3.76-3.70 (m, 4H),

158

3.63-3.56 (m, 4H), 3.08-3.04 (m, 2H), 2.86-2.82 (m, 2H), 1.83-1.74 (m, 4H), 1.58-1.52 (m, 4H), 1.32 (s, 9H).

Example 254


N²-[2-(Dimethylamino)ethyl]-N⁴-[4-(1,1-dimethylethyl)phenyl]-N²-methyl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for $C_{29}H_{38}F_3N_7$, 541.31; m/z found, 542.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.38-8.37 (m, 1H), 7.86-7.85 (m, 1H), 7.50-7.46 (m, 2H), 7.33-7.30 (m, 2H), 6.94-6.90 (m, 1H), 6.29 (s, 1H), 3.72-3.70 (m, 2H), 3.63-3.55 (m, 4H), 3.15 (s, 3H), 3.08-3.04 (m, 2H), 2.86-2.82 (m, 2H), 2.52-2.46 (m, 2H), 2.26 (s, 6H), 1.31 (s, 9H).

Example 255

2-Azepan-1-yl-N-[(3,4-dichlorophenyl)methyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{27}H_{29}Cl_2F_3N_6$, 564.18; m/z found, 565.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.37-8.35 (m, 1H), 7.86-7.83 (m, 1H), 7.43-7.42 (m, 1H), 7.36 (d, J=8.2 Hz, 1H), 7.17-7.15 (m, 1H), 6.91-6.89 (m, 1H), 4.83-4.79 (m, 1H),

159

4.59 (d, J=5.7 Hz, 2H), 3.69-3.52 (m, 8H), 3.03-3.00 (m, 2H), 2.72-2.69 (m, 2H), 1.72-1.61 (m, 4H), 1.52-1.47 (m, 4H).

Example 256


N-[(3,4-Dichlorophenyl)methyl]-2-(4-methylpiperazin-1-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{26}H_{28}Cl_2F_3N_7$, 565.17; m/z found, 566.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.37-8.35 (m, 1H), 7.86-7.84 (m, 1H), 7.44-7.43 (m, 1H), 7.38 (d, J=8.2 Hz, 1H), 7.17-7.15 (m, 1H), 6.93-6.90 (m, 1H), 4.86-4.82 (m, 1H), 4.60 (d, J=5.7 Hz, 2H), 3.77-3.69 (m, 4H), 3.57-3.52 (m, 4H), 3.04-3.00 (m, 2H), 2.73-2.69 (m, 2H), 2.43-2.39 (m, 4H), 2.32 (s, 3H).

Example 257

N⁴-[4-(1,1-Dimethylethyl)phenyl]-N²-methyl-N²-[2-(methyloxy)ethyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for $C_{28}H_{35}F_3N_6O$, 528.28; m/z found, 529.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.38-8.37 (m, 1H),

160

7.86 (dd, J=7.8, 1.9 Hz, 1H), 7.52-7.49 (m, 2H), 7.34-7.30 (m, 2H), 6.94-6.90 (m, 1H), 6.32 (s, 1H), 3.77 (t, J=6.1 Hz, 2H), 3.62-3.56 (m, 6H), 3.34 (s, 3H), 3.19 (s, 3H), 3.07-3.05 (m, 2H), 2.86-2.82 (m, 2H), 1.32 (s, 9H).

5

Example 258

N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-pyrrolidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine

10


15

20

25

30

35



MS (ESI): mass calcd. for $C_{25}H_{23}ClF_6N_6$, 556.16; m/z found, 557.4 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.38 (m, 1H), 8.23 (d, J=1.9 Hz, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.58 (d, J=8.7 Hz, 1H), 7.46-7.42 (m, 1H), 6.97-6.93 (m, 1H), 6.54 (s, 1H), 3.65-3.53 (m, 8H), 3.14-3.06 (m, 2H), 2.90-2.84 (m, 2H), 2.02-1.94 (m, 4H).

Example 259

[1-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)piperidin-2-yl]methanol


40

45

50

55

60



MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6O$, 566.22; m/z found, 567.5 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.37 (m, 1H), 7.87 (dd, J=7.8, 1.8 Hz, 1H), 7.65-7.61 (m, 2H), 7.59-7.56 (m, 2H), 6.97-6.92 (m, 1H), 6.52 (s, 1H), 4.94-4.87 (m, 1H),


65

161

4.58-4.51 (m, 1H), 4.05-4.00 (m, 1H), 3.74-3.65 (m, 2H), 3.61-3.53 (m, 4H), 3.15-3.04 (m, 3H), 2.89-2.84 (m, 2H), 1.78-1.57 (m, 5H).

Example 260


[(2S)-1-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]pyrrolidin-2-yl]methanol hydrochloride salt



MS (ESI): mass calcd. for $C_{26}H_{26}F_6N_6O$, 552.21; m/z found, 553.1 $[M+H]^+$. 1H NMR (CD_3OD): 8.48-8.45 (m, 1H), 8.06-8.01 (m, 1H), 7.86-7.81 (m, 2H), 7.72-7.67 (m, 2H), 7.19-7.12 (m, 1H), 4.26-4.14 (m, 1H), 3.87-3.49 (m, 8H), 3.30-3.19 (m, 2H), 3.15-3.08 (m, 2H), 2.23-1.85 (m, 4H).

Example 261

[(2R)-1-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]pyrrolidin-2-yl]methanol hydrochloride salt




MS (ESI): mass calcd. for $C_{26}H_{26}F_6N_6O$, 552.21; m/z found, 553.1 $[M+H]^+$. 1H NMR (CD_3OD): 8.47-8.44 (m, 1H), 8.04-8.01 (m, 1H), 7.84-7.81 (m, 2H), 7.71-7.69 (m,

162

2H), 7.16-7.12 (m, 1H), 4.24-4.16 (m, 1H), 3.84-3.52 (m, 8H), 3.28-3.20 (m, 2H), 3.13-3.10 (m, 2H), 2.22-1.85 (m, 4H).

Example 262


[(2S)-1-(7-[3-(Trifluoromethyl)pyridin-2-yl]-4-{[5-(trifluoromethyl)pyridin-2-yl]amino}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]pyrrolidin-2-yl]methanol hydrochloride salt



MS (ESI): mass calcd. for $C_{25}H_{25}F_6N_7O$, 553.20; m/z found, 554.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.66-8.62 (m, 1H), 8.50-8.40 (m, 2H), 8.07-8.01 (m, 1H), 7.94-7.89 (m, 1H), 7.07-7.02 (m, 1H), 5.15-5.03 (m, 1H), 3.91-3.56 (m, 10H), 3.09-2.98 (m, 2H), 2.16-1.99 (m, 4H).

Example 263

N^2 -[(3R)-Tetrahydrofuran-3-yl]-7-[3-(trifluoromethyl)pyridin-2-yl]- N^4 -[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




MS (ESI): mass calcd. for $C_{24}H_{23}F_6N_7O$, 539.19; m/z found, 540.2 $[M+H]^+$. 1H NMR (CD_3OD): 8.56-8.54 (m, 1H), 8.46-8.43 (m, 2H), 8.04-7.99 (m, 2H), 7.14-7.10 (m, 1H), 4.55-4.49 (m, 1H), 4.01-3.95 (m, 2H), 3.90-3.83 (m,

163

1H), 3.73-3.69 (m, 1H), 3.51-3.44 (m, 4H), 3.10-3.01 (m, 4H), 2.36-2.26 (m, 1H), 2.01-1.92 (m, 1H).

Example 264


N⁴-[4-(1,1-Dimethylethyl)phenyl]-N²-[(3R)-tetrahydrofuran-3-yl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₈H₃₃F₃N₆O, 526.27; m/z found, 527.3 [M+H]⁺. ¹H NMR (CD₃OD): 8.33-8.32 (m, 1H), 7.90 (dd, J=7.8, 1.8 Hz, 1H), 7.41-7.37 (m, 2H), 7.25-7.22 (m, 2H), 7.02-6.99 (m, 1H), 4.32-4.27 (m, 1H), 3.85-3.76 (m, 2H), 3.73-3.68 (m, 1H), 3.52 (dd, J=9.0, 3.9 Hz, 1H), 3.37-3.34 (m, 4H), 2.92-2.84 (m, 4H), 2.17-2.09 (m, 1H), 1.81-1.74 (m, 1H), 1.22 (s, 9H).

Example 265

N²-(Tetrahydro-furan-3-yl)-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt




MS (ESI): mass calcd. for C₂₅H₂₄F₆N₆O, 538.19; m/z found, 539.2 [M+H]⁺. ¹H NMR (CD₃OD): 8.49-8.46 (m, 1H), 8.04 (dd, J=7.8, 1.7 Hz, 1H), 7.78 (d, J=8.6 Hz, 2H), 7.73 (d, J=8.7 Hz, 2H), 7.19-7.15 (m, 1H), 4.42-4.38 (m, 1H), 3.98-3.92 (m, 1H), 3.84-3.78 (m, 2H), 3.71 (dd, J=9.5, 3.2 Hz,

164

1H), 3.65-3.62 (m, 2H), 3.57-3.55 (m, 2H), 3.23-3.18 (m, 2H), 3.14-3.10 (m, 2H), 2.31-2.22 (m, 1H), 1.98-1.92 (m, 1H).

Example 266


N²-Methyl-N²-(1-methylethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N⁴-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for C₂₄H₂₅F₆N₇, 525.21; m/z found, 526.2 [M+H]⁺.

Example 267

N²-Cyclohexyl-N²-methyl-N⁴-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




MS (ESI): mass calcd. for C₂₉H₃₂F₆N₆, 578.26; m/z found, 579.3 [M+H]⁺.

165

Example 268


2-(7-Azabicyclo[2.2.1]hept-7-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{26}F_6N_6$, 548.521 m/z found, 549.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.38 (m, 1H), 7.89-7.87 (m, 1H), 7.71 (d, J=8.5 Hz, 2H), 7.59 (d, J=8.5 Hz, 2H), 6.97-6.94 (m, 1H), 6.55 (s, 1H), 4.63 (s, 2H), 3.62-3.56 (m, 4H), 3.12-3.10 (m, 2H), 2.91-2.89 (m, 2H), 1.84-1.80 (m, 4H), 1.51-1.46 (m, 4H).

Example 269

2-[2-(1-Methylethyl)pyrrolidin-1-yl]-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{29}H_{32}F_6N_6$, 578.26; m/z found, 579.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.37 (m, 2H), 7.88-7.85 (m, 1H), 7.45-7.42 (m, 2H), 6.95-6.91 (m, 1H), 6.33 (s, 1H), 4.04-4.02 (m, 1H), 3.76-3.69 (m, 1H), 3.65-3.56 (m, 4H), 3.54-3.48 (m, 1H), 3.11-3.08 (m, 2H), 2.89-2.86 (m,

166

Example 270


N²-(Cyclohexylmethyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N⁴-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for $C_{27}H_{29}F_6N_7$, 565.24; m/z found, 566.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.75 (s, 1H), 8.40-8.38 (m, 2H), 7.88-7.86 (m, 1H), 7.62 (d, J=8.5 Hz, 1H), 6.97-6.94 (m, 1H), 6.60 (s, 1H), 3.60-3.55 (m, 4H), 3.22 (t, J=6.0 Hz, 2H), 3.08-3.05 (m, 2H), 2.91-2.89 (m, 2H), 1.80-1.72 (m, 3H), 1.68-1.64 (m, 1H), 1.63-1.51 (m, 3H), 1.27-1.22 (m, 3H), 1.02-0.94 (m, 2H).

Example 271

[4-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)morpholin-2-yl]methanol




167

MS (ESI): mass calcd. for $C_{26}H_{26}F_6N_6O_2$, 568.20; m/z found, 569.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.38 (m, 1H), 7.88-7.86 (m, 1H), 7.62 (d, $J=11.0$ Hz, 2H), 7.56 (d, $J=11.0$ Hz, 2H), 6.97-6.93 (m, 1H), 6.54 (s, 1H), 4.48-4.38 (m, 2H), 4.04-4.01 (m, 1H), 3.76-3.72 (m, 1H), 3.70-3.62 (m, 3H), 3.61-3.52 (m, 4H), 3.10-3.06 (m, 3H), 2.89-2.86 (m, 3H), 2.03-1.95 (m, 1H).

Example 272


N^2 -Methyl- N^2 -(1-methylethyl)- N^4 -[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine



MS (ESI): mass calcd. for $C_{25}H_{26}F_6N_6$, 524.21; m/z found, 525.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.88-7.85 (m, 1H), 7.70 (d, $J=8.5$ Hz, 2H), 7.55 (d, $J=8.5$ Hz, 2H), 6.95-6.92 (m, 1H), 6.50 (s, 1H), 5.05-5.00 (m, 1H), 3.61-3.56 (m, 4H), 3.11-3.07 (m, 2H), 2.98 (s, 3H), 2.90-2.84 (m, 2H), 1.18 (d, $J=6.5$ Hz, 6H).

Example 273

[4-(4-{[2-Methyl-4-(trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)morpholin-2-yl] methanol




168

MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6O_2$, 582.22; m/z found, 583.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 8.04 (d, $J=11.5$ Hz, 1H), 7.88-7.86 (m, 1H), 7.45 (d, $J=9.0$ Hz, 2H), 6.96-6.93 (m, 1H), 6.31 (s, 1H), 4.43-4.34 (m, 2H), 4.02-3.98 (m, 1H), 3.74-3.71 (m, 1H), 3.66-3.55 (m, 7H), 3.11-3.08 (m, 2H), 3.07-2.99 (m, 1H), 2.89-2.80 (m, 3H), 2.34 (s, 3H), 1.99 (br s, 1H).

Example 274


2-[2-(1-Methylethyl)pyrrolidin-1-yl]-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{29}F_6N_7$, 565.24; m/z found, 566.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.86 (d, $J=2.5$ Hz, 1H), 8.41-8.40 (m, 1H), 8.14-8.11 (m, 1H), 7.90-7.88 (m, 1H), 7.66 (d, $J=9.0$ Hz, 1H), 6.99-6.96 (m, 1H), 6.60 (s, 1H), 4.47 (d, $J=13.0$ Hz, 1H), 4.39 (d, $J=13.0$ Hz, 1H), 4.06-4.03 (m, 1H), 3.79-3.75 (m, 1H), 3.71-3.56 (m, 7H), 3.13-3.05 (m, 3H), 2.95-2.85 (m, 3H), 2.07 (2.04 (m, 1H).

Example 275

N^2 -Cyclohexyl- N^2 -methyl-7-[3-(trifluoromethyl)pyridin-2-yl]- N^4 -[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine




169

MS (ESI): mass calcd. for $C_{27}H_{29}F_6N_7$, 565.24; m/z found, 566.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.70 (s, 1H), 8.42 (d, $J=10.0$ Hz, 1H), 8.39-8.38 (m, 1H), 7.88-7.86 (m, 1H), 7.61 (d, $J=10.0$ Hz, 1H), 7.00-6.93 (m, 1H), 6.55 (s, 1H), 4.49 (br s, 1H), 3.61-3.55 (m, 4H), 3.11-3.08 (m, 2H), 3.01 (s, 3H), 2.91-2.88 (m, 2H), 1.87-1.84 (m, 2H), 1.75-1.71 (m, 3H), 1.52-1.12 (m, 5H).

Example 276


2-(2S or 2R)-2-Methylpiperidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6$, 550.23; m/z found, 551.3 $[M+H]^+$. 1H NMR (CD_3OD): 8.53-8.35 (m, 1H), 8.08-7.97 (m, 1H), 7.80 (d, $J=8.8$ Hz, 2H), 7.55 (d, $J=8.4$ Hz, 2H), 7.18-7.07 (m, 1H), 3.59-2.87 (m, 12H), 2.02-1.52 (m, 4H), 1.20 (d, $J=6.8$ Hz, 3H). $[\alpha]^{20}_D=+58.2$ ($c=0.005$, MeOH).

Example 277

2-[(2R or 2S)-2-Methylpiperidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6$, 550.23; m/z found, 551.3 $[M+H]^+$. 1H NMR (CD_3OD): 8.54-8.33 (m, 1H), 8.02 (dd, $J=7.9$, 1.8 Hz, 1H), 7.80 (d, $J=8.5$ Hz, 2H), 7.54 (d, $J=8.6$ Hz, 2H), 7.17-7.07 (m, 1H), 3.60-3.37 (m, 2H), 3.36-3.31 (m,


170

2H), 3.11-2.97 (m, 4H), 1.80-1.68 (m, 4H), 1.66-1.60 (m, 4H), 1.20 (d, $J=6.89$ Hz, 3H). $[\alpha]^{20}_D=-53.8$ ($c=0.005$, MeOH).

The following Examples 278-280 were prepared using methods analogous to those described in Example 54, substituting the appropriate amines.

Example 278


N²-(2-Methylphenyl)-N⁴-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{28}H_{24}F_6N_6$, 558.19; m/z found, 559.4 $[M+H]^+$. 1H NMR (MeOD): 8.45 (dd, $J=4.7$, 1.5 Hz, 1H), 8.02 (dd, $J=7.8$, 1.8 Hz, 1H), 7.58 (d, $J=8.5$ Hz, 2H), 7.41 (d, $J=8.6$ Hz, 2H), 7.33-7.28 (m, 3H), 7.28-7.22 (m, 1H), 7.14 (dd, $J=7.7$, 4.8 Hz, 1H), 3.66-3.62 (m, 2H), 3.57-3.54 (m, 2H), 3.27-3.23 (m, 2H), 3.14-3.09 (m, 2H), 2.21 (s, 3H).

Example 279

N²-(3-Methylphenyl)-N⁴-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt




171

MS (ESI): mass calcd. for $C_{28}H_{24}F_6N_6$, 558.20; m/z found, 559.1 $[M+H]^+$. 1H NMR (MeOD): 8.45 (dd, $J=4.7, 1.4$ Hz, 1H), 8.02 (dd, $J=7.8, 1.8$ Hz, 1H), 7.67 (d, $J=8.5$ Hz, 2H), 7.61 (d, $J=8.7$ Hz, 2H), 7.17-7.11 (m, 3H), 7.01-6.96 (m, 1H), 3.67-3.59 (m, 2H), 3.59-3.55 (m, 2H), 3.35 (s, 1H), 3.26-3.23 (m, 2H), 3.14-3.09 (m, 2H), 2.20 (s, 3H).

Example 280

N^2 -(4-Methylphenyl)- N^4 -[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{28}H_{24}F_6N_6$, 558.20; m/z found, 559.5 $[M+H]^+$. 1H NMR (MeOD): 8.46 (dd, $J=4.7, 1.3$ Hz, 1H), 8.03 (dd, $J=7.8, 1.7$ Hz, 1H), 7.65 (d, $J=8.6$ Hz, 2H), 7.58 (d, $J=8.6$ Hz, 2H), 7.21 (d, $J=8.4$ Hz, 2H), 7.18-7.12 (m, 1H), 7.10 (d, $J=8.2$ Hz, 2H), 3.66-3.60 (m, 2H), 3.59-3.53 (m, 2H), 3.25-3.19 (m, 2H), 3.14-3.08 (m, 2H), 2.33 (s, 3H).

The following Examples 281-295 were prepared using methods analogous to those described in Example 26, substituting the appropriate 2-chloro pyridines in Step C and anilines in Step E:

Example 281

N -{2-[2-(1-Methylethyl)-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl]pyridin-3-yl}methanesulfonamide




The title compound was prepared using methods analogous to those described by Richardson, T. I. et al. *J. Med. Chem.* 2004, 47, 744 starting from [7-(2-amino-phenyl)-2-

172

isopropyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-4-(trifluoromethyl-phenyl)-amine (Example 84). MS (ESI): mass calcd. for $C_{24}H_{27}F_3N_6O_2S$, 520.20; m/z found, 521.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.11 (dd, $J=4.8, 1.6$ Hz, 1H), 7.82-7.76 (m, 3H), 7.61-7.58 (m, 2H), 7.09 (dd, $J=8.1, 4.8$ Hz, 1H), 6.81-6.51 (m, 1H), 3.36-3.30 (m, 4H), 3.28-3.20 (m, 2H), 3.15-3.13 (m, 3H), 3.11-3.03 (m, 1H), 3.03-2.96 (m, 2H), 1.34 (d, $J=6.9$ Hz, 6H).

Example 282


2-(1-Methylethyl)-7-[3-(methylsulfonyl)pyridin-2-yl]-N-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



The title compound was prepared analogously to the methods described in Example 26, substituting 2-chloro-3-methanesulfonyl-pyridine (*J. Org. Chem.* 1979, 44(17), 3080-3082) in Step C. MS (ESI): mass calcd. for $C_{23}H_{25}F_3N_6O_2S$, 506.17; m/z found, 507.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.78 (dd, $J=4.8, 1.9$ Hz, 1H), 8.48 (dd, $J=7.9, 1.9$ Hz, 1H), 8.09-8.07 (m, 1H), 7.53 (dd, $J=7.9, 4.8$ Hz, 1H), 7.45 (d, $J=8.6$ Hz, 1H), 6.90 (dd, $J=8.5, 2.7$ Hz, 1H), 5.96-5.78 (m, 1H), 4.25-4.00 (m, 2H), 3.58-3.52 (m, 2H), 3.24 (s, 3H), 3.20-3.13 (m, 2H), 2.95-2.91 (m, 2H), 2.91-2.81 (m, 1H), 1.18 (d, $J=6.9$ Hz, 6H).

Example 283

7-[3-(Methylsulfonyl)pyridin-2-yl]-N-[4-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




The title compound was prepared analogously to the methods described in Example 26, substituting 2-chloro-3-methanesulfonyl-pyridine (*J. Org. Chem.* 1979, 44(17), 3080-

173

3082) in Step C. MS (ESI): mass calcd. for $C_{21}H_{20}F_3N_5O_2S$, 463.13; m/z found, 464 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.66-8.60 (m, 1H), 8.55 (dd, $J=4.8$, 1.9 Hz, 1H), 8.38 (dd, $J=7.8$, 1.9 Hz, 1H), 7.73 (d, $J=8.6$ Hz, 2H), 7.65 (d, $J=8.6$ Hz, 2H), 7.28-7.24 (m, 1H), 3.67-3.59 (m, 2H), 3.59-3.54 (m, 2H), 3.39-3.28 (m, 2H), 3.14-3.05 (m, 2H), 2.99 (s, 3H).

Example 284


7-(3-Aminopyridin-2-yl)-N-[4-(1,1-dimethylethyl)phenyl]-2-(1-methylethyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{26}H_{34}N_6$, 430.28; m/z found, 431.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 7.78 (dd, $J=4.8$, 1.6 Hz, 1H), 7.63-7.56 (m, 2H), 7.39-7.32 (m, 2H), 7.01-6.95 (m, 1H), 6.88-6.83 (m, 1H), 6.51-6.47 (m, 1H), 3.87-3.75 (m, 2H), 3.44-3.30 (m, 4H), 3.23-3.15 (m, 2H), 3.08-2.99 (m, 1H), 2.94-2.88 (m, 2H), 1.37-1.30 (m, 1H).

Example 285

7-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]-N-[4-(1,1-dimethylethyl)phenyl]-2-(1-methylethyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{31}ClF_3N_5$, 517.22; m/z found, 518.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.26 (m, 1H),

174

7.64-7.55 (m, 2H), 7.40-7.33 (m, 2H), 7.28-7.23 (m, 1H), 3.99-3.78 (m, 4H), 3.28-3.17 (m, 2H), 3.08-2.94 (m, 3H), 1.43-1.26 (m, 6H).

Example 286

7-(5-Bromo-3-chloropyridin-2-yl)-N-[4-(1,1-dimethylethyl)phenyl]-2-(1-methylethyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine


10

15

20

25

30



35

40

45

50

55

60

65

MS (ESI): mass calcd. for $C_{26}H_{31}BrClN_5$, 527.15; m/z found, 530.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.21-8.08 (m, 1H), 7.73-7.68 (m, 1H), 7.63-7.57 (m, 2H), 7.40-7.31 (m, 2H), 6.46 (s, 1H), 3.79-3.58 (m, 4H), 3.26-3.15 (m, 2H), 3.06-2.98 (m, 1H), 2.96-2.91 (m, 2H), 1.37-1.30 (m, 6H).

Example 287

7-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]-2-(1-methylethyl)-N-[4-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine


45

50

55

60

65




MS (ESI): mass calcd. for $C_{24}H_{22}ClF_6N_5$, 529.15; m/z found, 530.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.28 (m, 1H),

175

7.83-7.77 (m, 2H), 7.77-7.74 (m, 1H), 7.62-7.57 (m, 2H), 3.99-3.81 (m, 4H), 3.33-3.18 (m, 2H), 3.11-2.98 (m, 3H), 1.32 (d, J=6.9 Hz, 6H).

Example 288


5-Chloro-6-[2-(1-methylethyl)-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl]pyridine-3-carboxylic acid trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{24}H_{23}ClF_3N_5O_2$, 505.15; m/z found, 506.1 $[M+H]^+$. 1H NMR (CD_3OD): 8.75-8.57 (m, 1H), 8.18-8.10 (m, 1H), 7.87-7.78 (m, 2H), 7.72-7.67 (m, 2H), 4.08-3.82 (m, 4H), 3.43-3.34 (m, 2H), 3.28-3.22 (m, 2H), 3.10-3.02 (m, 1H), 1.29 (d, J=6.8 Hz, 6H).

Example 289

N-[4-(1,1-Dimethylethyl)phenyl]-2-(1-methylethyl)-7-(3-methyl-5-nitropyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{27}H_{34}N_6O_2$, 474.27; m/z found, 475.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.97-8.85 (m, 1H), 8.16-8.02 (m, 1H), 7.63-7.54 (m, 2H), 7.39-7.33 (m, 2H),

176

6.45 (s, 1H), 3.99-3.88 (m, 2H), 3.86-3.81 (m, 2H), 3.27-3.16 (m, 2H), 3.05-2.94 (m, 3H), 2.39 (s, 3H), 1.34-1.33 (m, 9H), 1.31 (d, J=6.9 Hz, 6H).

Example 290


N-[4-(1,1-Dimethylethyl)phenyl]-2-(1-methylethyl)-7-[5-nitro-3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{31}F_3N_6O_2$, 528.25; m/z found, 529.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 9.12-9.01 (m, 1H), 8.63-8.57 (m, 1H), 7.67-7.50 (m, 2H), 7.40-7.32 (m, 2H), 6.38 (s, 1H), 4.22-4.14 (m, 2H), 4.00-3.95 (m, 2H), 3.32-3.22 (m, 2H), 3.06-3.02 (m, 2H), 3.02-2.95 (m, 1H), 1.34-1.32 (m, 9H), 1.29 (d, J=6.9 Hz, 6H).

Example 291

2-(1-Methylethyl)-7-[5-nitro-3-(trifluoromethyl)pyridin-2-yl]-N-[4-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{24}H_{22}F_6N_6O_2$, 540.17; m/z found, 541.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 9.14-9.04 (m, 1H), 8.64-8.56 (m, 1H), 7.86-7.74 (m, 2H), 7.63-7.58 (m, 2H),

177

6.57 (s, 1H), 4.23-4.15 (m, 2H), 4.02-3.94 (m, 2H), 3.35-3.24 (m, 2H), 3.12-3.06 (m, 2H), 3.07-2.97 (m, 1H), 1.30 (d, J=6.9 Hz, 6H).

Example 292


N-[4-(1,1-Dimethylethyl)phenyl]-7-(5-fluoro-3-methylpyridin-2-yl)-2-(1-methylethyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



The title compound was prepared from N-[4-(1,1-dimethylethyl)phenyl]-2-(1-methylethyl)-7-(3-methyl-5-nitropyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine (Example 289) using procedures analogous to those reported in US 2000/006150343 and Marsais, F. et al. *J. Heterocycl. Chem.* 1988, 25(1), 81. MS (ESI): mass calcd. for $C_{27}H_{34}FN_5$, 447.28; m/z found, 448.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.03-7.92 (m, 1H), 7.66-7.55 (m, 2H), 7.40-7.31 (m, 2H), 7.24-7.17 (m, 1H), 6.54-6.43 (m, 1H), 3.45-3.36 (m, 2H), 3.36-3.31 (m, 2H), 3.21-3.14 (m, 2H), 3.07-2.98 (m, 1H), 2.93-2.88 (m, 2H), 2.33 (s, 3H), 1.60-1.53 (m, 9H), 1.37-1.31 (m, 6H).

Example 293

2-(4-{[4-(Trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-carbonitrile




MS (ESI): mass calcd. for $C_{21}H_{17}F_3N_6$, 410.15; m/z found, 411.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.60 (s, 1H), 8.34 (dd, J=4.7, 1.9 Hz, 1H), 7.78 (dd, J=7.6, 1.9 Hz, 1H), 7.73 (d, J=8.7 Hz, 2H), 7.64 (d, J=8.4 Hz, 2H), 6.78-6.66 (m, 1H), 4.25-4.14 (m, 2H), 4.11-4.07 (m, 2H), 3.47-3.30 (m, 2H), 3.20-3.13 (m, 2H).

178

Example 294


2-(4-{[4-(Trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-carboxamide trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{21}H_{19}F_3N_6O$, 428.16; m/z found, 429.1 $[M+H]^+$. 1H NMR (CD_3OD): 8.62 (s, 1H), 8.22 (dd, J=5.0, 1.9 Hz, 1H), 7.83 (dd, J=7.5, 1.9 Hz, 1H), 7.78 (d, J=8.7 Hz, 2H), 7.73 (d, J=8.7 Hz, 2H), 6.89 (dd, J=7.5, 5.0 Hz, 1H), 3.94-3.80 (m, 4H), 3.51-3.38 (m, 2H), 3.31-3.26 (m, 2H).

Example 295


7-(3-Fluoropyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{20}H_{17}F_4N_5$, 403.14; m/z found, 404.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.62 (s, 1H), 8.11-7.79 (m, 2H), 7.77-7.62 (m, 4H), 7.34-7.22 (m, 1H), 6.86-6.60 (m, 1H), 4.15-3.90 (m, 4H), 3.26-2.96 (m, 4H).

Example 296

N-[4-(1,1-Dimethylethyl)phenyl]-7-[3-(ethylsulfonyl)pyridin-2-yl]-2-(1-methylethyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




179

The title compound was prepared analogously to the methods described in Example 26, substituting 2-chloro-3-ethanesulfonyl-pyridine (prepared using methods analogous to those reported in *J. Org. Chem.* 1979, 44(17), 3080-3082) in Step C. MS (ESI): mass calcd. for $C_{28}H_{37}N_5O_2S$, 507.27; m/z found, 508.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.44 (dd, $J=4.7$, 1.9 Hz, 1H), 8.27 (dd, $J=7.8$, 1.9 Hz, 1H), 7.61-7.47 (m, 2H), 7.32-7.24 (m, 2H), 7.14 (dd, $J=7.8$, 4.8 Hz, 1H), 6.56 (s, 1H), 3.53-3.43 (m, 2H), 3.45-3.41 (m, 2H), 3.22 (q, $J=7.4$ Hz, 2H), 3.15-3.08 (m, 2H), 3.01-2.92 (m, 1H), 2.91-2.86 (m, 2H), 1.29-1.22 (m, 15H).

Example 297

7-[3-(Ethylsulfonyl)pyridin-2-yl]-2-piperidin-1-yl-N-[4-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




The title compound was prepared analogously to the methods described in Example 26, substituting 2-chloro-3-ethanesulfonyl-pyridine (prepared using methods analogous to those reported in *J. Org. Chem.* 1979, 44(17), 3080-3082) in Step C. MS (ESI): mass calcd. for $C_{27}H_{31}F_3N_6O_2S$, 560.22; m/z found, 561.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.44 (dd, $J=4.7$, 1.9 Hz, 1H), 8.27 (dd, $J=7.8$, 1.9 Hz, 1H), 7.58 (d, $J=8.5$ Hz, 2H), 7.49 (d, $J=8.7$ Hz, 2H), 7.13 (dd, $J=7.8$, 4.8 Hz, 1H), 6.60 (s, 1H), 3.76-3.58 (m, 4H), 3.49-3.42 (m, 2H), 3.41-3.37 (m, 2H), 3.28 (q, $J=7.4$ Hz, 2H), 3.03-2.96 (m, 2H), 2.85-2.78 (m, 2H), 1.65-1.49 (m, 4H), 1.02 (t, $J=7.5$ Hz, 3H).

The following Examples 298-302 were prepared using methods analogous to those described in Example 26, substituting the appropriate 2-chloro pyridines (see Cordi, A. A. et al. *II Farmaco*, 2002, 57, 787) in Step C and anilines in Step E.

180

Example 298


2-(2-Piperidin-1-yl-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-sulfonamide



MS (ESI): mass calcd. for $C_{25}H_{28}F_3N_7O_2S$, 547.20; m/z found, 548.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.45 (dd, $J=4.8$, 1.9 Hz, 1H), 8.23 (dd, $J=7.8$, 1.9 Hz, 1H), 7.57 (d, $J=8.6$ Hz, 2H), 7.49 (d, $J=8.6$ Hz, 2H), 7.15 (dd, $J=7.8$, 4.8 Hz, 1H), 6.60 (s, 1H), 3.72-3.61 (m, 4H), 3.46-3.38 (m, 2H), 3.36-3.31 (m, 2H), 3.05-2.95 (m, 2H), 2.85-2.80 (m, 2H), 1.66-1.51 (m, 4H).

Example 299

N-Cyclopropyl-2-(2-piperidin-1-yl-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-sulfonamide




MS (ESI): mass calcd. for $C_{28}H_{32}F_3N_7O_2S$, 587.23; m/z found, 588.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.44 (dd, $J=4.8$, 1.9

181

Hz, 1H), 8.26 (dd, J=7.8, 1.9 Hz, 1H), 7.56 (d, J=8.6 Hz, 2H), 7.49 (d, J=8.8 Hz, 2H), 7.13 (dd, J=7.8, 4.8 Hz, 1H), 6.62 (s, 1H), 5.68-5.41 (m, 1H), 3.72-3.64 (m, 3H), 3.46-3.39 (m, 2H), 3.36-3.32 (m, 2H), 3.03-2.93 (m, 2H), 2.84-2.78 (m, 2H), 1.68-1.50 (m, 4H), 0.41-0.16 (m, 4H).

Example 300


N-(1-Methylethyl)-2-(2-piperidin-1-yl-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-sulfonamide



MS (ESI): mass calcd. for $C_{28}H_{34}F_3N_7O_2S$, 589.24; m/z found, 590.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41 (dd, J=4.8, 1.9 Hz, 1H), 8.21 (dd, J=7.7, 1.9 Hz, 1H), 7.58 (d, J=8.5 Hz, 2H), 7.49 (d, J=8.6 Hz, 2H), 7.10 (dd, J=7.7, 4.8 Hz, 1H), 6.72 (s, 1H), 3.72-3.63 (m, 4H), 3.45-3.38 (m, 2H), 3.36-3.31 (m, 2H), 3.11-3.02 (m, 1H), 3.00-2.95 (m, 2H), 2.86-2.79 (m, 2H), 1.67-1.48 (m, 4H), 0.70 (d, J=6.5 Hz, 6H).

Example 301

7-[3-(Ethylsulfonyl)pyridin-2-yl]-N-[4-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{22}H_{22}F_3N_5O_2S$, 477.14; m/z found, 478.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.63 (s, 1H), 8.55 (dd, J=4.7, 1.9 Hz, 1H), 8.35 (dd, J=7.8, 1.8 Hz, 1H), 7.72 (d, J=8.6 Hz, 2H), 7.65 (d, J=8.5 Hz, 2H), 7.27-7.24 (m, 1H),

182

3.66-3.58 (m, 2H), 3.58-3.54 (m, 2H), 3.41-3.30 (m, 2H), 3.17-3.06 (m, 4H), 1.04 (t, J=7.4 Hz, 3H).

Example 302


2-(4-{[4-(Trifluoromethyl)phenyl]amino}-5,6,7,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-sulfonamide



MS (ESI): mass calcd. for $C_{20}H_{19}F_3N_6O_2S$, 464.12; m/z found, 465.1 $[M+H]^+$. 1H NMR (MeOD): 8.45-8.34 (m, 2H), 8.23 (dd, J=7.8, 1.8 Hz, 1H), 7.63 (d, J=8.5 Hz, 2H), 7.52 (d, J=8.6 Hz, 2H), 7.15 (dd, J=7.8, 4.8 Hz, 1H), 3.49-3.39 (m, 2H), 3.39-3.34 (m, 2H), 3.23-3.17 (m, 2H), 3.07-3.02 (m, 2H).

Example 303

Methyl 5-chloro-6-[2-(methylsulfonyl)-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl]pyridine-3-carboxylate



Step A. 4-Hydroxy-2-methylsulfonyl-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepine-7-carboxylic acid tert-butyl ester

To solution of 5-oxo-azepane-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester (10.5 g, 0.04 mol) in EtOH (168 mL) was added NaOEt (8.1 g, 0.12 mol) and thiourea (4.2 g, 0.06 mol). The mixture was heated at reflux for 12 h. The mixture was cooled, treated with MeI (3.0 mL, 0.05 mol) drop-wise, and stirred at rt for 1 h. The mixture was concentrated and the residue was dissolved in water and acidified to pH=7 with HOAc (a precipitate formed). The solid was filtered to give the title compound (8.4 g, 73%), which was used in the next step without further purification.

183

Step B: 2-Methylsulfanyl-4-trifluoromethanesulfonyloxy-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepine-7-carboxylic acid tert-butyl ester

To a solution of 4-hydroxy-2-methylsulfanyl-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepine-7-carboxylic acid tert-butyl ester (1.2 g, 3.86 mmol) in THF (129 mL) was added KOtBu (518 mg, 4.63 mmol) at rt. After 20 min, N-phenyl-bis(trifluoromethanesulfonimide) (1.9 g, 5.40 mmol) was added. The reaction mixture was stirred for an additional 24 h at rt and then concentrated. The residue was purified (FCC) to afford the title compound (1.4 g, 82%)

Step C: (2-Methylsulfanyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)-(4-trifluoromethyl-phenyl)-amine

A solution containing methylsulfanyl-4-trifluoromethanesulfonyloxy-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepine-7-carboxylic acid tert-butyl ester (950 mg, 2.15 mmol), 4-trifluoromethylaniline (0.6 mL, 4.74 mmol) and DMSO (8 mL) was heated at 100° C. for 24 h. The reaction mixture was cooled to rt and diluted with water and extracted with EtOAc. The combined organic extracts were dried and concentrated. The residue was purified (FCC; MeOH/CH₂Cl₂) to give the title compound (422 mg, 55%).


Step D

A solution of (2-methylsulfanyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)-(4-trifluoromethyl-phenyl)-amine (187 mg, 0.53 mmol), 5,6-dichloro-nicotinic acid methyl ester (129 mg, 0.58 mmol), and Et₃N (0.2 mL, 1.58 mmol) in DMF (1.2 mL) was heated at 120° C. for 2 h. The mixture was cooled to rt, diluted with water, and extracted with EtOAc. The combined organic layers were dried and concentrated. The residue was purified (FCC) to give the title compound (203 mg, 74%). MS (ESI): mass calcd. for C₂₃H₂₁ClF₃N₅O₂S, 523.11; m/z found, 524.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.57 (d, J=2.0 Hz, 1H), 8.00 (d, J=2.0 Hz, 1H), 7.59 (d, J=8.6 Hz, 2H), 7.48 (d, J=8.6 Hz, 2H), 6.73-6.59 (m, 1H), 3.89-3.65 (m, 7H), 3.19-3.07 (m, 2H), 2.95-2.87 (m, 2H), 2.40 (s, 3H).

The following Examples 304-306 were prepared using methods analogous to those described in Example 303, substituting the appropriate anilines in Step C and 2-chloro pyridines in Step D.

Example 304

2-(Methylsulfanyl)-7-[3-(methylsulfonyl)pyridin-2-yl]-N-[4-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for C₂₂H₂₂F₃N₅O₂S₂, 509.11; m/z found, 510.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.62-8.49 (m, 1H),

184

8.40-8.35 (m, 1H), 7.73 (d, J=8.5 Hz, 2H), 7.62 (d, J=8.5 Hz, 2H), 7.25 (dd, J=7.8, 4.7 Hz, 1H), 7.05-6.94 (m, 1H), 3.61-3.54 (m, 2H), 3.55-3.50 (m, 2H), 3.28-3.17 (m, 2H), 3.06 (s, 3H), 3.04-2.99 (m, 2H), 2.55 (s, 3H).

Example 305


[7-(3-Ethanesulfonyl-pyridin-2-yl)-2-methylsulfanyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



MS (ESI): mass calcd. for C₂₃H₂₄F₃N₅O₂S₂, 523.13; m/z found, 524.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.62-8.46 (m, 1H), 8.38-8.31 (m, 1H), 7.72 (d, J=8.5 Hz, 2H), 7.62 (d, J=8.5 Hz, 2H), 7.26-7.22 (m, 1H), 3.63-3.42 (m, 4H), 3.30-3.17 (m, 4H), 3.05-2.96 (m, 2H), 2.54 (s, 3H), 1.10-1.05 (m, 3H).

Example 306

{5-Chloro-6-[2-(methylsulfanyl)-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl]pyridin-3-yl}methanol




185

The title compound was prepared analogously to that reported starting methyl 5-chloro-6-[2-(methylsulfanyl)-4-{4-(trifluoromethyl)-phenyl}amino]-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl]pyridine-3-carboxylate (Example 303) (Boechat, N. et al. *Tetrahedron Lett.* 2004, 45, 6021). MS (ESI): mass calcd. for $C_{22}H_{21}ClF_3N_5OS$, 495.11; m/z found, 496.1 $[M+H]^+$. 1H NMR (MeOD): 8.38-8.26 (m, 1H), 8.03 (d, $J=8.6$ Hz, 2H), 7.96-7.92 (m, 1H), 7.80 (d, $J=8.6$ Hz, 2H), 4.79-4.69 (m, 2H), 3.86-3.69 (m, 4H), 3.41-3.27 (m, 4H), 2.68 (s, 3H).

Example 307

2-({[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]methyl}oxy)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




A dispersion of NaH in mineral oil (12.0 mg, 0.28 mmol) was added to a flask containing (2,2-dimethyl-[1,3]dioxolan-4-yl)-methanol (116 μ L, 0.94 mmol) and DMF (1.0 mL). After 30 min, the mixture was transferred to a flask containing [2-methanesulfonyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-[4-(trifluoromethyl-phenyl)-amine (Example 53; 50 mg, 0.094 mmol). The resulting mixture was then heated at 70° C. for 24 h. The mixture was cooled, diluted with MeOH (1.0 mL) and purified by reverse phase HPLC, yielding 39 mg (70%) of the title compound. MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_5O_3$, 583.20; m/z found, 584.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.89-7.86 (m, 1H), 7.69 (d, $J=11.0$ Hz, 2H), 7.59 (d, $J=11.0$ Hz, 2H), 6.98-6.94 (m, 1H), 6.68 (s, 1H), 4.52-4.56 (m, 1H), 4.42-4.38 (m, 1H), 4.28-4.24 (m, 1H), 4.16-4.12 (m, 1H), 3.94-3.90 (m, 1H), 3.63-3.56 (m, 4H), 3.18-3.15 (m, 2H), 2.96-2.93 (m, 2H), 1.46 (s, 3H), 1.38 (s, 3H).

186

The following Examples 308-340 were prepared using methods analogous to those described in Example 307, substituting the appropriate alcohols.

Example 308


2-(Cyclohexyloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[4-(trifluoromethyl)sulfonyl]phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_5O_3S$, 615.17; m/z found, 616.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (d, $J=5.0$ Hz, 1H), 7.98 (d, $J=9.0$ Hz, 2H), 7.93-7.87 (m, 3H), 7.00-6.97 (m, 1H), 6.96 (s, 1H), 4.92-4.87 (m, 1H), 3.64-3.57 (m, 4H), 3.22-3.18 (m, 2H), 3.00-2.95 (m, 2H), 2.11-2.08 (m, 2H), 1.89-1.86 (m, 2H), 1.69-1.63 (m, 2H), 1.46-1.25 (m, 4H).

Example 309

2-[(1-Cyclohexylethyl)oxy]-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{30}H_{33}F_6N_5O$, 593.26; m/z found, 594.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 8.08 (d, $J=11.0$ Hz, 1H), 7.89-7.86 (m, 1H), 7.46 (s, 2H), 6.97-6.94 (m, 1H), 6.42 (s, 1H), 4.84-4.78 (m, 1H), 3.66-3.53

187

(m, 4H), 3.19-3.16 (m, 2H), 2.94-2.91 (m, 2H), 2.36 (s, 3H), 1.80-1.72 (m, 4H), 1.68-1.57 (m, 2H), 1.24 (d, J=8.0 Hz, 3H), 1.21-0.97 (m, 5H).

Example 310


2-(Cyclopentyloxy)-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_5O$, 551.21; m/z found, 552.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 8.17 (d, J=11.0 Hz, 1H), 7.89-7.87 (m, 1H), 7.46 (s, 2H), 6.97-6.94 (m, 1H), 6.44 (s, 1H), 5.25-5.20 (m, 1H), 3.66-3.57 (m, 4H), 3.18-3.15 (m, 2H), 2.95-2.92 (m, 2H), 2.36 (s, 3H), 1.88-1.76 (m, 6H), 1.63-1.54 (m, 2H).

Example 311

2-[(1-Methylpiperidin-4-yl)oxy]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{27}H_{28}F_6N_6O$, 566.22; m/z found, 567.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.37 (m, 2H), 7.88-7.86 (m, 1H), 7.60 (s, 3H), 7.00-6.97 (m, 1H), 5.24 (br s,

188

1H), 3.57-3.52 (m, 4H), 3.46-3.05 (m, 6H), 3.05-3.02 (m, 2H), 2.79 (s, 3H), 2.65 (s, 1H), 2.37-2.30 (m, 2H), 2.18-2.13 (m, 2H).

Example 312


N-[2-Methyl-4-(trifluoromethyl)phenyl]-2-(tetrahydro-2H-pyran-4-yloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_5O_2$, 567.21; m/z found, 568.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.38 (m, 1H), 8.01 (d, J=10.5 Hz, 1H), 7.89-7.86 (m, 1H), 7.48-7.46 (m, 2H), 6.98-6.95 (m, 1H), 6.43 (s, 1H), 4.99-4.92 (m, 1H), 4.02-3.96 (m, 2H), 3.90 (s, 1H), 3.65-3.57 (m, 4H), 3.53-3.47 (m, 2H), 3.19-3.16 (m, 2H), 2.96-2.93 (m, 2H), 2.36 (s, 2H), 2.03-1.98 (m, 2H), 1.86-1.77 (m, 2H).

Example 313

N-[2-Methyl-4-(trifluoromethyl)phenyl]-2-(tetrahydrofuran-3-yloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{26}H_{25}F_6N_5O_2$, 553.19; m/z found, 554.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 7.97 (d, J=11.0 Hz, 1H), 7.89-7.86 (m, 1H), 7.49 (s, 2H), 6.98-6.95 (m, 1H), 6.42 (s, 1H), 5.33-5.28 (m, 1H), 3.97-3.85

189

(m, 4H), 3.66-3.57 (m, 4H), 3.19-3.16 (m, 2H), 2.96-2.93 (m, 2H), 2.35 (s, 3H), 2.20-2.08 (m, 2H).

Example 314


N-[4-(Pyrrolidin-1-ylsulfonyl)phenyl]-2-(tetrahydrofuran-3-yloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{28}H_{31}F_3N_6O_4S$, 604.21; m/z found, 605.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 7.89-7.87 (m, 1H), 7.79 (d, $J=11.0$ Hz, 2H), 7.72 (d, $J=11.0$ Hz, 2H), 6.99-6.96 (m, 1H), 6.81 (s, 1H), 5.46-5.42 (m, 1H), 4.70-3.90 (m, 4H), 3.63-3.56 (m, 4H), 3.27-3.24 (m, 4H), 3.19-3.16 (m, 2H), 2.98-2.95 (m, 2H), 2.25-2.20 (m, 2H), 1.80-1.76 (m, 4H).

Example 315

2-[[1-(1-Methylethyl)pyrrolidin-3-yl]oxy]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{28}H_{30}F_6N_6O$, 580.24; m/z found, 581.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.90-7.88 (m, 1H), 7.70 (d, $J=9.0$ Hz, 2H), 7.61 (d, $J=9.0$ Hz, 2H), 6.99-6.96 (m, 1H), 6.67 (s, 1H), 5.37-5.33 (m, 1H),

190

3.65-3.58 (m, 4H), 3.31-3.28 (m, 1H), 3.20-3.17 (m, 2H), 2.97-2.94 (m, 2H), 2.83-2.79 (m, 1H), 2.69-2.62 (m, 2H), 2.47-2.42 (m, 1H), 2.34-2.27 (m, 1H), 2.08-2.02 (m, 1H), 1.12-1.10 (m, 6H).

5

Example 316

2-[(1-Cyclohexylethyl)oxy]-N-(1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine

10

15

20

25

30

MS (ESI): mass calcd. for $C_{32}H_{39}F_3N_6O$, 580.31; m/z found, 581.4 $[M+H]^+$.

35

Example 317

2-[(1-Cyclopropylethyl)oxy]-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[4-(trifluoromethyl)sulfonylphenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine


40

45

50

55

60



MS (ESI): mass calcd. for $C_{26}H_{25}F_6N_5O_3S$, 601.16; m/z found, 602.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.97 (d, $J=9.0$ Hz, 2H), 7.90-7.88 (m, 1H), 7.88 (d, $J=9.0$ Hz, 2H), 7.00-6.97 (m, 1H), 6.95 (s, 1H), 4.64-4.58 (m, 1H), 3.63-3.57 (m, 4H), 3.21-3.19 (m, 2H), 3.00-2.98 (m, 2H),


65

191

1.45 (d, J=1.5 Hz, 3H), 1.24-1.17 (m, 1H), 0.61-0.51 (m, 2H), 0.47-0.42 (m, 1H), 0.34-0.29 (m, 1H).

Example 318


2-[(1-Cyclohexylethyl)oxy]-7-[3-(trifluoromethyl)pyridin-2-yl]-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{29}H_{31}F_6N_5O_3S$, 643.21; m/z found, 644.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.98 (d, J=9.0 Hz, 2H), 7.92-7.88 (m, 1H), 7.90 (d, J=9.0 Hz, 2H), 7.00-6.98 (m, 1H), 6.95 (s, 1H), 4.95-4.90 (m, 1H), 3.63-3.58 (m, 4H), 3.22-3.20 (m, 2H), 3.00-2.97 (m, 2H), 1.91-1.88 (m, 1H), 1.83-1.76 (m, 3H), 1.72-1.66 (m, 2H), 1.33 (d, J=1.5 Hz, 3H), 1.30-1.08 (m, 5H).

Example 319

2-(Cyclopentylloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{26}H_{25}F_6N_5O_3S$, 601.16; m/z found, 602.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.99 (d, J=9.0 Hz, 2H), 7.94 (d, J=9.0 Hz, 2H), 7.90-7.88 (m, 1H), 7.00-6.97 (m, 1H), 6.97 (s, 1H), 5.37-5.33 (m, 1H),

192

3.63-3.57 (m, 4H), 3.22-3.19 (m, 2H), 3.00-2.98 (m, 2H), 2.00-1.91 (m, 4H), 1.91-1.85 (m, 2H), 1.69-1.63 (m, 2H).

Example 320


2-[(1-Cyclohexylethyl)oxy]-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{32}H_{39}F_3N_6O_3S$, 644.28; m/z found, 645.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 7.89-7.86 (m, 1H), 7.80 (d, J=9.0 Hz, 2H), 7.74 (d, J=9.0 Hz, 2H), 6.96 (m, 1H), 6.75 (s, 1H), 4.93-4.87 (m, 1H), 3.62-3.54 (m, 4H), 3.27-3.23 (m, 4H), 3.19-3.16 (m, 2H), 2.95-2.93 (m, 2H), 1.89-1.85 (m, 1H), 1.82-1.71 (m, 7H), 1.68-1.62 (m, 2H), 1.29 (d, J=1.5 Hz, 3H), 1.27-1.04 (m, 5H).

Example 321

2-[(1-Cyclopropylethyl)oxy]-N-(1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




193

MS (ESI): mass calcd. for $C_{32}H_{39}F_3N_6O$, 580.7; m/z found, 581.4 [M+H]⁺.

Example 322


2-(Tetrahydro-2H-pyran-4-yloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{26}H_{25}F_6N_5O_4S$, 617.15; m/z found, 618.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.41-8.40 (m, 1H), 7.99 (d, J=9.0 Hz, 2H), 7.91-7.87 (m, 3H), 7.01-6.98 (m, 1H), 6.95 (s, 1H), 5.16-5.11 (m, 1H), 4.07-4.03 (m, 2H), 3.64-3.58 (m, 6H), 3.23-3.21 (m, 2H), 3.01-2.99 (m, 2H), 2.13-2.08 (m, 2H), 1.94-1.87 (m, 2H).

Example 323

N-(1-Methyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-(tetrahydrofuran-3-yloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{28}H_{31}F_3N_6O_2$, 540.24; m/z found, 541.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.41-8.39 (m, 1H), 7.89-7.87 (m, 1H), 6.97-6.94 (m, 1H), 6.92 (d, J=8.0 Hz, 1H), 6.81-6.79 (m, 1H), 6.60 (d, J=2.0 Hz, 1H), 6.44 (s, 1H), 5.45-5.42 (m, 1H), 4.10-4.06 (m, 1H), 4.00-3.95 (m, 1H), 3.93-3.88 (m, 2H), 3.65-3.58 (m, 4H), 3.26-3.23 (m, 2H),

194

3.16-3.14 (m, 2H), 2.92-2.89 (m, 4H), 2.76 (t, J=6.0 Hz, 2H), 2.23-2.13 (m, 3H), 2.02-1.97 (m, 2H).

Example 324


2-(Cyclopentyloxy)-N-(1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{29}H_{33}F_3N_6O$, 538.27; m/z found, 539.3 [M+H]⁺.

Example 325

2-[(1-Cyclopropylethyl)oxy]-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_5O$, 551.21; m/z found, 552.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.39-8.37 (m, 1H), 8.03 (d, J=11.5 Hz, 1H), 7.89-7.86 (m, 1H), 7.47 (s, 1H), 7.45 (s, 1H), 6.97-6.94 (m, 1H), 6.39 (s, 1H), 4.52-4.45 (m, 1H), 3.65-3.57 (m, 4H), 3.18-3.15 (m, 2H), 2.93-2.90 (m, 2H),

195

2.35 (s, 3H), 1.37 (d, J=8.0 Hz, 3H), 1.18-1.09 (m, 1H), 0.55-0.43 (m, 2H), 0.40-0.33 (m, 1H), 0.25-0.19 (m, 1H).

Example 326


2-(Cyclohexyloxy)-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{28}H_{29}F_6N_5O$, 565.23; m/z found, 566.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 8.16 (d, J=9.0 Hz, 1H), 7.90-7.88 (m, 1H), 7.49-7.48 (m, 2H), 6.99-6.96 (m, 1H), 6.46 (s, 1H), 4.81-4.76 (m, 1H), 3.67-3.65 (m, 2H), 3.61-3.59 (m, 2H), 3.20-3.17 (m, 2H), 2.96-2.94 (m, 2H), 2.38 (s, 3H), 2.05-2.01 (m, 2H), 1.85-1.80 (m, 2H), 1.63-1.51 (m, 1H), 1.38-1.27 (m, 5H).

Example 327

2-(Butyloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{24}H_{24}F_6N_6O$, 526.19; m/z found, 527.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.82 (d, J=2.5 Hz, 1H), 8.39-8.34 (m, 2H), 7.89-7.87 (m, 1H), 7.67 (d, J=8.5 Hz, 1H), 6.98-6.95 (m, 1H), 6.83 (brs, 1H), 4.29 (t, J=6.5 Hz, 2H),

196

3.64-3.61 (m, 2H), 3.59-3.56 (m, 2H), 3.21-3.19 (m, 2H), 3.01-2.98 (m, 2H), 1.80-1.74 (m, 2H), 1.55-1.47 (m, 2H), 0.96 (t, J=7.0 Hz, 3H).

Example 328


2-(Cyclohexyloxy)-N-(1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{30}H_{35}F_3N_6O$, 552.28; m/z found, 553.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.87-7.84 (m, 1H), 6.94-6.88 (m, 3H), 6.56 (d, J=2.5 Hz, 1H), 6.41 (s, 1H), 4.93-4.86 (m, 1H), 3.63-3.56 (m, 4H), 3.23 (t, J=7.0 Hz, 2H), 3.14-3.11 (m, 2H), 2.89 (s, 3H), 2.88-2.86 (m, 2H), 2.74 (t, J=8.0 Hz, 2H), 2.0-1.94 (m, 4H), 1.81-1.78 (m, 2H), 1.59-1.53 (m, 3H), 1.37-1.26 (m, 3H).

Example 329

N-(1-Methyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-(tetrahydro-2H-pyran-4-yloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{29}H_{33}F_3N_6O_2$, 554.26; m/z found, 555.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.89-7.87 (m, 1H), 6.97-6.94 (m, 1H), 6.91 (d, J=8.0 Hz, 1H), 6.86-6.83 (m, 1H), 6.59 (d, J=2.0 Hz, 1H), 6.43 (s, 1H), 5.13-5.08 (m, 1H), 4.03-3.99 (m, 2H), 3.65-3.53 (m, 6H),

197

3.26-3.24 (m, 2H), 3.17-3.14 (m, 2H), 2.92-2.89 (m, 5H), 2.76 (t, J=6.5 Hz, 2H), 2.08-1.97 (m, 4H), 1.89-1.81 (m, 2H).

Example 330


2-({[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]methyl}oxy)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_5O_3$, 583.20; m/z found, 584.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.89-7.86 (m, 1H), 7.69 (d, J=11.0 Hz, 2H), 7.59 (d, J=11.0 Hz, 2H), 6.98-6.94 (m, 1H), 6.68 (s, 1H), 4.52-4.56 (m, 1H), 4.42-4.38 (m, 1H), 4.28-4.24 (m, 1H), 4.16-4.12 (m, 1H), 3.94-3.90 (m, 1H), 3.63-3.56 (m, 4H), 3.18-3.15 (m, 2H), 2.96-2.93 (m, 2H), 1.46 (s, 3H), 1.38 (s, 3H).

Example 331

2-(Tetrahydrofuran-3-yloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{25}H_{23}F_6N_5O_4S$, 603.14; m/z found, 604.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.39 (m, 1H),

198

7.99 (d, J=9.0 Hz, 2H), 7.91-7.87 (m, 3H), 7.01-6.98 (m, 2H), 5.50-5.46 (m, 1H), 4.12-4.08 (m, 1H), 4.06-3.93 (m, 3H), 3.64-3.58 (m, 4H), 3.23-3.20 (m, 2H), 3.02-2.99 (m, 2H), 2.28-2.24 (m, 2H).

Example 332


2-[(1-Cyclohexylethyl)oxy]1-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{29}H_{31}F_6N_5O$, 579.24; m/z found, 580.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.90-7.88 (m, 1H), 7.70 (d, J=8.5 Hz, 2H), 7.59 (d, J=8.5 Hz, 2H), 6.99-6.96 (m, 1H), 6.67 (s, 1H), 4.94-4.88 (m, 1H), 3.65-3.58 (m, 4H), 3.20-3.17 (m, 2H), 2.96-2.94 (m, 2H), 1.90-1.87 (m, 1H), 1.83-1.75 (m, 3H), 1.72-1.65 (m, 2H), 1.31 (d, J=6.5 Hz, 3H), 1.28-1.07 (m, 5H).

Example 333

2-(Cyclopentyloxy)-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{29}H_{33}F_3N_6O_3S$, 602.23; m/z found, 603.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.89-7.86 (m, 1H), 7.79 (s, 4H), 6.98-6.94 (m, 1H), 6.77 (s,

199

1H), 5.33-5.30 (m, 1H), 3.62-3.55 (m, 4H), 3.27-3.23 (m, 4H), 3.18-3.16 (m, 2H), 2.96-2.93 (m, 2H), 1.96-1.75 (m, 9H), 1.66-1.58 (m, 3H).

Example 334


2-[(1-Cyclopropylethyl)oxy]-N-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{29}H_{33}F_3N_6O_3S$, 602.23; m/z found, 603.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39-8.37 (m, 1H), 7.89-7.86 (m, 1H), 7.78 (d, $J=11.0$ Hz, 2H), 7.71 (d, $J=11.0$ Hz, 2H), 6.98-6.94 (m, 1H), 6.74 (s, 1H), 4.61-4.54 (m, 1H), 3.62-3.55 (m, 4H), 3.27-3.23 (m, 4H), 3.18-3.15 (m, 2H), 2.95-2.93 (m, 2H), 1.79-1.75 (m, 4H), 1.42 (d, $J=8.0$ Hz, 3H), 1.21-1.15 (m, 1H), 0.58-0.39 (m, 3H), 0.30-0.24 (m, 1H).

Example 335

N-[4-(Pyrrolidin-1-ylsulfonyl)phenyl]-2-(tetrahydro-2H-pyran-4-yloxy)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{29}H_{33}F_3N_6O_4S$, 618.22; m/z found, 619.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 7.89-7.86 (m, 1H), 7.79 (d, $J=11.0$ Hz, 2H), 7.72 (d, $J=11.0$

200

Hz, 2H), 6.99-6.95 (m, 1H), 6.80 (s, 1H), 5.13-5.06 (m, 1H), 4.06-4.00 (m, 2H), 3.62-3.54 (m, 6H), 3.27-3.24 (m, 4H), 3.19-3.16 (m, 2H), 2.97-2.94 (m, 2H), 2.11-2.06 (m, 2H), 1.92-1.83 (m, 2H), 1.80-1.75 (m, 4H).

Example 336


2-(Cycloheptyloxy)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{28}H_{29}F_6N_5O$, 565.23; m/z found, 566.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.90-7.88 (m, 1H), 7.71 (d, $J=9.0$ Hz, 2H), 7.60 (d, $J=9.0$ Hz, 2H), 6.99-6.96 (m, 1H), 6.68 (s, 1H), 5.08-5.03 (m, 1H), 3.65-3.58 (m, 4H), 3.19-3.17 (m, 2H), 2.96-2.94 (m, 2H), 2.13-2.07 (m, 2H), 1.88-1.74 (m, 4H), 1.64-1.58 (m, 4H), 1.51-1.44 (m, 2H).

Example 337

2-(Cyclopentylloxy)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{26}H_{25}F_6N_5O$, 537.20; m/z found, 538.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.90-7.87 (m, 1H), 7.74 (d, $J=8.5$ Hz, 2H), 7.60 (d, $J=8.5$ Hz, 2H), 6.99-6.96 (m, 1H), 6.70 (s, 1H), 5.34-5.30 (m, 1H),

201

3.64-3.57 (m, 4H), 3.19-3.17 (m, 2H), 2.97-2.94 (m, 2H), 1.97-1.92 (m, 4H), 1.88-1.83 (2H), 1.65-1.62 (m, 2H).

Example 338


2-(Cyclohexyloxy)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_5O$, 551.21; m/z found, 552.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 7.90-7.87 (m, 1H), 7.72 (d, $J=8.5$ Hz, 2H), 7.59 (d, $J=8.5$ Hz, 2H), 6.98-6.96 (m, 1H), 6.71 (s, 1H), 4.90-4.84 (m, 1H), 3.64-3.57 (m, 4H), 3.19-3.17 (m, 2H), 2.96-2.94 (m, 2H), 2.10-2.07 (m, 2H), 1.88-1.84 (m, 2H), 1.65-1.55 (m, 3H), 1.44-1.27 (m, 3H).

Example 339

2-(Tetrahydro-2H-pyran-4-yloxy)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{26}H_{25}F_6N_5O_2$, 553.19; m/z found, 554.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.40 (m, 1H), 7.91-7.88 (m, 1H), 7.68 (d, $J=8.5$ Hz, 2H), 7.60 (d, $J=8.5$ Hz, 2H), 6.99-6.96 (m, 1H), 6.69 (s, 1H), 5.12-5.06 (m, 1H),

202

4.06-4.02 (m, 2H), 3.97 (s, 1H), 3.65-3.56 (m, 5H), 3.20-3.18 (m, 2H), 2.97-2.95 (m, 2H), 2.11-2.04 (m, 2H), 1.93-1.85 (m, 2H).

Example 340

2-(Tetrahydrofuran-3-yloxy)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{25}H_{23}F_6N_5O_2$, 539.18; m/z found, 540.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.38 (m, 1H), 7.89-7.86 (m, 1H), 7.65 (d, $J=11.0$ Hz, 2H), 7.60 (d, $J=11.0$ Hz, 2H), 6.98-6.95 (m, 1H), 6.67 (s, 1H), 5.43-5.39 (m, 1H), 4.09-4.05 (m, 1H), 4.00-3.89 (m, 3H), 3.64-3.56 (m, 4H), 3.19-3.15 (m, 2H), 2.96-2.93 (m, 2H), 2.24-2.17 (m, 2H).

The following Examples 341-343 were prepared using methods analogous to those described in Example 307, substituting the appropriate alcohols and using the appropriate alcohol as the solvent.

Example 341

2-[(1-Methylethyl)oxy]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




MS (ESI): mass calcd. for $C_{24}H_{23}F_6N_5O$, 511.18; m/z found, 512.5 $[M+H]^+$. 1H NMR (MeOD): 8.46-8.44 (m, 1H), 8.03 (dd, $J=7.8, 1.7$ Hz, 1H), 7.74 (s, 4H), 7.17-7.12 (m, 1H),

203

5.22-5.16 (m, 1H), 3.65-3.61 (m, 2H), 3.60-3.56 (m, 2H), 3.26-3.21 (m, 2H), 3.19-3.14 (m, 2H), 1.37 (d, J=6.2 Hz, 6H).

Example 342


2-(Phenylthio)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt



MS (ESI): mass calcd. for $C_{27}H_{21}F_6N_5O$, 545.17; m/z found, 546.5 $[M+H]^+$. 1H NMR (MeOD): 8.48-8.46 (m, 1H), 8.04 (dd, J=7.8, 1.7 Hz, 1H), 7.51-7.46 (m, 2H), 7.44 (d, J=8.6 Hz, 2H), 7.40-7.34 (m, 3H), 7.24 (d, J=7.7 Hz, 2H), 7.16 (dd, J=7.7, 4.8 Hz, 1H), 3.69-3.64 (m, 2H), 3.61-3.55 (m, 2H), 3.35-3.31 (m, 2H), 3.21-3.16 (m, 2H).

Example 343

2-(Butyloxy)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{25}H_{25}F_6N_5O$, 525.20; m/z found, 526.1 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.40-8.37 (m, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.72-7.69 (m, 2H), 7.61-7.57 (m, 2H), 6.98-6.94 (m, 1H), 6.66 (s, 1H), 4.29 (t, J=6.6 Hz, 2H),

204

3.64-3.56 (m, 4H), 3.20-3.15 (m, 2H), 2.97-2.94 (m, 2H), 1.81-1.75 (m, 2H), 1.54-1.47 (m, 2H), 0.96 (t, J=7.4 Hz, 3H).

Example 344


4-{{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-ol trifluoroacetic acid salt



A solution of [2-methanesulfonyl-7-(3-trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl-[(4-trifluoromethyl-phenyl)-amine (Example 53; 112 mg, 0.21 mmol) and NaOH (25 mg, 0.63 mmol) in 1:3 H_2O /dioxane (4 mL) was heated at 60° C. for 1 h. The mixture was cooled, acidified with TFA (3 drops), and directly purified using Preparative HPLC (conditions as in Example 54) to give the title compound (60 mg, 98%). MS (ESI): mass calcd. for $C_{21}H_{17}F_6N_5O$, 469.13; m/z found, 470.5 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.46-8.41 (m, 1H), 7.97 (dd, J=7.8, 1.5 Hz, 1H), 7.64 (s, 4H), 7.09 (dd, J=7.7, 4.9 Hz, 1H), 3.63-3.58 (m, 2H), 3.58-3.53 (m, 2H), 3.18-3.12 (m, 2H), 2.89-2.84 (m, 2H).

Example 345

2-(Ethoxy)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




The title compound was prepared using methods analogous to those described in Example 62. MS (ESI): mass calcd. for $C_{23}H_{21}F_6N_5O$, 497.17; m/z found, 498.4 $[M+H]^+$. 1H NMR (MeOD): 8.45 (dd, J=4.7, 1.5 Hz, 1H), 8.03 (dd, J=7.8, 1.8 Hz, 1H), 7.75 (q, J=8.9 Hz, 4H), 7.15 (dd, J=7.5, 4.8 Hz, 1H), 4.45 (q, J=7.1 Hz, 2H), 3.64-3.61 (m, 2H), 3.59-3.56 (m, 2H), 3.25-3.22 (m, 2H), 3.17-3.15 (m, 2H), 1.38 (t, J=7.1 Hz, 3H).

205

Example 346

2-[(Methoxy)methyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[6-(trifluoromethyl)pyridin-3-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine trifluoroacetic acid salt




The title compound was prepared using methods analogous to those described for Example 39 with modifications to Step A as follows:

Step A. 2-Hydroxymethyl-7-(3-(trifluoromethyl)pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol

To solution of NaOMe (1.9 mL) in MeOH (0.5 mL) was added 5-oxo-1-(3-(trifluoromethyl)pyridin-2-yl)-azepane-4-carboxylic acid ethyl ester (Intermediate B; 285 mg, 0.96 mmol), followed by 2-chloro-acetamidine (149 mg, 1.16 mmol). After heating at 100° C. in a microwave for 15 min, the mixture was cooled and concentrated. The residue was dissolved in water and extracted with CH₂Cl₂. The combined organic layers were dried, concentrated, and directly purified using Preparative HPLC (conditions as in Example 54) to give the title compound (86 mg, 26%). MS (ESI): mass calcd. for C₂₂H₂₀F₆N₆O, 498.16; m/z found, 499.3 [M+H]⁺. ¹H NMR (MeOD): 8.95 (d, J=2.3 Hz, 1H), 8.47-8.45 (m, 1H), 8.29 (dd, J=8.5, 2.2 Hz, 1H), 8.04 (dd, J=7.8, 1.7 Hz, 1H), 7.88 (d, J=8.6 Hz, 1H), 7.16 (dd, J=7.7, 4.9 Hz, 1H), 4.61 (s, 2H), 3.68-3.61 (m, 4H), 3.53 (s, 3H), 3.49-3.45 (m, 2H), 3.30-3.28 (m, 2H).

Example 347

2-Methyl-2-[4-(2-[(methoxy)methyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)amino]phenyl]propanenitrile trifluoroacetic acid salt




206

The title compound was prepared using methods analogous to those described in Example 346, substituting the appropriate anilines in Step E. MS (ESI): mass calcd. for C₂₆H₂₇F₃N₆O, 496.22; m/z found, 497.5 [M+H]⁺. ¹H NMR (MeOD): 8.45 (dd, J=4.7, 1.4 Hz, 1H), 8.03 (dd, J=7.8, 1.8 Hz, 1H), 7.58 (s, 4H), 7.14 (dd, J=7.4, 4.8 Hz, 1H), 4.54 (s, 2H), 3.68-3.60 (m, 4H), 3.51 (s, 3H), 3.44-3.40 (m, 2H), 3.25-3.21 (m, 2H), 1.75 (s, 6H).

Example 348

2-(Methylsulfonyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



The title compound was synthesized in a manner similar to Example 53 with modifications to Step C in Example 52 as follows:


Step C.

To a solution of 4-chloro-2-methylsulfonyl-7-(3-(trifluoromethyl)pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine (400 mg, 1.07 mmol), 4-trifluoromethyl-aminopyridine (208 mg, 1.28 mmol), and NaOtBu (144 mg, 1.5 mmol) in toluene (4 mL) in a microwave vial was added a solution of Pd(OAc)₂ (3.7 mg, 0.016 mmol) and 2-(dicyclohexylphosphino)biphenyl (DCPB) (11.9 mg, 0.034 mmol) in toluene (1 mL). The mixture was flushed with N_{2(g)} and heated in a microwave at 200° C. for 2 h. The mixture was cooled, filtered through a plug of diatomaceous earth, and concentrated. The residue was purified (FCC) to afford the title compound (230 mg, 48%). MS (ESI): mass calcd. for C₂₁H₁₈F₆N₆O₂S, 532.11; m/z found, 533.1 [M+H]⁺. ¹H NMR (CDCl₃): 8.67 (d, J=8.9 Hz, 1H), 8.56-8.54 (m, 1H), 8.42-8.40 (m, 1H), 8.03-8.00 (m, 1H), 7.89 (dd, J=7.8, 1.8 Hz, 1H), 7.85 (s, 1H), 7.03-6.98 (m, 1H), 3.70-3.65 (m, 2H), 3.63-3.59 (m, 2H), 3.39-3.36 (m, 2H), 3.32 (s, 3H), 3.19-3.15 (m, 2H).

207

Example 349

2-(Phenylsulfanyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




To a microwave reaction vial were added [2-methanesulfonyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine (53 mg, 0.1 mmol), thiophenol (16 mg, 0.15 mmol), p-toluenesulfonic acid monohydrate (10 mg, 0.05 mmol), and DMF (0.4 mL). The vial was capped, and the mixture was heated via microwave irradiation at 100° C. for 10 min, filtered through a 0.45 µm filter, and the filtrate was purified by reversed phase HPLC (Phenomenex Gemini 30 mm×100 mm column, gradient of acetonitrile in 20 mM aqueous NH₄OH). The title compound was obtained as a white solid (27 mg, 48%). MS (ESI): mass calcd. for C₂₇H₂₁F₆N₅S, 561.14; m/z found, 562 [M+H]⁺. ¹H NMR (CDCl₃): 8.38 (dd, J=4.7, 1.5 Hz, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.68-7.62 (m, 2H), 7.56-7.50 (m, 1H), 7.50-7.42 (m, 2H), 7.23 (d, J=8.7 Hz, 2H), 7.16 (d, J=8.7 Hz, 2H), 6.96 (dd, J=7.4, 4.6 Hz, 1H), 6.58 (bs, 1H), 3.66-3.55 (m, 4H), 3.23-3.17 (m, 2H), 2.96-2.90 (m, 2H).

Examples 350-352 were synthesized in a manner similar to Example 349 substituting the appropriate thiols.

Example 350


2-(Phenylsulfanyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



208

Example 351


N-[2-Methyl-4-(trifluoromethyl)phenyl]-2-(phenylsulfanyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for C₂₈H₂₃F₆N₅S, 575.16; m/z found, 576 [M+H]⁺. ¹H NMR (CDCl₃): 8.38 (dd, J=4.7, 1.4 Hz, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.61-7.56 (m, 2H), 7.48-7.42 (m, 2H), 7.42-7.33 (m, 2H), 7.32-7.28 (m, 1H), 7.02-6.93 (m, 2H), 6.43 (bs, 1H), 3.70-3.62 (m, 2H), 3.62-3.56 (m, 2H), 3.23-3.16 (m, 2H), 2.97-2.91 (m, 2H), 2.22 (s, 3H).

Example 352

2-(Phenylsulfanyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-(1,4,4-trimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




209

MS (ESI): mass calcd. for $C_{32}H_{33}F_3N_5S$, 590.24; m/z found, 591 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.37 (dd, $J=4.7$, 1.6 Hz, 1H), 7.86 (dd, $J=7.8$, 1.8 Hz, 1H), 7.66-7.60 (m, 2H), 7.43-7.33 (m, 3H), 6.94 (dd, $J=7.7$, 4.8 Hz, 1H), 6.77 (d, $J=8.3$ Hz, 1H), 6.53 (dd, $J=8.3$, 2.2 Hz, 1H), 6.35 (bs, 1H), 6.23 (d, $J=2.2$ Hz, 1H), 3.65-3.54 (m, 4H), 3.22-3.10 (m, 4H), 2.91-2.83 (m, 2H), 2.77 (s, 3H), 1.76-1.70 (m, 2H), 1.25 (s, 6H).

Examples 353-375 were synthesized in a manner similar to Example 349 substituting the appropriate thiols and substituting Cs_2CO_3 (4 molar equivalents) for p-toluenesulfonic acid.

Example 353


2-[(Phenylmethyl)sulfanyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{28}H_{23}F_6N_5S$, 575.16; m/z found, 576 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.6$, 1.4 Hz, 1H), 7.88 (dd, $J=7.8$, 1.8 Hz, 1H), 7.59 (d, $J=8.6$ Hz, 2H), 7.52 (d, $J=8.7$ Hz, 2H), 7.37-7.32 (m, 2H), 7.30-7.20 (m, 3H), 6.96 (dd, $J=7.4$, 4.8 Hz, 1H), 6.62 (bs, 1H), 4.36 (s, 2H), 3.67-3.60 (m, 2H), 3.60-3.54 (m, 2H), 3.21-3.15 (m, 2H), 2.98-2.91 (m, 2H).

Example 354

2-(Cyclohexylsulfanyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_5S$, 567.19; m/z found, 568 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.6$, 1.4 Hz, 1H), 7.87 (dd, $J=7.8$, 1.8 Hz, 1H), 7.67 (d, $J=8.6$ Hz, 2H),

210

7.58 (d, $J=8.6$ Hz, 2H), 6.96 (dd, $J=7.5$, 4.6 Hz, 1H), 6.63 (bs, 1H), 3.73-3.61 (m, 1H), 3.68-3.60 (m, 2H), 3.60-3.53 (m, 2H), 3.19-3.12 (m, 2H), 2.98-2.92 (m, 2H), 2.14-2.05 (m, 2H), 1.82-1.73 (m, 2H), 1.68-1.60 (m, 1H), 1.56-1.43 (m, 2H), 1.43-1.23 (m, 3H).

Example 355


2-[(1-Methylethyl)sulfanyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{24}H_{23}F_6N_5S$, 527.16; m/z found, 528 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.6$, 1.4 Hz, 1H), 7.87 (dd, $J=7.8$, 1.8 Hz, 1H), 7.68 (d, $J=8.6$ Hz, 2H), 7.58 (d, $J=8.6$ Hz, 2H), 6.96 (dd, $J=7.8$, 5.1 Hz, 1H), 6.63 (bs, 1H), 3.87 (sept, $J=6.8$ Hz, 1H), 3.67-3.61 (m, 2H), 3.61-3.54 (m, 2H), 3.20-3.14 (m, 2H), 2.98-2.92 (m, 2H), 1.41 (d, $J=6.8$ Hz, 6H).

Example 356

1-[(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)sulfanyl]propan-2-ol




MS (ESI): mass calcd. for $C_{24}H_{23}F_6N_5OS$, 543.15; m/z found, 544 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39 (dd, $J=4.7$, 1.5 Hz, 1H), 7.88 (dd, $J=7.8$, 1.8 Hz, 1H), 7.65 (d, $J=8.8$ Hz, 2H), 7.60 (d, $J=8.8$ Hz, 2H), 6.97 (dd, $J=7.5$, 4.7 Hz, 1H), 6.67 (bs, 1H), 4.24 (bs, 1H), 4.15-4.05 (m, 1H), 3.65-3.60 (m, 2H),

211

3.60-3.53 (m, 2H), 3.29 (dd, J=14.6, 3.0 Hz, 1H), 3.19-3.12 (m, 2H), 3.08 (dd, J=14.6, 7.4 Hz, 1H), 2.99-2.92 (m, 2H), 1.26 (d, J=6.2 Hz, 3H).

Example 357


[2-(2-Methyl-tetrahydro-furan-3-ylsulfanyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine



The title compound was isolated as a mixture of isomers. MS (ESI): mass calcd. for $C_{26}H_{25}F_6N_5OS$, 569.17; m/z found, 570 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.6, 1.3 Hz, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.65 (d, J=8.6 Hz, 2H), 7.54 (d, J=8.7 Hz, 2H), 6.97 (dd, J=7.4, 4.8 Hz, 1H), 6.63 (bs, 1H), 4.35-4.23 (m, 2H), 4.06-3.98 (m, 1H), 3.82-3.74 (m, 1H), 3.68-3.61 (m, 2H), 3.61-3.54 (m, 2H), 3.20-3.14 (m, 2H), 2.98-2.92 (m, 2H), 2.55-2.43 (m, 1H), 2.11-2.02 (m, 1H), 1.27 (d, J=6.1 Hz, 3H).

Example 358

[2-(2-Methyl-tetrahydro-furan-3-ylsulfanyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine




The title compound was isolated as a mixture of isomers. MS (ESI): mass calcd. for $C_{26}H_{25}F_6N_5OS$, 569.17; m/z

212

found, 570 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39 (dd, J=4.6, 1.4 Hz, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.64 (d, J=8.7 Hz, 2H), 7.59 (d, J=8.7 Hz, 2H), 6.97 (dd, J=7.2, 4.8 Hz, 1H), 6.63 (bs, 1H), 4.00-3.92 (m, 1H), 3.90-3.81 (m, 2H), 3.81-3.74 (m, 1H), 3.67-3.60 (m, 2H), 3.60-3.53 (m, 2H), 3.31-3.25 (m, 2H), 2.99-2.92 (m, 2H), 2.59-2.46 (m, 1H), 2.04-1.93 (m, 1H), 1.30 (d, J=6.0 Hz, 3H).

Example 359


2-[(Phenylmethyl)sulfanyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{28}H_{23}F_6N_5O_2S_2$, 639.12; m/z found, 640 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.7, 1.5 Hz, 1H), 7.91-7.85 (m, 3H), 7.79-7.74 (m, 2H), 7.42-7.37 (m, 2H), 7.33-7.26 (m, 2H), 7.26-7.22 (m, 1H), 6.98 (dd, J=8.2, 5.2 Hz, 1H), 6.86 (bs, 1H), 4.40 (s, 2H), 3.65-3.55 (m, 4H), 3.25-3.20 (m, 2H), 3.01-2.96 (m, 2H).

Example 360

2-(Cyclohexylsulfanyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_5O_2S_2$, 631.15; m/z found, 632 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.8, 1.6 Hz, 1H), 7.97 (d, J=8.9 Hz, 2H), 7.90-7.84 (m, 3H), 6.98 (dd, J=7.6, 4.7 Hz, 1H), 6.88 (bs, 1H), 3.75-3.67 (m, 1H), 3.64-

213

3.60 (m, 2H), 3.60-3.54 (m, 2H), 3.21-3.15 (m, 2H), 3.02-2.95 (m, 2H), 2.16-2.07 (m, 2H), 1.85-1.74 (m, 2H), 1.69-1.61 (m, 1H), 1.57-1.45 (m, 2H), 1.45-1.25 (m, 3H).

Example 361


2-[(1-Methylethyl)sulfanyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{24}H_{23}F_6N_5O_2S_2$, 591.12; m/z found, 592 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.7$, 1.5 Hz, 1H), 7.96 (d, $J=8.9$ Hz, 2H), 7.90-7.84 (m, 3H), 6.98 (dd, $J=7.4$, 4.8 Hz, 1H), 6.90 (bs, 1H), 3.90 (sept, $J=6.8$ Hz, 1H), 3.66-3.60 (m, 2H), 3.60-3.54 (m, 2H), 3.23-3.18 (m, 2H), 3.03-2.95 (m, 2H), 1.43 (d, $J=6.8$ Hz, 3H).

Example 362

1-({7-[3-(Trifluoromethyl)pyridin-2-yl]-4-({4-[(trifluoromethyl)sulfonyl]phenyl}amino)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl} sulfanyl)propan-2-ol



MS (ESI): mass calcd. for $C_{24}H_{23}F_6N_5O_3S_2$, 607.11; m/z found, 608 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.7$, 1.6 Hz, 1H), 8.01-7.95 (m, 2H), 7.91-7.84 (m, 3H), 7.02-6.94 (m, 2H), 4.19 (bs, 1H), 4.19-4.10 (m, 1H), 3.65-3.58 (m, 2H), 3.58-3.52 (m, 2H), 3.33 (dd, $J=14.6$, 3.1 Hz, 1H), 3.21-3.13 (m, 2H), 3.15 (dd, $J=14.6$, 7.2 Hz, 1H), 3.03, 2.95 (m, 2H), 1.30 (d, $J=6.2$ Hz, 3H).

214

Example 363

[2-(2-Methyl-tetrahydro-furan-3-ylsulfanyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine


5

10

15

20

25



The title compound was prepared using 2-methyltetrahydrofuran-3-thiol, obtained as a mixture of isomers from Acros Organics (cat. #33270 0010). Upon purification by reverse phase HPLC (Phenomenex Gemini 5 μm C_{18} column, 30 \times 100 mm, gradient of acetonitrile in 20 mM aqueous NH_4OH), the title compound was isolated as a single diastereomer of unknown stereochemistry. Analytical HPLC: Waters Xterra MS C_{18} 5 μm column, 4.6 \times 100 mm, gradient over 7 min from 1 to 99% acetonitrile in water modified with 0.05% TFA, 1.0 mL/min; $t_R=8.07$ min. MS (ESI): mass calcd. for $C_{26}H_{25}F_6N_5O_3S_2$, 633.13; m/z found, 634 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.6$, 1.5 Hz, 1H), 7.97 (d, $J=8.9$ Hz, 2H), 7.89 (dd, $J=7.8$, 1.8 Hz, 1H), 7.85 (d, $J=9.0$ Hz, 2H), 6.98 (dd, $J=8.1$, 5.4 Hz, 1H), 6.89 (bs, 1H), 4.03-3.96 (m, 1H), 3.93-3.84 (m, 2H), 3.84-3.78 (m, 1H), 3.66-3.61 (m, 2H), 3.23-3.18 (m, 2H), 3.03-2.95 (m, 2H), 2.61-2.50 (m, 1H), 2.06-1.95 (m, 1H), 1.33 (d, $J=6.0$ Hz, 3H).

30

35

40

45

Example 364


N-[2-Methyl-4-(trifluoromethyl)phenyl]-2-[(phenylmethyl)sulfanyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine

50

55

60

65




215

MS (ESI): mass calcd. for $C_{29}H_{25}F_6N_5S$, 589.17; m/z found, 590 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.6$, 1.4 Hz, 1H), 7.88 (dd, $J=7.8$, 1.8 Hz, 1H), 7.86 (d, $J=8.3$ Hz, 1H), 7.48-7.45 (m, 1H), 7.42-7.37 (m, 1H), 7.26-7.16 (m, 5H), 6.96 (dd, $J=7.7$, 4.8 Hz, 1H), 6.35 (bs, 1H), 4.25 (s, 2H), 3.68-3.61 (m, 2H), 3.61-3.54 (m, 2H), 3.21-3.15 (m, 2H), 2.97-2.91 (m, 2H), 2.31 (s, 3H).

Example 365


2-(Cyclohexylsulfanyl)-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{28}H_{25}F_6N_5S$, 581.20; m/z found, 582 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.8$, 1.6 Hz, 1H), 7.98 (d, $J=9.0$ Hz, 1H), 7.87 (dd, $J=7.8$, 1.8 Hz, 1H), 7.49-7.44 (m, 2H), 6.96 (dd, $J=7.6$, 4.7 Hz, 1H), 6.37 (bs, 1H), 3.68-3.61 (m, 2H), 3.61-3.45 (m, 3H), 3.19-3.12 (m, 2H), 2.98-2.92 (m, 2H), 2.34 (s, 3H), 2.05-1.95 (m, 2H), 1.77-1.65 (m, 2H), 1.65-1.53 (m, 1H), 1.48-1.34 (m, 2H), 1.33-1.17 (m, 3H).

Example 366

2-[(1-Methylethyl)sulfanyl]-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




216

MS (ESI): mass calcd. for $C_{25}H_{25}F_6N_5S$, 541.17; m/z found, 542 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, $J=4.7$, 1.5 Hz, 1H), 8.03 (d, $J=9.0$ Hz, 1H), 7.88 (dd, $J=7.8$, 1.8 Hz, 1H), 7.49-7.43 (m, 2H), 6.96 (dd, $J=7.8$, 5.1 Hz, 1H), 6.38 (bs, 1H), 3.74 (sept, $J=6.8$ Hz, 1H), 3.69-3.62 (m, 2H), 3.62-3.55 (m, 2H), 3.21-3.14 (m, 2H), 2.98-2.91 (m, 2H), 2.35 (s, 3H), 1.34 (d, $J=6.8$ Hz, 6H).

Example 367


1-[(4-{[2-Methyl-4-(trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)sulfanyl]propan-2-ol



MS (ESI): mass calcd. for $C_{25}H_{25}F_6N_5OS$, 557.17; m/z found, 558 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39 (dd, $J=4.7$, 1.5 Hz, 1H), 7.88 (dd, $J=7.7$, 1.8 Hz, 1H), 7.86 (d, $J=8.6$ Hz, 1H), 7.53-7.47 (m, 2H), 6.97 (dd, $J=7.6$, 4.8 Hz, 1H), 6.39 (bs, 1H), 4.02-3.93 (m, 1H), 3.67-3.61 (m, 2H), 3.61-3.53 (m, 2H), 3.22-3.13 (m, 3H), 2.33 (s, 3H), 1.17 (d, $J=6.2$ Hz, 3H).

Example 368

2,5-Anhydro-1,4-dideoxy-3-S-(4-{[2-methyl-4-(trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)-3-thiopentitol




The title compound was isolated as a mixture of isomers. MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_5OS$, 583.18; m/z found, 584 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.37 (m, 1H),

217

7.91-7.85 (m, 2H), 7.48 (s, 2H), 6.97 (dd, J=7.8, 4.8 Hz, 1H), 6.37 (bs, 1H), 4.20-4.15 (m, 1H), 3.92-3.83 (m, 1H), 3.83-3.76 (m, 2H), 3.68-3.55 (m, 4H), 3.20-3.14 (m, 2H), 2.99-2.92 (m, 2H), 2.42-2.32 (m, 1H), 2.34 (s, 3H), 1.96-1.88 (m, 1H), 1.23 (d, J=6.1 Hz, 3H).

Example 369


2,5-Anhydro-1,4-dideoxy-3-S-(4-{[2-methyl-4-(trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)-3-thiopentitol



The title compound was isolated as a mixture of isomers. MS (ESI): mass calcd. for $C_{27}H_{27}F_6N_8OS$, 583.18; m/z found, 584 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.39 (dd, J=4.8, 1.5 Hz, 1H), 7.92-7.85 (m, 2H), 7.50-7.45 (m, 2H), 6.97 (dd, J=7.4, 4.8 Hz, 1H), 6.37 (bs, 1H), 3.92-3.83 (m, 1H), 3.85-3.76 (m, 2H), 3.68-3.55 (m, 5H), 3.21-3.15 (m, 2H), 3.00-2.93 (m, 2H), 2.42-2.32 (m, 1H), 2.34 (s, 3H), 1.96-1.87 (m, 1H), 1.23 (d, J=6.1 Hz, 3H).

Example 370

2-[(Phenylmethyl)sulfanyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-N-(1,4,4-trimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{33}H_{35}F_3N_6S$, 604.26; m/z found, 605 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.7, 1.5 Hz, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.29-7.14 (m, 5H), 7.11

218

(d, J=8.0 Hz, 1H), 6.94 (dd, J=7.4, 4.5 Hz, 1H), 6.77-6.71 (m, 2H), 6.37 (bs, 1H), 4.33 (s, 2H), 3.68-3.54 (m, 4H), 3.27-3.19 (m, 2H), 3.19-3.11 (m, 2H), 2.93-2.84 (m, 2H), 2.89 (s, 3H), 1.78-1.71 (m, 2H), 1.26 (s, 6H).

Example 371


2-(Cyclohexylsulfanyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-N-(1,4,4-trimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS (ESI): mass calcd. for $C_{32}H_{35}F_3N_6S$, 596.29; m/z found, 597 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.7, 1.5 Hz, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.13 (d, J=8.2 Hz, 1H), 6.93 (dd, J=7.6, 4.6 Hz, 1H), 6.88 (dd, J=8.2, 2.0 Hz, 1H), 6.51 (d, J=2.0 Hz, 1H), 6.33 (bs, 1H), 3.69-3.59 (m, 3H), 3.59-3.53 (m, 2H), 3.26-3.21 (m, 2H), 3.17-3.10 (m, 2H), 2.92-2.84 (m, 2H), 2.90 (s, 3H), 2.09-2.01 (m, 2H), 1.79-1.65 (m, 4H), 1.62-1.53 (m, 1H), 1.48-1.37 (m, 2H), 1.37-1.15 (m, 3H), 1.28 (s, 6H).

Example 372

2-[(1-Methylethyl)sulfanyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-N-(1,4,4-trimethyl-1,2,3,4-tetrahydroquinolin-7-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{29}H_{35}F_3N_6S$, 556.26; m/z found, 557 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.6, 1.4 Hz, 1H), 7.86 (dd, J=7.8, 1.9 Hz, 1H), 7.11 (d, J=8.2 Hz, 1H), 6.96-6.90 (m, 1H), 6.87-6.82 (m, 1H), 6.69-6.65 (m, 1H),

219

6.37 (bs, 1H), 3.95-3.85 (m, 1H), 3.65-3.60 (m, 2H), 3.60-3.54 (m, 2H), 3.26-3.20 (m, 2H), 3.17-3.10 (m, 2H), 2.93-2.85 (m, 5H), 1.79-1.74 (m, 2H), 1.37 (d, J=6.8 Hz, 6H), 1.28 (s, 6H).

Example 373


1-({7-[3-(Trifluoromethyl)pyridin-2-yl]-4-[(1,4,4-trimethyl-1,2,3,4-tetrahydroquinolin-7-yl)amino]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl}sulfanyl)propan-2-ol



MS (ESI): mass calcd. for $C_{29}H_{35}F_3N_6OS$, 572.25; m/z found, 573 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.6, 1.4 Hz, 1H), 7.86 (dd, J=7.8, 1.8 Hz, 1H), 7.14 (d, J=8.2 Hz, 1H), 6.95 (dd, J=7.7, 4.8 Hz, 1H), 6.75 (d, J=2.1 Hz, 1H), 6.68 (dd, J=8.2, 2.2 Hz, 1H), 6.40 (bs, 1H), 4.33 (bs, 1H), 4.07-3.99 (m, 1H), 3.66-3.60 (m, 2H), 3.60-3.52 (m, 2H), 3.27-3.21 (m, 2H), 3.20-3.10 (m, 3H), 3.05 (dd, J=14.5, 7.0 Hz, 1H), 2.92 (s, 3H), 2.91-2.84 (m, 2H), 1.78-1.71 (m, 2H), 1.27 (s, 6H), 1.20 (d, J=6.2 Hz, 3H).

Example 374

2,5-Anhydro-1,4-dideoxy-3-thio-3-S-{7-[3-(trifluoromethyl)pyridin-2-yl]-4-[(1,4,4-trimethyl-1,2,3,4-tetrahydroquinolin-7-yl)amino]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl}pinitol




The title compound was isolated as a mixture of isomers. MS (ESI): mass calcd. for $C_{31}H_{37}F_3N_6OS$, 598.27; m/z found, 599 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.6, 1.7 Hz, 1H), 7.86 (dd, J=7.7, 1.8 Hz, 1H), 7.12 (d, J=8.2 Hz, 1H), 6.94 (dd, J=7.8, 4.2 Hz, 1H), 6.75 (dd, J=8.2, 2.2 Hz, 1H), 6.64 (d, J=2.1 Hz, 1H), 6.36 (bs, 1H), 3.93-3.80 (m, 3H),

220

3.78-3.71 (m, 1H), 3.66-3.61 (m, 2H), 3.61-3.54 (m, 2H), 3.24 (t, J=5.9 Hz, 2H), 3.17-3.11 (m, 2H), 2.93-2.87 (m, 2H), 2.91 (s, 3H), 2.52-2.42 (m, 1H), 2.00-1.90 (m, 1H), 1.76 (t, J=5.9 Hz, 2H), 1.27 (s, 6H), 1.24 (d, J=6.1 Hz, 3H).

Example 375

2-(Propylsulfanyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS (ESI): mass calcd. for $C_{24}H_{23}F_3N_5S$, 527.16; m/z found, 528 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.38 (dd, J=4.7, 1.4 Hz, 1H), 7.88 (dd, J=7.8, 1.8 Hz, 1H), 7.67 (d, J=8.6 Hz, 2H), 7.58 (d, J=8.6 Hz, 2H), 6.96 (dd, J=7.2, 4.8 Hz, 1H), 6.62 (bs, 1H), 3.66-3.61 (m, 2H), 3.61-3.54 (m, 2H), 3.20-3.13 (m, 2H), 3.08-3.02 (m, 2H), 2.98-2.91 (m, 2H), 1.73 (sextet, J=7.4 Hz, 2H), 1.00 (t, J=7.3 Hz, 3H).

The compounds in Examples 376-394 were prepared using methods analogous to those described in the preceding examples.

Example 376

2-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethylpyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionic acid methyl ester




MS: mass calcd. for $C_{29}H_{33}F_3N_6O_3$, 570.2567; m/z found, 571.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.38 (m, 1H), 7.88 (dd, J=1.8, 7.8 Hz, 1H), 7.53-7.48 (m, 2H), 7.33-7.29 (m,

221

2H), 6.98-6.92 (m, 1H), 6.40 (s, 1H), 3.80-3.72 (m, 8H), 3.67 (s, 3H), 3.64-3.56 (m, 4H), 3.11-3.06 (m, 2H), 2.89-2.85 (m, 2H), 1.60 (s, 6H).

Example 377


2-(1-Methylethyl)-N-(4-pyrrolidin-1-ylphenyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine



MS: mass calcd. for $C_{27}H_{31}F_3N_6$, 496.2562; m/z found, 497.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.38 (m, 1H), 7.88 (dd, $J=1.8, 7.8$ Hz, 1H), 7.47-7.43 (m, 2H), 6.97-6.92 (m, 1H), 6.60-6.55 (m, 2H), 6.31 (s, 1H), 3.69-3.59 (m, 4H), 3.34-3.28 (m, 4H), 3.22-3.17 (m, 2H), 3.02-2.94 (m, 1H), 2.93-2.87 (m, 2H), 2.07-1.98 (m, 4H), 1.30 (d, $J=6.9$ Hz, 6H).

Example 378

2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine




MS: mass calcd. for $C_{26}H_{26}F_6N_6O_2S$, 600.1742; m/z found, 601.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.42-8.38 (m, 1H), 7.97-7.93 (m, 2H), 7.89 (dd, $J=1.8, 7.8$ Hz, 1H), 7.86-7.82 (m,

222

2H), 6.99-6.95 (m, 1H), 6.78 (s, 1H), 3.81-3.72 (m, 4H), 3.63-3.52 (m, 4H), 3.14-3.09 (m, 2H), 2.94-2.88 (m, 2H), 1.74-1.60 (m, 6H).

Example 379


N,N-Dimethyl-4-({2-morpholin-4-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)benzenesulfonamide



MS: mass calcd. for $C_{26}H_{30}F_3N_7O_3S$, 577.2083; m/z found, 578.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.42-8.39 (m, 1H), 7.89 (dd, $J=1.8, 7.8$ Hz, 1H), 7.79-7.67 (m, 4H), 7.00-6.95 (m, 1H), 6.64 (s, 1H), 3.82-3.73 (m, 8H), 3.64-3.55 (m, 4H), 3.15-3.09 (m, 2H), 2.95-2.88 (m, 2H), 2.73 (s, 6H).

Example 380

1-[4-({2-Morpholin-4-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]ethanone




MS: mass calcd. for $C_{26}H_{27}F_3N_6O_2$, 512.2148; m/z found, 513.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.42-8.39 (m, 1H), 7.99-7.94 (m, 2H), 7.89 (dd, $J=1.8, 7.8$ Hz, 1H), 7.66-7.60 (m, 2H),

223

6.99-6.94 (m, 1H), 6.63 (s, 1H), 3.82-3.74 (m, 8H), 3.64-3.55 (m, 4H), 3.14-3.09 (m, 2H), 2.93-2.89 (m, 2H), 2.60 (s, 3H).

Example 381


(3-Chloro-4-trifluoromethyl-phenyl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine



MS: mass calcd. for $C_{25}H_{23}ClF_6N_6O$, 572.1526; m/z found, 573.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.42-8.39 (m, 1H), 8.00 (d, J=2.0 Hz, 1H), 7.89 (dd, J=1.8, 7.8 Hz, 1H), 7.61 (d, J=8.6 Hz, 1H), 7.38-7.35 (m, 1H), 7.00-6.95 (m, 1H), 6.55 (s, 1H), 3.83-3.74 (m, 8H), 3.63-3.55 (m, 4H), 3.14-3.08 (m, 2H), 2.92-2.87 (m, 2H).

Example 382

2-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionitrile




MS: mass calcd. for $C_{28}H_{30}F_3N_7O$, 537.2464; m/z found, 538.2 [M+H]⁺. ¹H NMR (CDCl₃): 8.40-8.36 (m, 1H), 7.87 (dd, J=1.8, 7.8 Hz, 1H), 7.58-7.52 (m, 2H), 7.44-7.39 (m,

224

2H), 6.97-6.90 (m, 1H), 6.42 (s, 1H), 3.81-3.69 (m, 8H), 3.64-3.53 (m, 4H), 3.11-3.05 (m, 2H), 2.90-2.84 (m, 2H), 1.73 (s, 6H).

Example 383


2-Methyl-2-{4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-1-ol



MS: mass calcd. for $C_{29}H_{35}F_3N_6O$, 540.2825; m/z found, 541.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.43-8.36 (m, 1H), 7.87 (dd, J=1.8, 7.8 Hz, 1H), 7.58-7.53 (m, 2H), 7.36-7.32 (m, 2H), 6.96-6.91 (m, 1H), 6.35 (s, 1H), 3.78-3.72 (m, 4H), 3.65-3.56 (m, 6H), 3.11-3.05 (m, 2H), 2.89-2.83 (m, 2H), 1.71-1.58 (m, 6H), 1.36 (s, 6H).

Example 384

2-Methyl-2-{4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionitrile




MS: mass calcd. for $C_{29}H_{32}F_3N_7$, 535.2672; m/z found, 536.3 [M+H]⁺. ¹H NMR (CDCl₃): 8.42-8.36 (m, 1H), 7.88 (dd, J=1.8, 7.8 Hz, 1H), 7.62-7.57 (m, 2H), 7.44-7.40 (m, 2H), 6.96-6.92 (m, 1H), 6.40 (s, 1H), 3.78-3.72 (m, 4H),

225

3.65-3.54 (m, 4H), 3.11-3.06 (m, 2H), 2.89-2.84 (m, 2H), 1.75 (s, 6H), 1.71-1.58 (m, 6H).

Example 385


2-Fluoro-4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester



MS: mass calcd. for $C_{27}H_{28}F_4N_6O_2$, 544.221; m/z found, 545.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.43-8.37 (m, 1H), 7.93-7.86 (m, 2H), 7.75 (dd, $J=2.1, 14.0$ Hz, 1H), 7.14 (dd, $J=2.1, 8.7$ Hz, 1H), 6.98-6.94 (m, 1H), 6.60 (s, 1H), 3.93 (s, 3H), 3.79-3.75 (m, 4H), 3.61-3.55 (m, 4H), 3.13-3.06 (m, 2H), 2.90-2.85 (m, 2H), 1.73-1.59 (m, 6H).

Example 386

(6-Methoxy-5-trifluoromethyl-pyridin-2-yl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




MS: mass calcd. for $C_{26}H_{27}F_3N_7O$, 567.2181; m/z found, 568.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.43-8.39 (m, 1H), 7.93-7.87 (m, 2H), 7.83 (d, $J=8.5$ Hz, 1H), 7.16 (s, 1H), 6.98-6.94

226

(m, 1H), 4.00 (s, 3H), 3.81-3.75 (m, 4H), 3.65-3.55 (m, 4H), 3.14-3.09 (m, 2H), 2.96-2.92 (m, 2H), 1.73-1.60 (m, 6H).

Example 387


4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester



MS: mass calcd. for $C_{27}H_{29}F_3N_6O_2$, 526.2304; m/z found, 527.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.39 (m, 1H), 8.04-7.99 (m, 2H), 7.88 (dd, $J=1.8, 7.8$ Hz, 1H), 7.67-7.60 (m, 2H), 6.97-6.92 (m, 1H), 6.56 (s, 1H), 3.92 (s, 3H), 3.79-3.73 (m, 4H), 3.63-3.55 (m, 4H), 3.12-3.07 (m, 2H), 2.91-2.86 (m, 2H), 1.71-1.58 (m, 6H).

Example 388

4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid




MS: mass calcd. for $C_{26}H_{27}F_3N_6O_2$, 512.2148; m/z found, 513.2 $[M+H]^+$. 1H NMR (CD_3OD): 8.47-8.42 (m, 1H), 8.03-8.00 (m, 1H), 7.93-7.88 (m, 2H), 7.62-7.58 (m, 2H), 7.14-

227

7.09 (m, 1H), 3.76-3.69 (m, 4H), 3.49-3.44 (m, 4H), 3.07-3.03 (m, 2H), 3.02-2.97 (m, 2H), 1.72-1.65 (m, 2H), 1.63-1.55 (m, 4H).

Example 389


2-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol



MS: mass calcd. for $C_{27}H_{31}F_3N_6O_2$, 528.246; m/z found, 529.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.42-8.38 (m, 1H), 7.88 (dd, $J=1.8, 7.8$ Hz, 1H), 7.53-7.49 (m, 2H), 7.48-7.44 (m, 2H), 6.97-6.93 (m, 1H), 6.40 (s, 1H), 3.82-3.72 (m, 8H), 3.67-3.56 (m, 4H), 3.12-3.07 (m, 2H), 2.90-2.86 (m, 2H), 1.62 (s, 6H).

Example 390

(6-Chloro-5-trifluoromethyl-pyridin-2-yl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine




MS: mass calcd. for $C_{25}H_{24}ClF_3N_7$, 571.1686; m/z found, 572.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.44-8.39 (m, 1H), 8.34 (d, $J=8.7$ Hz, 1H), 7.95 (d, $J=8.7$ Hz, 1H), 7.89 (dd, $J=1.8, 7.8$ Hz,

228

1H), 7.43 (s, 1H), 7.00-6.95 (m, 1H), 3.81-3.73 (m, 4H), 3.57-3.52 (m, 4H), 3.13-3.09 (m, 2H), 2.94-2.90 (m, 2H), 1.74-1.59 (m, 6H).

Example 391


2-{2-Fluoro-4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol



MS: mass calcd. for $C_{28}H_{32}F_4N_6O$, 544.2574; m/z found, 545.3 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.41-8.35 (m, 1H), 7.86 (dd, $J=1.8, 7.8$ Hz, 1H), 7.61 (dd, $J=2.2, 14.9$ Hz, 1H), 7.45-7.40 (m, 1H), 7.08 (dd, $J=2.2, 8.5$ Hz, 1H), 6.95-6.90 (m, 1H), 6.38 (s, 1H), 3.78-3.71 (m, 4H), 3.62-3.53 (m, 4H), 3.10-3.03 (m, 2H), 2.87-2.80 (m, 2H), 2.09 (d, $J=3.5$ Hz, 1H), 1.69-1.57 (m, 12H).

Example 392

2-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionic acid




MS: mass calcd. for $C_{28}H_{31}F_3N_6O_3$, 556.241; m/z found, 557.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.46-8.42 (m, 1H), 8.02 (dd, $J=1.8, 7.8$ Hz, 1H), 7.55-7.51 (m, 2H), 7.35-7.32 (m,

229

2H), 7.13-7.10 (m, 1H), 3.76-3.65 (m, 8H), 3.49-3.44 (m, 4H), 3.08-3.03 (m, 2H), 3.01-2.97 (m, 2H), 1.55 (s, 6H).

Example 393


5-Chloro-6-[2-piperidin-1-yl-4-(4-trifluoromethyl-phenylamino)-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl]-nicotinic acid methyl ester



MS: mass calcd. for $C_{27}H_{28}ClF_3N_6O_2$, 560.1914; m/z found, 561.2 $[M+H]^+$. 1H NMR ($CDCl_3$): 8.77-8.62 (m, 1H), 8.38-7.86 (m, 1H), 7.73-7.63 (m, 2H), 7.61-7.55 (m, 1H), 7.35-7.28 (m, 1H), 6.62-6.37 (m, 1H), 4.03-3.79 (m, 7H), 3.80-3.70 (m, 4H), 3.21-3.04 (m, 2H), 2.98-2.88 (m, 2H), 1.74-1.61 (m, 6H).

Example 394

{5-Chloro-6-[2-piperidin-1-yl-4-(4-trifluoromethyl-phenylamino)-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl]-pyridin-3-yl}-methanol



MS: mass calcd. for $C_{26}H_{28}ClF_3N_6O$, 532.1965; m/z found, 533.2 $[M+H]^+$. 1H NMR ($(CD_3)_2CO$): 8.20-8.09 (m,

230

2H), 7.96-7.88 (m, 2H), 7.71 (d, $J=2.0$ Hz, 1H), 7.61 (d, $J=8.7$ Hz, 2H), 4.66-4.48 (m, 2H), 3.84-3.69 (m, 4H), 3.60-3.47 (m, 4H), 3.13-2.97 (m, 4H), 1.75-1.49 (m, 6H).

The compounds in Examples 395-518 are prepared using methods analogous to those described in the preceding examples.

Ex- ample	Chemical Name
395	N^2,N^2 -Dimethyl- N^6 -[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-3-trifluoromethyl-pyridine-2,6-diamine
396	2-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}- N -methyl-isobutyramide
397	[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-[4-(piperazine-1-sulfonyl)-phenyl]-amine
398	(4-Methanesulfonyl-phenyl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
399	[4-(2-Amino-1,1-dimethyl-ethyl)-phenyl]-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
400	[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-[4-(trifluoromethanesulfonyl-phenyl)-amine
401	1,1,1-Trifluoro-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol
402	2-{2-Fluoro-4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol
403	2-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-1-ol
404	[4-(2-Amino-1,1-dimethyl-ethyl)-phenyl]-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
405	N^6 -[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]- N^2 -methyl-3-trifluoromethyl-pyridine-2,6-diamine
406	2-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-isobutyramide
407	N^6 -[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-3-trifluoromethyl-pyridine-2,6-diamine
408	[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-[6-trifluoromethyl-pyridin-3-yl]-amine
409	2-{4-[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-isobutyramide
410	(3-Fluoro-4-trifluoromethyl-phenyl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
411	1-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid methyl ester
412	[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine
413	1-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid dimethylamide
414	[4-(2-Dimethylamino-1,1-dimethyl-ethyl)-phenyl]-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
415	2-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-isobutyramide
416	N^6 -[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-3-trifluoromethyl-pyridine-2,6-diamine
417	(6-Chloro-5-trifluoromethyl-pyridin-2-yl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine

231

-continued

Ex- ample	Chemical Name
418	[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethoxy-phenyl)-amine
419	[4-(1,1-Dimethyl-2-methylamino-ethyl)-phenyl]-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
420	(4-Bromo-phenyl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
421	(4-Chloro-phenyl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
422	(1-Methyl-1,2,3,4-tetrahydro-quinolin-7-yl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
423	[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(1,4,4-trimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-amine
424	2-Methyl-2-[4-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl]-propionitrile
425	4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester
426	4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid
427	N ² -Methyl-N ⁶ -[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-3-trifluoromethyl-pyridine-2,6-diamine
428	2-Fluoro-4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester
429	2-Fluoro-4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid
430	1-{4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanol
431	[4-(2-Dimethylamino-1,1-dimethyl-ethyl)-phenyl]-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
432	N,N-Dimethyl-2-{4-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-isobutyramide
433	1-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid methyl ester
434	(6-Chloro-5-trifluoromethyl-pyridin-2-yl)-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
435	1-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid
436	(1-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropyl)-methanol
437	[4-(1-Dimethylaminomethyl-cyclopropyl)-phenyl]-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
438	[4-(1-Aminomethyl-cyclopropyl)-phenyl]-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
439	1-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid amide
440	1-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid methylamide
441	N-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-isobutyramide
442	N,N-Dimethyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-isobutyramide
443	[4-(2-Dimethylamino-1,1-dimethyl-ethyl)-phenyl]-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine

232

-continued

Ex- ample	Chemical Name
5 444	[4-(1,1-Dimethyl-2-methylamino-ethyl)-phenyl]-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
445	N ⁶ -[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-3-trifluoromethyl-pyridine-2,6-diamine
10 446	N ² -Methyl-N ⁶ -[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-3-trifluoromethyl-pyridine-2,6-diamine
447	N ² ,N ² -Dimethyl-N ⁶ -[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-3-trifluoromethyl-pyridine-2,6-diamine
15 448	[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-[4-(piperazine-1-sulfonyl)-phenyl]-amine
449	[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine
20 450	[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-[4-(piperazine-1-sulfonyl)-phenyl]-amine
451	[4-(Morpholine-4-sulfonyl)-phenyl]-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
452	[4-(Piperazine-1-sulfonyl)-phenyl]-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
453	N ⁶ -[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-N ² ,N ² -dimethyl-3-trifluoromethyl-pyridine-2,6-diamine
454	N ⁶ -[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-3-trifluoromethyl-pyridine-2,6-diamine
455	[4-(1-Methylaminomethyl-cyclopropyl)-phenyl]-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
456	N ² -Methyl-N ⁶ -[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-3-trifluoromethyl-pyridine-2,6-diamine
35 457	N ² ,N ² -Dimethyl-N ⁶ -[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-3-trifluoromethyl-pyridine-2,6-diamine
458	1,1,1-Trifluoro-2-{4-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol
40 459	[4-(2-Amino-1,1-dimethyl-ethyl)-phenyl]-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
460	[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-[5-(3-trifluoromethyl-pyrazin-2-yl)-amine
45 461	(6-Methoxy-5-trifluoromethyl-pyridin-2-yl)-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
462	2-{2-Fluoro-4-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol
50 463	2-Fluoro-4-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid
464	2-Fluoro-4-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester
55 465	(3-Fluoro-4-trifluoromethyl-phenyl)-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
466	2-{4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-isobutyramide
60 467	N-Methyl-2-{4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-isobutyramide
468	N,N-Dimethyl-2-{4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-isobutyramide
65	

-continued

Ex- ample	Chemical Name
469	2-{2-Fluoro-4-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol
470	2-Fluoro-4-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid
471	2-Fluoro-4-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester
472	2-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-N,N-dimethyl-isobutyramide
473	N-Methyl-2-{4-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-isobutyramide
474	(6-Methoxy-5-trifluoromethyl-pyridin-2-yl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
475	(4-Bromo-phenyl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
476	[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethoxy-phenyl)-amine
477	[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethoxy-phenyl)-amine
478	[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(5-trifluoromethyl-pyrazin-2-yl)-amine
479	1-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid methylamide
480	1-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanol
481	1-{4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid amide
482	(4-Bromo-phenyl)-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
483	(4-Methanesulfonyl-phenyl)-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
484	(1-{4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropyl)-methanol
485	[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine
486	[4-(2-Dimethylamino-1,1-dimethyl-ethyl)-phenyl]-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
487	[4-(1,1-Dimethyl-2-methylamino-ethyl)-phenyl]-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
488	[4-(2-Amino-1,1-dimethyl-ethyl)-phenyl]-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
489	2-Methyl-2-{4-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-1-ol
490	1-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid
491	[4-(1,1-Dimethyl-2-methylamino-ethyl)-phenyl]-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
492	1-{4-[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid methylamide
493	[4-(1-Methylaminomethyl-cyclopropyl)-phenyl]-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
494	[4-(1-Aminomethyl-cyclopropyl)-phenyl]-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine

-continued

Ex- ample	Chemical Name
5 495	[4-(1-Aminomethyl-cyclopropyl)-phenyl]-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
496	[4-(1-Dimethylaminomethyl-cyclopropyl)-phenyl]-[2-(2-methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
10 497	1-{4-[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid dimethylamide
498	1-{4-[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid amide
15 499	1-{4-[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid methyl ester
500	1-{4-[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid
20 501	[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-pyrrolidine-1-sulfonyl)-phenyl]-amine
502	(1-{4-[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropyl)-methanol
25 503	1-{4-[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanol
504	[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(1,4,4-trimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-amine
30 505	[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(1-methyl-1,2,3,4-tetrahydro-quinolin-7-yl)-amine
506	[2-(2-Methyl-pyrrolidin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine
35 507	[4-(1-Aminomethyl-cyclopropyl)-phenyl]-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
508	[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-(1-methylaminomethyl-cyclopropyl)-phenyl)-amine
40 509	[4-(1-Dimethylaminomethyl-cyclopropyl)-phenyl]-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
510	1-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid dimethylamide
45 511	1-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid amide
512	(1-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropyl)-methanol
50 513	1-{4-[2-Isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanol
514	1-{4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid methyl ester
55 515	[4-(Morpholine-4-sulfonyl)-phenyl]-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine
516	1-{4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid
517	1-{4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid methylamide
518	1-{4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-cyclopropanecarboxylic acid dimethylamide
65	

Biological Testing:

Functional Assay: Block of Capsaicin-Induced Ca²⁺ Influx

A. Human Assay

HEK293 cells were transfected with human TRPV1 cloned in pcDNA3.1zeo(+) using the Effectene non-liposomal lipid based transfection kit (Qiagen) (hTRPV1/HEK293). hTRPV1/HEK293 cells were routinely grown as monolayers under selection in zeocin (200 µg/mL; Invitrogen) in Dulbecco's Modified Eagle Medium (DMEM, Gibco BRL) supplemented with 10% fetal bovine serum, and penicillin/streptomycin (50 units/mL) in 5% CO₂ at 37° C. Cells were passaged frequently, every 3-5 days, to avoid overgrowth, depletion of essential medium components, or acidic medium exposure. Cells were passaged using a brief wash in 0.05% trypsin with 1 mM EDTA, followed by dissociation in divalent-free phosphate-buffered saline (Hyclone #SH30028.02). Dissociated cells were seeded onto poly-D-lysine coated black-walled 96-well plates (Biocoat; Becton Dickinson #354640) at about 40,000 cells per well and grown for approximately 1 day in culture medium to near confluency. The assay buffer was composed of 130 mM NaCl, 2 mM KCl, 2 mM MgCl₂, 10 mM HEPES, 5 mM glucose, and either 2 mM or 20 µM CaCl₂. On the day of the experiment, the culture medium was replaced with 2 mM calcium assay buffer using an automated plate washer (ELx405; Biotek, VT). The cells were incubated in 100 µL/well Fluo-3/AM (2 µM; TEFLabs #0116) with Pluronic F127 (100 µg/mL; Sigma #P2443) for 1 h at rt in the dark. After loading the cells, the dye solution was replaced with 50 µL/well of 20 µM calcium assay buffer using the ELx405 plate washer. Test compounds (50 µL/well) were added to the plate and incubated for 30 min. Intracellular Ca²⁺ levels were subsequently assayed using a Fluorometric Imaging Plate Reader (FLIPR™ instrument, Molecular Devices, CA) to simultaneously monitor Fluo-3 fluorescence in all wells ($\lambda_{excitation}$ =488 nm, $\lambda_{emission}$ =540 nm) during challenge with agonist (capsaicin). The IC₅₀ values were determined. Cells were challenged with 150 nM capsaicin and the fluorescence counts were captured following agonist addition at a sampling rate of 0.33 Hz. The contents of the wells were mixed 3 times (40 µL mix volume) immediately after the additions were made. Concentration dependence of block was determined by exposing each well of cells in duplicate rows of a 96 well plate to a serial dilution of test compound. The concentration series usually started at 10 µM with a three-fold serial decrement in concentration. The magnitude of the capsaicin response was determined by measuring the change in fluo3 fluorescence before and 100 seconds after the addition of the agonist. Data were analyzed using a non-linear regression program (Origin; OriginLab, MA). Results for the compounds tested in this assay are presented in Table 1. IC₅₀ values shown are the average (mean) of the results obtained.

B. Rat Assay

The assay was performed as described above, using HEK293 cells transfected with rat TRPV1 (rTRPV1/HEK293). These cells had a geneticin selection marker and were grown in Dulbecco's Modified Eagle Medium (DMEM, Gibco BRL) supplemented with 10% fetal bovine serum, penicillin/streptomycin (50 units/mL), and 500 µg/mL geneticin in 5% CO₂ at 37° C. Results for the compounds tested in this assay are also presented in Table 1. IC₅₀ values shown are the average (mean) of the results obtained. Where activity is shown as greater than (>) a particular value, the value is the solubility limit of the compound in the assay medium.

TABLE 1

	Human	Rat		Human	Rat
Ex.	IC ₅₀ (µM)	IC ₅₀ (µM)	Ex.	IC ₅₀ (µM)	IC ₅₀ (µM)
1	0.029	0.090	52	0.028	0.053
1A	0.016	0.049	53	0.50	>6.7
2	0.072	0.79	54	0.15	0.23
2A	0.075	0.42	55B	0.14	0.15
3	0.019	0.095	56B	0.024	0.064
4	0.20	0.50	57B	3.3	5.5
5	0.060	0.15	58B	0.34	1.5
5A	0.042	0.19	59B	0.073	0.38
6	0.0059	0.49	60B	0.031	0.14
7	0.018	0.14	61B	0.11	0.23
8	0.018	0.025	62	0.037	0.053
9	0.078	0.092	63B	0.44	2.5
9A	0.051	0.052	64	>6.7	>6.7
10	0.63	0.93	65B	0.030	0.65
11	0.20	0.20	66B	0.42	0.93
12	0.53	0.95	67B	0.090	0.034
13	0.46	1.3	68B	3.6	3.2
14	0.010	0.040	69	0.37	0.50
15	0.082	0.046	70B	>20	4.4
16	0.041	0.10	71B	>20	>20
17	0.081	NT	72B	0.064	0.18
18	>6.7	>6.7	73B	>20	6.7
19	0.36	0.51	74B	>6.7	3.9
20	0.050	0.032	75B	NT	0.040
20A	0.17	0.25	76B	0.090	0.091
21	0.82	1.1	77B	0.66	0.58
22	0.075	0.13	78B	0.69	1.8
23	0.14	0.31	79B	NT	1.3
24	0.18	0.29	80B	0.065	0.13
25	>6.7	0.77	81B	NT	0.97
26	>6.7	>6.7	82B	NT	2.8
27	5.2	10	83	0.62	0.99
28	>6.7	>6.7	84	NT	>20
29	0.70	0.34	85	>2.2	>6.7
30	0.51	1.3	86	0.37	0.85
31	0.39	0.53	87	0.84	0.35
32	1.74	0.013	88	1.8	0.96
33	1.1	0.11	89	>6.7	>6.7
34	1.5	0.36	90B	NT	>6.7
35	1.5	2.4	91B	NT	0.24
36	0.17	0.37	92B	0.16	0.27
37	0.41	0.15	93B	0.0089	0.037
38	1.1	1.4	94B	0.086	0.19
39	0.0060	0.018	95B	0.062	0.082
39A	0.0095	0.023	96	0.28	0.34
40	0.0037	0.056	97	0.55	0.49
40A	0.0053	0.019	98	>6.7	>6.7
41	0.038	0.049	99B	3.3	7.2
42	0.018	0.049	100	0.022	0.031
43B	0.061	0.39	101B	>2.2	0.99
44	0.12	0.25	102	0.046	0.17
45	0.042	0.090	103	0.37	0.34
46	0.20	0.38	104	0.47	0.32
47	0.0068	0.023	105	14	>20
48	0.018	0.074	106	0.0054	0.062
49	0.027	0.24	107	>20	>20
50	50B	0.18	108	1.9	0.94
51	0.93	1.2	109	0.45	0.58
115	>6.67	3.79	255	4.29	0.70
116	>20	7.03	256	>6.67	>6.67
117	>20	13.49	257	0.04	0.02
118	0.65	0.50	258	0.02	NT
119	1.09	1.22	259	0.03	0.09
120	>20	12.05	260	0.02	0.05
121	>20	>20	261	0.15	0.34
122	1.96	0.19	262	0.56	1.64
123	1.02	0.99	263	1.13	1.46
124	0.63	0.57	264	0.43	1.30
125	0.52	0.61	265	0.20	0.39
126	2.06	1.19	266	0.12	0.45
127	>20	19.20	267	2.48	1.87
128	0.13	0.15	268	0.05	0.15
129	0.58	0.23	269	0.13	0.18
130	>20	>20	270	0.38	0.83
131	>6.67	NT	271	0.18	0.84
132	>6.67	NT	272	0.04	0.20
133	0.47	NT	273	0.57	0.68

237

TABLE 1-continued

Ex.	Human IC ₅₀ (μM)	Rat IC ₅₀ (μM)	Ex.	Human IC ₅₀ (μM)	Rat IC ₅₀ (μM)
134	>6.67	NT	274	0.04	0.26
135	0.07	NT	275	0.17	0.19
136	0.07	0.11	276	0.01	0.04
137	0.09	0.06	277	0.02	0.05
138	0.06	0.03	278	0.63	0.67
139	0.65	0.62	279	0.38	>6.67
140	0.10	0.19	280	>6.67	>6.67
141	0.42	0.13	281	1.78	2.62
142	1.66	2.09	282	0.31	0.13
143	0.08	0.13	283	2.99	8.52
144	0.06	0.24	284	1.67	0.55
145	0.08	0.24	285	>6.67	>6.67
146	0.20	0.72	286	>6.67	>6.67
147	0.10	0.11	287	>6.67	>6.67
148	0.48	2.17	288	2.99	2.02
149	0.02	0.15	289	2.84	0.29
150	0.02	0.20	290	0.41	0.10
151	2.31	0.82	291	0.27	0.17
152	0.62	0.55	292	0.12	0.05
153	0.11	0.14	293	9.34	3.49
154	0.45	1.14	294	3.39	2.94
155	0.62	3.28	295	4.66	10.43
156	0.06	0.59	296	0.42	0.12
157	0.004	0.07	297	0.45	1.08
158	0.02	0.06	298	0.45	0.37
159	0.004	0.03	299	>6.67	3.00
160	0.02	0.10	300	4.07	2.00
161	0.29	0.13	301	3.43	8.97
162	0.09	0.03	302	0.84	9.46
163	0.08	0.12	303	2.03	>6.67
164	0.03	0.02	304	>6.67	NT
165	3.51	2.25	305	1.78	1.12
166	0.04	0.38	306	0.61	1.21
167	0.06	0.37	307	0.02	0.03
168	0.02	0.03	308	0.34	0.36
169	0.28	1.01	309	>6.67	1.42
170	0.15	0.06	310	0.28	0.07
171	0.10	0.08	311	5.00	>20
172	0.06	0.13	312	0.22	0.45
173	0.15	0.21	313	0.83	0.56
174	0.39	2.01	314	0.19	0.16
175	0.06	0.08	315	1.54	5.52
176	0.54	0.81	316	0.09	1.18
177	0.02	0.09	317	0.13	0.61
178	0.09	0.11	318	0.03	>6.67
179	0.23	1.34	319	0.03	0.24
180	0.03	>6.67	320	0.005	0.02
181	0.70	0.82	321	0.33	0.18
182	0.87	0.79	322	0.16	0.01
183	2.06	2.37	323	0.56	0.67
184	1.42	1.95	324	0.81	0.10
185	>20	>20	325	0.05	0.30
186	0.05	0.14	326	0.21	0.60
187	1.60	2.85	327	0.26	0.89
188	0.24	1.59	328	0.08	0.25
189	1.94	1.93	329	1.12	0.12
190	0.60	1.16	330	0.01	0.05
191	0.11	0.26	331	0.07	0.50
192	0.02	0.07	332	0.01	2.04
193	1.39	2.11	333	0.01	0.04
194	0.05	0.07	334	0.04	0.04
195	4.42	4.32	335	0.03	0.15
196	0.13	0.10	336	0.05	1.64
197	0.13	0.15	337	0.02	0.17
198	>20	9.16	338	0.03	0.40
199	0.39	1.36	339	0.03	0.19
200	0.03	0.11	340	0.05	0.26
201	0.56	0.32	341	0.06	0.15
202	2.93	12.42	342	0.18	0.06
203	>20	>6.67	343	0.04	0.06
204	1.22	0.56	344	>20	>20
205	0.17	2.28	345	0.08	0.19
206	0.13	0.29	346	1.38	>6.67
207	0.51	0.77	347	1.86	1.32
208	>20	>20	348	3.02	3.22
209	>6.67	3.45	349	0.50	2.35
210	0.90	NT	350	0.06	0.03

238

TABLE 1-continued


Ex.	Human IC ₅₀ (μM)	Rat IC ₅₀ (μM)	Ex.	Human IC ₅₀ (μM)	Rat IC ₅₀ (μM)
211	>20	11.40	351	>6.67	0.75
212	0.09	0.22	352	1.01	>6.67
213	0.15	0.11	353	0.01	0.24
214	0.01	0.01	354	0.01	0.25
215	0.02	0.01	355	0.03	0.06
216	0.06	0.05	356	0.11	0.29
217	0.20	0.39	357	0.02	0.14
218	0.09	0.12	358	0.07	0.07
219	2.92	3.38	359	0.63	0.32
220	0.65	1.52	360	0.65	0.25
221	0.28	0.72	361	0.10	1.53
222	0.01	0.02	362	0.003	0.19
223	0.01	0.03	363	0.01	0.06
224	0.01	0.02	364	>6.67	1.18
225	3.43	4.67	365	1.09	>6.67
226	1.71	1.73	366	0.23	0.13
227	>20	>20	367	1.30	>6.67
228	0.09	0.04	368	0.13	0.02
229	0.04	0.06	369	0.19	0.01
230	2.13	0.94	370	NT	2.61
231	0.07	0.10	371	2.19	>6.67
232	>6.67	>6.67	372	0.03	0.33
233	0.04	0.17	373	0.07	0.18
234	0.05	0.08	374	0.19	0.004
235	0.01	0.01	375	0.07	>6.67
236	0.01	0.01	376	0.07	0.11
237	0.01	0.01	377	2.69	1.41
238	0.02	0.04	378	0.04	0.04
239	0.03	0.03	379	0.04	0.07
240	0.01	0.02	380	0.05	0.23
241	0.01	0.17	381	0.01	0.04
242	0.01	0.09	382	0.02	0.04
243	0.31	0.45	383	0.14	0.16
244	0.002	0.01	384	0.02	0.04
245	0.01	0.02	385	0.13	0.82
246	0.003	0.05	386	>6.67	>6.67
247	>20	>20	387	0.10	0.55
248	0.25	0.53	388	NT	NT
249	0.12	0.83	389	0.05	0.32
250	0.05	0.09	390	0.01	0.09
251	>6.67	1.98	391	NT	NT
252	0.47	0.45	392	0.12	1.54
253	0.01	0.01	393	0.05	0.12
254	0.18	0.10	394	0.17	0.29

NT = not tested

While the invention has been illustrated by reference to exemplary and preferred embodiments, it will be understood that the invention is intended not to be limited to the foregoing detailed description, but to be defined by the appended claims as properly construed under principles of patent law.

What is claimed is:

1. A compound of Formula (I):



(I)

wherein:

R¹ is NR^aR^b;

R^a and R^b taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl

239

or bridged bicyclic heterocycloalkyl group unsubstituted or substituted with one, two, or three moieties independently selected from the group consisting of —C₁₋₆alkyl, —C₁₋₄alkyl-OH, —C₁₋₂alkyl-OC₁₋₂alkyl, —OH, —OC₁₋₄alkyl, —NR^pR^q, halo, —CO₂H, and benzyl substituents;

where R^p and R^q are each independently —H or —C₁₋₆alkyl; or R^p and R^q taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl;

R² is —H or —C₁₋₆alkyl;

R³ is a phenyl group unsubstituted or substituted with one, two, or three R^s substituents;

where each R^s substituent is —C₁₋₆alkyl; —C₁₋₄alkyl-OH unsubstituted or substituted with —CF₃; saturated monocyclic cycloalkyl; —OH; —OC₁₋₆alkyl; phenoxy; —CN; —NO₂; —N(R^h)Rⁱ; —C₁₋₄alkyl-N(R^h)Rⁱ; —C(O)N(R^h)Rⁱ; —N(R^h)C(O)Rⁱ; —N(R^h)SO₂C₁₋₆alkyl; —C(O)C₁₋₆alkyl; —S(O)₀₋₂—C₁₋₆alkyl; —SO₂CF₃; —SO₂N(R^h)Rⁱ; —SCF₃; halo; —CF₃; —OCF₃; —CO₂H; —CO₂C₁₋₆alkyl; —C(R^j)(R^x)—CN; —C(R^j)(R^x)—OH; —C(R^j)(R^x)—CO₂C₁₋₆alkyl; —C(R^j)(R^x)—CO₂H; —C(R^j)(R^x)—C(O)N(R^h)Rⁱ; phenyl; or monocyclic heteroaryl;

where R^h and Rⁱ are each independently —H or —C₁₋₆alkyl; or R^h and Rⁱ (when both are present) taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl group;

R^j is independently —H, —C₁₋₆alkyl, or —CF₃;

R^x is —H or —C₁₋₆alkyl; or R^j and R^x taken together with the carbon to which they are attached form a monocyclic cycloalkyl ring;

and

Ar is a pyridyl, group unsubstituted or substituted with one, two, or three R^k substituents;

where each R^k substituent is independently —C₁₋₆alkyl, —C₁₋₂alkyl —OH, —OH, —OC₁₋₆alkyl, phenoxy, —CN, —NO₂, —N(R¹)R^m, —C(O)N(R¹)R^m, —N(R¹)C(O)R^m, —N(R¹)SO₂C₁₋₆alkyl, —N(R¹)SO₂CF₃, —C(O)C₁₋₆alkyl, —S(O)₀₋₂—C₁₋₆alkyl, —SO₂CF₃, —SO₂N(R¹)R^m, —SCF₃, halo, —CF₃, —OCF₃, —CO₂H, or —CO₂C₁₋₆alkyl;

where R¹ and R^m are each independently —H, —C₁₋₆alkyl, saturated monocyclic cycloalkyl, or —CF₃;

or a pharmaceutically acceptable salt of such compound.

2. A compound or pharmaceutically acceptable salt as defined in claim 1, wherein R^a and R^b taken together with their nitrogen of attachment form an aziridinyl, pyrrolidinyl, piperidinyl, 2-oxo-piperidin-1-yl, piperazinyl, oxo-piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-1λ⁶-thiomorpholin-4-yl, 1,1-dioxo-λ⁶-[1,2]thiazinan-2-yl, azepanyl, 1,4-oxazepanyl, or 7-azabicyclo[2.2.1]hept-7-yl group unsubstituted or substituted with a —C₁₋₆alkyl, hydroxymethyl, hydroxyethyl, methoxymethyl, methoxyethyl, fluoro, —OH, or —CO₂H substituent.

3. A compound, pharmaceutically or pharmaceutically acceptable salt as defined in claim 1, wherein R² is —H.

4. A compound or pharmaceutically acceptable salt as defined in claim 1, wherein Ar is 2-pyridyl substituted with —CF₃, —NO₂, or —N(R¹)R^m.

5. A compound or pharmaceutically acceptable salt as defined in claim 1, wherein Ar is 2-pyridyl substituted with —CF₃.

6. A compound selected from the group consisting of:

[2-Isopropyl-7-(3-methyl-quinoxalin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

240

[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine

[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

(4-tert-Butyl-phenyl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine;

N⁴-(3-Chloro-4-trifluoromethyl-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine;

(4-Bromo-phenyl)-[2-isopropyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine;

(4-tert-Butyl-phenyl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine;

N⁴-(4-tert-Butyl-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine;

N²,N²-Dimethyl-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine;

N⁴-(4-Chloro-phenyl)-N²,N²-dimethyl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine;

N⁴-(4-Trifluoromethyl-phenyl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine;

[2-Azetidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidine-4-carboxylic acid;

1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidin-4-ol;

[2-(4-Isopropyl-piperazin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

4-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperazin-2-one;

(R)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidin-3-ol;

[2-(4-Methyl-piperazin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

(S)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]-piperidin-3-ol;

[2-Piperazin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

[2-Thiomorpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

[2-(4-Benzyl-piperazin-1-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

[2-Pyrrolidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

2-{4-[2-Azetidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol; and
 2-{4-[2-Azepan-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol;
 and pharmaceutically acceptable salts thereof.
 7. A compound selected from the group consisting of:
 1-[4-({2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]ethanone;
 N-[3-Fluoro-4-(trifluoromethyl)phenyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 N,N-Dimethyl-4-({2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)benzenesulfonamide;
 N-[4-(1,1-Dimethylethyl)-3-nitrophenyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 N-[4-(Methylsulfonyl)phenyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 (2-Fluoro-4-trifluoromethyl-phenyl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine;
 Methyl 2-methyl-2-[4-({2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanoate;
 2-[4-({2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propan-2-ol;
 1,1,1-Trifluoro-2-[4-({2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propan-2-ol;
 2-Methyl-2-[4-({2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanoic acid;
 4-(1,1-Dimethylethyl)-N1-[2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]benzene-1,3-diamine;
 2-(1,1-Dioxido-1,2-thiazinan-2-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-[3-(Methyloxy)piperidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-[(2S)-2-[(Methyloxy)methyl]pyrrolidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-(4-methylpiperazin-1-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-Azepan-1-yl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-Azepan-1-yl-N-[3-chloro-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-Azetidin-1-yl-N-[3-chloro-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-Azetidin-1-yl-N-[(3,4-dichlorophenyl)methyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;


N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(2,6-Dimethylmorpholin-4-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(1,4-Oxazepan-4-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(3,3-Difluoropiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(4-Methylpiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(3-Methylpiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(3,3-Difluoroazetidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(4,4-Difluoropiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(3,3-Difluoropyrrolidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(2-Methylpyrrolidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-(1,4-oxazepan-4-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(2-Methylpiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(1,1-Dioxidothiomorpholin-4-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 N-[4-(1,1-Dimethylethyl)phenyl]-2-pyrrolidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-Azetidin-1-yl-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 N-[4-(1,1-Dimethylethyl)phenyl]-2-(4-methylpiperazin-1-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-Azepan-1-yl-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-pyrrolidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 [1-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]piperidin-2-yl]methanol;
 [(2S)-1-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl]pyrrolidin-2-yl]methanol;

243

[(2R)-1-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)pyrrolidin-2-yl]methanol;
 2-(7-Azabicyclo[2.2.1]hept-7-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-[2-(1-Methylethyl)pyrrolidin-1-yl]-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 4-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)morpholin-2-yl]methanol;
 4-(4-{[2-Methyl-4-(trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)morpholin-2-yl]methanol;
 2-[(2S or 2R)-2-Methylpiperidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridine-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-[(2S or 2R)-2-Methylpiperidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridine-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 7-[3-(Ethylsulfonyl)pyridin-2-yl]-2-piperidin-1-yl-N-[4-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 2-(2-Piperidin-1-yl-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-sulfonamide;
 N-Cyclopropyl-2-(2-piperidin-1-yl-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-sulfonamide;
 N-(1-Methylethyl)-2-(2-piperidin-1-yl-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-sulfonamide;
 2-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionic acid methyl ester;
 2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[4-{(trifluoromethyl)sulfonyl}phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;
 N,N-Dimethyl-4-(2-morpholin-4-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)amino)benzenesulfonamide;
 1-[4-(2-Morpholin-4-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)amino]phenyl]ethanone;
 (3-Chloro-4-trifluoromethyl-phenyl)-[2-morpholin-4-yl-7-(3-trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl-amine;
 2-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionitrile;
 2-Methyl-2-{4-[2-piperidin-1-yl-7-(3-trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-1-ol;
 2-Methyl-2-{4-[2-piperidin-1-yl-7-(3-trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionitrile;
 2-Fluoro-4-[2-piperidin-1-yl-7-(3-trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester;
 (6-Methoxy-5-trifluoromethyl-pyridin-2-yl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine;

244

4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester;
 4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid;
 2-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol;
 (6-Chloro-5-trifluoromethyl-pyridin-2-yl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine;
 2-{2-Fluoro-4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol;
 2-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionic acid;
 5-Chloro-6-[2-piperidin-1-yl-4-(4-trifluoromethyl-phenylamino)-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl]-nicotinic acid methyl ester;
 {5-Chloro-6-[2-piperidin-1-yl-4-(4-trifluoromethyl-phenylamino)-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl]-pyridin-3-yl}-methanol;
 and pharmaceutically acceptable salts thereof.
 8. A pharmaceutical composition comprising:
 (a) an effective amount of an agent selected from the group consisting of compounds of Formula (I):



(I)

wherein:

 R^1 is NR^aR^b

R^a and R^b taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl or bridged bicyclic heterocycloalkyl group unsubstituted or substituted with one, two, or three moieties independently selected from the group consisting of $-C_{1-6}alkyl$, $-C_{1-4}alkyl-OH$, $-C_{1-2}alkyl-OC_{1-2}alkyl$, $-OH$, $-OC_{1-4}alkyl$, $-NR^pR^q$, halo, $-CO_2H$, and benzyl substituents;

where R^p and R^q are each independently $-H$ or $-C_{1-6}alkyl$; or R^p and R^q taken together with their nitrogen of attachment form a saturated monocyclic heterocycloalkyl;

 R^2 is $-H$ or $-C_{1-6}alkyl$;

R^3 is a phenyl group unsubstituted or substituted with one, two, or three R^s substituents;

where each R^s substituent is $-C_{1-6}alkyl$; $-Cl_4alkyl$; $-OH$ unsubstituted or substituted with $-CF_3$; saturated monocyclic cycloalkyl; $-OH$; $-OC_{1-6}alkyl$; phenoxy; $-CN$; $-NO_2$; $-N(R^h)R^i$; $-C_{1-4}alkyl-N(R^h)R^i$; $-C(O)N(R^h)R^i$; $-N(R^h)C(O)R^i$; $-N(R^h)SO_2C_{1-6}alkyl$; $-C(O)C_{1-6}alkyl$; $-S(O)_{0-2}C_{1-6}alkyl$; $-SO_2CF_3$; $-SO_2N(R^h)R^i$; $-SCF_3$; halo;

245

—CF₃; —OCF₃; —CO₂H; —CO₂C₁₋₆alkyl; —C(R')
(R^x)—CN; —C(R')(R^x)—OH; —C(R')(R^x)—
CO₂C₁₋₆alkyl; —C(R')(R^x)—CO₂H; —C(R')(R^x)—
C(O)N(R^h)Rⁱ; phenyl; or monocyclic heteroaryl;
where R^h and Rⁱ are each independently —H or
—C₁₋₆alkyl; or R^h and Rⁱ (when both are present)
taken together with their nitrogen of attachment
form a saturated monocyclic heterocycloalkyl
group;

R' is independently —H, —C₁₋₆alkyl, or —CF₃;

R^x is —H or —C₁₋₆alkyl; or R' and R^x taken together
with the carbon to which they are attached form a
monocyclic cycloalkyl ring;

and

Ar is a pyridyl group unsubstituted or substituted with one,
two, or three R^k substituents;

where each R^k substituent is independently —C₁₋₆alkyl,
—C₁₋₂alkyl-OH, —OH, —OC₁₋₆alkyl, phenoxy,
—CN, —NO₂, —N(R¹)R^m, —C(O)N(R¹)R^m,
—N(R¹)C(O)R^m, —N(R¹)SO₂C₁₋₆alkyl,
—N(R¹)SO₂CF₃, —C(O)C₁₋₆alkyl, —S(O)₀₋₂—
C₁₋₆alkyl, —SO₂CF₃, —SO₂N(R¹)R^m, —SCF₃,
halo, —CF₃, —OCF₃, —CO₂H, or —CO₂C₁₋₆alkyl;
where R¹ and R^m are each independently —H,
—C₁₋₆alkyl, saturated monocyclic cycloalkyl, or
—CF₃;

and pharmaceutically acceptable salts thereof; and

(b) a pharmaceutically acceptable excipient.

9. A pharmaceutical composition according to claim 8,
wherein said agent is selected from the group consisting of:

[2-Isopropyl-7-(3-methyl-quinoxalin-2-yl)-6,7,8,9-tet-
rahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trifluo-
romethyl-phenyl)-amine;

[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,
8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trif-
luoromethyl-phenyl)-amine

[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,
7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-
trifluoromethyl-phenyl)-amine;

(4-tert-Butyl-phenyl)-[2-piperidin-1-yl-7-(3-trifluorom-
ethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,
5-d]azepin-4-yl]-amine;

N⁴-(3-Chloro-4-trifluoromethyl-phenyl)-N²,N²-dim-
ethyl-7-(3-trifluoro-methyl-pyridin-2-yl)-6,7,8,9-tet-
rahydro-5H-pyrimido[4,5-d]azepine-2,4-diamine;

(4-Bromo-phenyl)-[2-isopropyl-7-(3-trifluoromethyl-py-
ridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]
azepin-4-yl]-amine;

(4-tert-Butyl-phenyl)-[2-morpholin-4-yl-7-(3-trifluorom-
ethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,
5-d]azepin-4-yl]-amine;

N⁴-(4-tert-Butyl-phenyl)-N²,N²-dimethyl-7-(3-trifluo-
romethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-py-
rimido[4,5-d]azepine-2,4-diamine;

N²,N²-Dimethyl-N⁴-(4-trifluoromethyl-phenyl)-7-(3-trif-
luoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-py-
rimido[4,5-d]azepine-2,4-diamine;

N⁴-(4-Chloro-phenyl)-N²,N²-dimethyl-7-(3-trifluorom-
ethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,
5-d]azepine-2,4-diamine;

N⁴-(4-Trifluoromethyl-phenyl)-7-(3-trifluoromethyl-py-
ridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]
azepine-2,4-diamine;

[2-Azetidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,
8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-tri-
fluoromethyl-phenyl)-amine;

1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluorom-
ethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,
5-d]azepin-2-yl]-piperidine-4-carboxylic acid;

246

1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluorom-
ethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,
5-d]azepin-2-yl]-piperidin-4-ol;

[2-(4-Isopropyl-piperazin-1-yl)-7-(3-trifluoromethyl-py-
ridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]
azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

4-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluorom-
ethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,
5-d]azepin-2-yl]-piperazin-2-one;

(R)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluo-
romethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-py-
rimido[4,5-d]azepin-2-yl]-piperidin-3-ol;

[2-(4-Methyl-piperazin-1-yl)-7-(3-trifluoromethyl-pyri-
din-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]
azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

(S)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluo-
romethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-py-
rimido[4,5-d]azepin-2-yl]-piperidin-3-ol;

[2-Piperazin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,
8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trif-
luoromethyl-phenyl)-amine;

[2-Thiomorpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-
yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-
yl]-(4-trifluoromethyl-phenyl)-amine;

[2-(4-Benzyl-piperazin-1-yl)-7-(3-trifluoromethyl-pyri-
din-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]
azepin-4-yl]-(4-trifluoromethyl-phenyl)-amine;

[2-Pyrrolidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,
8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-(4-trif-
luoromethyl-phenyl)-amine;

2-{4-[2-Azetidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-
6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-
ylamino]-phenyl}-propan-2-ol; and

2-{4-[2-Azepan-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-
6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-
ylamino]-phenyl}-propan-2-ol;

and pharmaceutically acceptable salts thereof.

10. A pharmaceutical composition according to claim 8,
wherein said agent is selected from the group consisting of:

1-[4-(2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-
yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-
yl]amino)phenyl]ethanone;

N-[3-Fluoro-4-(trifluoromethyl)phenyl]-2-piperidin-1-yl-
7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-
5H-pyrimido[4,5-d]azepin-4-amine;

N,N-Dimethyl-4-({2-piperidin-1-yl-7-[3-(trifluorom-
ethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,
5-d]azepin-4-yl}amino)benzenesulfonamide;

N-[4-(1,1-Dimethylethyl)-3-nitrophenyl]-2-piperidin-1-
yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahy-
dro-5H-pyrimido[4,5-d]azepin-4-amine;

N-[4-(Methylsulfonyl)phenyl]-2-piperidin-1-yl-7-[3-(trif-
luoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-py-
rimido[4,5-d]azepin-4-amine;

(2-Fluoro-4-trifluoromethyl-phenyl)-[2-piperidin-1-yl-7-
(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-
5H-pyrimido[4,5-d]azepin-4-yl]-amine;

Methyl 2-methyl-2-[4-({2-piperidin-1-yl-7-[3-(trifluo-
romethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-py-
rimido[4,5-d]azepin-4-yl}amino)phenyl]propanoate;

2-[4-({2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-
yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-
yl}amino)phenyl]propan-2-ol;

1,1,1-Trifluoro-2-[4-({2-piperidin-1-yl-7-[3-(trifluorom-
ethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,
5-d]azepin-4-yl}amino)phenyl]propan-2-ol;

247

2-Methyl-2-[4-({2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]propanoic acid;

4-(1,1-Dimethylethyl)-N1-[2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]benzene-1,3-diamine;

2-(1,1-Dioxido-1,2-thiazinan-2-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-[3-(Methyloxy)piperidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-[(2S)-2-[(Methyloxy)methyl]pyrrolidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-(4-methylpiperazin-1-yl)-7-[3-(trifluoromethyl)pyridine-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-Azepan-1-yl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-Azepan-1-yl-N-[3-chloro-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-Azetidin-1-yl-N-[3-chloro-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-Azetidin-1-yl-N-[(3,4-dichlorophenyl)methyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(2,6-Dimethylmorpholin-4-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(1,4-Oxazepan-4-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(3,3-Difluoropiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(4-Methylpiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(3-Methylpiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(3,3-Difluoroazetidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(4,4-Difluoropiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(3,3-Difluoropyrrolidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(2-Methylpyrrolidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-(1,4-oxazepan-4-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

248

2-(2-Methylpiperidin-1-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(1,1-Dioxidothiomorpholin-4-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

N-[4-(1,1-Dimethylethyl)phenyl]-2-pyrrolidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-Azetidin-1-yl-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

N-[4-(1,1-Dimethylethyl)phenyl]-2-(4-methylpiperazin-1-yl)-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-Azepan-1-yl-N-[4-(1,1-dimethylethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

N-[3-Chloro-4-(trifluoromethyl)phenyl]-2-pyrrolidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

[1-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)piperidin-2-yl]methanol;

[(2S)-1-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)pyrrolidin-2-yl]methanol;

[(2R)-1-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)pyrrolidin-2-yl]methanol;

2-(7-Azabicyclo[2.2.1]hept-7-yl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-[2-(1-Methylethyl)pyrrolidin-1-yl]-N-[2-methyl-4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

[4-(4-{[4-(Trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)morpholin-2-yl]methanol;

[4-(4-{[2-Methyl-4-(trifluoromethyl)phenyl]amino}-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-2-yl)morpholin-2-yl]methanol;

2-[(2S or 2R)-2-Methylpiperidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridine-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-[(2S or 2R)-2-Methylpiperidin-1-yl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridine-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

7-[3-(Ethylsulfonyl)pyridin-2-yl]-2-piperidin-1-yl-N-[4-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine;

2-(2-Piperidin-1-yl-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-sulfonamide;

N-Cyclopropyl-2-(2-piperidin-1-yl-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-sulfonamide;

N-(1-Methylethyl)-2-(2-piperidin-1-yl-4-{[4-(trifluoromethyl)phenyl]amino}-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepin-7-yl)pyridine-3-sulfonamide;

249

2-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionic acid methyl ester;

2-Piperidin-1-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine; 5

N,N-Dimethyl-4-({2-morpholin-4-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)benzenesulfonamide; 10

1-[4-({2-Morpholin-4-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl}amino)phenyl]ethanone;

(3-Chloro-4-trifluoromethyl-phenyl)-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine; 15

2-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionitrile; 20

2-Methyl-2-{4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-1-ol;

2-Methyl-2-{4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionitrile; 25

2-Fluoro-4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester;

250

(6-Methoxy-5-trifluoromethyl-pyridin-2-yl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine;

4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid methyl ester;

4-[2-Piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-benzoic acid;

2-{4-[2-Morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol;

(6-Chloro-5-trifluoromethyl-pyridin-2-yl)-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl]-amine;

2-{2-Fluoro-4-[2-piperidin-1-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propan-2-ol;

2-Methyl-2-{4-[2-morpholin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ylamino]-phenyl}-propionic acid;

5-Chloro-6-[2-piperidin-1-yl-4-(4-trifluoromethyl-phenylamino)-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl]-nicotinic acid methyl ester;

{5-Chloro-6-[2-piperidin-1-yl-4-(4-trifluoromethyl-phenylamino)-5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl]-pyridin-3-yl}-methanol;

and pharmaceutically acceptable salts thereof.

* * * * *